<?xml version="1.0" encoding="UTF-8"?>
<registryObjects xmlns="http://ands.org.au/standards/rif-cs/registryObjects"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xsi:schemaLocation="http://ands.org.au/standards/rif-cs/registryObjects https://researchdata.edu.au/documentation/rifcs/schema/registryObjects.xsd">
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2002047</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2002047</identifier>
            <identifier type="nhmrc">2002047</identifier>
            <name type="primary">
                <namePart>ALIVE - A National Research Translation Centre to implement Mental Health
                    Care at Scale</namePart>
            </name>
            <name type="alternative">
                <namePart>Special Initiative</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">mental health </subject>
            <subject type="local">implementation </subject>
            <subject type="local">translation </subject>
            <subject type="local">aboriginal mental health </subject>
            <subject type="local">intervention</subject>
            <description type="Chief Investigator">A/Pr Victoria Palmer</description>
            <description type="Date Announced">2021-03-16T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">ALIVE is a national research translation Centre to implement
                mental health care at scale. Our vision is to reduce the individual, social and
                economic impacts of mental illness burden and health inequities by transforming the
                primary care and community settings to: 1) embed novel preventive life course
                models; 2) implement mental-physical health tailored models of care with priority
                populations; 3) be informed by lived-experience models and leadership.</description>
            <description type="fundingAmount">$10,000,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007001</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007001</identifier>
            <identifier type="nhmrc">2007001</identifier>
            <name type="primary">
                <namePart>Revolution of sleep diagnostics and personalized health care based on
                    digital diagnostics and therapeutics with health data integration</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">obstructive sleep apnoea </subject>
            <subject type="local">apnoea </subject>
            <subject type="local">biomedical engineering </subject>
            <subject type="local">sleep </subject>
            <subject type="local">somnolence</subject>
            <description type="Chief Investigator">Prof Juha Toyras</description>
            <description type="Date Announced">2021-03-26T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Almost 1 billion people suffer from sleep apnoea.
                Unfortunately, the current diagnostic metric relates poorly to the symptoms and
                comorbidities of sleep apnoea merely measuring the frequency of breathing
                cessations. We aim to develop machine learning techniques to better estimate sleep
                apnoea severity. These techniques are implemented to high-end wearables developed in
                this project. Finally, we aim to design a digital diagnostic platform and create new
                standardised guidelines for sleep medicine.</description>
            <description type="fundingAmount">$499,999.75</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007006</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007006</identifier>
            <identifier type="nhmrc">2007006</identifier>
            <name type="primary">
                <namePart>DigiCare4You - An intersectoral innovative solution involving DIGItal
                    tools, empowering families and integrating community CARE services for the
                    prevention and management of type 2 diabetes and hypertension</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rxfrp27</identifier>
                <title>La Trobe University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">community health care </subject>
            <subject type="local">health promotion </subject>
            <subject type="local">diabetes prevention </subject>
            <subject type="local">behaviour change </subject>
            <subject type="local">electronic health information</subject>
            <description type="Chief Investigator">A/Pr George Moschonis</description>
            <description type="Date Announced">2021-03-26T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The overall aim of the research is to design and implement an
                innovative intervention that will bring together the available community-care
                infrastructure, human resources and services, as well as technological advancements
                on digital health, for the early prevention and treatment of type 2 diabetes and
                hypertension. The active involvement of Australian researchers in this international
                collaboration ensures that this innovation and its benefits will be transferred to
                Australia in the future.</description>
            <description type="fundingAmount">$489,307.09</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007014</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007014</identifier>
            <identifier type="nhmrc">2007014</identifier>
            <name type="primary">
                <namePart>Intelligent total body scanner for early detection of melanoma</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">melanoma </subject>
            <subject type="local">artificial neural networks </subject>
            <subject type="local">diagnostic imaging </subject>
            <subject type="local">multiple risk factors </subject>
            <subject type="local">risk assessment</subject>
            <description type="Chief Investigator">Prof H. Peter Soyer</description>
            <description type="Date Announced">2021-03-26T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Melanoma is the 4th most common cancer in Australia; the main
                screening tool is a time-consuming total body examination with a hand-held
                dermoscope. This project aims to develop a total body scanner using fast-refocusing
                lenses to take total body dermoscopy images of all skin lesions in approximately 6
                minutes, integrated with a computer aided diagnostic tool providing a risk score for
                each lesion incorporating medical history, genotypic and phenotypic risk
                markers.</description>
            <description type="fundingAmount">$499,963.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007048</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007048</identifier>
            <identifier type="nhmrc">2007048</identifier>
            <name type="primary">
                <namePart>ManagemenT of chronIc cardioMetabolic diseasE and treatment diScontinuity
                    in adult ADHD PAtieNts (TIMESPAN)</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">attention deficit hyperactivity disorder (adhd) </subject>
            <subject type="local">cardiovascular disease </subject>
            <subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes mellitus) </subject>
            <subject type="local">pharmacoepidemiology </subject>
            <subject type="local">data linkage</subject>
            <description type="Chief Investigator">A/Pr Helga Zoega</description>
            <description type="Date Announced">2021-03-26T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The aim of TIMESPAN is to improve the management of patients
                with Attention Deficit Hyperactivity Disorders (ADHD) and co-occurring
                cardiometabolic disease (i.e. obesity, type-2 diabetes, and cardiovascular disease).
                Inadequate treatment of these common conditions can lead to premature death and
                substantial societal costs. We will use linked electronic health records and novel
                research methods to improve clinical outcomes and quality of life of adults with
                ADHD and cardiometabolic disease.</description>
            <description type="fundingAmount">$499,612.50</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007059</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007059</identifier>
            <identifier type="nhmrc">2007059</identifier>
            <name type="primary">
                <namePart>Re-imagining Environments for Connection and Engagement: Testing Actions
                    for Social Prescribing in Natural Spaces</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04ttjf776</identifier>
                <title>RMIT University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">mental health </subject>
            <subject type="local">social health issues </subject>
            <subject type="local">psychosocial </subject>
            <subject type="local">environmental influences </subject>
            <subject type="local">environmental intervention</subject>
            <description type="Chief Investigator">Prof Sarah Bekessy</description>
            <description type="Date Announced">2021-03-26T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project will evaluate whether and how nature-based social
                prescribing (NBSP) can address mental well-being. We will experimentally test the
                effectiveness of NBSP in promoting connection among populations experiencing social
                isolation and loneliness with socially oriented opportunities in safe, inclusive and
                accessible, green and blue outdoor urban spaces. The project will build the evidence
                base for the value of NBSP investments in improving mental health.</description>
            <description type="fundingAmount">$499,749.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2002381</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2002381</identifier>
            <identifier type="nhmrc">2002381</identifier>
            <name type="primary">
                <namePart>Parenting+ Improving health and service-use outcomes through health
                    literacy training for new parents: an effectiveness-implementation hybrid
                    trial</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">health literacy </subject>
            <subject type="local">maternal and child health </subject>
            <subject type="local">socioeconomic </subject>
            <subject type="local">health education </subject>
            <subject type="local">ethnic health</subject>
            <description type="Chief Investigator">Prof Kirsten McCaffery</description>
            <description type="Date Announced">2021-03-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The Parenting+ project will evaluate an educational program for
                socio-economically and culturally diverse new parents. The study will assess the
                impact of the program on parents' health literacy, parent and infant health and
                psychosocial outcomes and health service use over one year. It additionally will
                identify key characteristics and reproducible steps in the successful implementation
                of the program in order to support wider adoption by other health
                services.</description>
            <description type="fundingAmount">$495,760.80</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2002625</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2002625</identifier>
            <identifier type="nhmrc">2002625</identifier>
            <name type="primary">
                <namePart>Enhancing behavioural surveillance to address gaps and disparities in
                    Australia's HIV response in a changing HIV epidemic</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">human immunodeficiency virus (hiv) </subject>
            <subject type="local">sexual behaviour </subject>
            <subject type="local">prevention </subject>
            <subject type="local">social identity </subject>
            <subject type="local">social and cultural issues</subject>
            <description type="Chief Investigator">Prof Martin Holt</description>
            <description type="Date Announced">2021-03-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project will test and evaluate changes to Australia's HIV
                behavioural surveillance system, increasing recruitment and data collection from
                overseas-born, bisexual and heterosexual men who have sex with men (MSM). This is
                necessary because Australia's HIV epidemic is changing, with falling infections
                among Australian-born gay men, but rising infections in other groups, such as
                Asian-born MSM. The project will use technological advancements in recruitment,
                survey research and interviews.</description>
            <description type="fundingAmount">$1,268,159.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2003399</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2003399</identifier>
            <identifier type="nhmrc">2003399</identifier>
            <name type="primary">
                <namePart>Novel strategies for improving syphilis testing and control</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">syphilis </subject>
            <subject type="local">sexually-transmitted infections (sti) </subject>
            <subject type="local">public health </subject>
            <subject type="local">screening </subject>
            <subject type="local">surveillance</subject>
            <description type="Chief Investigator">Prof Marcus Chen</description>
            <description type="Date Announced">2021-03-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Syphilis has been resurgent in many countries including
                Australia. Our research will evaluate novel strategies to improve syphilis testing,
                surveillance, and control and ensure these new strategies are effective at targeting
                affected groups attending health services. The research findings will help guide
                better syphilis testing and control by health care providers, pathology services and
                health policy makers.</description>
            <description type="fundingAmount">$1,256,040.80</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2005191</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2005191</identifier>
            <identifier type="nhmrc">2005191</identifier>
            <name type="primary">
                <namePart>Defining and optimising the economic and social return on investment of
                    telephone cancer information and support services for all Australians</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02czsnj07</identifier>
                <title>Deakin University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">evidence-based health care </subject>
            <subject type="local">cancer </subject>
            <subject type="local">health care delivery </subject>
            <subject type="local">health care evaluation </subject>
            <subject type="local">economic analysis</subject>
            <description type="Chief Investigator">Dr Nikki McCaffrey</description>
            <description type="Date Announced">2021-03-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The economic and social value of telephone cancer information
                and support services (CISS) for Australia is undefined thus hindering decisions
                about the future direction of services and levels of funding. This research will
                identify and compare the broad monetised, social benefits of CISS with the costs of
                providing the service. We will identify different strategies to deliver, promote and
                target services to improve cancer outcomes for all Australians and maximise the
                return on investment.</description>
            <description type="fundingAmount">$936,786.70</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2005403</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2005403</identifier>
            <identifier type="nhmrc">2005403</identifier>
            <name type="primary">
                <namePart>Improving the safety and quality of emergency nursing care</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">nursing practice </subject>
            <subject type="local">emergency medicine </subject>
            <subject type="local">deterioration </subject>
            <subject type="local">adverse events </subject>
            <subject type="local">patient safety</subject>
            <description type="Chief Investigator">Prof Kate Curtis</description>
            <description type="Date Announced">2021-03-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Failure to assess, treat comprehensively and escalate emergency
                patient care can be catastrophic. However, there is no emergency nursing framework
                in use for the 29,000+ emergency nurses working in Australia. We aim to improve
                access, consistency, safety and quality of emergency care for the best possible
                patient outcomes through system wide implementation of HIRAID - the only validated
                framework designed to teach emergency nurses how to systematically assess and manage
                emergency patients.</description>
            <description type="fundingAmount">$1,498,877.45</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2005589</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2005589</identifier>
            <identifier type="nhmrc">2005589</identifier>
            <name type="primary">
                <namePart>I-HEART - Implementation of HEArt failure guidelines in Regional
                    AusTralia</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02czsnj07</identifier>
                <title>Deakin University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">heart failure </subject>
            <subject type="local">nursing </subject>
            <subject type="local">translational research </subject>
            <subject type="local">health services </subject>
            <subject type="local">regional health</subject>
            <description type="Chief Investigator">Prof Andrea Driscoll</description>
            <description type="Date Announced">2021-03-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Heart failure (HF) is a common disease of the heart with a high
                rehospitalisation and mortality rate. Regional HF patients rarely receive the full
                benefits of evidence-based care simply due to inaccessibility to a HF specialist
                team. This translational project will implement key recommendations from clinical
                guidelines in regional health services and improve access to specialist services. It
                has the potential to keep patients out of hospital and save lives.</description>
            <description type="fundingAmount">$1,266,172.55</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2005759</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2005759</identifier>
            <identifier type="nhmrc">2005759</identifier>
            <name type="primary">
                <namePart>Improving interpreting for dementia assessments: The MINDSET
                    Study</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00200ya62</identifier>
                <title>National Ageing Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">cognitive assessment </subject>
            <subject type="local">cross-cultural </subject>
            <subject type="local">communication skills </subject>
            <subject type="local">translational research </subject>
            <subject type="local">dementia</subject>
            <description type="Chief Investigator">A/Pr Bianca Brijnath</description>
            <description type="Date Announced">2021-03-27T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">The MINDSET Study aims to improve the quality of communication
                in an interpreter mediated cognitive assessment for dementia. Working with
                interpreters, clinicians, culturally and linguistically diverse people with
                dementia, and their carers we will co-design, trial, and implement national online
                training targeted at interpreters. This training will enable interpreters to be
                prepared and confident in performing their role impartially, effectively, and
                accurately.</description>
            <description type="fundingAmount">$271,586.20</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2005779</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2005779</identifier>
            <identifier type="nhmrc">2005779</identifier>
            <name type="primary">
                <namePart>Improving the management of Obstructive Sleep Apnea and Insomnia in
                    General Practice</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">primary care </subject>
            <subject type="local">obstructive sleep apnoea </subject>
            <subject type="local">insomnia </subject>
            <subject type="local">general practice </subject>
            <subject type="local">health service management</subject>
            <description type="Chief Investigator">Prof Robert Adams</description>
            <description type="Date Announced">2021-03-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The two most common clinical sleep disorders, insomnia and
                obstructive sleep apnea (OSA), affect &gt;4 million Australians, costing Australia
                over $66 billion annually. People with sleep disorders are receiving care that is
                far from best practice and is potentially dangerous. This novel partnership study
                represents a major step towards improving management of sleep disorders in primary
                care (PC) using new, evidence-based, models of care for insomnia and OSA, designed
                specifically for PC.</description>
            <description type="fundingAmount">$1,439,099.70</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2005790</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2005790</identifier>
            <identifier type="nhmrc">2005790</identifier>
            <name type="primary">
                <namePart>Partnership for Precision Prevention in CAD (PPP-CAD)</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cardiovascular risk factors </subject>
            <subject type="local">cohort study </subject>
            <subject type="local">implementation </subject>
            <subject type="local">health economics </subject>
            <subject type="local">primary care</subject>
            <description type="Chief Investigator">Prof Gemma Figtree</description>
            <description type="Date Announced">2021-03-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">There is an urgent need for new tools to improve risk
                prediction for coronary artery disease which accounts for one fifth of deaths in
                Australia. Polygenic risk scores that incorporate the information from millions of
                genetic variants have shown great promise, but need prospective evaluation. Our team
                of clinical, research, industry and government leaders will develop clinical
                pathways and implement polygenic risk scores in primary care to improve precision of
                preventative strategies.</description>
            <description type="fundingAmount">$1,413,165.50</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2005797</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2005797</identifier>
            <identifier type="nhmrc">2005797</identifier>
            <name type="primary">
                <namePart>The Personalising Acute Myocardial Infarction Care to improve Outcomes
                    (PAMICO Project)</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">acute myocardial infarction (ami) </subject>
            <subject type="local">acute care </subject>
            <subject type="local">evidence-based health care </subject>
            <subject type="local">quality of care </subject>
            <subject type="local">clinical practice</subject>
            <description type="Chief Investigator">Prof John Beltrame</description>
            <description type="Date Announced">2021-03-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The modern management of heart attacks has improved survival
                dramatically, however, not all patients receive the best care available, leading to
                variation in quality and health outcomes. The PAMICO Project (Personalising Acute
                Myocardial Infarction Care to improve Outcomes) aims to bridge this gap using
                sophisticated electronic data systems and integrated care teams to produce
                personalised clinical management pathways so that care is patient-centered and
                aligned with best practice.</description>
            <description type="fundingAmount">$1,499,233.80</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006408</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006408</identifier>
            <identifier type="nhmrc">2006408</identifier>
            <name type="primary">
                <namePart>Steroid-Reducing Options for ReLapsING PMR (STERLING-PMR): a pragmatic,
                    randomised trial to compare the clinical and cost-effectiveness of adding
                    immunosuppression to steroid-tapering treatment for patients with relapsing PMR,
                    versus steroid-tapering</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">clinical trial </subject>
            <subject type="local">methotrexate </subject>
            <subject type="local">glucocorticoids </subject>
            <subject type="local">rheumatic diseases </subject>
            <subject type="local">musculoskeletal disorders</subject>
            <description type="Chief Investigator">Prof Catherine Hill</description>
            <description type="Date Announced">2021-05-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Polymyalgia rheumatica (PMR) is a common inflammatory disease
                of older people, treated with prednisolone (steroid tablet). About 50% will relapse
                and often suffer from steroid side effects (eg diabetes, bone fracture). This study
                will determine whether an extra treatment can reduce prednisolone use in people with
                relapsing PMR; and improve quality of life. The study will include participants in
                UK and Australia and provide a unique opportunity for further research in this
                under-researched area.</description>
            <description type="fundingAmount">$823,722.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007142</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007142</identifier>
            <identifier type="nhmrc">2007142</identifier>
            <name type="primary">
                <namePart>The Meniscal Transplant surgery or Optimised Rehabilitation full
                    randomised trial (MeTeOR2)</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">knee cartilage </subject>
            <subject type="local">orthopaedic surgery </subject>
            <subject type="local">physiotherapy management </subject>
            <subject type="local">clinical trial </subject>
            <subject type="local">cost-effectiveness</subject>
            <description type="Chief Investigator">Prof Manuela Ferreira</description>
            <description type="Date Announced">2021-05-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">It can be hard to decide what treatment to use for people with
                pain and disability who have had the meniscus cartilage removed from the knee. Some
                surgeons try to improve pain and function by replacing the lost meniscus with a
                transplant from a donor who has died. The alternatives include exercises,
                physiotherapy, and bracing. This study will help us understand if the results for
                people who have the transplant are better or worse than for exercise and
                physiotherapy.</description>
            <description type="fundingAmount">$1,025,882.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2005944</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2005944</identifier>
            <identifier type="nhmrc">2005944</identifier>
            <name type="primary">
                <namePart>National First Nations Research Network</namePart>
            </name>
            <name type="alternative">
                <namePart>National Network for Aboriginal and Torres Strait Islander health
                    researchers</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/006mbby82</identifier>
                <title>Menzies School of Health Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">indigenous australians </subject>
            <subject type="local">capacity building </subject>
            <subject type="local">indigenous health </subject>
            <subject type="local">social support networks </subject>
            <subject type="local">education</subject>
            <description type="Chief Investigator">Prof Gail Garvey</description>
            <description type="Date Announced">2021-05-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">The National First Nations Research Network will mark a
                transformation in First Peoples livelihoods and Health Equity. Delivered and led by
                Indigenous Peoples for Indigenous Peoples, guided by self-determination, this
                Network will nurture culturally safe environments, connect expertise, catalyse
                research methods, training and development. The Network will create career pathways
                to achieve national capability and generational growth, for sustained health and
                wellbeing of our communities.</description>
            <description type="fundingAmount">$10,000,000.00</description>
            <coverage>
                <spatial type="text">NT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006719</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006719</identifier>
            <identifier type="nhmrc">2006719</identifier>
            <name type="primary">
                <namePart>Emerging techniques for earlier diagnosis and assessment of severity and
                    progression of artificial stone silicosis</namePart>
            </name>
            <name type="alternative">
                <namePart>Targeted Call for Research</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">adult respiratory diseases </subject>
            <subject type="local">medical imaging </subject>
            <subject type="local">occupational health </subject>
            <subject type="local">occupational rehabilitation </subject>
            <subject type="local">screening</subject>
            <description type="Chief Investigator">Prof Malcolm Sim</description>
            <description type="Date Announced">2021-05-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Stonemasons who have worked with engineered stone have been
                shown to develop a rapidly progressive and potentially fatal form of silicosis. This
                research will use data from affected workers from Victoria, Western Australia and
                Queensland. The research will comprise a suite of projects to investigate many
                uncertainties related to radiological screening methods, as well as investigating
                new methods to assess disease severity and identify indicators of progression to
                inform future practice.</description>
            <description type="fundingAmount">$994,642.40</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009196</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009196</identifier>
            <identifier type="nhmrc">2009196</identifier>
            <name type="primary">
                <namePart>HPV-based testing and treatment for the elimination of cervical cancer in
                    Papua New Guinea (HPVTATE)</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">cervical screening </subject>
            <subject type="local">cervical precancer </subject>
            <subject type="local">cervical cancer </subject>
            <subject type="local">health services research </subject>
            <subject type="local">developing countries</subject>
            <description type="Chief Investigator">Prof Andrew Vallely</description>
            <description type="Date Announced">2021-06-16T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Building on the innovative cervical screening model that we
                successfully designed and delivered in partnership with provincial health
                authorities in urban primary care settings in PNG, the overarching aim of the
                proposed study is to determine the reach, effectiveness, cost-effectiveness,
                acceptability and scalability of HPV-based testing and treatment for the elimination
                of cervical cancer (HPVTATE) among women in rural and remote communities in Papua
                New Guinea.</description>
            <description type="fundingAmount">$1,590,166.78</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009206</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009206</identifier>
            <identifier type="nhmrc">2009206</identifier>
            <name type="primary">
                <namePart>SISTAQUIT scale-up in Indigenous populations in Australia</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">smoking cessation </subject>
            <subject type="local">indigenous health </subject>
            <subject type="local">pregnancy </subject>
            <subject type="local">health professionals </subject>
            <subject type="local">health advice</subject>
            <description type="Chief Investigator">A/Pr Gillian Gould</description>
            <description type="Date Announced">2021-06-16T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">SISTAQUIT®(Supporting Indigenous Smokers to Assist Quitting) is
                a research backed training program that provides free, online training in quit
                smoking methods to health providers. This study aims to expand the SISTAQUIT
                intervention to all Australian health services that cater to Indigenous women during
                pregnancy. This research will test numerous methods to implement SISTAQUIT to
                identify the most effective and economical strategy suitable for roll-out, and build
                Indigenous workforce capacity.</description>
            <description type="fundingAmount">$1,800,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009317</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009317</identifier>
            <identifier type="nhmrc">2009317</identifier>
            <name type="primary">
                <namePart>Developing a scalable, woman-centred model for cervical cancer screening
                    in vulnerable women in India</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://acpcc.org.au</identifier>
                <title>VCS Foundation Limited</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">cervical screening </subject>
            <subject type="local">cervical precancer </subject>
            <subject type="local">cancer screening </subject>
            <subject type="local">population screening </subject>
            <subject type="local">health services research</subject>
            <description type="Chief Investigator">A/Pr Julia Brotherton</description>
            <description type="Date Announced">2021-06-16T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Cervical cancer is a devastating but preventable disease and 1
                in 5 cases of cervical cancer in the world occur in India. We will work with women,
                communities, and health services in two States of India (Tamil Nadu and Mizoram) to
                design a woman friendly approach to prevent cervical cancer. This project brings
                together international and Indian experts to overcome current barriers to cervical
                screening by using a newer, more effective way of screening to reach underserved
                women and save lives.</description>
            <description type="fundingAmount">$1,330,369.04</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010271</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010271</identifier>
            <identifier type="nhmrc">2010271</identifier>
            <name type="primary">
                <namePart>Developing and testing a community-informed intervention to increase VIA
                    cervical cancer screening in Eswatini</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">cervical screening </subject>
            <subject type="local">cancer prevention </subject>
            <subject type="local">implementation </subject>
            <subject type="local">community health care </subject>
            <subject type="local">nursing practice</subject>
            <description type="Chief Investigator">Prof Robert Sanson-Fisher</description>
            <description type="Date Announced">2021-06-16T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Eswatini has the highest rate of cervical cancer in the world.
                Cervical cancer screening is effective at reducing deaths from this disease.
                However, in Eswatini rates of cervical screening are very low, with one study
                estimating that only 5% of women had ever undergone screening. This project will
                explore barriers to cervical screening in Eswatini, and develop and test culturally
                appropriate strategies to improve participation in cervical screening.</description>
            <description type="fundingAmount">$1,206,527.95</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2000344</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2000344</identifier>
            <identifier type="nhmrc">2000344</identifier>
            <name type="primary">
                <namePart>Pragmatic trial of a targeted digital intervention for youth with suicidal
                    thoughts and behaviours attending outpatient care</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">major depression </subject>
            <subject type="local">youth </subject>
            <subject type="local">mental health </subject>
            <subject type="local">suicide prevention </subject>
            <subject type="local">suicide risk</subject>
            <description type="Chief Investigator">A/Pr Simon Rice</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Existing programs aiming to reduce suicide ideation in youth
                often fail to impart lasting benefits in helping young people stay well. Our team
                have developed an online social media-based intervention (called Affinity) that
                addresses limitations of past programs by allowing 24/7 access to digital therapy,
                alongside therapist and peer support. This trial will aim to uncover whether
                Affinity is effective in reducing suicide ideation in young people, relative to a
                control program.</description>
            <description type="fundingAmount">$1,443,572.40</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2000375</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2000375</identifier>
            <identifier type="nhmrc">2000375</identifier>
            <name type="primary">
                <namePart>A Phase III randomised placebo-controlled trial of mirtazapine as a
                    pharmacotherapy for methamphetamine ("Ice") dependence</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">substance dependence </subject>
            <subject type="local">pharmacotherapy </subject>
            <subject type="local">clinical trial </subject>
            <subject type="local">amphetamine </subject>
            <subject type="local">medications</subject>
            <description type="Chief Investigator">A/Pr Rebecca McKetin</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Crystalline methamphetamine ('ice') is a growing concern in
                Australia. There are no approved medications that can be used to treat dependence on
                this drug. This clinical trial will examine whether mirtazapine, a newly identified
                treatment agent for methamphetamine use, can be used safely and effectively in
                routine clinical care to manage methamphetamine dependence in
                Australia.</description>
            <description type="fundingAmount">$3,923,009.33</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2000376</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2000376</identifier>
            <identifier type="nhmrc">2000376</identifier>
            <name type="primary">
                <namePart>Breathing Control as a treatment for Non-Epileptic Seizures</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">control of breathing </subject>
            <subject type="local">seizures </subject>
            <subject type="local">somatoform disorders </subject>
            <subject type="local">clinical trial </subject>
            <subject type="local">physiotherapy management</subject>
            <description type="Chief Investigator">Prof Richard Kanaan</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Non-epileptic Seizures (NES) are fits that look like epilepsy
                but are not, and are instead thought to be a psychological response to problems.
                Treating them psychologically is difficult, however, and doesn't usually work. We
                have discovered that patients' fits involve hyperventilation, like a panic attack,
                and can be stopped by teaching them to control their breathing in a similar way. In
                this study we aim to prove this, by completing a trial of breath control training in
                NES.</description>
            <description type="fundingAmount">$1,740,186.67</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2000404</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2000404</identifier>
            <identifier type="nhmrc">2000404</identifier>
            <name type="primary">
                <namePart>Providing translatable evidence to advance prevention and management of
                    COPD: a longitudinal study from the 1st to 7th decade of life</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">disease prevention </subject>
            <subject type="local">risk prediction </subject>
            <subject type="local">chronic obstructive pulmonary disease (copd) </subject>
            <subject type="local">asthma </subject>
            <subject type="local">lung function</subject>
            <description type="Chief Investigator">Prof Shyamali Dharmage</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Chronic obstructive pulmonary disease (COPD) makes breathing
                difficult and reduces wellbeing. People are more likely to get COPD from the age of
                60 years, but we do not know why and who. Our study will develop tools to identify
                early who will develop COPD by 60 years. We will also develop a tool to identify
                60-year-old individuals whose lung function is declining faster than normal. These
                findings will help us to better prevent and manage COPD.</description>
            <description type="fundingAmount">$2,893,319.94</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2000540</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2000540</identifier>
            <identifier type="nhmrc">2000540</identifier>
            <name type="primary">
                <namePart>PRogrEssion of DIabetic ComplicaTions - PREDICT</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03rke0285</identifier>
                <title>Baker Heart and Diabetes Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">diabetes </subject>
            <subject type="local">diabetic complications </subject>
            <subject type="local">biomarkers </subject>
            <subject type="local">cardiovascular complications </subject>
            <subject type="local">kidney disease</subject>
            <description type="Chief Investigator">Prof Jonathan Shaw</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">The PREDICT study will fill a very important gap in our
                understanding of diabetes. By studying what happens to over 3,000 people with type 2
                diabetes over the next decade, it will identify improved ways of identifying which
                people with diabetes will develop its devastating complications. This will allow
                targeting of intensive treatment on those who need it the most, and will also
                provide an important means of identifying potential new ways of treating and
                supporting people with type 2 diabetes.</description>
            <description type="fundingAmount">$4,784,627.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2000711</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2000711</identifier>
            <identifier type="nhmrc">2000711</identifier>
            <name type="primary">
                <namePart>AGITG TOP GEAR: A randomised phase II/III trial of preoperative
                    chemoradiotherapy versus preoperative chemotherapy for resectable gastric
                    cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">clinical trial </subject>
            <subject type="local">gastric cancer </subject>
            <subject type="local">radiotherapy </subject>
            <subject type="local">surgery </subject>
            <subject type="local">chemotherapy</subject>
            <description type="Chief Investigator">Prof Trevor Leong</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">While surgery to remove stomach cancer has been traditionally
                accepted as the only way to potentially cure the disease, there have been several
                recent advances using chemotherapy and/or radiotherapy both before and after
                surgery. Doctors' opinions remain divided regarding best treatments to give and in
                what order. This trial will address the important question of whether combined
                chemotherapy plus radiotherapy is more effective than chemotherapy alone in
                improving cure rates for stomach cancer.</description>
            <description type="fundingAmount">$621,644.20</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2000780</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2000780</identifier>
            <identifier type="nhmrc">2000780</identifier>
            <name type="primary">
                <namePart>Intermittent preventive treatment in pregnancy with
                    sulphadoxine-pyrimethamine plus dihydroartemisinin-piperaquine to reduce adverse
                    pregnancy outcomes and prevent malaria in Papua New Guinea: a randomised
                    controlled trial</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/006mbby82</identifier>
                <title>Menzies School of Health Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">clinical trial </subject>
            <subject type="local">antimalarial </subject>
            <subject type="local">malaria </subject>
            <subject type="local">pregnancy </subject>
            <subject type="local">low birth weight infant</subject>
            <description type="Chief Investigator">Dr Holger Unger</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Millions of pregnancies are complicated by malaria worldwide.
                Monthly sulphadoxine-pyrimethamine (SP) treatments, the current treatment strategy,
                no longer protects from malaria but improves birth outcomes through non-malarial
                effects. Dihydroartemisinin-piperaquine clears malaria but babies are smaller
                compared to women who received SP. A clinical trial of their combination has
                potential to substantially improve health outcomes for women and babies in Papua New
                Guinea and beyond.</description>
            <description type="fundingAmount">$2,938,452.97</description>
            <coverage>
                <spatial type="text">NT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2000842</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2000842</identifier>
            <identifier type="nhmrc">2000842</identifier>
            <name type="primary">
                <namePart>Uncovering the hidden impacts and costs of exposure to intimate partner
                    violence in childhood: a 20-year cohort study</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">maternal and child health </subject>
            <subject type="local">domestic violence </subject>
            <subject type="local">adolescent health </subject>
            <subject type="local">maternal mental health </subject>
            <subject type="local">health economics</subject>
            <description type="Chief Investigator">Prof Stephanie Brown</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Intimate partner violence (IPV) and adverse childhood
                experiences are common, and cluster within families. This longitudinal study will
                improve understanding of intergenerational impacts and costs of IPV and provide
                evidence regarding strategies that may reduce the risk of poor mental health in
                adult life for the more than 1 in 3 Australian children growing up in households
                where IPV is occurring.</description>
            <description type="fundingAmount">$1,595,473.40</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2000989</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2000989</identifier>
            <identifier type="nhmrc">2000989</identifier>
            <name type="primary">
                <namePart>IMPLORE - Implementing an opioid stewardship intervention to reduce opioid
                    use</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">clinical trial </subject>
            <subject type="local">opioid analgesia </subject>
            <subject type="local">patient education </subject>
            <subject type="local">low back pain </subject>
            <subject type="local">clinical decision making</subject>
            <description type="Chief Investigator">Dr Christina Abdel Shaheed</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Back pain is the leading cause for opioid use globally.
                Guidelines actively discourage opioid use for this condition but unfortunately it
                commonly ends up managed with opioid medicines. Urgent efforts are needed to reduce
                the burden of harm associated with excessive prescribing of opioids for back pain.
                This trial will evaluate a clinical care model that is grounded in research, and
                designed to curb opioid analgesic use and achieve better health outcomes for people
                with back pain.</description>
            <description type="fundingAmount">$2,352,236.17</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2001237</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2001237</identifier>
            <identifier type="nhmrc">2001237</identifier>
            <name type="primary">
                <namePart>Low OxyGen Intervention for Cardiac Arrest injury Limitation trial
                    (LOGICAL)</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">oxygen therapy </subject>
            <subject type="local">mechanical ventilation </subject>
            <subject type="local">randomised controlled trial (rct) </subject>
            <subject type="local">intensive care </subject>
            <subject type="local">clinical research</subject>
            <description type="Chief Investigator">Prof Carol Hodgson</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Life support with mechanical ventilation (MV) is required for
                most patients after cardiac arrest. Delivery of liberal oxygen therapy to patients
                receiving MV is standard care and exposes them to a high oxygen dose and higher
                blood oxygen levels. A higher amount of oxygen might be harmful after cardiac
                arrest, but the optimal oxygen therapy in these patients is uncertain. This study
                tests standard care versus a protective conservative dose of oxygen on neurological
                recovery after cardiac arrest.</description>
            <description type="fundingAmount">$2,314,402.60</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2001264</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2001264</identifier>
            <identifier type="nhmrc">2001264</identifier>
            <name type="primary">
                <namePart>Reducing household air pollution exposure to improve early child health
                    and development; extending the intervention and follow-up of "Poriborton: the
                    CHANge trial".</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">clinical trial </subject>
            <subject type="local">indoor air pollution </subject>
            <subject type="local">child development </subject>
            <subject type="local">respiratory diseases </subject>
            <subject type="local">public health</subject>
            <description type="Chief Investigator">A/Pr Camille Raynes-Greenow</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Around the world each year household air pollution causes 4.3
                million deaths. Mothers, babies and children, who spend the most time at home are
                extremely vulnerable. We will study the health of infants who have had reduced
                exposure in their first critical years of life and compare them to infants whose
                exposure was not reduced. This will provide compelling evidence for governments
                around the world of the need to assist families in developing settings to adopt
                clean energy.</description>
            <description type="fundingAmount">$2,916,420.55</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2001375</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2001375</identifier>
            <identifier type="nhmrc">2001375</identifier>
            <name type="primary">
                <namePart>A randomised controlled trial of N-acetylcysteine for the treatment of
                    alcohol use disorder</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">alcohol use disorders </subject>
            <subject type="local">alcohol dependence </subject>
            <subject type="local">pharmacotherapy </subject>
            <subject type="local">substance use </subject>
            <subject type="local">alcoholic liver disease</subject>
            <description type="Chief Investigator">A/Pr Kirsten Morley</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We urgently require new treatment strategies. Alcohol misuse is
                a leading cause of preventable death yet treatment options are limited. We will
                undertake the first human trial of N-acetylcysteine (NAC) for the management of
                alcohol use disorder (NAC-AUD). The NAC-AUD project will evaluate the efficacy and
                cost-efficacy of NAC to reduce alcohol consumption. The results will generate high
                level clinical evidence for a safe new treatment for a common life threatening
                disease.</description>
            <description type="fundingAmount">$1,294,923.44</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2001391</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2001391</identifier>
            <identifier type="nhmrc">2001391</identifier>
            <name type="primary">
                <namePart>Cognitive Improvement through early Restoration of cirCADian rhythms in
                    very preterm Infants via Environmental Modification: The CIRCA DIEM
                    Study</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">circadian rhythms </subject>
            <subject type="local">neurodevelopment </subject>
            <subject type="local">premature infant </subject>
            <subject type="local">maternal mental health </subject>
            <subject type="local">sleep</subject>
            <description type="Chief Investigator">Prof Jane Pillow</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">When very premature infants are born, they no longer receive
                important signals from their mother about whether it is daytime or night-time, and
                are cared for in hospital environments that are noisy and brightly lit all day. The
                absence of the maternal signals and the constant light and noise may interfere with
                normal brain development. We will determine if wearing eye masks and ear muffs at
                night in hospital will improve brain development and general health in premature
                babies.</description>
            <description type="fundingAmount">$3,077,039.40</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2001517</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2001517</identifier>
            <identifier type="nhmrc">2001517</identifier>
            <name type="primary">
                <namePart>Reconceiving early detection of melanoma</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">malignant melanoma </subject>
            <subject type="local">skin cancer </subject>
            <subject type="local">computer-assisted diagnosis </subject>
            <subject type="local">risk prediction </subject>
            <subject type="local">dermatology</subject>
            <description type="Chief Investigator">A/Pr Victoria Mar</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Treatment for skin cancer costs the Australian healthcare
                system &gt;$1 billion annually. Early detection and accurate diagnosis of melanoma
                improves survival, however a standardised approach to diagnosis does not currently
                exist. This study will prospectively recruit 15,000 patients to develop and validate
                a risk stratified image-based approach to melanoma prevention, early detection and
                surveillance which will incorporate cutting edge technologies to standardise
                diagnosis and optimise care.</description>
            <description type="fundingAmount">$3,217,920.20</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2001568</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2001568</identifier>
            <identifier type="nhmrc">2001568</identifier>
            <name type="primary">
                <namePart>A large-scale clinical effectiveness (health services) trial to determine
                    whether personalised health care packages, combined with digitally-supported
                    measurement-based care, improve functional outcomes in young people with mood
                    disorders</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">mood disorders </subject>
            <subject type="local">depression </subject>
            <subject type="local">youth </subject>
            <subject type="local">intervention </subject>
            <subject type="local">translational research</subject>
            <description type="Chief Investigator">Prof Ian Hickie</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">One of our greatest current health challenges is to develop
                highly-personalised interventions for teenagers and young adults with emerging mood
                disorders. This research will combine our national expertise to develop and
                implement care packages utilising digital technologies, personalised assessment
                techniques, targeted treatment choices, and long-term outcome tracking. In a
                clinical trial we will assess the clinical effectiveness of these innovative
                healthcare packages.</description>
            <description type="fundingAmount">$3,434,588.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2001578</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2001578</identifier>
            <identifier type="nhmrc">2001578</identifier>
            <name type="primary">
                <namePart>Australasian Malignant Pleural Effusion (AMPLE)-3 trial</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">adult respiratory diseases </subject>
            <subject type="local">cancer care </subject>
            <subject type="local">palliative treatment </subject>
            <subject type="local">malignant mesothelioma </subject>
            <subject type="local">lung cancer</subject>
            <description type="Chief Investigator">Prof Y C Gary Lee</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cancers can spread to the lung causing fluid build-up and
                requires drainages in hospital that are painful and costly. Surgery is previously
                seen as the definitive option to stop fluid forming, but is invasive with
                complications. Indwelling pleural catheter (IPC) is a novel implanted device inside
                the chest that allows patients to drain fluid at home. AMPLE Trial-3 is the first
                multicenter randomized clinical trial to compare surgery vs IPC to provide fluid
                control and improve quality of life.</description>
            <description type="fundingAmount">$1,105,748.65</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2001751</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2001751</identifier>
            <identifier type="nhmrc">2001751</identifier>
            <name type="primary">
                <namePart>'Azithromycin before Birth'- Single dose azithromycin shortly before birth
                    to reduce infection in Aboriginal mothers and babies: a randomised controlled
                    trial.</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/006mbby82</identifier>
                <title>Menzies School of Health Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">clinical trial </subject>
            <subject type="local">aboriginal health </subject>
            <subject type="local">pregnancy </subject>
            <subject type="local">neonatal </subject>
            <subject type="local">evidence-based clinical practice</subject>
            <description type="Chief Investigator">Prof Peter Morris</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Aboriginal mothers and babies in the Northern Territory have
                high rates of infection. A single dose of azithromycin given during labour (or prior
                to caesarean section) may reduce the rates of subsequent bacterial infection. This
                pragmatic clinical trial ('Azithromycin before Birth') will assess a simple
                intervention that has the potential to substantially improve health outcomes for
                women and babies at risk of new bacterial infection after birth.</description>
            <description type="fundingAmount">$3,205,108.60</description>
            <coverage>
                <spatial type="text">NT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2001834</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2001834</identifier>
            <identifier type="nhmrc">2001834</identifier>
            <name type="primary">
                <namePart>A Scalable Insomnia Program during the Pregnancy and Postpartum Periods:
                    An Effectiveness-Implementation Hybrid Trial</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">insomnia </subject>
            <subject type="local">pregnancy </subject>
            <subject type="local">cognitive behaviour therapy </subject>
            <subject type="local">sleep </subject>
            <subject type="local">postnatal</subject>
            <description type="Chief Investigator">Dr Bei Bei</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Persistent sleep problems are common during
                pregnancy/postpartum periods and have significant consequences. Cognitive
                behavioural interventions are efficacious for improving sleep but are not currently
                available in perinatal care. This study examines the effectiveness, cost-
                effectiveness, and implementation potential of an innovative nonpharmacological
                intervention for better maternal sleep and wellbeing, with high potential for
                sustainable integration with routine perinatal care.</description>
            <description type="fundingAmount">$877,335.40</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006101</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006101</identifier>
            <identifier type="nhmrc">2006101</identifier>
            <name type="primary">
                <namePart>Prospective Ovarian Cancer Cohort to Authenticate Stratification of
                    Prognosis in Ovarian Tumours (POCCA-SPOT)</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cancer prognosis </subject>
            <subject type="local">cancer follow-up </subject>
            <subject type="local">ovarian cancer </subject>
            <subject type="local">cancer treatment </subject>
            <subject type="local">validation</subject>
            <description type="Chief Investigator">Prof Susan Ramus</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Ovarian cancer has poor survival, with less than 40% of women
                surviving 5 years. There is a wide range of survival, but very few characteristics
                that indicate which patients will do well or poorly. We have developed a tumour test
                at diagnosis, that can predict prognosis at 5 years. In newly diagnosed cases, we
                will test tumours to predict prognosis and then determine the accuracy and assess
                patient acceptability. This study will lead to clinical use of the test and improve
                treatment decisions.</description>
            <description type="fundingAmount">$993,580.25</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006403</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006403</identifier>
            <identifier type="nhmrc">2006403</identifier>
            <name type="primary">
                <namePart>INTERCEPT (Investigating Novel Therapy to target Early Relapse and Clonal
                    Evolution as Pre-emptive Therapy in AML): a multi-arm, precision-based,
                    recursive, platform trial</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">acute myeloid leukaemia (aml) </subject>
            <subject type="local">targeted therapy </subject>
            <subject type="local">myeloid leukaemia </subject>
            <subject type="local">clinical trial </subject>
            <subject type="local">drug resistance</subject>
            <description type="Chief Investigator">Prof Andrew Wei</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Acute myeloid leukemia is a rare and lethal blood cancer with
                limitless potential to evolve resistance. New technologies allow early detection of
                molecular 'fingerprints' of returning disease. We propose an international research
                team to conduct a multi-arm, precision-based platform trial aimed at increasing and
                extending the duration of patient response and survival using novel combination
                options. INTERCEPT will suppress and eradicate relapse before the patient becomes
                clinically unwell.</description>
            <description type="fundingAmount">$5,789,515.10</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006415</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006415</identifier>
            <identifier type="nhmrc">2006415</identifier>
            <name type="primary">
                <namePart>Anti-PD 1 Brain Collaboration + Radiotherapy Extension: The ABC-X
                    Study</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02jxrhq31</identifier>
                <title>Melanoma Institute Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cancer immunotherapy </subject>
            <subject type="local">melanoma </subject>
            <subject type="local">brain lesion </subject>
            <subject type="local">radiotherapy </subject>
            <subject type="local">cohort study</subject>
            <description type="Chief Investigator">Prof Georgina Long</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">The purpose of this research study is to determine whether
                administering radiotherapy to melanoma brain tumours, in combination with 2 drugs
                called nivolumab and ipilimumab(also known as Immunotherapy), will be more effective
                than treating brain tumours with immunotherapy. Patients in this trial will be
                randomly assigned to 1 of 2 treatment groups. Group 1 will receive radiotherapy to
                their melanoma brain lesion(s), combined with immunotherapy. Group 2 will receive
                immunotherapy treatment alone.</description>
            <description type="fundingAmount">$1,010,141.60</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006451</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006451</identifier>
            <identifier type="nhmrc">2006451</identifier>
            <name type="primary">
                <namePart>Preventing infections in patients with blood cancer through evidence-based
                    use of immunoglobulin or alternatives: The RATIONALISE trial</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">blood transfusion </subject>
            <subject type="local">infectious diseases </subject>
            <subject type="local">haematological malignancy </subject>
            <subject type="local">immunoglobulin (ig) </subject>
            <subject type="local">clinical trial</subject>
            <description type="Chief Investigator">Prof Erica Wood</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Patients with blood cancers, with immune deficiency from low
                antibody levels and other disease or treatment factors, are at risk of
                life-threatening infection. Immunoglobulins (Ig) made from plasma can supplement
                antibody levels. Government criteria recommend stopping Ig therapy in stable
                patients, but with no evidence for when or how to do so. RATIONALISE will provide
                this evidence, to improve patient outcomes, reduce risks and costs, and make better
                use of blood products for the community.</description>
            <description type="fundingAmount">$2,490,421.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006491</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006491</identifier>
            <identifier type="nhmrc">2006491</identifier>
            <name type="primary">
                <namePart>Whole-of-population CRISPR point-of-care testing for congenital
                    cytomegalovirus to prevent hearing and neurodevelopment disabilities through a
                    public health approach</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cytomegalovirus (cmv) infection </subject>
            <subject type="local">congenital disease </subject>
            <subject type="local">population screening </subject>
            <subject type="local">public health costs </subject>
            <subject type="local">treatment</subject>
            <description type="Chief Investigator">A/Pr Valerie Sung</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Congenital cytomegalovirus infection (cCMV) is the major
                infective cause of deafness and brain disability, both of which are potentially
                reversible with early treatment. Currently, there is no screening at birth, and cCMV
                is diagnosed too late for treatment. Our team will test and validate CRISPR, a new
                and cheap technology, on 110,000+ newborns to detect cCMV. This will revolutionise
                how cCMV is detected, make treatment more accessible and pave way to lower rates of
                deafness and cerebral palsy.</description>
            <description type="fundingAmount">$2,058,920.60</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006529</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006529</identifier>
            <identifier type="nhmrc">2006529</identifier>
            <name type="primary">
                <namePart>Trans20: A longitudinal cohort study to improve outcomes for transgender
                    children and adolescents</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">gender </subject>
            <subject type="local">paediatric </subject>
            <subject type="local">mental health </subject>
            <subject type="local">psychological distress </subject>
            <subject type="local">health services research</subject>
            <description type="Chief Investigator">A/Pr Kenneth Pang</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">1% of young people now identify as transgender or gender
                diverse (TGD), and increasing numbers are presenting for specialist gender-affirming
                clinical care. This study will prospectively evaluate the health outcomes and well
                being of a large cohort of TGD children and adolescents who received such care. By
                doing so, this research will address critical knowledge gaps in this important and
                emerging area of health care so as to maximise health outcomes and minimise harm for
                this vulnerable group.</description>
            <description type="fundingAmount">$1,566,662.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006611</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006611</identifier>
            <identifier type="nhmrc">2006611</identifier>
            <name type="primary">
                <namePart>Clinical trial to determine the effects of statins on cognition:
                    STAREE-Mind</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cognition </subject>
            <subject type="local">clinical trial </subject>
            <subject type="local">statins </subject>
            <subject type="local">primary prevention </subject>
            <subject type="local">dementia</subject>
            <description type="Chief Investigator">A/Pr Joanne Ryan</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Statins may improve brain health in older individuals but there
                is need for a large randomised trial to directly address this important question.
                This study of 10,000 community dwelling older individuals aged 70 years and over
                will provide crucial, high quality evidence on the effects of statins on cognitive
                function and dementia.</description>
            <description type="fundingAmount">$2,795,199.60</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006658</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006658</identifier>
            <identifier type="nhmrc">2006658</identifier>
            <name type="primary">
                <namePart>Food allergy in the first 15 year of life: wave 5 of the HealthNuts
                    longitudinal study</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">food allergy </subject>
            <subject type="local">anaphylaxis </subject>
            <subject type="local">asthma </subject>
            <subject type="local">lung function assessment </subject>
            <subject type="local">risk factors</subject>
            <description type="Chief Investigator">Dr Rachel Peters</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Understanding why some food allergy persists into adolescence
                is critical because adolescents are at highest risk of life-threatening allergic
                reactions. Food allergy also has lifelong impacts on children's health. HealthNuts
                is a longitudinal study of 5300 children that measured allergic diseases from
                infancy. At the age 15 follow-up, we will identify predictors of food allergy
                persistence and severity, and the consequences of infant food allergy on later
                respiratory health.</description>
            <description type="fundingAmount">$2,435,075.24</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006773</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006773</identifier>
            <identifier type="nhmrc">2006773</identifier>
            <name type="primary">
                <namePart>The effect of high SPF sunscreen application on vitamin D</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/004y8wk30</identifier>
                <title>QIMR Berghofer Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">sunscreens </subject>
            <subject type="local">skin cancer </subject>
            <subject type="local">vitamin d </subject>
            <subject type="local">clinical trial </subject>
            <subject type="local">cancer prevention</subject>
            <description type="Chief Investigator">Prof Rachel Neale</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Sunscreen prevents sunburn and skin cancer, and current
                guidelines are that it should be routinely used when the maximum UV index is
                forecast to reach at least 3. However, applying sunscreen in laboratory experiments
                reduces vitamin D production, and there is concern that regular application of high
                SPF sunscreens might increase the risk of vitamin D deficiency. We propose a
                randomised controlled trial to determine if adhering to the current guidelines
                decreases vitamin D.</description>
            <description type="fundingAmount">$1,175,123.60</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006867</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006867</identifier>
            <identifier type="nhmrc">2006867</identifier>
            <name type="primary">
                <namePart>ACTIVE STRIDES-CP: Randomised trial of Intensive Rehabilitation (Combined
                    Intensive Gait and Cycling Training) for children with moderate to severe
                    bilateral cerebral palsy</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cerebral palsy treatments </subject>
            <subject type="local">physiotherapy management </subject>
            <subject type="local">mobility </subject>
            <subject type="local">participation </subject>
            <subject type="local">randomised controlled trial (rct)</subject>
            <description type="Chief Investigator">A/Pr Leanne Sakzewski</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">In Australia, 35,000 people have cerebral palsy, and 40%
                experience moderate to severe difficulties with movement and reduced participation
                in physical activity. There are currently no effective interventions for children
                with moderate to severe CP to improve their ability to move, perform daily life
                tasks and engage in physically active leisure. We have promising data about a new
                intervention, called Active Strides-CP, which we will test in 150 children with CP
                and compare to usual care.</description>
            <description type="fundingAmount">$2,401,294.20</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006883</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006883</identifier>
            <identifier type="nhmrc">2006883</identifier>
            <name type="primary">
                <namePart>Predicting Renal, Ophthalmic and Heart Events in the Aboriginal Community:
                    The PROPHECY Diabetes Multi-Omics Cohort Study</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes mellitus) </subject>
            <subject type="local">aboriginal health </subject>
            <subject type="local">diabetic complications </subject>
            <subject type="local">genomics </subject>
            <subject type="local">population health</subject>
            <description type="Chief Investigator">Prof Alex Brown</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Diabetes is at epidemic levels in Indigenous Australians,
                impairing quality of life, and contributing to poor health. This is a result of
                rapid development of kidney, heart and eye complications. We have established a
                large long-term population study among Aboriginal communities within South Australia
                and will explore the burden, natural history and the social, psychological,
                environmental, clinical and genomic predictors of diabetes and its
                complications.</description>
            <description type="fundingAmount">$3,955,505.38</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006893</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006893</identifier>
            <identifier type="nhmrc">2006893</identifier>
            <name type="primary">
                <namePart>A randomised trial of the effects of SGLT2 inhibition versus metformin on
                    decline in renal function when used as first line therapy in type 2
                    diabetes</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">diabetes </subject>
            <subject type="local">kidney disease </subject>
            <subject type="local">clinical trial </subject>
            <subject type="local">diabetic nephropathy </subject>
            <subject type="local">blood pressure</subject>
            <description type="Chief Investigator">Prof Bruce Neal</description>
            <description type="Date Announced">2021-06-20T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Type 2 diabetes affects 5 in 100 Australians with many going on
                to develop serious heart and kidney complications. Sodium glucose co-transporter 2
                (SGLT2) inhibitors are a new type of medicine that may provide benefit when used
                early in diabetes, but that are currently only used once complications have
                developed. This study will test the value of SGLT2 inhibitor treatment for kidney
                protection in Australians with newly diagnosed type 2 diabetes.</description>
            <description type="fundingAmount">$3,815,692.70</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006514</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006514</identifier>
            <identifier type="nhmrc">2006514</identifier>
            <name type="primary">
                <namePart>A Centre for Research Excellence to Transform Outcomes of Critically Ill
                    Patients in ICU (CRE-ICU)</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">intensive care </subject>
            <subject type="local">critical care </subject>
            <subject type="local">critical illness </subject>
            <subject type="local">adult </subject>
            <subject type="local">intensive care medicine</subject>
            <description type="Chief Investigator">Prof Carol Hodgson</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Patients who are admitted to intensive care (ICU) and require
                mechanical ventilation for life support account for 63,000 ICU admissions and 8,190
                deaths each year in Australia, higher than the national road toll. CRE-ICU will
                transform outcomes for these patients by using data within registries and electronic
                medical records to perform high-impact, low cost clinical trials, generating new
                knowledge to inform national guidelines and policies and training the next
                generation of researchers.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006523</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006523</identifier>
            <identifier type="nhmrc">2006523</identifier>
            <name type="primary">
                <namePart>Centre of Research Excellence in Stillbirth</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">stillbirth </subject>
            <subject type="local">antenatal care </subject>
            <subject type="local">bereavement </subject>
            <subject type="local">implementation </subject>
            <subject type="local">prediction</subject>
            <description type="Chief Investigator">Prof Vicki Flenady</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">In Australia, over 2000 families suffer the tragedy of
                stillbirth each year. By building on our achievements of the first Stillbirth CRE
                rapidly translating new research into maternity care, we will reduce stillbirth
                rates by 20%, and reduce inequities in stillbirth rates by Australia by 2025. We
                also anticipate a reduction in adverse neonatal outcomes. When stillbirth or
                neonatal death does occur, our research aims to ensure that all women and families
                receive optimal care.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006545</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006545</identifier>
            <identifier type="nhmrc">2006545</identifier>
            <name type="primary">
                <namePart>Wiser healthcare: better value care for all Australians</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">health policy </subject>
            <subject type="local">early detection </subject>
            <subject type="local">public health impact </subject>
            <subject type="local">behavioural science </subject>
            <subject type="local">evidence-based health care</subject>
            <description type="Chief Investigator">Prof Kirsten McCaffery</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This CRE develops a new solutions-based approach to overuse of
                unnecessary, ineffective healthcare. Overuse causes harm and diverts resources from
                areas of need. We will produce new solutions to address four drivers of overuse. We
                will: build health literacy in patients, communities and health professionals;
                respond to changing screening and diagnostic technology; address financial drivers;
                and change clinical practices, to minimise harm and waste, achieving more
                sustainable healthcare for all.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006551</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006551</identifier>
            <identifier type="nhmrc">2006551</identifier>
            <name type="primary">
                <namePart>Skin Imaging and Precision Diagnosis</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">melanoma </subject>
            <subject type="local">non-melanoma skin cancer </subject>
            <subject type="local">cancer prevention </subject>
            <subject type="local">cancer screening </subject>
            <subject type="local">early detection</subject>
            <description type="Chief Investigator">Prof Monika Janda</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Skin cancers, including melanoma, present a significant health,
                social and economic burden in Australia. Despite the rising incidence of melanoma,
                the most deadly form of skin cancer, there is currently no national or
                population-based screening program available. The aim of this CRE is to identify how
                novel skin imaging technologies can be integrated into the pathway to improve early
                detection, and ultimately reduce the health and economic burden caused by melanoma
                skin cancer.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006579</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006579</identifier>
            <identifier type="nhmrc">2006579</identifier>
            <name type="primary">
                <namePart>CRE for Better Outcomes in Inflammatory Arthritis</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">data linkage </subject>
            <subject type="local">targeted therapy </subject>
            <subject type="local">outcomes research </subject>
            <subject type="local">biomarkers </subject>
            <subject type="local">health economics</subject>
            <description type="Chief Investigator">Prof Lyn March</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We aim to find the right treatment for children and adults with
                inflammatory arthritis to give the best path to symptom relief with least risk of
                side effects. We will build on our national data-base and biospecimens bank
                (A3BC-ARAD) to collect a broad range of patient-reported, biological, environmental
                and health information to unlock the answers using big-data analysis. We will build
                a resource and workforce to continue to look for cures to deliver the best outcomes
                for patients and society.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006595</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006595</identifier>
            <identifier type="nhmrc">2006595</identifier>
            <name type="primary">
                <namePart>BREATHE - mitigating airborne threats to health</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">respiratory </subject>
            <subject type="local">coronavirus </subject>
            <subject type="local">health services </subject>
            <subject type="local">epidemiology </subject>
            <subject type="local">prevention</subject>
            <description type="Chief Investigator">Prof Raina MacIntyre</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The COVID-19 pandemic has highlighted the risk of closed,
                indoor settings due to accumulation of aerosols generated from breathing, speaking,
                coughing or sneezing. Any airborne threat, whether an infectious virus or a chemical
                agent, will create a higher exposure in indoor settings. To mitigate this risk,
                using inter-disciplinary expertise, this research will improve preparedness, reduce
                health impacts of airborne threats, inform worker and occupant safety, building
                design and healthy futures.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006620</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006620</identifier>
            <identifier type="nhmrc">2006620</identifier>
            <name type="primary">
                <namePart>Healthy Food, Healthy Planet, Healthy People</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">food </subject>
            <subject type="local">nutrition </subject>
            <subject type="local">environmental health </subject>
            <subject type="local">prevention </subject>
            <subject type="local">health policy</subject>
            <description type="Chief Investigator">Prof Simone Pettigrew</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Food is the biggest issue for health on the planet. High levels
                of obesity and related illnesses such as heart disease, diabetes, and cancer
                highlight the need for consumers to have better access to meaningful nutrition
                information across more food choice contexts. The substantial contribution of the
                food system to climate change means consumers, industry, and governments need
                information about which products are better or worse for the environment. This
                Centre will provide this information.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006765</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006765</identifier>
            <identifier type="nhmrc">2006765</identifier>
            <name type="primary">
                <namePart>Vascular Contributions to Dementia (VCD-CRE) - a transformative approach
                    to reducing the burden of cognitive disorders</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">vascular dementia </subject>
            <subject type="local">cerebrovascular disorders </subject>
            <subject type="local">mild cognitive impairment </subject>
            <subject type="local">prevention </subject>
            <subject type="local">diagnosis</subject>
            <description type="Chief Investigator">Prof Perminder Sachdev</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The total contribution of vascular pathology to dementia is
                estimated to be as high as 50-70%. The Vascular Contributions to Dementia CRE brings
                together leading researchers in cerebrovascular disease and dementia to address the
                most important issues relating to the epidemiology of Vascular Dementia, its robust
                biomarkers and its treatment and prevention, so as to reduce its overall health
                burden, and meet the promise of vascular dementia as a truly 'preventable
                dementia''.</description>
            <description type="fundingAmount">$3,000,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006797</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006797</identifier>
            <identifier type="nhmrc">2006797</identifier>
            <name type="primary">
                <namePart>On TRACK (Teaching, Research And Community Knowledges) : CRE promoting
                    brain health with older Aboriginal and Torres Strait Islander
                    peoples.</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">aboriginal health </subject>
            <subject type="local">dementia </subject>
            <subject type="local">ageing population </subject>
            <subject type="local">risk factors </subject>
            <subject type="local">community preferences</subject>
            <description type="Chief Investigator">A/Pr Dina LoGiudice</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Aboriginal and Torres Strait Islander peoples experience high
                rates of dementia at younger ages of onset, having far reaching consequences for the
                person, their family and their communities. The OnTRACK (Teaching, Research and
                Community Knowledges) Centre for Research Excellence will generate knowledge about
                culturally safe approaches to optimise the well being and quality of life of
                Aboriginal and Torres Strait Islander peoples at risk of or living with
                dementia.</description>
            <description type="fundingAmount">$3,000,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006841</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006841</identifier>
            <identifier type="nhmrc">2006841</identifier>
            <name type="primary">
                <namePart>Centre for Research Excellence in Developmental and Epileptic
                    Encephalopathies</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">epilepsy </subject>
            <subject type="local">natural history </subject>
            <subject type="local">genetics </subject>
            <subject type="local">health outcomes </subject>
            <subject type="local">paediatric</subject>
            <description type="Chief Investigator">Prof Ingrid Scheffer</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We will study the clinical, genetic and psychological aspects
                of patients with the most severe group of epilepsies, the Developmental and
                Epileptic Encephalopathies (DEEs). We will define the clinical spectrum of each
                genetic DEE, improve health outcomes through understanding the natural history of
                these diseases, build an integrated model of care, produce family resources and
                assess health economic impacts. This program will ensure Australia is poised for
                emerging Precision Medicine trials.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006899</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006899</identifier>
            <identifier type="nhmrc">2006899</identifier>
            <name type="primary">
                <namePart>Centre of Research Excellence in Precision Public Health Approaches to
                    Breast Cancer Screening, Early Detection and Mortality Reduction</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">breast cancer </subject>
            <subject type="local">mammogram screening </subject>
            <subject type="local">breast cancer prevention </subject>
            <subject type="local">radiological diagnostics </subject>
            <subject type="local">general practice</subject>
            <description type="Chief Investigator">Prof John Hopper</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The ultimate aim of the CRE is to make it possible to further
                reduce mortality from breast cancer, and in a more effective way, by identifying
                women at vastly different levels of risk at younger ages, determining which
                screening modalities are likely to be more effective, and helping radiologists to
                better detect cancers. Given that digital mammography is the contemporary standard,
                and the incidence of breast cancer is increasing across the world, this CRE has
                global relevance.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006999</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006999</identifier>
            <identifier type="nhmrc">2006999</identifier>
            <name type="primary">
                <namePart>Centre of Research Excellence in the Early Prevention of Obesity in
                    Childhood -Translate (EPOCH-Translate)</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">early childhood </subject>
            <subject type="local">obesity </subject>
            <subject type="local">implementation </subject>
            <subject type="local">health economics </subject>
            <subject type="local">behavioural intervention</subject>
            <description type="Chief Investigator">Prof Louise Baur</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Overweight &amp; obesity affect 1:4 Australian children by the
                time they start school. The Centre of Research Excellence in the Early Prevention of
                Obesity in Childhood: Translate (EPOCH-translate) brings together researchers from
                across Australia and New Zealand to work out how best to prevent obesity in children
                aged 0-5 years. We will look at what works in the long-term, what is the best value
                for money, and what works for parents as well as health professionals.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007007</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007007</identifier>
            <identifier type="nhmrc">2007007</identifier>
            <name type="primary">
                <namePart>Centre of Research Excellence - REduce the burden of antimicrobial
                    reSistance through oPtimal, persONalised Dosing (RESPOND)</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">antibiotic resistance </subject>
            <subject type="local">pharmacotherapy </subject>
            <subject type="local">sepsis </subject>
            <subject type="local">critical illness </subject>
            <subject type="local">microbiology</subject>
            <description type="Chief Investigator">Prof Jason Roberts</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Each year more than 17 million people die from infectious
                diseases. Many of these deaths are due to the poor use of antimicrobial drugs and an
                increase in infections caused by antimicrobial-resistant 'superbugs'. CRE RESPOND
                will enable an optimal treatment of infection by empowering clinicians with an
                evidence-based, patient-centred approach to guide antimicrobial dosing. We will
                generate new knowledge, educate healthcare workers, and build research capacity
                through our network of collaborators</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007026</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007026</identifier>
            <identifier type="nhmrc">2007026</identifier>
            <name type="primary">
                <namePart>Centre of Research Excellence: Partnering with patients with chronic
                    kidney disease to transform care and outcomes (CRE-PACT)</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">clinical epidemiology </subject>
            <subject type="local">patient participation </subject>
            <subject type="local">patient outcomes </subject>
            <subject type="local">patient preference </subject>
            <subject type="local">kidney failure</subject>
            <description type="Chief Investigator">Prof Allison Tong</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">CRE-PACT will partner with patients to generate and translate
                new high-priority evidence to improve outcomes that are important to people living
                with chronic kidney disease (CKD). We will address the topics and questions most
                important to patients. We will build the next generation of research leaders and a
                community of research-ready patient-partners. There will be an integrated pathway
                for evidence translation and implementation at a global scale to improve
                patient-centred outcomes.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007037</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007037</identifier>
            <identifier type="nhmrc">2007037</identifier>
            <name type="primary">
                <namePart>Centre of Research Excellence in Enhanced Dementia Diagnosis
                    (CREEDD)</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">dementia </subject>
            <subject type="local">diagnosis </subject>
            <subject type="local">magnetic resonance imaging (mri) </subject>
            <subject type="local">biomarkers </subject>
            <subject type="local">cognitive assessment</subject>
            <description type="Chief Investigator">Dr Scott Ayton</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The diagnosis of dementia is often difficult, especially in its
                early stages. The current delays and uncertainties in diagnosing dementia cause
                anxiety in patients and limit treatment options. A number of new technologies have
                demonstrated their value in clinical dementia research, but have not been adopted
                into clinical practice. The Centre of Research Excellence in Enhanced Dementia
                Diagnosis will provide a pathway to implement new technologies to transform dementia
                diagnosis in Australia.</description>
            <description type="fundingAmount">$3,000,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007049</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007049</identifier>
            <identifier type="nhmrc">2007049</identifier>
            <name type="primary">
                <namePart>Centre of Research Excellence in Alcohol and Other Drug sector capacity
                    building for outcome focused, evidence based and cost effective care (CRE in AOD
                    -CB)</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">substance dependence </subject>
            <subject type="local">addiction treatment </subject>
            <subject type="local">health services research </subject>
            <subject type="local">clinical outcome </subject>
            <subject type="local">measurement</subject>
            <description type="Chief Investigator">Prof Leanne Hides</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">AOD use is the number one risk factor for the most death and
                disability combined in all age groups in Australia. This CRE's mission is to reduce
                the burden and cost of primary and complex comorbid AOD problems in Australia, by
                using MBC to increase the capacity of the AOD sector to deliver evidence based,
                efficient and cost effective care to clients.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007062</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007062</identifier>
            <identifier type="nhmrc">2007062</identifier>
            <name type="primary">
                <namePart>Centre of Research Excellence - Better Health Outcomes for Compensable
                    Injury</namePart>
            </name>
            <name type="alternative">
                <namePart>Centres of Research Excellence</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">motor vehicle accidents </subject>
            <subject type="local">injury </subject>
            <subject type="local">workers compensation </subject>
            <subject type="local">pain </subject>
            <subject type="local">legal issues</subject>
            <description type="Chief Investigator">Prof Michele Sterling</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Many people do not recover after a road traffic injury but
                develop chronic pain, disability and poor mental health. Health outcomes are worse
                for people who lodge a claim for injury compensation and/or engage a lawyer. The CRE
                will extend research and implementation beyond health services to the compensation
                and legal systems. Results will improve health outcomes advancing knowledge of
                system processes mediating recovery and implementing interventions that promote not
                hinder recovery.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008140</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008140</identifier>
            <identifier type="nhmrc">2008140</identifier>
            <name type="primary">
                <namePart>Reverse or Anatomical (replacement) for Painful Shoulder Osteoarthritis:
                    Differences between Interventions -Aus</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02czsnj07</identifier>
                <title>Deakin University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">orthopaedic </subject>
            <subject type="local">arthritis </subject>
            <subject type="local">joint replacement </subject>
            <subject type="local">surgery </subject>
            <subject type="local">randomised controlled trial (rct)</subject>
            <description type="Chief Investigator">Prof Richard Page</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Shoulder osteoarthritis is common in older adults, causing
                severe pain and making daily life difficult. Shoulder replacement is an effective
                treatment - it replaces the damaged joint with metal and plastic implants. Two types
                of shoulder replacement exist, but the best option is uncertain as they have not
                been compared in randomised trials. We will produce evidence about the benefits,
                harms and cost-effectiveness of each shoulder surgery to enable patients to receive
                the best type of surgery.</description>
            <description type="fundingAmount">$1,540,874.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006089</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006089</identifier>
            <identifier type="nhmrc">2006089</identifier>
            <name type="primary">
                <namePart>Working it Out Together! Aboriginal and Torres Strait Islander led
                    co-design for a strong and deadly health workforce</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04gsp2c11</identifier>
                <title>James Cook University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">primary care </subject>
            <subject type="local">indigenous health </subject>
            <subject type="local">rural and remote health services </subject>
            <subject type="local">rural workforce </subject>
            <subject type="local">community participation</subject>
            <description type="Chief Investigator">Prof Sarah Larkins</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">High primary health care (PHC) workforce turnover and few
                Aboriginal and Torres Strait Islander staff in rural/remote areas affects community
                trust and cultural safety. This impacts health care quality and costs. This
                Indigenous-led project sees local communities in four rural/remote areas driving new
                workforce plans with PHC services and partners. Implementation with continuous
                evaluation and adaption will increase workforce stability, trust, engagement and
                health improvements.</description>
            <description type="fundingAmount">$904,772.20</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006138</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006138</identifier>
            <identifier type="nhmrc">2006138</identifier>
            <name type="primary">
                <namePart>BALANCE: Promoting wellBeing in AdoLescent and young Adult caNCEr
                    survivors</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">adolescent health </subject>
            <subject type="local">cancer therapy </subject>
            <subject type="local">quality of life </subject>
            <subject type="local">behavioural intervention </subject>
            <subject type="local">wellbeing</subject>
            <description type="Chief Investigator">Prof Alexandra McCarthy</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Almost 5000 adolescents and young adults (AYAs) in Australia
                were diagnosed with cancer in the last 5 years, and many will survive well into
                adulthood. Survival does not mean AYAs return to their former state of health. They
                need support to manage the detrimental effects of their cancer experience - support
                that is scarce in this country. This project tests a lifestyle program to address
                this issue. We aim to ensure young people who survive cancer have the same quality
                of life as their peers.</description>
            <description type="fundingAmount">$1,250,178.35</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006240</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006240</identifier>
            <identifier type="nhmrc">2006240</identifier>
            <name type="primary">
                <namePart>Developing a model of Preventative Healthcare for People with Intellectual
                    Disability</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">intellectual disability </subject>
            <subject type="local">preventive health </subject>
            <subject type="local">population health </subject>
            <subject type="local">health promotion </subject>
            <subject type="local">health policy</subject>
            <description type="Chief Investigator">Prof Julian Trollor</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">People with intellectual disability face stark health
                inequalities, die prematurely from potentially avoidable causes and experience poor
                access to preventative health care. Access to preventative health care is one of the
                key pillars of Australia's long-term national health plan. This project will find
                out why there are gaps in preventative health care for people with intellectual
                disability, determine how these gaps affect people and develop a new model of health
                care.</description>
            <description type="fundingAmount">$1,244,755.50</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006282</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006282</identifier>
            <identifier type="nhmrc">2006282</identifier>
            <name type="primary">
                <namePart>Enhancing hepatitis C testing and treatment among people who inject drugs
                    in drug treatment settings: the ETHOS III Study</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">liver disease </subject>
            <subject type="local">hepatitis c infection </subject>
            <subject type="local">injecting drug use </subject>
            <subject type="local">treatment strategies </subject>
            <subject type="local">health policy</subject>
            <description type="Chief Investigator">Prof Jason Grebely</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Progress towards hepatitis C elimination has been slowed. Given
                that most people with hepatitis C have a history of injecting drug use, reducing
                hepatitis C burden requires scale-up of enhanced testing and treatment for people
                who inject drugs. This Partnership project will evaluate an intervention to enhance
                hepatitis C testing and treatment in drug treatment clinics and develop a
                translational framework to scale-up hepatitis C care in this setting
                nationally.</description>
            <description type="fundingAmount">$1,349,603.80</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006306</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006306</identifier>
            <identifier type="nhmrc">2006306</identifier>
            <name type="primary">
                <namePart>Be Healthy: Implementing culturally secure programs for obesity and
                    chronic disease prevention with remote Aboriginal communities and
                    families</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">chronic illness prevention </subject>
            <subject type="local">overweight/obesity </subject>
            <subject type="local">aboriginal health </subject>
            <subject type="local">community development </subject>
            <subject type="local">program evaluation</subject>
            <description type="Chief Investigator">A/Pr Julia Marley</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Environments cultivated in recent decades encouraging physical
                inactivity and poor diet have disproportionately affected Aboriginal people.
                Appropriate lifestyle modification programs substantially improves outcomes. We have
                co-designed, piloted and refined the 'Be Healthy' program with Derby Aboriginal
                people. This project aims to show how this program can be scaled up and transferred
                to other Aboriginal communities, leading to reduced rates of obesity, and improved
                health and quality of life.</description>
            <description type="fundingAmount">$1,499,972.00</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006448</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006448</identifier>
            <identifier type="nhmrc">2006448</identifier>
            <name type="primary">
                <namePart>Implementation research to guide the elimination of HIV transmission in
                    NSW</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">human immunodeficiency virus (hiv) </subject>
            <subject type="local">prevention </subject>
            <subject type="local">implementation </subject>
            <subject type="local">prophylaxis </subject>
            <subject type="local">sexually-transmitted infections (sti)</subject>
            <description type="Chief Investigator">Prof Andrew Grulich</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The implementation of new biomedical forms of HIV prevention
                since 2015 has been accompanied by a 40% reduction in HIV diagnoses in gay and
                bisexual men in New South Wales (NSW). Reductions in HIV have been much smaller in
                the overseas-born, the young, and in those living outside of inner Sydney. We
                propose a 5-year program of implementation research, integrated with the NSW HIV
                Strategy 2021-25, which will see NSW become the first jurisdiction globally to
                virtually eliminate HIV.</description>
            <description type="fundingAmount">$1,499,408.50</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006486</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006486</identifier>
            <identifier type="nhmrc">2006486</identifier>
            <name type="primary">
                <namePart>A digital sexual health hub: Co-design, development and evaluation of an
                    online sexual health clinic</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">sexually-transmitted infections (sti) </subject>
            <subject type="local">sexual health </subject>
            <subject type="local">primary care </subject>
            <subject type="local">health services research </subject>
            <subject type="local">information systems/decision support systems</subject>
            <description type="Chief Investigator">Prof Jane Hocking</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Sexually transmitted infection rates have increased
                dramatically in recent years in Australia, with major health consequences -
                congenital syphilis is killing babies, chlamydia in females is causing pelvic
                inflammatory disease, increasing the risk of infertility, and drug-resistant
                gonorrhoea is an urgent global threat. Our specialist sexual health services are at
                capacity. We will develop an innovative online sexual health hub providing online
                testing and treatment for STIs and HIV.</description>
            <description type="fundingAmount">$1,424,364.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006528</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006528</identifier>
            <identifier type="nhmrc">2006528</identifier>
            <name type="primary">
                <namePart>Prostate Cancer Survivorship Essentials for Men with Prostate Cancer on
                    Androgen Deprivation Therapy: Transforming Care to Improve Outcomes</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04sjbnx57</identifier>
                <title>University of Southern Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">prostate cancer </subject>
            <subject type="local">survivorship </subject>
            <subject type="local">health psychology </subject>
            <subject type="local">quality of life </subject>
            <subject type="local">health care delivery</subject>
            <description type="Chief Investigator">Prof Jeffrey Dunn</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Up to half of all men diagnosed with prostate cancer will
                undergo androgen deprivation therapy (ADT) as part of their treatment at some point.
                Although ADT is effective in treating prostate cancer, many men will experience
                considerable side effects that negatively impact their quality of life. This
                research study will identify if a nurse-led survivorship care intervention,
                delivered by phone or video-call, improves the quality of life for men with prostate
                cancer who are receiving ADT.</description>
            <description type="fundingAmount">$1,133,942.05</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006628</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006628</identifier>
            <identifier type="nhmrc">2006628</identifier>
            <name type="primary">
                <namePart>Improving outcomes for hip osteoarthritis: program evaluation of
                    HipHealth, an evidence-based telehealth exercise and weight loss
                    program</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">osteoarthritis </subject>
            <subject type="local">exercise </subject>
            <subject type="local">rehabilitation </subject>
            <subject type="local">allied health </subject>
            <subject type="local">telemedicine</subject>
            <description type="Chief Investigator">Prof Kim Bennell</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Hip osteoarthritis is a common problem leading to chronic pain
                and disability and high rates of joint replacement surgery. This project aims to
                improve the health and well-being of Australians with hip osteoarthritis (OA) by
                implementing and evaluating an education, exercise and weight loss program
                (HipHealth) delivered remotely by physiotherapists and dietitians. The program will
                be tested in the private health insurance setting with view to future scale-up in
                this and other settings.</description>
            <description type="fundingAmount">$1,005,359.15</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006751</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006751</identifier>
            <identifier type="nhmrc">2006751</identifier>
            <name type="primary">
                <namePart>Talk stroke: Developing Australia's first National tele stroke framework
                    and communications platform</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">stroke </subject>
            <subject type="local">brain imaging </subject>
            <subject type="local">thrombolysis treatment </subject>
            <subject type="local">regional health </subject>
            <subject type="local">policy development</subject>
            <description type="Chief Investigator">Prof Mark Parsons</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Patients with a stroke in the regional areas are twice as
                likely to suffer significant disability compared to patients living in inner city
                regions. We propose to develop technology to close this gap, and guide its
                implementation with a national tele stroke policy framework. The technology we
                develop with our partner organisations will facilitate tele medicine to close the
                gaps in critical patient care.</description>
            <description type="fundingAmount">$1,164,847.40</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006755</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006755</identifier>
            <identifier type="nhmrc">2006755</identifier>
            <name type="primary">
                <namePart>Establishing a digital health foundation for outcomes-based diagnostic
                    excellence, safety and value</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">health informatics </subject>
            <subject type="local">health services research </subject>
            <subject type="local">quality of care </subject>
            <subject type="local">information systems/decision support systems </subject>
            <subject type="local">patient safety</subject>
            <description type="Chief Investigator">Prof Andrew Georgiou</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Our partnership proposal will lead to the development of a
                digital infrastructure (involving big data resources and sophisticated decision
                support systems) as a foundation for outcomes-based research, optimised clinical
                care processes and translation into policy and practice. The partnership will
                encompass key research areas involving the quality, safety and value of care in
                musculoskeletal care, infectious diseases, diabetes care and emergency/intensive
                care.</description>
            <description type="fundingAmount">$1,027,500.90</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006950</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006950</identifier>
            <identifier type="nhmrc">2006950</identifier>
            <name type="primary">
                <namePart>Improving physical activity and screen time in Outside School Hours Care
                    through evidence-based guidelines: an effectiveness-implementation hybrid
                    trial</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01p93h210</identifier>
                <title>University of South Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">health services research </subject>
            <subject type="local">community child health </subject>
            <subject type="local">community intervention study </subject>
            <subject type="local">child health </subject>
            <subject type="local">school health services</subject>
            <description type="Chief Investigator">A/Pr Carol Maher</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This study aims to lift the standards of physical activity and
                screen time offerings in Out of School Hours Care services throughout Australia, by
                implementing and evaluating newly developed Australian OSHC physical activity and
                screen time guidelines. The guidelines will be evaluated in a rigorous trial in OSHC
                services in SA, NSW and WA, prior to national release and evaluation
                Australia-wide.</description>
            <description type="fundingAmount">$1,398,569.90</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006957</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006957</identifier>
            <identifier type="nhmrc">2006957</identifier>
            <name type="primary">
                <namePart>A National Aged Care Medication Roundtable - Translating aged care data
                    into action to improve quality of care through collaboration and
                    co-design</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">medications </subject>
            <subject type="local">health informatics </subject>
            <subject type="local">electronic health information </subject>
            <subject type="local">patient safety </subject>
            <subject type="local">aged care</subject>
            <description type="Chief Investigator">Prof Johanna Westbrook</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Older Australians with the most complex health needs live in
                residential care. Greater than 80% of residents are on five or more medications
                daily, and 40% are taking 10 or more. Poor medication management is the greatest
                source of complaint to the Aged Care Quality &amp; Safety Commission. This project
                will provide timely information to a group of providers and consumers about the
                medicines residents receive, identify problem areas and trial innovative
                interventions to address these issues.</description>
            <description type="fundingAmount">$1,444,499.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006969</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006969</identifier>
            <identifier type="nhmrc">2006969</identifier>
            <name type="primary">
                <namePart>Control of neglected tropical diseases in the Pacific: integration of
                    programs to increase their impact</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">helminth infection </subject>
            <subject type="local">scabies </subject>
            <subject type="local">infectious diseases </subject>
            <subject type="local">tropical disease </subject>
            <subject type="local">population health</subject>
            <description type="Chief Investigator">A/Pr Susana Nery</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Our goal is to improve programs to control neglected tropical
                diseases, diseases of poverty common in Australia's neighbours: Papua New Guinea,
                Solomon Islands and Vanuatu. Our partners are supporting the Ministries of Health in
                these countries to implement integrated programs to better control these diseases.
                Our multidisciplinary research will use improved diagnostics, spatial mapping,
                health systems, social science and health economics to evaluate this integrated
                approach to disease control.</description>
            <description type="fundingAmount">$1,499,801.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006970</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006970</identifier>
            <identifier type="nhmrc">2006970</identifier>
            <name type="primary">
                <namePart>Implementation of Negative Pressure for Acute Paediatric Burns</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03pnv4752</identifier>
                <title>Queensland University of Technology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">burn injury </subject>
            <subject type="local">implementation </subject>
            <subject type="local">traumatic injury </subject>
            <subject type="local">child </subject>
            <subject type="local">multicentre</subject>
            <description type="Chief Investigator">Dr Bronwyn Griffin</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Over 4000 children present to our burns services every year.
                Contemporary burn care aims to speed up a patients time to healing which directly
                avoids the child's risk of developing a scar. We know that applying negative
                pressure wound therapy (NPWT) to a child's burn within 72 hours post injury will
                improve a child's time to healing, decreasing the risk of scarring &amp; cost of
                care. Co-developing a NPWT Pathway and implementation strategies will improve
                outcomes for childhood burns nationally.</description>
            <description type="fundingAmount">$1,410,475.76</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006987</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006987</identifier>
            <identifier type="nhmrc">2006987</identifier>
            <name type="primary">
                <namePart>Integration and expansion of a sentinel surveillance system to improve
                    infectious disease outcomes for Indigenous Australians; the ATLAS
                    network</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">aboriginal health </subject>
            <subject type="local">sexual health </subject>
            <subject type="local">vaccine-preventable diseases </subject>
            <subject type="local">blood-borne communicable diseases </subject>
            <subject type="local">population health</subject>
            <description type="Chief Investigator">Prof James Ward</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Infectious diseases remain a significant health issue for
                Indigenous Australians. Our proposal is to extend a sentinel surveillance network
                operating in 32 Aboriginal primary care services, with a focus on sexually
                transmissible infections and blood borne virsuses. By expanding, we will increase
                the number of sites, and add vaccine preventable diseases to the network. In doing
                this, we move from a surveillance system to a research network that can inform
                health service strategies and practice.</description>
            <description type="fundingAmount">$1,137,218.90</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006061</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006061</identifier>
            <identifier type="nhmrc">2006061</identifier>
            <name type="primary">
                <namePart>A randomised trial of a Carer End of Life Planning Intervention (CELPI) in
                    people dying with dementia</namePart>
            </name>
            <name type="alternative">
                <namePart>Targeted Call for Research</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">dementia </subject>
            <subject type="local">palliative care </subject>
            <subject type="local">caregiver burden </subject>
            <subject type="local">emergency medicine </subject>
            <subject type="local">health economics</subject>
            <description type="Chief Investigator">A/Pr Glenn Arendts</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Dementia is the second highest cause of death in Australia.
                Although palliative care helps individuals avoid suffering and futile interventions
                at the end of life, only 6% of people that die of dementia receive such care. Many
                older people with dementia attend an ED in their final year of life. In CELPI we
                will trial using that opportunity of an ED visit as the trigger to implement a triad
                of carer education, access to palliative care and a formal planning process for
                participants.</description>
            <description type="fundingAmount">$1,486,231.50</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006121</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006121</identifier>
            <identifier type="nhmrc">2006121</identifier>
            <name type="primary">
                <namePart>IMPART - IMproving PAlliative care in Residential aged care using
                    Telehealth</namePart>
            </name>
            <name type="alternative">
                <namePart>Targeted Call for Research</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00200ya62</identifier>
                <title>National Ageing Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">randomised controlled trial (rct) </subject>
            <subject type="local">intervention study </subject>
            <subject type="local">nursing homes </subject>
            <subject type="local">aged care </subject>
            <subject type="local">palliative care</subject>
            <description type="Chief Investigator">Prof Wen Lim</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Sixty-thousand Australians die every year in residential aged
                care facilities but the quality of their end-of-life care varies. The IMPART program
                aims to improve palliative care in residential aged care using telehealth. We
                provide training and palliative-geriatric support to aged care staff and general
                practitioners to enable timely end-of-life discussions, improve documentation of
                care preferences, reduce avoidable hospitalisation and improve residents' quality of
                care at the end of life.</description>
            <description type="fundingAmount">$1,047,057.77</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006170</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006170</identifier>
            <identifier type="nhmrc">2006170</identifier>
            <name type="primary">
                <namePart>Improving the wellbeing of people with advanced cancer and their family
                    carers: An effectiveness-implementation trial of an Australian dyadic digital
                    health intervention (FOCUSau)</namePart>
            </name>
            <name type="alternative">
                <namePart>Targeted Call for Research</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">palliative care </subject>
            <subject type="local">end-of-life decision making </subject>
            <subject type="local">psycho-oncology </subject>
            <subject type="local">family support </subject>
            <subject type="local">patient education</subject>
            <description type="Chief Investigator">Prof Peter Hudson</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The end-of-life-wishes for many Australians are not upheld
                which has a negative impact on their quality of life as well as their family carers.
                However, patient and carer wellbeing is improved when they are supported together.
                Our research will adapt and then examine the clinical and health economic benefits
                of an internet-based strategy (developed in the USA) which aims to improve the
                quality of life of patients with advanced cancer and their family
                carers.</description>
            <description type="fundingAmount">$1,095,278.03</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2006283</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2006283</identifier>
            <identifier type="nhmrc">2006283</identifier>
            <name type="primary">
                <namePart>The Enhanced Advance care planning and life Review Longitudinal
                    Intervention (EARLI) study: Increasing proactive care planning in Australian
                    community aged care settings</namePart>
            </name>
            <name type="alternative">
                <namePart>Targeted Call for Research</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">dementia care </subject>
            <subject type="local">end-of-life decision making </subject>
            <subject type="local">home care services </subject>
            <subject type="local">palliative care </subject>
            <subject type="local">decision support</subject>
            <description type="Chief Investigator">Dr Craig Sinclair</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The Enhanced Advance care planning and life Review Longitudinal
                Intervention (EARLI) project will proactively screen older adults at high-risk of
                health decline and provide assistance to discuss and document preferences for future
                care. The intervention is implemented in the community aged care setting, through
                partnerships with home care providers. Expected benefits include increased rates of
                advance care planning, higher quality documents and improved wellbeing among older
                adults and carers.</description>
            <description type="fundingAmount">$955,827.82</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007718</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007718</identifier>
            <identifier type="nhmrc">2007718</identifier>
            <name type="primary">
                <namePart>Post-stroke depression: vulnerability, mechanisms and novel treatment
                    targets</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">neuroimaging</subject>
            <subject type="local">neuropsychological impairments</subject>
            <subject type="local">magnetic resonance imaging (MRI)</subject>
            <subject type="local">stroke outcome</subject>
            <subject type="local">secondary prevention</subject>
            <description type="Chief Investigator">Dr Lena Oestreich</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">People with post-stroke depression have poor rehabilitation
                outcomes and reduced quality of life. Acute treatment has done very little to shift
                the burden of disability, which is largely due to the fact that brain-based
                mechanisms that lead to these problems are poorly understood. This project will
                combine neuroimaging and computational neuroscience approaches to identify
                vulnerability states, reveal underlying mechanisms, and propose promising new
                treatment targets for post-stroke depression.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007722</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007722</identifier>
            <identifier type="nhmrc">2007722</identifier>
            <name type="primary">
                <namePart>Improving the health status and reducing the mortality gap for vulnerable
                    young Australians</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">public health</subject>
            <subject type="local">health inequalities</subject>
            <subject type="local">health promotion</subject>
            <subject type="local">young adults</subject>
            <subject type="local">mortality</subject>
            <description type="Chief Investigator">Dr Jessica Heerde</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Disadvantage and inequality in health status emerge during
                adolescence and young adulthood, with profound consequences for later life,
                including premature death. My program of research will for the first-time
                characterise mortality and access to health care among 700,000 young Australians who
                have sought homeless services in the past decade. This work will inform policy
                regarding vulnerable adolescents and young adults as well as guide a range of
                services including health care and housing.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007725</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007725</identifier>
            <identifier type="nhmrc">2007725</identifier>
            <name type="primary">
                <namePart>Priority driven childhood respiratory research</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">asthma</subject>
            <subject type="local">cystic fibrosis</subject>
            <subject type="local">airway epithelium</subject>
            <subject type="local">SARS-CoV-2</subject>
            <subject type="local">innate immunity</subject>
            <description type="Chief Investigator">Prof Stephen Stick</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">My research program will focus on children’s lung health. I
                will measure how tissues in the nose fight viruses. These results will help develop
                new prevention methods and vaccines. Children with cystic fibrosis (CF), a genetic
                lung disease, often have difficult-to-treat lung infections. I will use friendly
                viruses to kill antibiotic-resistant bacteria causing these infections. We will
                investigate whether wearable devices can detect health changes so children with CF
                can receive treatment early.</description>
            <description type="fundingAmount">$1,899,839.13</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007726</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007726</identifier>
            <identifier type="nhmrc">2007726</identifier>
            <name type="primary">
                <namePart>Applied research to tackle the Australian poisoning epidemic</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">poisoning</subject>
            <subject type="local">pharmacoepidemiology</subject>
            <subject type="local">suicide prevention</subject>
            <subject type="local">toxicology</subject>
            <subject type="local">substance misuse</subject>
            <description type="Chief Investigator">Prof Nicholas Buckley</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Poisoning is a large and increasing cause of deaths and
                hospitalisation in Australia. The research will use poisons centre calls, medical
                and coronial records, and prescribing data to identify agents with higher toxicity.
                Restrictions or tighter regulation could reduce the risks from such poisoning. This
                research will also evaluate the effect of recent policies, clinical guidelines, and
                service enhancements that aim to reduce the harms from poisoning.</description>
            <description type="fundingAmount">$1,500,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007731</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007731</identifier>
            <identifier type="nhmrc">2007731</identifier>
            <name type="primary">
                <namePart>Prevention is better than cure: Development and implementation of an
                    effective multi-strategy approach for youth suicide prevention</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">suicide prevention</subject>
            <subject type="local">mental health</subject>
            <subject type="local">young adults</subject>
            <subject type="local">child health</subject>
            <subject type="local">implementation</subject>
            <description type="Chief Investigator">Dr Michelle Torok</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Suicide is a leading cause of death in young Australians, and
                young people are consistently identified as a group requiring specific attention in
                suicide prevention policy. By leading an innovative program of research which
                focuses on solving how to sustainably embed proven effective prevention practices
                into key settings of young people, at scale, this Fellowship will enable me to
                address grand challenges in youth suicide prevention both in Australia and
                internationally.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007732</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007732</identifier>
            <identifier type="nhmrc">2007732</identifier>
            <name type="primary">
                <namePart>Engineering T cells to promote peripheral immunity</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">immunology</subject>
            <subject type="local">molecular immunology</subject>
            <subject type="local">CD8 T cells</subject>
            <subject type="local">immunologic memory</subject>
            <subject type="local">T cell immunity</subject>
            <description type="Chief Investigator">Dr Raissa Fonseca</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Tissue-resident memory T cells (TRM) are key for immune
                protection against diseases. This has led to much interest in understanding how TRM
                develop, although elucidation of molecules that regulate TRM formation are still
                scarce. This project aims to identify genetic regulators of TRM in peripheral
                organs. Expected outcomes are to identify molecules shaping TRM development and
                modulate genetic regulators to enhance immune protection against infections and
                cancer.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007734</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007734</identifier>
            <identifier type="nhmrc">2007734</identifier>
            <name type="primary">
                <namePart>Generating an effective T-cell based influenza vaccine</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">influenza virus</subject>
            <subject type="local">vaccines</subject>
            <subject type="local">staphylococcus</subject>
            <subject type="local">CD8 T cells</subject>
            <subject type="local">mucosal immunity</subject>
            <description type="Chief Investigator">A/Prof Linda Wakim</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Influenza is a highly contagious, rapidly spreading respiratory
                pathogen that causes profound morbidity and mortality. Current influenza vaccines
                are suboptimal, they need to be updated and administered annually, and provide no
                protection in the event of a pandemic influenza outbreak. This research program will
                see the development of a novel universal 'one-shot’ influenza vaccine that provides
                long term protection against both seasonal and newly emerging pandemic influenza
                strains.</description>
            <description type="fundingAmount">$1,398,844.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007739</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007739</identifier>
            <identifier type="nhmrc">2007739</identifier>
            <name type="primary">
                <namePart>Control of cellular homeostasis in health and disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01p93h210</identifier>
                <title>University of South Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">caspases</subject>
            <subject type="local">mouse models</subject>
            <subject type="local">epithelial transport</subject>
            <subject type="local">ubiquitination</subject>
            <subject type="local">cell death</subject>
            <description type="Chief Investigator">Prof Sharad Kumar</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This research program will explore the roles of an essential
                cellular process called ubiquitination in influencing human health and disease.
                Abnormal ubiquitination is associated with many human ailments including cancer,
                inflammatory diseases, cardiovascular diseases and chronic kidney disease. Our
                research will uncover new mechanisms involved in these common diseases, thus
                generating new knowledge to better understand, prevent and help develop new
                therapeutic tools for their treatment.</description>
            <description type="fundingAmount">$2,927,015.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007741</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007741</identifier>
            <identifier type="nhmrc">2007741</identifier>
            <name type="primary">
                <namePart>Less pain in the back: how new approaches can improve care for low back
                    pain</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">back pain</subject>
            <subject type="local">orthopaedic surgery</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">disability</subject>
            <subject type="local">access to health care</subject>
            <description type="Chief Investigator">Prof Manuela Ferreira</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Low back pain causes more disability than any other health
                condition. Low back pain directly impacts a person’s ability to perform simple daily
                activities, such as lifting objects, bending and even working. Many treatments
                currently offered to patients with low back pain may be causing more harm than
                benefit. The project will improve access to high quality LBP care and will provide
                knowledge on the safety and efficacy of LBP treatments such as
                surgery.</description>
            <description type="fundingAmount">$2,548,555.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007747</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007747</identifier>
            <identifier type="nhmrc">2007747</identifier>
            <name type="primary">
                <namePart>Advancing Indigenous Australian oral health through clinical trials,
                    cohort studies and surveillance</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">Aboriginal</subject>
            <subject type="local">epidemiology</subject>
            <subject type="local">access to dental care</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">translation</subject>
            <description type="Chief Investigator">Prof Lisa Jamieson</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">There are gaps between what optimises Indigenous Australian
                oral health and what is experienced in everyday practice. In partnership with
                Indigenous stakeholders, this proposal will facilitate best practice oral care
                models for Indigenous Australians and result in: (1) improved Indigenous oral health
                outcomes; (2) raised standards of oral clinical care for Indigenous Australians
                through cultural competency workshops and; (3) capacity building of Indigenous oral
                health workforce.</description>
            <description type="fundingAmount">$2,598,056.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007765</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007765</identifier>
            <identifier type="nhmrc">2007765</identifier>
            <name type="primary">
                <namePart>Building a culture of safety in Australian residential aged care
                    facilities</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">culture</subject>
            <subject type="local">organisational processes</subject>
            <subject type="local">aged care</subject>
            <subject type="local">patient safety</subject>
            <subject type="local">quality improvement</subject>
            <description type="Chief Investigator">Dr Kate Churruca</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">In Australia, the aged care sector has been challenged by
                issues of quality and safety, including toxic cultures neglect and poor respect for
                residents. This research program will identify how the culture of residential aged
                care facilities affects the safety and quality of care provided to residents and put
                into action strategies to improve culture and thereby residents’
                outcomes.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007769</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007769</identifier>
            <identifier type="nhmrc">2007769</identifier>
            <name type="primary">
                <namePart>The missing genetics of rare diseases</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">medical genetics</subject>
            <subject type="local">neurogenetics</subject>
            <subject type="local">neuromuscular diseases</subject>
            <subject type="local">miscarriage</subject>
            <subject type="local">genetics</subject>
            <description type="Chief Investigator">Dr Gianina Ravenscroft</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">to find the genetic causes of rare, often severely
                debilitating, disease and recurrent miscarriage. These diseases result in a
                significant burden to the affected individuals and their families and also on
                Australia’s health care system. A genetic diagnosis provides families with answers,
                allows family planning, such that couples do not have another affected pregnancy or
                child, enables appropriate clinical management and gives researchers targets for
                development of new therapies.</description>
            <description type="fundingAmount">$1,284,836.30</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007778</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007778</identifier>
            <identifier type="nhmrc">2007778</identifier>
            <name type="primary">
                <namePart>Rapid evolution of a genome editing tool</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00jtmb277</identifier>
                <title>University of Wollongong</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">systematic evolution of ligands by exponential enrichment
                (SELEX)</subject>
            <subject type="local">fluorescence spectroscopy</subject>
            <subject type="local">phenotype-genotype correlation</subject>
            <subject type="local">biotechnology</subject>
            <subject type="local">molecular diagnostics</subject>
            <description type="Chief Investigator">Dr Lisanne Spenkelink</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">CRISPR–Cas9 is a powerful DNA targeting tool for genome editing
                and gene therapy. While the tool already shows promising results, its accuracy is
                not good enough for use in treatment of patients. I aim to develop a novel,
                high-throughput directed-evolution tool to improve the accuracy and specificity of
                Cas9 enzymes. The Cas9 with improved specificity will allow the wider and more
                reliable use of CRISPR technology in medical applications.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007800</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007800</identifier>
            <identifier type="nhmrc">2007800</identifier>
            <name type="primary">
                <namePart>Preterm birth and neurodevelopment: improving long-term
                    outcomes</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">maternal and child health</subject>
            <subject type="local">prematurity</subject>
            <subject type="local">evidence-based clinical practice</subject>
            <subject type="local">implementation</subject>
            <subject type="local">neurodevelopment</subject>
            <description type="Chief Investigator">Dr Emily Shepherd</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Globally, more than one in ten babies is born preterm (early).
                While most preterm babies survive, many face life-long health consequences,
                including impaired development. My program will focus on three important treatments
                (magnesium sulphate; omega-3 fatty acids; donor breast milk) for mothers and preterm
                babies. I will assess the effects of the treatments on preterm birth and long-term
                development of preterm babies, in order to improve and maximise their use and impact
                in Australia and beyond.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007812</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007812</identifier>
            <identifier type="nhmrc">2007812</identifier>
            <name type="primary">
                <namePart>Targeting T cell Interactions for Tailored Immunity</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">T cells</subject>
            <subject type="local">cell migration</subject>
            <subject type="local">cellular interactions</subject>
            <subject type="local">humoral immunology</subject>
            <subject type="local">infection</subject>
            <description type="Chief Investigator">Dr Joanna Groom</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Dynamic immune cell interactions determine the way our body
                responds to infection and cancer. My laboratory has developed imaging methods that
                allow us to observe and track immune cell interactions in real time. We will use
                this information to catalyse the development of precision immunotherapies that
                either eliminate chronic infection and cancer, or to prevent current and emerging
                infectious diseases.</description>
            <description type="fundingAmount">$1,948,555.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007839</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007839</identifier>
            <identifier type="nhmrc">2007839</identifier>
            <name type="primary">
                <namePart>Towards Zero Deaths from Melanoma: Innovative Clinical Trials with
                    Multi-omics Analyses</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">melanoma</subject>
            <subject type="local">immunotherapy</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">drug resistance</subject>
            <subject type="local">cancer therapy</subject>
            <description type="Chief Investigator">Prof Georgina Long</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Australia has the highest incidence of melanoma in the world.
                Survival in advanced-stage disease has risen from &lt;10% to &gt;50% at 5 yrs in a
                decade due to the unprecedented success of immunotherapy. But 30% of melanoma
                patients have had no change in survival due to drug resistance. This research
                proposal will rapidly develop novel drug therapies using innovative clinical trial
                designs, collecting unique high-value tumour, blood &amp; stool samples to
                understand the causes, and conquer drug resistance.</description>
            <description type="fundingAmount">$3,927,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007884</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007884</identifier>
            <identifier type="nhmrc">2007884</identifier>
            <name type="primary">
                <namePart>Discovery of novel inborn errors of immunity that underlie Common Variable
                    Immunodeficiency</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">immunodeficiency</subject>
            <subject type="local">adaptive immunity</subject>
            <subject type="local">cellular immunology</subject>
            <subject type="local">complex genetic disease</subject>
            <subject type="local">immunogenetics</subject>
            <description type="Chief Investigator">Dr Lauren Howson</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">My research will study the underlying causes of Common Variable
                Immunodeficiency (CVID), the most common type of inherited immunodeficiency. It is
                caused by mutations in genes that are important for normal immune function. However,
                diagnosis is complex as many different gene mutations cause CVID, and most are still
                unknown. This research will identify new gene mutations and determine how they cause
                disease. The findings will support future gene-based diagnoses and guide targeted
                therapies.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007887</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007887</identifier>
            <identifier type="nhmrc">2007887</identifier>
            <name type="primary">
                <namePart>Understanding the control of cell death and the functions of the tumour
                    suppressor p53 to develop improved therapies for cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">apoptosis</subject>
            <subject type="local">p53</subject>
            <subject type="local">cancer</subject>
            <subject type="local">novel therapeutic agents</subject>
            <subject type="local">translational research</subject>
            <description type="Chief Investigator">Prof Andreas Strasser</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Cancer is a leading cause of morbidity and mortality in
                Australia and worldwide, imposing a substantial burden on affected families and the
                health care system. I will build on my previous success of delivering a highly
                successful new anti-cancer drug (venetoclax) to market by determining the mechanisms
                that control the killing of cancer cells and the suppression of tumour development.
                My aim is to kick-start translational programs to develop new anti-cancer
                drugs.</description>
            <description type="fundingAmount">$3,927,015.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007896</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007896</identifier>
            <identifier type="nhmrc">2007896</identifier>
            <name type="primary">
                <namePart>Towards a Mechanistic Understanding of the Causes of Congenital Heart
                    Disease and Associated Extra-Cardiac Anomalies</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">embryogenesis</subject>
            <subject type="local">developmental genetics</subject>
            <subject type="local">heart development</subject>
            <subject type="local">gene-environment interaction</subject>
            <subject type="local">clinical genetics</subject>
            <description type="Chief Investigator">Prof Sally Dunwoodie</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Birth defects are common, devastating and costly. Heart defects
                are the most common type affecting about 9 per 1,000 babies. In most cases the cause
                of the birth defect is not known. This research seeks to identify the gene mutations
                and other factors, that cause birth defects and uses experimental models to
                understand why babies do not develop normally. This research will help families
                understand why birth defects occur and will help to prevent some cases in the
                future.</description>
            <description type="fundingAmount">$2,991,612.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007901</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007901</identifier>
            <identifier type="nhmrc">2007901</identifier>
            <name type="primary">
                <namePart>Innovative technologies to improve sexual and reproductive health among
                    women in high-burden, low-resource settings</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">cervical screening</subject>
            <subject type="local">cervical cancer</subject>
            <subject type="local">cervical precancer</subject>
            <subject type="local">maternal and child health</subject>
            <subject type="local">maternal infection</subject>
            <description type="Chief Investigator">Prof Andrew Vallely</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">I will evaluate novel, newly-available point-of-care
                technologies to improve sexual and reproductive health outcomes among women living
                in high-burden, low-resource settings. My vision is to improve the health of women
                and infants by reducing adverse birth outcomes due to undiagnosed and untreated
                sexually transmitted infections in pregnancy; and to prevent premature deaths due to
                cervical cancer by establishing and scaling-up robust clinical screening
                algorithms.</description>
            <description type="fundingAmount">$2,011,259.92</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007904</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007904</identifier>
            <identifier type="nhmrc">2007904</identifier>
            <name type="primary">
                <namePart>Using translational neuroscience to optimise treatment for older adults
                    with anxiety disorders</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">anxiety disorders</subject>
            <subject type="local">psychological treatment</subject>
            <subject type="local">ageing</subject>
            <subject type="local">clinical psychology</subject>
            <subject type="local">neuropsychological impairments</subject>
            <description type="Chief Investigator">Dr Carly Johnco</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The best way to treat anxiety disorders in older adults remains
                a critical question. Despite significant advances in our understanding of how we can
                most effectively reduce fears in younger adults based on experimental neuroscience
                research, this has not been extended to older adults where age-related changes in
                cognition may alter the efficacy. This research program will bridge this gap to
                examine whether treatment for late-life anxiety can be improved by targeting the
                underlying mechanisms.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007908</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007908</identifier>
            <identifier type="nhmrc">2007908</identifier>
            <name type="primary">
                <namePart>A curative approach for chronic myeloid leukaemia</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">chronic myeloid leukaemia (CML)</subject>
            <subject type="local">kinase inhibitors</subject>
            <subject type="local">genomics</subject>
            <subject type="local">novel therapeutic agents</subject>
            <subject type="local">molecular oncology</subject>
            <description type="Chief Investigator">Prof Timothy Hughes</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Patients with chronic myeloid leukaemia (CML) still have
                adverse outcomes in 2021 with the majority requiring ongoing toxic therapy to
                control their disease. My program will focus on improving outcomes by determining
                the key genetic events driving drug resistance and disease progression, further
                developing the new, highly targeted drug asciminib which promises to revolutionise
                CML therapy, and remove the current barriers to treatment free remission, the
                ultimate goal of CML therapy today.</description>
            <description type="fundingAmount">$2,241,612.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007912</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007912</identifier>
            <identifier type="nhmrc">2007912</identifier>
            <name type="primary">
                <namePart>Precise medication use in people with Alzheimer's disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">drug delivery</subject>
            <subject type="local">dose optimisation</subject>
            <subject type="local">pharmacokinetics</subject>
            <subject type="local">Alzheimer disease</subject>
            <subject type="local">aged health</subject>
            <description type="Chief Investigator">Dr YIJUN PAN</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">New evidence suggests that Alzheimer’s disease (AD) not only
                affects the brain, but also impacts on how our body handles medicines. That is to
                say, if one has AD, he/she will have a much higher chance to experience undesirable
                effects from medication(s). This project aims to develop a dose calculator
                specifically designed for people with AD, so that they can be given with the right
                dose of medication for better treatment outcomes.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007919</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007919</identifier>
            <identifier type="nhmrc">2007919</identifier>
            <name type="primary">
                <namePart>Pandemic-proofing our future</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">SARS-CoV-2</subject>
            <subject type="local">COVID-19</subject>
            <subject type="local">angiotensin-converting enzyme (ACE)</subject>
            <subject type="local">influenza virus</subject>
            <subject type="local">immunopathology</subject>
            <description type="Chief Investigator">Dr Kirsty Short</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We urgently need to generate better diagnostics and treatments
                for the next viral pandemic. Here, I will develop novel diagnostics and therapies
                for both severe influenza virus and coronavirus infections – two viruses of
                significant pandemic potential. The aim is to bring these treatments and diagnostics
                to clinical development now, so that we will have a ready stockpile of validated
                therapeutics and diagnostics to treat infected individuals at the inevitable outset
                of the next viral pandemic.</description>
            <description type="fundingAmount">$1,370,120.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007920</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007920</identifier>
            <identifier type="nhmrc">2007920</identifier>
            <name type="primary">
                <namePart>New directions in global tuberculosis control</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">Mycobacterium tuberculosis</subject>
            <subject type="local">tuberculosis</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">multidrug resistance</subject>
            <subject type="local">screening</subject>
            <description type="Chief Investigator">Prof Gregory Fox</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Tuberculosis (TB) is the greatest infectious killer in history,
                and still affects 10 million people each year. One third of cases are never
                diagnosed, and few of the 2 billion people with dormant infection ever receive
                treatment. This research programme addresses the major gaps in prevention, detection
                and treatment of TB. A series of trials will help to reduce the spread of infection
                and improve treatment outcomes globally and in Australia. Findings will underpin new
                global TB control policies.</description>
            <description type="fundingAmount">$3,149,133.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007929</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007929</identifier>
            <identifier type="nhmrc">2007929</identifier>
            <name type="primary">
                <namePart>Harnessing immunity for optimal SARS-CoV-2 and influenza
                    vaccines</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">SARS-CoV-2</subject>
            <subject type="local">influenza virus</subject>
            <subject type="local">vaccine</subject>
            <subject type="local">T cells</subject>
            <subject type="local">antibody</subject>
            <description type="Chief Investigator">Dr Sophie Valkenburg</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Vaccines are our most important public health measure to combat
                infection, however the optimal vaccine format and dosing, or duration of immunity
                towards influenza virus and SARS-CoV-2 is poorly understood. We need to pre-arm our
                immune system against antigenic drift and future outbreak strains. This proposal
                will determine the protective potential of broadly-reactive immune responses by
                current vaccines, recovered patients, and experimental vaccines for influenza
                viruses and SARS-CoV-2.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007944</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007944</identifier>
            <identifier type="nhmrc">2007944</identifier>
            <name type="primary">
                <namePart>Harnessing T follicular regulatory cell products and knowledge from
                    monogenic models to improve treatment for autoimmune disorders</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">autoimmunity</subject>
            <subject type="local">T cells</subject>
            <subject type="local">B cells</subject>
            <subject type="local">regulatory T cells</subject>
            <subject type="local">lupus</subject>
            <description type="Chief Investigator">Prof Carola Vinuesa</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">B cells of our immune system that have the potential to destroy
                our own tissues are normally kept in check by quality controls. If these controls
                fail, rogue B cells produce harmful antibodies that cause autoimmune diseases like
                lupus and allergies. We have discovered that a protein previously only known to
                function in the brain called “neuritin” keeps B cells in check. Understanding how
                neuritin acts, may uncover a completely novel and non-toxic treatment for autoimmune
                diseases and allergies.</description>
            <description type="fundingAmount">$3,927,015.00</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007946</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007946</identifier>
            <identifier type="nhmrc">2007946</identifier>
            <name type="primary">
                <namePart>Modernising cardiac rehabilitation and secondary prevention of heart
                    disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">allied health</subject>
            <subject type="local">cardiovascular disease prevention</subject>
            <subject type="local">health services research</subject>
            <subject type="local">prevention</subject>
            <subject type="local">physiotherapy</subject>
            <description type="Chief Investigator">Prof Julie Redfern</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Heart disease causes nearly 20% of deaths around the world.
                Unfortunately, the ongoing care people receive after they leave hospital has not
                kept up with medical advances. To fix this, I will lead a team of researchers and
                clinicians who will unite and join with people with heart disease to change care so
                it becomes more effective and efficient. I will set up and test tracking and
                monitoring systems, develop new ways to reach and support more people and improve
                clinician and researcher training.</description>
            <description type="fundingAmount">$2,872,570.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007957</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007957</identifier>
            <identifier type="nhmrc">2007957</identifier>
            <name type="primary">
                <namePart>Improving maternal metabolic health prior to pregnancy to prevent
                    metabolic disease in the offspring</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">obesity</subject>
            <subject type="local">pregnancy</subject>
            <subject type="local">pregnancy outcome</subject>
            <subject type="local">fetal programming</subject>
            <subject type="local">metabolic disease</subject>
            <description type="Chief Investigator">Dr Sarah Price</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The incidence of obesity in Australia is increasing most
                rapidly in young women of reproductive age. Currently around 1 in 5 Australian women
                enter pregnancy with obesity. This places both mother and baby at serious risk of
                complications during the pregnancy. It leaves the baby prone to metabolic diseases,
                such as obesity, which may present even before school-age. My program of research
                aims to prevent metabolic disease in children by addressing the health of women
                before and during pregnancy.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007970</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007970</identifier>
            <identifier type="nhmrc">2007970</identifier>
            <name type="primary">
                <namePart>Implementing and scaling an evidence-informed model for hip fracture
                    management: harnessing implementation science for complex adaptive healthcare
                    systems</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">implementation</subject>
            <subject type="local">translational research</subject>
            <subject type="local">quality improvement</subject>
            <subject type="local">evidence-based health care</subject>
            <subject type="local">hip fracture</subject>
            <description type="Chief Investigator">Dr Mitchell Sarkies</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project aims to improve the care provided in Australian
                hospitals for people with hip fractures. Approximately 50,000 Australians are
                hospitalised with hip fractures every year. Supporting health professionals to
                deliver care according to recommended guidelines will assist in reducing wait times
                for surgery, ensure more Australians with hip fractures get back on their feet after
                surgery, and help alleviate pain and suffering.</description>
            <description type="fundingAmount">$617,582.88</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007991</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007991</identifier>
            <identifier type="nhmrc">2007991</identifier>
            <name type="primary">
                <namePart>Improving translational pathways in kidney injury: from discovery to
                    clinical practice</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">kidney</subject>
            <subject type="local">ischaemia/reperfusion</subject>
            <subject type="local">kidney transplantation</subject>
            <subject type="local">cell therapy</subject>
            <subject type="local">drug delivery</subject>
            <description type="Chief Investigator">A/Prof Natasha Rogers</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Acute kidney injury is a common cause of death in hospitalized
                patients, with multiple negative long-term health implications in survivors. It
                greatly increases the cost of healthcare. No effective treatments exist. New targets
                for pharmaceutical intervention are desperately needed to improve the clinical
                outcomes of patients with this devastating disease. This proposal using cutting-edge
                technology, bioinformatics, drug repurposing and molecular biology to develop
                potential treatment options.</description>
            <description type="fundingAmount">$1,156,096.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2007996</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2007996</identifier>
            <identifier type="nhmrc">2007996</identifier>
            <name type="primary">
                <namePart>Unifying epigenetics with long-read sequencing to reveal hidden mechanisms
                    of health and disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">epigenetics</subject>
            <subject type="local">DNA methylation</subject>
            <subject type="local">sequencing</subject>
            <subject type="local">chromatin</subject>
            <subject type="local">genomic imprinting</subject>
            <description type="Chief Investigator">Dr Quentin Gouil</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Superimposed on the genetic sequence, the "epigenetic state"
                dictates how genes are expressed and silenced. Disrupted epigenetics are common to
                many diseases, but we lack a thorough understanding of epigenetics even in health.
                This project will develop a new and broadly applicable epigenetic toolkit to
                investigate epigenetic phenomena in patients and mouse models, including an
                incurable muscular dystrophy. The new insights into epigenetic mechanisms will drive
                the development of treatments.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008000</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008000</identifier>
            <identifier type="nhmrc">2008000</identifier>
            <name type="primary">
                <namePart>Developing Genetic Testing Tools for Optimising Pharmacotherapy and
                    Enabling a Precision Mental Health Care</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">bipolar disorder</subject>
            <subject type="local">depression</subject>
            <subject type="local">pharmacogenomics</subject>
            <subject type="local">genetic epidemiology</subject>
            <subject type="local">antidepressants</subject>
            <description type="Chief Investigator">Dr Azmeraw Amare</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">On average, 30-60% of patients with mental illness receiving
                medication do not show adequate response to treatment. Novel tools are needed to
                augment the current ‘trial and error’ approach to treatment selection. Over the next
                five years, I will apply advanced data science techniques on internationally
                collected datasets to develop genetic testing tools for optimising the treatment of
                patients with mental illness. Better prediction of treatment outcomes will reduce
                the burden of mental illness.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008001</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008001</identifier>
            <identifier type="nhmrc">2008001</identifier>
            <name type="primary">
                <namePart>Investigating sleep biomarkers of cognitive impairment and improving
                    cognitive outcomes through targeted sleep interventions in adults at risk for
                    dementia</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">mild cognitive impairment</subject>
            <subject type="local">obstructive sleep apnoea</subject>
            <subject type="local">electroencephalogram (EEG)</subject>
            <subject type="local">memory</subject>
            <subject type="local">sleep</subject>
            <description type="Chief Investigator">Dr Angela D'Rozario</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Sleep disturbance accelerates age-related memory decline and
                increases dementia risk. Monitoring the brain during sleep to understand how sleep
                disturbance underpins memory problems and contribute to dementia risk is of critical
                importance. This work will use innovative technology to identify abnormal brain
                waves that predict memory deficits and evaluate novel treatments that could enhance
                sleep and improve memory.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008017</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008017</identifier>
            <identifier type="nhmrc">2008017</identifier>
            <name type="primary">
                <namePart>Better care for HFpEF patients through integrated basic, clinical and
                    translational research</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03rke0285</identifier>
                <title>Baker Heart and Diabetes Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">heart failure</subject>
            <subject type="local">diastolic dysfunction</subject>
            <subject type="local">pathophysiology</subject>
            <subject type="local">cardiovascular physiology</subject>
            <subject type="local">end-stage heart disease</subject>
            <description type="Chief Investigator">Prof David Kaye</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Heart failure (HF) is a very common, life-limiting
                cardiovascular condition in which patients have a poor quality of life and require
                frequent hospitalization. As the population ages, the burden of HF is increasing and
                the patterns of HF are changing; 'HFpEF', in particular, is now the commonest cause
                of HF and the are no effective treatments. My program of research will address this
                challenge by comprehensively studying the cause of HFpEF and developing effective
                treatments.</description>
            <description type="fundingAmount">$2,741,612.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008018</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008018</identifier>
            <identifier type="nhmrc">2008018</identifier>
            <name type="primary">
                <namePart>Transformation of the implant paradigm in breast rehabilitation</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03pnv4752</identifier>
                <title>Queensland University of Technology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">tissue engineering</subject>
            <subject type="local">biomaterials</subject>
            <subject type="local">biomedical engineering</subject>
            <subject type="local">bacterial biofilm</subject>
            <subject type="local">antibiotic therapy</subject>
            <description type="Chief Investigator">Prof Dietmar W. Hutmacher</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Breast reconstruction via silicone implants require in 10-25%
                of cancer patients 5-10years post-surgery implant removal and/or additional surgery.
                Scaffold guided breast tissue engineering rooted in convergence of 3D printing,
                reconstructive surgery, drug delivery, &amp; liposuction processed adipose tissue
                grafts redefines rehabilitation for the breast cancer patient by providing a
                holistic therapy that addresses limitations realized with all other contemporary
                reconstructive surgery procedures.</description>
            <description type="fundingAmount">$1,500,000.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008019</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008019</identifier>
            <identifier type="nhmrc">2008019</identifier>
            <name type="primary">
                <namePart>Identifying and addressing preventable causes of asthma over the
                    lifespan</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">asthma</subject>
            <subject type="local">aetiology</subject>
            <subject type="local">prospective cohort study</subject>
            <subject type="local">phenotype</subject>
            <subject type="local">randomised controlled trial (RCT)</subject>
            <description type="Chief Investigator">A/Prof Caroline Lodge</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Asthma is the most common chronic non-communicable disease in
                children affecting more than 300 million children and adults worldwide. Little is
                known about what causes asthma so there are few preventive measures and resources
                are aimed at treating established disease. I aim to discover potential causes of
                asthma by investigating specific types of asthma (phenotypes) and to translate
                findings clinical practice and public health guidelines.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008020</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008020</identifier>
            <identifier type="nhmrc">2008020</identifier>
            <name type="primary">
                <namePart>Maximising quality of life in frontotemporal dementia</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">frontotemporal dementia</subject>
            <subject type="local">early diagnosis</subject>
            <subject type="local">early intervention</subject>
            <subject type="local">social cognition</subject>
            <subject type="local">brain imaging</subject>
            <description type="Chief Investigator">Prof Olivier Piguet</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">An early diagnosis is essential for the appropriate management
                of care of individuals with dementia. This is often missed in frontotemporal
                dementia, because of the variable symptoms and confusion with psychiatric disorders.
                Over the next 5 years, the objectives of this research program are to improve
                diagnosis and understanding of disease progression in frontotemporal dementia, and
                develop relevant therapeutic interventions that will maximise the quality of life of
                patients and their families.</description>
            <description type="fundingAmount">$2,072,570.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008024</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008024</identifier>
            <identifier type="nhmrc">2008024</identifier>
            <name type="primary">
                <namePart>Phage Therapy - a novel solution for difficult-to-treat infections in
                    children</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">bacteriophage</subject>
            <subject type="local">cystic fibrosis</subject>
            <subject type="local">Pseudomonas aeruginosa</subject>
            <subject type="local">Staphylococcus aureus</subject>
            <subject type="local">mycobacterial infection</subject>
            <description type="Chief Investigator">Dr Ameneh Khatami</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Phages are viruses that kill bacteria and offer a novel
                solution to treat infections, including antibiotic-resistant ones. This research
                aims to develop phage therapy as a treatment option for difficult-to-treat
                infections in children. It will combine the latest advances in bacterial genomics,
                rapid phage-bacteria matching and clinical trial methods to assess the value of
                phage therapy to treat serious infections in children with cystic fibrosis and other
                chronic debilitating infections.</description>
            <description type="fundingAmount">$570,592.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008064</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008064</identifier>
            <identifier type="nhmrc">2008064</identifier>
            <name type="primary">
                <namePart>Improving dementia outcomes with new targets, trials and national
                    standards</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">dementia</subject>
            <subject type="local">dementia-related decline in memory</subject>
            <subject type="local">sleep</subject>
            <subject type="local">health care delivery</subject>
            <subject type="local">mild cognitive impairment</subject>
            <description type="Chief Investigator">Prof Sharon Naismith</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">While there is no cure for dementia, we know that almost half
                the risk for dementia is due to factors that can be tackled from midlife. My work
                aims to a) improve understanding of how new emerging risk factors, namely sleep
                disturbance contribute to dementia onset and progression b) generate robust evidence
                for new treatments targeting modifiable risks and c) change practices in our health
                services to develop national standards, timely diagnoses and provision of
                appropriate treatments and care.</description>
            <description type="fundingAmount">$2,160,070.01</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008066</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008066</identifier>
            <identifier type="nhmrc">2008066</identifier>
            <name type="primary">
                <namePart>Molecular innovations for imaging microglial contributions to brain
                    disorders</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">medicinal chemistry</subject>
            <subject type="local">drug discovery</subject>
            <subject type="local">drug design</subject>
            <subject type="local">drug development</subject>
            <subject type="local">positron emission tomography (PET)</subject>
            <description type="Chief Investigator">Dr Jonathan Danon</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Microglia are the main defender cells in our brains. When
                injury or disease strikes, they rush to the affected area and perform a host of
                critical jobs to repair the damage caused, although the fine details of how they do
                this are unknown. I plan to develop molecules that can 1) track microglia when
                carrying out specific jobs and 2) be detected using a PET scanner to unravel some of
                these mysteries. This research could lead to better diagnostics and effective
                treatments for Alzheimer’s disease.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008071</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008071</identifier>
            <identifier type="nhmrc">2008071</identifier>
            <name type="primary">
                <namePart>Implementing point-of-care tools and precision medicine approaches for
                    antibiotic allergy to improve prescribing and medication safety in health
                    services</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">health services research</subject>
            <subject type="local">allergy testing</subject>
            <subject type="local">antimicrobial therapy</subject>
            <subject type="local">antimicrobial resistance</subject>
            <subject type="local">adverse drug reactions</subject>
            <description type="Chief Investigator">A/Prof Jason Trubiano</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Antibiotic allergies impact 1 in 4 hospitalised patients and
                range from low-risk allergies which can be removed by a test dose (e.g., childhood
                penicillin allergy) to high-risk allergies associated with 25% mortality (e.g.,
                Stevens-Johnson Syndrome). This program will translate piloted allergy tools into
                easy-to-use bedside tests, that are able to prevent, diagnose and remove antibiotic
                allergies to improve safe and appropriate antibiotic prescribing.</description>
            <description type="fundingAmount">$1,212,069.75</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008073</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008073</identifier>
            <identifier type="nhmrc">2008073</identifier>
            <name type="primary">
                <namePart>Reducing self-harm, suicide and early mortality in marginalised young
                    people.</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">suicide prevention</subject>
            <subject type="local">mental health</subject>
            <subject type="local">adolescent health</subject>
            <subject type="local">prison population</subject>
            <subject type="local">epidemiology</subject>
            <description type="Chief Investigator">A/Prof Rohan Borschmann</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Rates of mental disorders, self-harm, and suicide are all
                increasing, yet not enough is currently known to develop effective prevention
                strategies. My research will generate evidence on which we can base decisions
                regarding the best treatment options and the young people who will most benefit from
                them, including vulnerable populations at increased risk – such as young people in
                contact with the criminal justice system and those presenting to emergency
                departments following self-harm.</description>
            <description type="fundingAmount">$1,420,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008079</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008079</identifier>
            <identifier type="nhmrc">2008079</identifier>
            <name type="primary">
                <namePart>Improving the Impact and Efficiency of Perioperative Clinical
                    Trials</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">anaesthesia</subject>
            <subject type="local">abdominal surgery</subject>
            <subject type="local">cardiac surgery</subject>
            <subject type="local">clinical outcome</subject>
            <subject type="local">biostatistics</subject>
            <description type="Chief Investigator">Prof Paul Myles</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">More than 2 million Australians undergo surgery each year. A
                high proportion are elderly and many have chronic medical conditions that increase
                the risk of serious complications, ongoing disability, and death. My research aims
                to improve the design and usefulness of large clinical trials in perioperative
                medicine and surgery. Simpler designs that allow faster recruitment and completion
                at much lower cost, and better value because the trial outcomes are focussed on what
                matters to the patient.</description>
            <description type="fundingAmount">$3,241,612.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008090</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008090</identifier>
            <identifier type="nhmrc">2008090</identifier>
            <name type="primary">
                <namePart>Circadian control of innate immunity: strategies for treatment of chronic
                    diseases</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">innate immunity</subject>
            <subject type="local">chronic inflammatory disease</subject>
            <subject type="local">circadian rhythms</subject>
            <subject type="local">chronic inflammation</subject>
            <subject type="local">neuroimmunology</subject>
            <description type="Chief Investigator">Dr Cyril Seillet</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Living organisms adapt to light–dark rhythms using internal
                clocks. This body clock not only regulates our sleep and feeding behaviour but also
                our immune system. Disruption of the body clock can increase the risk of developing
                cancer, diabetes and asthma. We will discover how our body clock regulates our
                immune cells to allow future development of therapeutic targets to control these
                diseases.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008092</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008092</identifier>
            <identifier type="nhmrc">2008092</identifier>
            <name type="primary">
                <namePart>Serological Correlates of Protection and Pathogenesis in Infectious and
                    Autoimmune Disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">antibody</subject>
            <subject type="local">Fc receptors</subject>
            <subject type="local">serology</subject>
            <subject type="local">virology</subject>
            <subject type="local">autoantibodies</subject>
            <description type="Chief Investigator">Dr Amy Chung</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Antibodies are a vital component of the immune response
                required for protection and control of infectious diseases. Conversely, in rare
                circumstances, the body can produce antibodies that mistakenly target a person’s own
                organs, damaging the body. Applying "Systems serology," a novel technology developed
                by Dr Chung, these studies will dissect how antibodies contribute to protection or
                pathogenesis of disease, in order to develop improved antibody-based vaccines,
                therapies and diagnostic tools.</description>
            <description type="fundingAmount">$1,434,836.30</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008096</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008096</identifier>
            <identifier type="nhmrc">2008096</identifier>
            <name type="primary">
                <namePart>Harnessing cryo-electron microscopy to study the engineering of
                    microtubule networks in cancer and neurogenesis</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">structural biology</subject>
            <subject type="local">microtubules</subject>
            <subject type="local">microtubule associated protein (MAP)</subject>
            <subject type="local">electron microscopy</subject>
            <subject type="local">protein kinases</subject>
            <description type="Chief Investigator">Dr Joshua Hardy</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Just as our skeletons provide structure to our body and
                facilitate movement, our cells have internal structures which form a dynamic
                scaffold. This scaffold is composed of long filaments called microtubules.
                Microtubules are needed for healthy cell division and growth, but mutations can
                cause cells to divide too rapidly, resulting in cancer. This research program will
                focus on elucidating how the microtubule scaffold is constructed and maintained in
                healthy cells and how mutations cause disease.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008097</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008097</identifier>
            <identifier type="nhmrc">2008097</identifier>
            <name type="primary">
                <namePart>Improving cancer outcomes for Aboriginal and Torres Strait Islander women
                    diagnosed with gynaecological cancers</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/006mbby82</identifier>
                <title>Menzies School of Health Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">qualitative research</subject>
            <subject type="local">gynaecological cancers</subject>
            <subject type="local">cancer care</subject>
            <subject type="local">survivorship</subject>
            <subject type="local">equity</subject>
            <description type="Chief Investigator">Dr Tamara Butler</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Aboriginal and Torres Strait Islander women carry a higher
                burden of gynaecological cancers relative to other Australian women. Reducing this
                disparity will require mixed-methods evidence-based action across the cancer care
                continuum. Guided by an Indigenist research approach, this research program will
                improve outcomes for Aboriginal and Torres Strait Islander women diagnosed with
                gynaecological cancers through cancer prevention and improved the quality of
                treatment and survivorship care.</description>
            <description type="fundingAmount">$621,995.38</description>
            <coverage>
                <spatial type="text">NT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008099</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008099</identifier>
            <identifier type="nhmrc">2008099</identifier>
            <name type="primary">
                <namePart>Public health interventions to control sexually transmitted
                    infections</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">sexually-transmitted infections (STI)</subject>
            <subject type="local">human immunodeficiency virus (HIV)</subject>
            <subject type="local">prevention</subject>
            <subject type="local">diagnostic</subject>
            <subject type="local">epidemiology</subject>
            <description type="Chief Investigator">Prof Rebecca Guy</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Each year there are &gt;600 million new cases of sexually
                transmissible infections (STIs) which can lead to infertility, neonatal death and
                cancers. My vision for the next 5 years is to develop and trial more effective
                interventions which will move Australia and the Asia-Pacific Region substantially
                closer to the goal of controlling STIs in high-risk populations.</description>
            <description type="fundingAmount">$2,297,570.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008104</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008104</identifier>
            <identifier type="nhmrc">2008104</identifier>
            <name type="primary">
                <namePart>Leading the way in mesothelioma – a program of immunotherapy translational
                    research nested within novel clinical trials</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cancer</subject>
            <subject type="local">immunotherapy</subject>
            <subject type="local">mesothelioma</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">translational research</subject>
            <description type="Chief Investigator">Prof Anna Nowak</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Mesothelioma is a devastating cancer which is almost always
                fatal. My research is focused on clinical trials in mesothelioma and on
                understanding, from patient tumour samples and blood samples, why some people
                respond to treatment and others do not. This research will use cutting edge
                laboratory techniques to study samples from people participating in a 480-patient
                clinical trial of chemo-immunotherapy in mesothelioma, in addition to working with
                animal models of mesothelioma and immunotherapy.</description>
            <description type="fundingAmount">$1,500,000.00</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008119</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008119</identifier>
            <identifier type="nhmrc">2008119</identifier>
            <name type="primary">
                <namePart>Precision Medicine and Cancer Immunotherapy: A Multifactorial
                    Paradigm</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cancer epidemiology</subject>
            <subject type="local">cancer prognosis</subject>
            <subject type="local">cancer immunotherapy</subject>
            <subject type="local">cancer therapy</subject>
            <subject type="local">cancer research</subject>
            <description type="Chief Investigator">Dr Ashley Hopkins</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Big data from clinical trials and routine care will be pooled
                with novel laboratory information generated in collaboration with industry partners
                to identify biomarkers defining who will and will not respond to immune checkpoint
                inhibitors in advanced lung cancer. State-of-the-art machine learning and systems
                biology methodologies will unlock translational world leading insights that enable
                better treatment decisions and patient outcomes.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008129</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008129</identifier>
            <identifier type="nhmrc">2008129</identifier>
            <name type="primary">
                <namePart>Cardiovascular Disease Prevention in Cancer Survivors by Recognition and
                    Treatment of Subclinical Disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03rke0285</identifier>
                <title>Baker Heart and Diabetes Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">heart failure</subject>
            <subject type="local">atrial fibrillation</subject>
            <subject type="local">coronary artery disease</subject>
            <subject type="local">medical oncology</subject>
            <subject type="local">survivorship</subject>
            <description type="Chief Investigator">Prof Thomas Marwick</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">This research program seeks to develop a cardiovascular
                diseases (CVD) screening program and subsequent risk-based CVD prevention program to
                reduce the development of CVD in cancer survivors. This is important because
                survivors are at risk of CVD, both because of their cancer therapy and because the
                risk factors for cancer are shared with CVD. Early detection of CVD by screening
                will enable targeted prevention efforts to reduce incident CVD in cancer
                survivors.</description>
            <description type="fundingAmount">$1,944,017.22</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008157</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008157</identifier>
            <identifier type="nhmrc">2008157</identifier>
            <name type="primary">
                <namePart>A deadly duo: Defining the link between Obstructive Sleep Apnoea and
                    Cardiovascular Disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">obstructive sleep apnoea</subject>
            <subject type="local">cardiovascular risk factors</subject>
            <subject type="local">cardiovascular complications</subject>
            <subject type="local">cardiovascular health</subject>
            <subject type="local">cardiovascular disease prevention</subject>
            <description type="Chief Investigator">Prof Peter Cistulli</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Obstructive Sleep Apnoea (OSA) is a very common breathing
                disorder during sleep that causes low oxygen levels and disturbed sleep. This causes
                individuals to feel tired, increasing the risk of injury and reducing quality of
                life. OSA directly affects the heart and increases the risk of high blood pressure,
                heart attack, heart rhythm disorders, and stroke. This project aims to better
                understand this connection and to determine whether effective treatment of OSA
                improves heart health.</description>
            <description type="fundingAmount">$2,427,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008166</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008166</identifier>
            <identifier type="nhmrc">2008166</identifier>
            <name type="primary">
                <namePart>Gene2Care: a comprehensive program of research to revolutionise care for
                    children with rare genetic conditions</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">clinical genetics</subject>
            <subject type="local">health education</subject>
            <subject type="local">access to health care</subject>
            <subject type="local">child health</subject>
            <subject type="local">health inequalities</subject>
            <description type="Chief Investigator">Dr Elizabeth Palmer</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">There are at least 1.3 million Australians with a rare genetic
                disease. 1 in 2 patients with rare genetic diseases are children. 6 out of 10 deaths
                in childhood are attributed to rare disease. Gene2Care will explore how to improve
                the patient journey for children with rare genetic diseases and their families. We
                will find out how to get genetic diagnoses for more children, more quickly. We will
                show how to move from a diagnosis to the best possible lifelong support and
                care.</description>
            <description type="fundingAmount">$390,444.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008170</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008170</identifier>
            <identifier type="nhmrc">2008170</identifier>
            <name type="primary">
                <namePart>Men in Mind: Training clinicians to engage men in mental health
                    treatment</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">health care worker education</subject>
            <subject type="local">masculinity</subject>
            <subject type="local">men's mental health</subject>
            <subject type="local">depression</subject>
            <subject type="local">psychotherapy</subject>
            <description type="Chief Investigator">Dr Zac Seidler</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">While more men than ever are seeking help for their mental
                health, the male suicide rate is high and rising. The onus needs to move away from
                the male client adapting to treatment, and onto the systems and services designed to
                help them. This project focuses on training clinicians who work with men, to ensure
                they have evidence-based education to better understand and respond to their male
                clients' distress and suicidality.</description>
            <description type="fundingAmount">$490,444.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008190</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008190</identifier>
            <identifier type="nhmrc">2008190</identifier>
            <name type="primary">
                <namePart>Advanced graph genome analytics for clinical and public health
                    genomics</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03f0f6041</identifier>
                <title>University of Technology Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">comparative genomics</subject>
            <subject type="local">evolution</subject>
            <subject type="local">molecular epidemiology</subject>
            <subject type="local">antimicrobial resistance</subject>
            <subject type="local">genomics</subject>
            <description type="Chief Investigator">Prof Aaron Darling</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">By analysing the DNA of infectious microbes, public health
                officials can determine whether patients are part of the same or different
                outbreaks, and even determine the source of the outbreak. This has become common
                practice for many diseases, but genome data is rich and could be used to do much
                more. The proposed work enhances public health by providing advanced data analytics
                that will increase the precision of existing analyses and extends them to outbreaks
                of antibiotic resistance genes.</description>
            <description type="fundingAmount">$2,872,570.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008193</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008193</identifier>
            <identifier type="nhmrc">2008193</identifier>
            <name type="primary">
                <namePart>Transforming outcomes by investigating integrated treatments for
                    methamphetamine use and trauma</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">addiction treatment</subject>
            <subject type="local">drug dependence</subject>
            <subject type="local">substance use disorders</subject>
            <subject type="local">comorbidity</subject>
            <subject type="local">posttraumatic stress disorder (PTSD)</subject>
            <description type="Chief Investigator">Dr Shalini Arunogiri</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Methamphetamine use disorder is associated with a $5 billion
                burden annually in Australia, in part due to untreated co-occurring mental health
                problems. This program of research will address a gap in the treatment of
                methamphetamine use, by firstly quantifying the prevalence and impact of trauma and
                post-traumatic stress disorder in people who use methamphetamine; and secondly, by
                testing two new targeted approaches for trauma and methamphetamine
                use.</description>
            <description type="fundingAmount">$450,370.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008197</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008197</identifier>
            <identifier type="nhmrc">2008197</identifier>
            <name type="primary">
                <namePart>Investigating body clock dysfunction in mood disorders using wearable
                    sensors</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">circadian rhythms</subject>
            <subject type="local">depression</subject>
            <subject type="local">bipolar disorder</subject>
            <subject type="local">mental health</subject>
            <subject type="local">youth</subject>
            <description type="Chief Investigator">Dr Jacob Crouse</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We don't yet understand what causes depression and bipolar
                disorder or why some people don't get better after treatment. This Investigator
                Fellowship will allow me to explore whether dysfunction of “biological clocks”—which
                control the timing of most of our behaviours and bodily functions—are responsible
                for a number of problems that young people with mood disorders face, including
                fatigue, depressed mood, sleep/wake cycle irregularities, and bodily symptoms like
                upset stomach and muscle pain.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008212</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008212</identifier>
            <identifier type="nhmrc">2008212</identifier>
            <name type="primary">
                <namePart>Improving preterm respiratory outcomes from birth</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">newborn infant</subject>
            <subject type="local">lung mechanics</subject>
            <subject type="local">mechanical ventilation</subject>
            <subject type="local">lung injury</subject>
            <subject type="local">lung function assessment</subject>
            <description type="Chief Investigator">A/Prof David Tingay</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Rates of preterm birth are increasing, and survivors are now
                entering adulthood with chronic respiratory problems. My program addresses the clear
                need to re-define how we manage the fragile lung of preterm infants from their very
                first breaths, before the injury events leading to life long problems occur. My
                program uses world-leading lung imaging and molecular tools and large trials to
                understand the preterm lung and then develop new therapies that meaningfully impact
                infants and families.</description>
            <description type="fundingAmount">$1,649,133.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008255</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008255</identifier>
            <identifier type="nhmrc">2008255</identifier>
            <name type="primary">
                <namePart>Interstitial lung disease: Improving patient outcomes through risk
                    prediction and disease burden management</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00ymae584</identifier>
                <title>Institute for Breathing and Sleep</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">pulmonary fibrosis</subject>
            <subject type="local">symptom reduction</subject>
            <subject type="local">risk prediction</subject>
            <subject type="local">oxygen therapy</subject>
            <subject type="local">health outcomes</subject>
            <description type="Chief Investigator">Dr Yet Khor</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Interstitial lung diseases (ILD) are complex incurable lung
                scarring conditions, which cause distressing breathlessness, fatigue, and poor
                quality of life. It is the second most common cause of death due to chronic lung
                disease in Australia. My program will allow us to predict how the disease worsens
                over time, to understand how sleep and drug complexity affect health outcomes, and
                to better treat debilitating shortness of breath and low oxygen levels in people
                with ILD.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008276</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008276</identifier>
            <identifier type="nhmrc">2008276</identifier>
            <name type="primary">
                <namePart>Improving health outcomes for people who inject drugs: hepatitis C and
                    drug dependence</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">antiviral agents</subject>
            <subject type="local">hepatitis C virus</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">clinical epidemiology</subject>
            <subject type="local">injecting drug use</subject>
            <description type="Chief Investigator">Prof Gregory Dore</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">People who inject drugs are a vulnerable population within
                society. Recent advances in treatment of hepatitis C have provided optimism for
                improved health outcomes for people who inject drugs. Addressing other areas,
                particularly management of drug dependency, is essential to improving the lives of
                people who inject drugs.</description>
            <description type="fundingAmount">$1,827,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008287</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008287</identifier>
            <identifier type="nhmrc">2008287</identifier>
            <name type="primary">
                <namePart>Immunotherapy to prevent and cure autoimmune disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">rheumatoid arthritis</subject>
            <subject type="local">type 1 diabetes mellitus (insulin-dependent diabetes
                mellitus)</subject>
            <subject type="local">immunotherapy</subject>
            <subject type="local">immunological tolerance</subject>
            <subject type="local">disease prevention</subject>
            <description type="Chief Investigator">Prof Ranjeny Thomas</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Autoimmune diseases such as rheumatoid arthritis (RA) are
                incurable, inflammatory diseases, causing disability and early death. Building on
                early phase immunotherapy trials, my program develops ground-breaking immunotherapy
                research and technology to deliver: 1) tools to identify people at risk; and 2)
                preventive immunotherapy and lifestyle interventions to halt disease progression. My
                program will build pipeline drug development and delivery opportunities with
                industry to transform healthcare.</description>
            <description type="fundingAmount">$2,127,015.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008300</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008300</identifier>
            <identifier type="nhmrc">2008300</identifier>
            <name type="primary">
                <namePart>Maximising health and wellbeing for children with serious illness in
                    countries with the most, through to the least, resources.</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">health psychology</subject>
            <subject type="local">paediatric</subject>
            <subject type="local">psycho-oncology</subject>
            <subject type="local">quality of life</subject>
            <subject type="local">quality of care</subject>
            <description type="Chief Investigator">Prof Claire Wakefield</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">More than 10% of all children have a serious/chronic illness.
                My research aims to maximise their health and wellbeing by rolling out interventions
                to support families of seriously ill children across Australia. My new interventions
                will improve mental health in families undergoing paediatric precision medicine and
                improve quality of life, resilience, physical activity and diet in child cancer
                survivors. The program will also expand to low resource settings to reach those with
                the greatest need.</description>
            <description type="fundingAmount">$2,248,555.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008313</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008313</identifier>
            <identifier type="nhmrc">2008313</identifier>
            <name type="primary">
                <namePart>PLACE (Prioritising Location-based Analysis and Consumer Engagement) for
                    Change</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03pnv4752</identifier>
                <title>Queensland University of Technology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">health inequalities</subject>
            <subject type="local">cancer epidemiology</subject>
            <subject type="local">injury epidemiology</subject>
            <subject type="local">data linkage</subject>
            <subject type="local">applied statistics</subject>
            <description type="Chief Investigator">Dr Susanna Cramb</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Location plays a key role in Australia’s health inequities, yet
                is usually ignored or aggregated to large regions. This hinders identifying
                appropriate, localised solutions. This fellowship uniquely incorporates both complex
                spatial analyses and lived consumer experience to identify priority areas and
                propose actionable solutions to help reduce health inequities for cancer, diabetes
                and injuries.</description>
            <description type="fundingAmount">$575,740.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008317</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008317</identifier>
            <identifier type="nhmrc">2008317</identifier>
            <name type="primary">
                <namePart>Improving survival in lung cancer using novel minimally invasive
                    bronchoscopic techniques</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">non-small cell lung cancer</subject>
            <subject type="local">minimal intervention</subject>
            <subject type="local">cancer immunology</subject>
            <subject type="local">lung cancer</subject>
            <subject type="local">bronchoscopy</subject>
            <description type="Chief Investigator">A/Prof Daniel Steinfort</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">I will develop novel techniques to achieve tumour destruction
                via bronchoscopy for non-surgical cure of early stage lung cancer. I will explore
                the immune system response to tumour destruction, and determine the efficacy of
                combining tumour ablation (to enhance immune system recognition of tumour cells)
                with immunotherapy in patients with metastatic lung cancer to increase the
                proportion of patients who respond to immunotherapy, and increase the duration that
                responses are maintained.</description>
            <description type="fundingAmount">$1,235,060.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008339</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008339</identifier>
            <identifier type="nhmrc">2008339</identifier>
            <name type="primary">
                <namePart>Defining pathogenic mechanisms to improve diagnosis and treatment of
                    antibody-associated neurological disorders</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">neuroimmunology</subject>
            <subject type="local">demyelinating disease</subject>
            <subject type="local">encephalitis</subject>
            <subject type="local">immunotherapy</subject>
            <subject type="local">biomarkers</subject>
            <description type="Chief Investigator">Dr Sudarshini Ramanathan</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Autoimmune neurological disorders have recently been
                identified, and can result in severe disability including blindness, paralysis, and
                seizures. If diagnosed early and treated with specific immune therapy, brain injury
                can be reversed and patients can have a normal life. My program will identify how
                frequent these disorders are, increase our understanding of underlying disease
                processes to identify new treatment targets, and develop diagnostic and therapeutic
                guidelines to improve outcomes.</description>
            <description type="fundingAmount">$1,551,688.72</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008341</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008341</identifier>
            <identifier type="nhmrc">2008341</identifier>
            <name type="primary">
                <namePart>A personalised pharmacogenomic approach to inform autosomal dominant
                    hypocalcaemia treatment</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">membrane protein</subject>
            <subject type="local">structural biology</subject>
            <subject type="local">molecular pharmacology</subject>
            <subject type="local">drug discovery</subject>
            <subject type="local">endocrine disease</subject>
            <description type="Chief Investigator">Dr Tracy Josephs</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Autosomal dominant hypocalcemia (ADH) is a rare disorder caused
                by genetic mutations that disrupt the body’s ability to retain calcium. There is no
                treatment for ADH. Developing new therapies has been difficult as potential drugs
                behave differently depending on the underlying mutation. My research is
                characterising how mutations in ADH can change drug behaviour. I am using this
                information to design new therapies resistant to these effects, providing treatment
                options for ADH sufferers.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008344</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008344</identifier>
            <identifier type="nhmrc">2008344</identifier>
            <name type="primary">
                <namePart>Sex differences in alcohol use disorders: harnessing reverse translation
                    for target discovery</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">sex differences</subject>
            <subject type="local">amygdala</subject>
            <subject type="local">alcohol use disorders</subject>
            <subject type="local">neurochemistry</subject>
            <subject type="local">anxiety</subject>
            <description type="Chief Investigator">Dr Leigh Walker</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Alcohol use disorders are a major socioeconomic burden on
                society and treatment options are inadequate. One of the major hurdles in treatment
                development is translation from preclinical to clinical models, which in part is
                underpinned by a lack of appropriate examination in both male and female research
                subjects. My research will identify and characterise new targets for the treatment
                of alcohol use disorder in both men and women.</description>
            <description type="fundingAmount">$600,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008347</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008347</identifier>
            <identifier type="nhmrc">2008347</identifier>
            <name type="primary">
                <namePart>Developing novel therapeutic approaches by using innate lymphoid cells in
                    chronic kidney disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">nephropathy</subject>
            <subject type="local">chronic renal failure</subject>
            <subject type="local">innate immunity</subject>
            <subject type="local">immunotherapy</subject>
            <subject type="local">inflammation</subject>
            <description type="Chief Investigator">Dr Qi Cao</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Chronic kidney disease is a major cause of death and morbidity
                in Australia. Current strategies that delay progression of kidney disease are
                limited. Innate lymphoid cells (ILC) are a newly identified family of immune cells
                and include two protective subsets of ILC: regulatory ILC (ILCreg) and type 2 ILC
                (ILC2), which have been shown to suppress inflammation and promote tissue repair.
                The project will explore therapeutic potential of ILCreg and ILC2 in kidney
                disease.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008356</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008356</identifier>
            <identifier type="nhmrc">2008356</identifier>
            <name type="primary">
                <namePart>Germinal centres, antibodies and immunological disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">antibody production</subject>
            <subject type="local">autoimmunity</subject>
            <subject type="local">germinal centre</subject>
            <subject type="local">B cells</subject>
            <subject type="local">genetic engineering</subject>
            <description type="Chief Investigator">Prof Robert Brink</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Antibodies that latch strongly onto foreign pathogens provide
                us with immunological protection. They are produced by lymphocytes called B cells
                participating in the germinal centre phase of the immune response. Autoantibodies
                that attack the body’s own tissues are an unwanted by-product of the germinal
                centre. The aim of this study is to identify the processes by which B cells
                producing desirable protective antibodies versus autoantibodies are identified and
                controlled in the germinal centre.</description>
            <description type="fundingAmount">$2,927,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008359</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008359</identifier>
            <identifier type="nhmrc">2008359</identifier>
            <name type="primary">
                <namePart>Investigating new targets and treatments for Alzheimer’s disease: from
                    biochemistry through to clinical trial</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">Alzheimer disease</subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">iron</subject>
            <subject type="local">disease mechanisms</subject>
            <description type="Chief Investigator">A/Prof Scott Ayton</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Alzheimer’s disease is a major disease of the elderly that
                causes profound impairment to cognition. This disease has proven difficult to
                diagnose and treat. Over the next 5 years I will take advantage of our new
                laboratory research to test new drugs and diagnostics for Alzheimer’s disease. I
                will test in a clinical trial of Alzheimer’s patients whether a drug candidate slows
                disease progression, and test whether new technologies can be used to diagnose
                Alzheimer’s disease.</description>
            <description type="fundingAmount">$3,098,844.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008375</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008375</identifier>
            <identifier type="nhmrc">2008375</identifier>
            <name type="primary">
                <namePart>Co-designed Critical Care Recovery</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">critical care</subject>
            <subject type="local">recovery</subject>
            <subject type="local">survivorship</subject>
            <subject type="local">health outcomes</subject>
            <subject type="local">patient outcomes</subject>
            <description type="Chief Investigator">A/Prof Kimberley Haines</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This research aims to improve patient and family outcomes
                following critical illness by developing and evaluating a novel and promising
                intervention - peer support delivered virtually, where survivors can support each
                other to recover. The outcomes from this research will include two co-designed peer
                support interventions that can be delivered virtually. This will reduce inequities
                in access to recovery programs following critical illness in Australia, and will
                have global impact.</description>
            <description type="fundingAmount">$520,592.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008376</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008376</identifier>
            <identifier type="nhmrc">2008376</identifier>
            <name type="primary">
                <namePart>Harnessing the regenerative potential of the newborn heart.</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">regeneration</subject>
            <subject type="local">regenerative medicine</subject>
            <subject type="local">stem cells</subject>
            <subject type="local">heart development</subject>
            <subject type="local">transcriptional regulation</subject>
            <description type="Chief Investigator">A/Prof Enzo Porrello</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Heart failure is a massive and growing public health problem
                affecting over 25 million people worldwide. In contrast to the extremely limited
                regenerative capacity of the adult heart, we have discovered that the newborn
                mammalian heart retains a robust capacity for regeneration for a short period after
                birth. This Investigator Grant seeks to unlock the regenerative potential of the
                newborn heart for cardiac repair in children and adults with heart
                failure.</description>
            <description type="fundingAmount">$2,548,555.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008379</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008379</identifier>
            <identifier type="nhmrc">2008379</identifier>
            <name type="primary">
                <namePart>Optimising the uptake of effective underused evidence-based non-drug
                    interventions in primary care</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/006jxzx88</identifier>
                <title>Bond University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">primary care</subject>
            <subject type="local">general practice</subject>
            <subject type="local">evidence-based clinical practice</subject>
            <subject type="local">shared clinical decision making</subject>
            <subject type="local">clinical practice guidelines</subject>
            <description type="Chief Investigator">Dr Loai Albarqouni</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Non-drug treatments, such as exercise for low back pain or
                behavioural therapy for depression, can be equally or more effective than drugs -
                with fewer side effects. Despite clinicians’ and patients’ growing interest in
                non-drug treatments, they are less known and used. My research program will develop
                evidence-based guides for effective non-drug treatments and provide world-first
                evidence on the best way to improve the uptake of non-drug treatments by clinicians
                and patients in primary care.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008382</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008382</identifier>
            <identifier type="nhmrc">2008382</identifier>
            <name type="primary">
                <namePart>Preventing Irreversible Vision Loss from Age-Related Macular
                    Degeneration</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sqdef20</identifier>
                <title>Centre for Eye Research Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">macular degeneration</subject>
            <subject type="local">eye disease</subject>
            <subject type="local">diagnostic imaging</subject>
            <subject type="local">visual function</subject>
            <subject type="local">artificial neural networks</subject>
            <description type="Chief Investigator">Dr Zhichao Wu</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Age-related macular degeneration (AMD) is the leading cause of
                irreversible central vison loss in people over 50 years old. No treatments are
                available to slow or prevent degeneration of the tissue responsible for vision from
                the more common “dry” form of AMD. This project will use state-of-the-art imaging,
                vision testing and artificial intelligence to substantially improve our assessment
                of new treatments, and to gain critical insights into disease mechanisms, needed for
                treatment discovery.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008392</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008392</identifier>
            <identifier type="nhmrc">2008392</identifier>
            <name type="primary">
                <namePart>Building evidence for strategies to prevent healthcare acquired
                    infections</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">infection control</subject>
            <subject type="local">nosocomial infections</subject>
            <subject type="local">nursing practice</subject>
            <subject type="local">infectious diseases</subject>
            <subject type="local">health services research</subject>
            <description type="Chief Investigator">Prof Brett Mitchell</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Despite being common and affecting 160,000 Australians a year,
                strategies to prevent infection acquired healthcare are underpinned by low quality
                evidence. The proposed research program consists of three discrete, inter-related
                projects. The work will provide evidence for practical measures to reduce common
                infections – urinary tract infection, pneumonia as well as improving cleaning in
                healthcare.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008408</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008408</identifier>
            <identifier type="nhmrc">2008408</identifier>
            <name type="primary">
                <namePart>Understanding how DC-T cell interactions regulate human disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">CD8 T cells</subject>
            <subject type="local">innate immunity</subject>
            <subject type="local">viral infection</subject>
            <subject type="local">dendritic cell</subject>
            <subject type="local">adaptive immunity</subject>
            <description type="Chief Investigator">Prof Sammy Bedoui</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">My research has played a significant role in understanding how
                certain immune cells instruct the body to eliminate infections. Building on this
                expertise, my team and I will address fundamental question of immune cell function
                that will be vital for understanding immunity and to develop better therapies
                against virus infections.</description>
            <description type="fundingAmount">$2,297,570.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008426</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008426</identifier>
            <identifier type="nhmrc">2008426</identifier>
            <name type="primary">
                <namePart>A new systems approach to discharge and follow up care models for chronic
                    conditions in Aboriginal and Torres Strait Islander children.</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">Aboriginal health</subject>
            <subject type="local">Aboriginal child</subject>
            <subject type="local">burn injury</subject>
            <subject type="local">quality improvement</subject>
            <subject type="local">access to health care</subject>
            <description type="Chief Investigator">Dr Julieann Coombes</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">A program providing culturally safe discharge planning for
                Aboriginal children with a burn injury will be trailed in Darwin and Townsville. It
                includes a component ‘Building Cultural Capabilities’ an educational program for
                health workers to develop cultural capacity improving healthcare for Aboriginal and
                Torres Strait Islander patients. This project will improve the quality and safety of
                healthcare for Aboriginal children in Darwin and Townsville and will improving burn
                injury outcomes.</description>
            <description type="fundingAmount">$550,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008436</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008436</identifier>
            <identifier type="nhmrc">2008436</identifier>
            <name type="primary">
                <namePart>Reducing the burden of chronic obstructive pulmonary disease (COPD): novel
                    phenotypes, risk factors and biomarkers</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">epidemiology</subject>
            <subject type="local">chronic obstructive pulmonary disease (COPD)</subject>
            <subject type="local">prevention</subject>
            <subject type="local">risk factors</subject>
            <subject type="local">phenotype</subject>
            <description type="Chief Investigator">Dr Dinh Bui</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Chronic Obstructive Pulmonary Disease (COPD) is a major public
                health issue around the world. At present, the only known way to prevent COPD and
                lessen its severity is tobacco smoking avoidance. However, not everyone who gets
                COPD smokes and patients with COPD often have different forms of the disease. I will
                determine the different types and causes of COPD and develop tools to identify who
                is most at risk. My research will help develop interventions to prevent and better
                treat COPD.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008447</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008447</identifier>
            <identifier type="nhmrc">2008447</identifier>
            <name type="primary">
                <namePart>Healthcare resource utilisation and long term outcomes following critical
                    illness</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">critical care</subject>
            <subject type="local">health outcomes</subject>
            <subject type="local">health economics</subject>
            <subject type="local">randomised controlled trial (RCT)</subject>
            <subject type="local">health care utilisation</subject>
            <description type="Chief Investigator">Dr Alisa Higgins</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Patients admitted to intensive care units (ICU) are the sickest
                patients in hospital but little is known about what happens to these patients after
                they are discharged. This project will evaluate long-term outcomes such as
                disability, quality of life, anxiety and depression after ICU, along with ongoing
                healthcare use (including readmission to hospital). It will also conduct health
                economic analyses to determine which interventions provide the greatest value for
                money.</description>
            <description type="fundingAmount">$613,240.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008450</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008450</identifier>
            <identifier type="nhmrc">2008450</identifier>
            <name type="primary">
                <namePart>Next-generation therapeutics inspired by parasitic helminths</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04gsp2c11</identifier>
                <title>James Cook University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">helminth infection</subject>
            <subject type="local">biological therapy</subject>
            <subject type="local">hookworms</subject>
            <subject type="local">schistosomiasis</subject>
            <subject type="local">vaccines</subject>
            <description type="Chief Investigator">Prof Alexander Loukas</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Billions of people in developing countries are infected with
                parasitic worms, but they have been eradicated from industrialised nations. Humans
                co-evolved with worms, so their recent removal has deprived us of signals required
                to keep inflammation in check. My research focuses on worm molecules that can be
                used as: (1) vaccines and diagnostics to combat parasitic infections in developing
                countries, and (2) a novel platform of anti-inflammatory therapeutics for use in
                industrialised nations.</description>
            <description type="fundingAmount">$3,327,015.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008454</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008454</identifier>
            <identifier type="nhmrc">2008454</identifier>
            <name type="primary">
                <namePart>Tailored approaches to improve prevention and early detection of melanoma
                    and other skin cancers</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">cancer screening</subject>
            <subject type="local">melanoma</subject>
            <subject type="local">skin cancer</subject>
            <subject type="local">cancer prevention</subject>
            <subject type="local">cancer epidemiology</subject>
            <description type="Chief Investigator">Prof Anne Cust</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This proposal will evaluate ways to tailor melanoma and skin
                cancer prevention and early detection strategies to a person’s individual risk. It
                will help us understand the overall benefits and harms of different approaches, how
                to implement good national strategies, and measure the value for money for the
                health system. This research will improve skin cancer outcomes for the community and
                patients.</description>
            <description type="fundingAmount">$2,023,555.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008460</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008460</identifier>
            <identifier type="nhmrc">2008460</identifier>
            <name type="primary">
                <namePart>Using social media to reduce suicide and self-harm in young
                    people</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">suicide prevention</subject>
            <subject type="local">suicide</subject>
            <subject type="local">internet</subject>
            <subject type="local">young adults</subject>
            <subject type="local">adolescent</subject>
            <description type="Chief Investigator">A/Prof Jo Robinson</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This program will address the role of social media on youth
                suicide and self-harm. It will lead to increased understanding of the harms and
                benefits of online communication from the perspective of young people, parents,
                professionals and the social media industry. Outputs include evidence-based guidance
                plus co-designed social media campaign targeting young people. If effective, this
                work will directly translate into increased online safety for at-risk young people
                in Australia and overseas.</description>
            <description type="fundingAmount">$2,248,555.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008462</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008462</identifier>
            <identifier type="nhmrc">2008462</identifier>
            <name type="primary">
                <namePart>Developing more accurate cardiovascular disease detection with a
                    cellular-resolution imaging catheter</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">diagnostic imaging</subject>
            <subject type="local">acute myocardial infarction (AMI)</subject>
            <subject type="local">instrumentation</subject>
            <subject type="local">plaque rupture</subject>
            <subject type="local">atherosclerosis</subject>
            <description type="Chief Investigator">Dr Jiawen Li</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Most heart attacks are caused by high-risk plaques. The holy
                grail in cardiology would be to reliably detect high-risk plaques before they are
                life-threatening. This research program will deliver a clinically applicable device
                to detect high-risk plaques, helping cardiologists determine the most efficient
                treatment on an individual basis. The imaging device will be the first-of-its-kind
                worldwide, holding great hope of significantly reducing cost and complications in
                cardiovascular diseases.</description>
            <description type="fundingAmount">$588,308.31</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008488</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008488</identifier>
            <identifier type="nhmrc">2008488</identifier>
            <name type="primary">
                <namePart>Optimising outcomes from child concussion from sidelines to recovery:
                    improving diagnostic precision, effective treatment and community
                    knowledge</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">concussion</subject>
            <subject type="local">child</subject>
            <subject type="local">youth</subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">early intervention</subject>
            <description type="Chief Investigator">Prof Vicki Anderson</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">In the context of wide media attention, child concussion is of
                increasing community concern, despite limited empirical evidence regarding its real
                consequences. My research will identify mechanisms underlying persistent symptoms
                and link these predictive markers to individual recovery profiles and to treatment
                responses to optimise outcomes for children with concussion.</description>
            <description type="fundingAmount">$3,198,056.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008501</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008501</identifier>
            <identifier type="nhmrc">2008501</identifier>
            <name type="primary">
                <namePart>Interventions to eliminate Plasmodium vivax malaria</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/006mbby82</identifier>
                <title>Menzies School of Health Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">clinical malaria</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">health economics</subject>
            <subject type="local">molecular biology</subject>
            <subject type="local">pharmacology</subject>
            <description type="Chief Investigator">Prof Richard Price</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Malaria affects more 230 million people each year. In Asia, the
                Americas and the Horn of Africa malaria due to Plasmodium vivax accounts for more
                than half of these cases. I will work with partners in malaria endemic countries to
                develop better, safer and more effective treatment strategies and design better
                surveillance to identify populations at greatest risk of infection. The ultimate aim
                of my program is to change policy, impact on health outcomes and eliminate vivax
                malaria globally.</description>
            <description type="fundingAmount">$2,897,045.75</description>
            <coverage>
                <spatial type="text">NT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008523</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008523</identifier>
            <identifier type="nhmrc">2008523</identifier>
            <name type="primary">
                <namePart>Reducing the burden of knee osteoarthritis in young adults</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rxfrp27</identifier>
                <title>La Trobe University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">knee osteoarthritis</subject>
            <subject type="local">rehabilitation</subject>
            <subject type="local">exercise therapy</subject>
            <subject type="local">physiotherapy</subject>
            <subject type="local">sports injury</subject>
            <description type="Chief Investigator">Dr Adam Culvenor</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">In young people (&lt;40 years), arthritis commonly occurs after
                knee injury, forcing them to live with old knees and reducing their quality of life.
                This program of research leverages established resources to address the urgent need
                to prevent arthritis in young adults by: i) understanding why some people are more
                likely to get knee arthritis; ii) enhancing the care of knee injuries to prevent
                arthritis; and iii) uniting international efforts with a world-first database of
                early arthritis outcomes.</description>
            <description type="fundingAmount">$1,432,688.31</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008535</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008535</identifier>
            <identifier type="nhmrc">2008535</identifier>
            <name type="primary">
                <namePart>Enhancing policy implementation for healthy food environments</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02czsnj07</identifier>
                <title>Deakin University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">overweight/obesity</subject>
            <subject type="local">health policy</subject>
            <subject type="local">population health</subject>
            <subject type="local">nutrition</subject>
            <subject type="local">translational research</subject>
            <description type="Chief Investigator">A/Prof Gary Sacks</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This Investigator Grant aims to enhance the implementation of
                policies for creating healthy food environments. It is expected that the research
                program will provide new evidence to support effective policy action, and powerful
                mechanisms for holding governments and the food industry to account for their roles
                in improving population diets and preventing obesity. In so doing, the research will
                improve the policy response to the leading contributors to poor health in Australia
                and globally.</description>
            <description type="fundingAmount">$1,427,980.49</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008542</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008542</identifier>
            <identifier type="nhmrc">2008542</identifier>
            <name type="primary">
                <namePart>Harnessing immune cell programs to drive immune protection</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">transcription factor</subject>
            <subject type="local">innate immunity</subject>
            <subject type="local">mucosal immunity</subject>
            <subject type="local">immune protection</subject>
            <subject type="local">lymphocytes</subject>
            <description type="Chief Investigator">Prof Gabrielle Belz</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Immunity is essential for life. Harnessing the immune system to
                drive increased protection against disease has never been more urgent than now.
                Achieving this requires understanding the cues that regulate the activation of
                immune cells and the wiring needed for them to function efficiently and defeat
                pathogens. My work aims to unravel this complex network to harness the immune
                switches that will facilitate the future development of therapeutics and vaccines to
                treat world disease.</description>
            <description type="fundingAmount">$1,941,612.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008546</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008546</identifier>
            <identifier type="nhmrc">2008546</identifier>
            <name type="primary">
                <namePart>Novel oxygen sensing pathways in hypoxic disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">hypoxia</subject>
            <subject type="local">oxygen</subject>
            <subject type="local">protein characterisation</subject>
            <subject type="local">protein degradation</subject>
            <subject type="local">solid tumours</subject>
            <description type="Chief Investigator">Dr Mark White</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Oxygen (O2) is a vital biological resource and sufficient
                concentrations are needed for normal metabolism. Reductions in O2 (hypoxia) can
                cause significant stress that subverts life and is a key feature of disorders such
                as cancer and cardiovascular disease. By understanding how cells respond to changes
                in O2 we can develop effective methods to treat these detrimental conditions. This
                project aims to increase knowledge of a new O2 sensing system to combat hypoxic
                cancers such as glioblastoma.</description>
            <description type="fundingAmount">$624,389.97</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008565</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008565</identifier>
            <identifier type="nhmrc">2008565</identifier>
            <name type="primary">
                <namePart>From dreams to delirium and dementia: Cognitive fluctuations as a window
                    into novel biomarkers and therapeutic targets for neurodegeneration</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">dementia with Lewy bodies</subject>
            <subject type="local">Parkinson disease</subject>
            <subject type="local">rapid eye movement (REM) sleep</subject>
            <subject type="local">neurodegeneration</subject>
            <subject type="local">biomarkers</subject>
            <description type="Chief Investigator">Dr Elie Matar</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Lewy body dementias are characterized by marked swings in
                attention and arousal known as cognitive fluctuations. We aim to show that
                disturbances in the biology maintaining the normal balance between wakefulness and
                sleep underlie this core symptom and use this to identify new disease biomarkers and
                novel therapeutic targets of Lewy body disease. We apply this to recruit the first
                prodromal cohort of delirium-onset Lewy body dementia and to improve prediction and
                treatment of delirium generally.</description>
            <description type="fundingAmount">$250,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008572</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008572</identifier>
            <identifier type="nhmrc">2008572</identifier>
            <name type="primary">
                <namePart>Phosphatases in the pathogenesis of obesity and cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">protein tyrosine phosphatase (PTP)</subject>
            <subject type="local">insulin signalling</subject>
            <subject type="local">immunotherapy</subject>
            <subject type="local">liver cancer</subject>
            <subject type="local">obesity</subject>
            <description type="Chief Investigator">Prof Tony Tiganis</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Obesity has reached epidemic proportions and is major driver of
                chronic human diseases, including type 2 diabetes, cardiovascular disease, fatty
                liver disease and cancer. This proposal will define key molecular mechanisms
                contributing to the development of obesity and its co-morbidities, especially liver
                disease and cancer. We will thereon seek to develop novel therapeutic approaches for
                combating obesity and these insidious and recalcitrant diseases.</description>
            <description type="fundingAmount">$1,927,015.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008574</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008574</identifier>
            <identifier type="nhmrc">2008574</identifier>
            <name type="primary">
                <namePart>Defining effective health actions for adolescents globally</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05ktbsm52</identifier>
                <title>Burnet Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">adolescent health</subject>
            <subject type="local">health inequalities</subject>
            <subject type="local">intervention</subject>
            <subject type="local">indigenous health</subject>
            <subject type="local">regional health</subject>
            <description type="Chief Investigator">A/Prof Peter Azzopardi</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">The world is now home to 1.8 billion adolescents, the largest
                population in human history. My earlier work has described the unmet health needs of
                these adolescents- the task now is to define how to best respond. Working in
                partnership with adolescents across Indigenous communities, Papua New Guinea and
                Myanmar, I will define the actions required to improve their health. I will define a
                package of actions that is informed by adolescents and can be implemented across
                health and education sectors.</description>
            <description type="fundingAmount">$870,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008600</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008600</identifier>
            <identifier type="nhmrc">2008600</identifier>
            <name type="primary">
                <namePart>Measuring unmet menstrual health needs and their impacts on health and
                    education</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05ktbsm52</identifier>
                <title>Burnet Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">menstruation</subject>
            <subject type="local">developing countries</subject>
            <subject type="local">social determinants</subject>
            <subject type="local">reproductive health</subject>
            <subject type="local">adolescent health</subject>
            <description type="Chief Investigator">Dr Julie Hennegan</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Each day, over 300 million females are menstruating. Their
                menstrual health matters for gender equality, health, and education. My work will
                transform the way we measure women’s and girls’ menstrual health needs in low- and
                middle-income countries and advance evidence-based action in Southeast Asia and the
                Pacific. I will grow our understanding of how adolescent girls’ needs change over
                time and quantify the impacts of menstrual health on broader health and education
                outcomes.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008612</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008612</identifier>
            <identifier type="nhmrc">2008612</identifier>
            <name type="primary">
                <namePart>Generative models of brain disorders</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">dynamic process modelling</subject>
            <subject type="local">neuroimaging</subject>
            <subject type="local">mathematical modelling</subject>
            <subject type="local">schizophrenia</subject>
            <subject type="local">dementia</subject>
            <description type="Chief Investigator">Prof Michael Breakspear</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The management of many neurological and psychiatric disorders
                remains underwhelming, due in part to of our limited understanding of how the brain
                works. Consequently, clinical practice remains rooted in trial-and-error and expert
                opinion. To make progress, we need to improve our knowledge of the brain using tools
                that embrace its complexity. I will use advanced mathematical modelling to
                understand the rules that govern neural circuits in health and as they fail in
                common brain disorders.</description>
            <description type="fundingAmount">$2,872,570.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008616</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008616</identifier>
            <identifier type="nhmrc">2008616</identifier>
            <name type="primary">
                <namePart>Immunity mediated by MHC class I-related protein (MR1)</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cellular immunology</subject>
            <subject type="local">antigen presentation</subject>
            <subject type="local">immune protection</subject>
            <subject type="local">tumour immunity</subject>
            <subject type="local">innate immunity</subject>
            <description type="Chief Investigator">Prof James McCluskey</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Immune T cells react to molecular changes in cells during
                infection revealed by antigen-presenting molecules that constantly sample molecular
                patterns. MR1 is a newly discovered Ag presentation molecule involved in microbial
                immunity, but new evidence indicates that MR1 can present unique molecules from
                cancer cells driving T cell immunity. This proposal seeks to understand this process
                to harness a new arm of immunity amenable to development of novel anti-tumour
                vaccines and immunotherapy.</description>
            <description type="fundingAmount">$2,000,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008625</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008625</identifier>
            <identifier type="nhmrc">2008625</identifier>
            <name type="primary">
                <namePart>Achieving precision care in chronic lung disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03e3kts03</identifier>
                <title>South Australian Health and Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">molecular microbiology</subject>
            <subject type="local">chronic suppurative lung disorders</subject>
            <subject type="local">asthma</subject>
            <subject type="local">airway inflammation</subject>
            <subject type="local">airway diseases</subject>
            <description type="Chief Investigator">Dr Steven Taylor</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Current treatment guidelines poorly manage up to 30% of all
                patients with a chronic lung disease (CLD). In order to improve this, we need to
                identify useful disease markers that inform treatment response. Using stored samples
                and data from thousands of CLD patients, I will meticulously measure markers of
                disease and identify patient characteristics that inform treatment response. This
                research will improve guidelines for the large number of patients with poor disease
                control.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008631</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008631</identifier>
            <identifier type="nhmrc">2008631</identifier>
            <name type="primary">
                <namePart>Improving outcomes for patients with homologous recombination deficient
                    cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/004y8wk30</identifier>
                <title>QIMR Berghofer Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">ovarian cancer</subject>
            <subject type="local">breast cancer</subject>
            <subject type="local">DNA repair</subject>
            <subject type="local">targeted therapy</subject>
            <subject type="local">medical genomics</subject>
            <description type="Chief Investigator">Dr Olga Kondrashova</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Some cancers, including ovarian and breast, have faulty DNA
                repair, which makes them respond to powerful cancer drugs called PARP inhibitors.
                Unfortunately, many cancers eventually develop resistance to these drugs. I will use
                genomic technologies to study the portraits of cancers with faulty DNA repair. I
                will look at how we can prevent resistance to PARP inhibitors and to treat each
                cancer most effectively. This important work aims to improve the cancer survival
                rates.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008632</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008632</identifier>
            <identifier type="nhmrc">2008632</identifier>
            <name type="primary">
                <namePart>Improving antimicrobial use and reducing harms in children</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">antimicrobial therapy</subject>
            <subject type="local">infection</subject>
            <subject type="local">paediatric</subject>
            <subject type="local">health service decision making</subject>
            <subject type="local">clinical epidemiology</subject>
            <description type="Chief Investigator">Dr Brendan McMullan</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Antibiotics are often given to children in hospital incorrectly
                or for longer than needed. My program makes use of routinely collected Australian
                data, and introduces improved systems for managing antibiotics in hospital,
                including guidelines and policy. The program will improve the reporting of how
                antibiotics are used in Australian hospitals, improve management of those
                antibiotics in children, and lead to better outcomes for children and families, with
                less time spent in hospital.</description>
            <description type="fundingAmount">$450,370.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008640</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008640</identifier>
            <identifier type="nhmrc">2008640</identifier>
            <name type="primary">
                <namePart>Developing Bioinformatics Capability to Diagnose Infectious Diseases using
                    Clinical Metagenomics</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04gsp2c11</identifier>
                <title>James Cook University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">bioinformatics</subject>
            <subject type="local">DNA sequencing</subject>
            <subject type="local">sequence analysis</subject>
            <subject type="local">genetic variation</subject>
            <subject type="local">computers</subject>
            <description type="Chief Investigator">A/Prof Matthew Field</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Current methods to identify infectious pathogens are
                time-consuming, inaccurate, and unable to detect novel pathogens. This research will
                develop the bioinformatics and clinical tools needed to implement unbiased
                metagenomic sequencing as an improvement to current practice in pathogen
                diagnostics. This new approach can be implemented in remote and regional healthcare
                settings and will have enormous global impact on the world’s expanding tropical
                population, who have limited access to healthcare.</description>
            <description type="fundingAmount">$1,420,530.96</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008645</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008645</identifier>
            <identifier type="nhmrc">2008645</identifier>
            <name type="primary">
                <namePart>Bringing artificial intelligence into the real world of healthcare - the
                    implementation challenge</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">implementation</subject>
            <subject type="local">safety</subject>
            <subject type="local">replication</subject>
            <subject type="local">computer-based decision support</subject>
            <subject type="local">artificial neural networks</subject>
            <description type="Chief Investigator">Prof Enrico Coiera</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This research program focuses on three foundational challenges
                to bringing artificial intelligence (AI) into the clinical world. To ensure AI is
                safe, the 1st challenge, the program will research optimal mechanisms for
                surveillance and governance of AI safety. The 2nd challenge addressed is the lack of
                genuine independent testing of claims for the benefits of AI. The 3rd challenge for
                clinical AI is that good performance in one setting may not be repeated in even
                closely related settings.</description>
            <description type="fundingAmount">$1,500,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008648</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008648</identifier>
            <identifier type="nhmrc">2008648</identifier>
            <name type="primary">
                <namePart>Understanding natural and vaccine-induced immunity to malaria</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">malaria</subject>
            <subject type="local">B cells</subject>
            <subject type="local">T cells</subject>
            <subject type="local">vaccines</subject>
            <subject type="local">innate immunity</subject>
            <description type="Chief Investigator">A/Prof Ian Cockburn</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Malaria is responsible for the deaths of &gt;400,000
                individuals per year. Eradication of malaria will require a safe and effective
                vaccine. Vaccine development requires an understanding of the immune responses to
                malaria parasites and vaccines. The work here aims to understand the necessary
                components for a successful vaccine and to understand why our immune system
                struggles to make effective responses to malaria.</description>
            <description type="fundingAmount">$1,836,259.93</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008649</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008649</identifier>
            <identifier type="nhmrc">2008649</identifier>
            <name type="primary">
                <namePart>Transforming Young Aboriginal and Torres Strait Islander Mental Health
                    through New Knowledge and Co-designed Healings</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">Aboriginal mental health</subject>
            <subject type="local">Aboriginal child</subject>
            <subject type="local">suicide prevention</subject>
            <subject type="local">primary care</subject>
            <subject type="local">disease prevalence</subject>
            <description type="Chief Investigator">A/Prof Maree Toombs</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Young Indigenous Australians have one of the highest rates of
                suicide in the world and this tragic situation is worsening. My research program
                will address this call to action through collaborating with Indigenous youth and
                experts in the field, including traditional healers, to co-design a scalable Youth
                Model of Mental Health Care to reduce the rates of inter-generational trauma leading
                to mental illness and suicide/self-harm in young Indigenous
                Australians.</description>
            <description type="fundingAmount">$1,000,625.46</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008650</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008650</identifier>
            <identifier type="nhmrc">2008650</identifier>
            <name type="primary">
                <namePart>Integrating social science evidence into the fight against
                    vaccine-preventable and vector-borne diseases in the Australasian, South East
                    Asian and Pacific regions.</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">social and behavioural research</subject>
            <subject type="local">vector-borne disease</subject>
            <subject type="local">vaccine-preventable diseases</subject>
            <subject type="local">behavioural intervention</subject>
            <subject type="local">disease prevention</subject>
            <description type="Chief Investigator">Dr Kerrie Wiley</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Rejection of preventive health measures like vaccination is a
                global issue. Knowing what drives it is crucial to how health authorities respond
                but they don’t currently have tools to measure these drivers . This research adds
                social / behavioural data and new analysis methods to health authorities’ toolkit, e
                allowing new understanding of how diseases behave in human populations, and how
                humans behave around those diseases, enabling targeted public health interventions
                to reduce disease.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008652</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008652</identifier>
            <identifier type="nhmrc">2008652</identifier>
            <name type="primary">
                <namePart>In situ visualisation of cell fate</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">microenvironment</subject>
            <subject type="local">imaging</subject>
            <subject type="local">cancer cell biology</subject>
            <subject type="local">blood diseases</subject>
            <subject type="local">autoimmunity</subject>
            <description type="Chief Investigator">A/Prof Edwin Hawkins</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Maintaining millions of blood cells every day is crucial for
                health and development. When this process is compromised, we can develop a range of
                diseases including cancer and a compromised immune system. To understand how this
                complex system is regulated, we have developed technology to watch blood cell
                behaviour in living tissue. Using this approach, I aim to develop new ways of
                driving healthy blood cell production and eliminating cells that cause
                disease.</description>
            <description type="fundingAmount">$2,598,844.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008692</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008692</identifier>
            <identifier type="nhmrc">2008692</identifier>
            <name type="primary">
                <namePart>Inflammatory Responses to Programmed Cell Death Signalling</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">cell death</subject>
            <subject type="local">inflammation</subject>
            <subject type="local">signal transduction</subject>
            <subject type="local">innate immunity</subject>
            <subject type="local">ubiquitination</subject>
            <description type="Chief Investigator">A/Prof James Vince</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Inflammatory cytokines are the alarms that cells in our body
                engage to protect us against infections. However, when made in excess cytokines
                contribute to diseases such as arthritis, heart disease and hereditary inflammatory
                syndromes. This project aims to define the molecular mechanisms by which
                inappropriate cell death induces damaging levels of cytokines to cause disease.
                Understanding how inflammation is controlled at the molecular level will allow the
                design of new, targeted, therapies.</description>
            <description type="fundingAmount">$2,348,555.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008697</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008697</identifier>
            <identifier type="nhmrc">2008697</identifier>
            <name type="primary">
                <namePart>Geospatial applications for the control of Tropical Infectious Diseases in
                    the Asia-Pacific Region</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">tropical disease</subject>
            <subject type="local">surveillance</subject>
            <subject type="local">disease modelling</subject>
            <subject type="local">prevention</subject>
            <subject type="local">cost-effectiveness</subject>
            <description type="Chief Investigator">Dr Kinley Wangdi</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">My research program will improve geographical mapping to better
                prevent, detect, and manage malaria, dengue, and intestinal worms in tropical
                countries. Projects include developing systems to rapidly map and report new cases
                of malaria to facilitate effective interventions, building an early warning system
                for dengue, and predicting high-risk areas for intestinal worms. The research will
                improve in the prediction, early warning, and rapid response to control and
                elimination of these diseases.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008698</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008698</identifier>
            <identifier type="nhmrc">2008698</identifier>
            <name type="primary">
                <namePart>Novel nanotechnology strategies towards a new paradigm of precision
                    nanomedicine</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">drug delivery systems</subject>
            <subject type="local">nanotechnology</subject>
            <subject type="local">biomaterials</subject>
            <subject type="local">drug delivery</subject>
            <subject type="local">biotechnology</subject>
            <description type="Chief Investigator">Prof Chun-Xia Zhao</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Nanotechnology offers exciting prospects for many devastating
                diseases such as cancer. Despite the clinical success of a few nanomedicines, the
                development of cancer nanomedicines for effective and targeted delivery to
                pathogenic areas has been limited. This project aims to develop revolutionising
                nanomedicines capable of simultaneous administration of two or more drugs in
                targeted cancer disease for synergistic therapy.</description>
            <description type="fundingAmount">$2,248,555.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008699</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008699</identifier>
            <identifier type="nhmrc">2008699</identifier>
            <name type="primary">
                <namePart>Diagnosis and Therapy based on new Mechanisms of Autoinflammatory
                    Disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">innate immunity</subject>
            <subject type="local">inflammation</subject>
            <subject type="local">inflammatory diseases</subject>
            <subject type="local">immunogenetics</subject>
            <subject type="local">neuroinflammation</subject>
            <description type="Chief Investigator">A/Prof Seth Masters</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Mutations of our genetic code can affect cells of our immune
                system, leading to a functional loss or gain that can cause recurrent infection, or
                in some cases, promote autoimmunity and autoinflammation. Our investigation of these
                inborn errors of immunity will advance our understanding of disease mechanisms, and
                the fundamental workings of our immune system, in order to identify and improve
                therapies that will potentially treat a range of inflammatory
                diseases.</description>
            <description type="fundingAmount">$1,948,555.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008702</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008702</identifier>
            <identifier type="nhmrc">2008702</identifier>
            <name type="primary">
                <namePart>Moving beyond one-size-fits-all: Exploring the optimal doses of physical
                    activity and sedentary behaviour across the lifespan for prevention of
                    non-communicable chronic diseases</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">behavioural epidemiology</subject>
            <subject type="local">physical activity</subject>
            <subject type="local">sedentary behaviour</subject>
            <subject type="local">chronic diseases</subject>
            <subject type="local">epidemiology</subject>
            <description type="Chief Investigator">Dr Gregore Mielke</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">It is well known that physical inactivity is a risk factor for
                the development of non-communicable chronic diseases. This research program will
                determine the optimal doses of physical activity and sedentary behaviour during
                childhood, adolescence, adulthood and old age to prevent mental and physical health
                conditions. This research program will inform the development of strategies to
                reduce the social and fiscal burden of non-communicable chronic diseases in
                Australia.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008715</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008715</identifier>
            <identifier type="nhmrc">2008715</identifier>
            <name type="primary">
                <namePart>Towards elimination of tuberculosis</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04gsp2c11</identifier>
                <title>James Cook University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">Mycobacterium tuberculosis</subject>
            <subject type="local">vaccine</subject>
            <subject type="local">pre-clinical studies</subject>
            <subject type="local">indigenous Australians</subject>
            <subject type="local">mucosal immunity</subject>
            <description type="Chief Investigator">Dr Andreas Kupz</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The development of new safe and effective vaccines is necessary
                for the control of tuberculosis, the leading infectious cause of death globally.
                Bacillus Calmette-Guérin (BCG), the only licensed tuberculosis vaccine, prevents
                severe forms of tuberculosis in children, but fails to protect adults. This project
                aims to further develop a new tuberculosis vaccine, to perform pre-clinical efficacy
                studies and to increase BCG coverage in vulnerable children in Far North Queensland
                and Papua New Guinea.</description>
            <description type="fundingAmount">$1,170,120.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008723</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008723</identifier>
            <identifier type="nhmrc">2008723</identifier>
            <name type="primary">
                <namePart>Using genetics to identify optimal times to intervene on early life growth
                    and reduce future risk of cardio-metabolic disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">statistical genetics</subject>
            <subject type="local">genetic association</subject>
            <subject type="local">growth</subject>
            <subject type="local">cardiovascular risk</subject>
            <subject type="local">body mass index</subject>
            <description type="Chief Investigator">Dr Nicole Warrington</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The prevalence of cardiovascular disease and diabetes is
                increasing and the financial burden on society is substantial. Children who have
                unfavourable growth through early life are at increased risk of these diseases. This
                study aims to perform the largest genetic study of fetal growth and body mass index
                over childhood, and then investigate the relationship between early life growth and
                future risk of diseases like diabetes. Knowledge gained will inform the design of
                public health initiatives.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008727</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008727</identifier>
            <identifier type="nhmrc">2008727</identifier>
            <name type="primary">
                <namePart>Identifying the underlying causes and discovering novel therapeutic
                    treatments for chronic visceral pain (CVP)</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">chronic pain</subject>
            <subject type="local">irritable bowel syndrome (IBS)</subject>
            <subject type="local">nociception</subject>
            <subject type="local">ion channels</subject>
            <subject type="local">sensory nerves</subject>
            <description type="Chief Investigator">Prof Stuart Brierley</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Chronic visceral pain is a major but underappreciated clinical,
                social and economic challenge affecting &gt;1.5 billion people globally. Leading
                forms of chronic visceral pain include irritable bowel syndrome, endometriosis and
                bladder pain syndrome, but all lack effective treatments. Using scientific models,
                human biospecimens and translational science my program will identify the causes of
                these prevalent forms of chronic pain and develop novel treatments for these
                debilitating conditions.</description>
            <description type="fundingAmount">$2,173,555.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008735</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008735</identifier>
            <identifier type="nhmrc">2008735</identifier>
            <name type="primary">
                <namePart>Real-time prediction and monitoring of head and neck cancer
                    treatment</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cancer immunotherapy</subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">cancer biology</subject>
            <subject type="local">cancer prognosis</subject>
            <description type="Chief Investigator">Dr Jenny Lee</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Survival in patients with advanced head and neck cancer remains
                &lt;12 months in the majority. Immunotherapy has durable response, however &lt;20%
                of patients derive benefit. My program of research uses the patient’s tumour to test
                responses to new drugs and select the best therapy. The research applied novel,
                innovative methods and detects cancer using blood samples. Novel clinical trials
                will be designed to improve patient outcomes and avoid unnecessary side effects and
                drive down health care cost.</description>
            <description type="fundingAmount">$530,518.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008737</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008737</identifier>
            <identifier type="nhmrc">2008737</identifier>
            <name type="primary">
                <namePart>Phenotyping Neurobehavioural Disorders in People with Epilepsy</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">epilepsy</subject>
            <subject type="local">neuropsychology</subject>
            <subject type="local">phenotype-genotype correlation</subject>
            <subject type="local">behaviour disorders</subject>
            <subject type="local">cognitive dysfunction</subject>
            <description type="Chief Investigator">Dr Genevieve Rayner</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Neurobehavioural disorders like depression, psychosis, and
                cognitive impairment are common in people with epilepsy. Recent discoveries suggest
                there may be a shared genetic underpinning of the two. This project aims to identify
                whether there are distinct profiles of neurobehavioural disorders in families who
                carry epilepsy genes. Exploring the genetic basis of neurobehavioural disorders will
                improve detection and management of comorbid neurobehavioural disorders in
                epilepsy.</description>
            <description type="fundingAmount">$370,353.39</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008743</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008743</identifier>
            <identifier type="nhmrc">2008743</identifier>
            <name type="primary">
                <namePart>A single cell, single molecule and multi-omics approach to identifying
                    novel targets in heart failure</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">fibroblasts</subject>
            <subject type="local">myofibroblast</subject>
            <subject type="local">heart disease</subject>
            <subject type="local">acute myocardial infarction (AMI)</subject>
            <subject type="local">adult stem cells</subject>
            <description type="Chief Investigator">Prof Richard Harvey</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Heart failure (HF) is a significant problem in our society.
                Fibrosis is associated with virtually all forms of CV disease and leads to problems
                with heart contraction. We hypothesise that a deeper understanding of fibrosis will
                facilitate cardiac regenerative medicine. Our grant focuses on technologies that
                allow us to understand tissue complexity down to the level of single cells. Applying
                these methods, we hope to revolutionise our understanding of cardiac health, ageing
                and disease.</description>
            <description type="fundingAmount">$3,027,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008774</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008774</identifier>
            <identifier type="nhmrc">2008774</identifier>
            <name type="primary">
                <namePart>Partnering with patients to assess and address loneliness in chronic
                    kidney disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">social and behavioural research</subject>
            <subject type="local">kidney disease</subject>
            <subject type="local">nephrology</subject>
            <subject type="local">social networks</subject>
            <subject type="local">health behaviours</subject>
            <description type="Chief Investigator">Ms Karine Manera</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Strong social connections and healthy lifestyles are vital for
                the health of people with chronic kidney disease. This research program will
                establish world-first evidence of the predictors and impacts of loneliness in CKD.
                In partnership with consumers, it will identify patient and caregiver priorities for
                interventions to reduce loneliness and improve social connections, and implement
                these patient-prioritised interventions in a novel trial to improve patient-centred
                care and outcomes.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008781</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008781</identifier>
            <identifier type="nhmrc">2008781</identifier>
            <name type="primary">
                <namePart>Driving Improvements in Ovarian Cancer Survival through Molecular and
                    Clinical Studies</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">ovarian cancer</subject>
            <subject type="local">genomics</subject>
            <subject type="local">cancer biology</subject>
            <subject type="local">drug resistance</subject>
            <subject type="local">targeted therapy</subject>
            <description type="Chief Investigator">Prof David Bowtell</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The Investigator grant would support Professor Bowtell, one of
                the world’s leading ovarian cancer researchers. His work focuses on clinical
                problems of chemotherapy resistance, investigator of rare, exceptional survival
                patient cohorts, and the development of new therapeutic approaches. His studies are
                underpinned by the Australian Ovarian Cancer Study (AOCS), one of the world’s most
                sophisticated clinical cohort studies of ovarian cancer.</description>
            <description type="fundingAmount">$2,427,015.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008793</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008793</identifier>
            <identifier type="nhmrc">2008793</identifier>
            <name type="primary">
                <namePart>Cell Therapies for Newborn Infants: Translating Promise to
                    Benefits</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">prematurity</subject>
            <subject type="local">cell therapy</subject>
            <subject type="local">neuroprotection</subject>
            <subject type="local">early detection</subject>
            <subject type="local">cerebral palsy</subject>
            <description type="Chief Investigator">Dr Atul Malhotra</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Premature babies are at increased risk of brain injury and
                cerebral palsy. Stem cell therapies offer a paradigm shifting treatment strategy for
                preterm brain injury. Over the next five years, I will lead a world-first research
                program to evaluate umbilical cord blood derived cell therapies as an early
                treatment of brain injury in high-risk preterm infants. I will conduct three proof
                of concept studies that are crucial to progress my research pipeline of cell-based
                therapies for preterm infants.</description>
            <description type="fundingAmount">$431,671.37</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008813</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008813</identifier>
            <identifier type="nhmrc">2008813</identifier>
            <name type="primary">
                <namePart>New Knowledge and Research Capacity for Health Impacts of Global
                    Environmental Change with Big Data, Novel Approach and New Technology</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">climate change</subject>
            <subject type="local">air pollution</subject>
            <subject type="local">environmental health</subject>
            <subject type="local">environmental epidemiology</subject>
            <subject type="local">environmental risk factors</subject>
            <description type="Chief Investigator">Prof Yuming Guo</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This Investigator Grant research program will produce extremely
                significant outputs, including transformative changes to guidelines on global
                environmental change (e.g., climate change adaptation strategy, air quality standard
                and extreme weathers’ early warning system), new information to ensure direct
                impacts on public health policy and practice, and development of novel research
                methods for environmental epidemiology and strengthening the Australia’s leadership
                in the field.</description>
            <description type="fundingAmount">$2,598,844.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008839</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008839</identifier>
            <identifier type="nhmrc">2008839</identifier>
            <name type="primary">
                <namePart>Improving outcomes for people with Illness Anxiety Disorder</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">anxiety disorders</subject>
            <subject type="local">psychosomatics</subject>
            <subject type="local">internet service delivery</subject>
            <subject type="local">mental health</subject>
            <subject type="local">mental health services</subject>
            <description type="Chief Investigator">A/Prof Jill Newby</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Illness anxiety disorder emerges early in life, causing great
                distress and disability, but if we detect and treat it early, this can yield great
                benefits in quality of life, and improved mental and physical health. This program
                of research will discover the best ways to assess, diagnose, and detect Illness
                anxiety disorder, improve access to evidence-based treatment using technology-based
                solutions, and develop new and improved treatments for Illness Anxiety
                Disorder.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008853</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008853</identifier>
            <identifier type="nhmrc">2008853</identifier>
            <name type="primary">
                <namePart>Age-associated properties of intraepithelial lymphocytes, and their
                    relation to intestinal diseases</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04gsp2c11</identifier>
                <title>James Cook University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">immunology</subject>
            <subject type="local">mucosal immunology</subject>
            <subject type="local">T cells</subject>
            <subject type="local">cellular immunology</subject>
            <subject type="local">gut immunity</subject>
            <description type="Chief Investigator">Dr Roland Ruscher</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Inflammatory bowel disease (IBD) and colorectal cancer are a
                severe burden to those affected. While the peak onset age of IBD lies in early
                adulthood, colorectal cancer predominantly affects people over 50 years of age. How
                gut immunity fails in the context of age is poorly understood. This program will
                establish cornerstones of the intestinal immune system over different stages in
                life, and thereby help to design better treatment strategies that are adjusted to an
                individual’s age.</description>
            <description type="fundingAmount">$600,740.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008871</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008871</identifier>
            <identifier type="nhmrc">2008871</identifier>
            <name type="primary">
                <namePart>Repetitive DNA as a contributing factor to tauopathy</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">genomics</subject>
            <subject type="local">genomic instability</subject>
            <subject type="local">neurodegeneration</subject>
            <subject type="local">age-related</subject>
            <subject type="local">dementia</subject>
            <description type="Chief Investigator">Dr Jay Rasmussen</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The genome contains many regions of repetitive DNA sequence,
                some of which, termed mobile elements, can "copy-and-paste" themselves into new
                segments of the host genetic material. While a lot is known about the molecular
                mechanism behind their mobility, less is known about how mobile elements contribute
                to diseased states such as neurodegeneration. This project will investigate how
                mobile elements are regulated in tau pathology and whether this is age- or
                cell-specific.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008887</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008887</identifier>
            <identifier type="nhmrc">2008887</identifier>
            <name type="primary">
                <namePart>Microbiome Manipulation to Treat and Cure Inflammatory Bowel
                    Disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">Crohn's disease</subject>
            <subject type="local">inflammatory bowel disease (IBD)</subject>
            <subject type="local">clinical microbiology</subject>
            <subject type="local">translational research</subject>
            <subject type="local">gastrointestinal disease</subject>
            <description type="Chief Investigator">Prof Michael Kamm</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Immunosuppressive therapies for inflammatory bowel disease
                cause side effects and often don’t achieve remission. Targeting gut bacteria, which
                cause these disorders, is a promising alternative strategy. My programs have shown
                that faecal transplantation (FMT) is effective in ulcerative colitis, and identified
                key causative &amp; protective bacteria. I will now assess FMT in Crohn’s disease,
                define how diet &amp; bacteria combined cause inflammation, and identify bacteria
                causing disease complications.</description>
            <description type="fundingAmount">$2,927,015.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008909</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008909</identifier>
            <identifier type="nhmrc">2008909</identifier>
            <name type="primary">
                <namePart>Improving Outcomes in Inflammatory Bowel Disease: A Multifaceted Program
                    of Research</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">chronic inflammatory disease</subject>
            <subject type="local">inflammatory bowel disease (IBD)</subject>
            <subject type="local">Crohn's disease</subject>
            <subject type="local">ulcerative colitis</subject>
            <subject type="local">drug treatment</subject>
            <description type="Chief Investigator">A/Prof Peter De Cruz</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Inflammatory bowel diseases (IBD) are chronic disorders
                involving damage to the gut. IBD is thought to result from an inherited tendency to
                develop an exaggerated immune response to the gut bugs. IBD adversely impacts
                patients’ quality of life, psychological and social functioning. This research
                program seeks to develop new treatments and use existing treatments more
                effectively, discover factors contributing to IBD development and explore
                cost-effective ways of optimally caring for patients.</description>
            <description type="fundingAmount">$1,456,096.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008911</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008911</identifier>
            <identifier type="nhmrc">2008911</identifier>
            <name type="primary">
                <namePart>Reducing the food allergy epidemic through prevention and early
                    intervention</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">food allergy</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">allergy prevention</subject>
            <subject type="local">treatment strategies</subject>
            <subject type="local">translational research</subject>
            <description type="Chief Investigator">A/Prof Kirsten Perrett</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">One in ten Australian infants has food allergy. My research
                program aims to reduce this burden and give every child the best chance of going to
                school without food allergy. Using high-quality clinical trials, I will test
                strategies to prevent food allergy (e.g.: infant vitamin D drops), and early
                intervention strategies to treat young children newly diagnosed with food allergy.
                Through established national collaborations, I will ensure my research findings
                rapidly become standard clinical care.</description>
            <description type="fundingAmount">$1,306,096.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008913</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008913</identifier>
            <identifier type="nhmrc">2008913</identifier>
            <name type="primary">
                <namePart>Unconventional T cells: Fundamental biology and therapeutic
                    potential</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">immunity</subject>
            <subject type="local">T cell immunity</subject>
            <subject type="local">tumour immunity</subject>
            <subject type="local">antiviral immunity</subject>
            <subject type="local">innate immunity</subject>
            <description type="Chief Investigator">Prof Dale Godfrey</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">There are many cell types in the human immune system that we
                still do not understand, in particular, a group of white blood cells broadly known
                as unconventional T cells. These cells detect abnormalities in molecules such as
                lipids, signatures of microbial infection, and drug metabolites, and they play a
                unique role in infection, cancer, allergy, autoimmunity, and tissue maintenance.
                This project aims to better understand the development and function of these cells
                in health and disease.</description>
            <description type="fundingAmount">$3,927,015.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008920</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008920</identifier>
            <identifier type="nhmrc">2008920</identifier>
            <name type="primary">
                <namePart>Taking neuroinflammation out of TDP-43 proteinopathies</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">neuroinflammation</subject>
            <subject type="local">neurodegenerative disorders</subject>
            <subject type="local">mitochondrial disease</subject>
            <subject type="local">neuronal cell death</subject>
            <subject type="local">type I interferon</subject>
            <description type="Chief Investigator">Dr Chien-Hsiung Yu</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Abnormal accumulation of proteins inside cells of the central
                nervous system is a disease hallmark of ALS/FTLD. I have discovered that one protein
                in particular, TDP-43, triggers an inflammatory response that precedes overt disease
                symptoms. My investigation of this inflammatory pathway will define how it triggers
                cell death. Further, understanding how TDP-43 causes disease will aid drug
                development and advance our knowledge of the pathogenesis of these incurable
                conditions.</description>
            <description type="fundingAmount">$600,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008921</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008921</identifier>
            <identifier type="nhmrc">2008921</identifier>
            <name type="primary">
                <namePart>Better treatments for autoimmune kidney disease and vasculitis</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">glomerulonephritis</subject>
            <subject type="local">kidney disease</subject>
            <subject type="local">vasculitis</subject>
            <subject type="local">autoimmune disease</subject>
            <subject type="local">cellular immunity</subject>
            <description type="Chief Investigator">Prof Arthur Kitching</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Severe kidney disease caused by autoimmune inflammation of
                small blood vessels has no cure, and treatments cause significant side effects.
                However, opportunities exist for therapies that target only the abnormal parts of
                the immune response. Work in this application will provide a pathway for the
                development and testing of these new approaches, by understanding how disease occurs
                and which parts of the critical proteins involved are the culprits in these damaging
                and debilitating diseases.</description>
            <description type="fundingAmount">$2,297,570.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008928</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008928</identifier>
            <identifier type="nhmrc">2008928</identifier>
            <name type="primary">
                <namePart>SPatially ACcurate Evaluation (SPACE) of Cancer Biopsies</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">bioinformatics</subject>
            <subject type="local">differential gene expression</subject>
            <subject type="local">computer-assisted diagnosis</subject>
            <subject type="local">malignant skin melanoma</subject>
            <subject type="local">cancer biology</subject>
            <description type="Chief Investigator">Dr Quan Nguyen</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Almost all suspected cancer patients have tissue biopsies
                manually examined. For decades, histological images are essential for diagnosis and
                treatment-decision making. Such an image diagnosis, however, fails to identify many
                cell types and their molecular signatures that underpin cancer metastasis. This
                program aims to establish a paradigm-shifting approach that maps spatially defined
                molecular data to tissue images, allowing for mechanistic understandings and
                accurate prediction of metastasis.</description>
            <description type="fundingAmount">$1,353,726.56</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008955</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008955</identifier>
            <identifier type="nhmrc">2008955</identifier>
            <name type="primary">
                <namePart>CultureCare: Co-designing an aged care decision aid for the South Asian
                    communities to empower informed and culturally safe decision making about aged
                    care services</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00200ya62</identifier>
                <title>National Ageing Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">aged care</subject>
            <subject type="local">cross-cultural</subject>
            <subject type="local">ageing population</subject>
            <subject type="local">access to health care</subject>
            <subject type="local">dementia care</subject>
            <description type="Chief Investigator">Dr Josefine Antoniades</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">This program of work seeks to develop a decision aid to empower
                older people and their families from South Asian backgrounds to plan, navigate and
                appraise aged care services to ensure these meet the needs of the older person. In
                this work, members of the South Asian community will be involved at every step of
                the project to ensure that the decision aid is culturally relevant, meets the needs
                of the community and is useful in the decision making process.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008956</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008956</identifier>
            <identifier type="nhmrc">2008956</identifier>
            <name type="primary">
                <namePart>Improving the health and wellbeing of transgender Australians</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">gender differences</subject>
            <subject type="local">gender</subject>
            <subject type="local">testosterone</subject>
            <subject type="local">estradiol</subject>
            <subject type="local">suicide prevention</subject>
            <description type="Chief Investigator">Dr Ada Cheung</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Transgender Australians are arguably among the most
                marginalised and socioeconomically disadvantaged groups in our community with high
                rates of depression, suicidality and a lack of research to guide optimal
                gender-affirming hormone and surgical interventions. This project will provide
                robust evidence to improve the health and well-being of the transgender community to
                guide treatment guidelines, and health policy, to enable trans people to live a life
                without barriers and discrimination.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008971</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008971</identifier>
            <identifier type="nhmrc">2008971</identifier>
            <name type="primary">
                <namePart>Nutritional Psychiatry: Investigation and translation of personalised
                    nutritional therapies for depression</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02czsnj07</identifier>
                <title>Deakin University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">mental health</subject>
            <subject type="local">nutrition</subject>
            <subject type="local">diet</subject>
            <subject type="local">depression</subject>
            <subject type="local">treatment</subject>
            <description type="Chief Investigator">Dr Wolfgang Marx</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Mental disorders account for the leading cause of disability.
                Dietary interventions represent a novel efficacious treatment to avert this
                significant burden. To advance the field of Nutritional Psychiatry, we need to
                establish how diet affects depression, who is most receptive to treatment, and
                design guidelines on how best to integrate diet into mental health care. My program
                of research will advance the evidence base and facilitate translation of this new
                knowledge into policy and practice.</description>
            <description type="fundingAmount">$551,268.65</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008981</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008981</identifier>
            <identifier type="nhmrc">2008981</identifier>
            <name type="primary">
                <namePart>A molecular investigation into T cell antigen receptor function and
                    dysfunction in humans</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">cellular immunology</subject>
            <subject type="local">innate immunity</subject>
            <subject type="local">major histocompatibility complex (MHC)</subject>
            <subject type="local">X-ray crystallography</subject>
            <subject type="local">autoimmune disease</subject>
            <description type="Chief Investigator">Prof Jamie Rossjohn</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">I am a biomedical researcher who focuses on understanding
                processes central to infection and immunity. My research program covers the
                pathogenesis of infectious human diseases, adaptive and innate immunity and
                autoimmunity. I use biochemical approaches and structural biology as my main
                research tool, and my research program, which involves an international network of
                basic, clinical and industrial collaborators, has considerable relevance to applied
                outcomes for human immunological diseases.</description>
            <description type="fundingAmount">$3,927,015.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008983</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008983</identifier>
            <identifier type="nhmrc">2008983</identifier>
            <name type="primary">
                <namePart>Leveraging human genetics to inform treatment in fatty liver
                    disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">fatty liver disease</subject>
            <subject type="local">hepatic fibrosis</subject>
            <subject type="local">liver</subject>
            <subject type="local">hepatic</subject>
            <subject type="local">liver cirrhosis</subject>
            <description type="Chief Investigator">A/Prof Mohammed Eslam</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Fatty liver disease affects 1 in 3 Australians and a quarter
                will develop liver failure or cancer; it has no drug treatments. The disease is
                characterized by tremendous variability in its clinical course, in part due to a
                lack of understanding of its genetic basis. To move towards personalised medicine,
                this program will undertake human and small animal studies to develop novel
                gene-based tests for diagnostics and risk classification and identify genes that are
                targets for drug development.</description>
            <description type="fundingAmount">$1,270,120.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008990</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008990</identifier>
            <identifier type="nhmrc">2008990</identifier>
            <name type="primary">
                <namePart>Reducing the burden of DNA viruses on human health</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">virology</subject>
            <subject type="local">antiviral immunity</subject>
            <subject type="local">antigen presentation</subject>
            <subject type="local">CD8 T cells</subject>
            <subject type="local">Herpes simplex virus (HSV)</subject>
            <description type="Chief Investigator">Prof David Tscharke</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">I aim to improve health by understanding how viruses interact
                with our bodies. This includes processes inside cells that keep microbes like the
                cold sore virus dormant. Also the way in which the white blood cells that allow our
                immune system to remember and respond more quickly to an infection after vaccination
                choose the parts of a virus to target. Finally we will find ways to help people on
                some treatments for diseases like multiple sclerosis avoid a common virus that is
                dangerous for them.</description>
            <description type="fundingAmount">$2,072,570.00</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009005</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009005</identifier>
            <identifier type="nhmrc">2009005</identifier>
            <name type="primary">
                <namePart>Primordial prevention of cardiovascular disease from childhood</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01nfmeh72</identifier>
                <title>University of Tasmania</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">cardiovascular disease prevention</subject>
            <subject type="local">cardiovascular risk factors</subject>
            <subject type="local">cardiovascular health</subject>
            <subject type="local">child health</subject>
            <subject type="local">arterial stiffness</subject>
            <description type="Chief Investigator">Dr Rachel Climie</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cardiovascular disease (CVD) is the leading cause of death
                worldwide. The risk factors for CVD begin to develop in childhood. Given the
                increasing rates of poor health in children worldwide, my research program will
                identify factors contributing to cardiovascular health in childhood, establish new
                ways to detect children at risk of developing CVD, and will develop strategies to
                improve cardiovascular health in children that can be easily implemented into policy
                and practice.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">TAS</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009010</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009010</identifier>
            <identifier type="nhmrc">2009010</identifier>
            <name type="primary">
                <namePart>The Dormant Cancer Cell Life Cycle</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">bone biology</subject>
            <subject type="local">bone cancer</subject>
            <subject type="local">bone cells</subject>
            <subject type="local">multiple myeloma</subject>
            <subject type="local">bone metastasis</subject>
            <description type="Chief Investigator">Prof Peter Croucher</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">In many major cancers, tumour cells spread to the skeleton and
                hide there in a long-term ‘dormant’ state where they resist current therapies. When
                they are ‘woken up’, they cause cancer relapse, at which point prognosis is poor. My
                vision is to devise new treatments that eradicate these rare dormant cells, so as to
                cure cancers that spread to bone. I will achieve this by defining the cell and
                molecular pathways, in dormant cells and in the surrounding bone, that control
                dormancy and relapse.</description>
            <description type="fundingAmount">$3,427,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009026</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009026</identifier>
            <identifier type="nhmrc">2009026</identifier>
            <name type="primary">
                <namePart>Hypoxaemia detection and management for at-risk newborns and children in
                    Sub-Saharan Africa</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">pulse oximetry</subject>
            <subject type="local">oxygen</subject>
            <subject type="local">pneumonia</subject>
            <subject type="local">premature infant</subject>
            <subject type="local">hypoxaemia</subject>
            <description type="Chief Investigator">Dr Hamish Graham</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Low blood oxygen levels (hypoxaemia) are common in COVID-19,
                pneumonia, and many other illnesses. In low-resource settings, many patients who
                need oxygen will not receive it, and could die. My research aims to make oxygen more
                accessible and safe to patients, particularly small newborns, children, and people
                living in remote locations. I will test a new device to deliver oxygen to babies
                more safely, and test whether introducing pulse oximetry to small clinics saves
                lives.</description>
            <description type="fundingAmount">$570,592.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009035</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009035</identifier>
            <identifier type="nhmrc">2009035</identifier>
            <name type="primary">
                <namePart>Transforming the prevention and treatment of child and adolescent
                    obesity</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">obesity</subject>
            <subject type="local">adolescent health</subject>
            <subject type="local">early childhood</subject>
            <subject type="local">health promotion</subject>
            <subject type="local">health services</subject>
            <description type="Chief Investigator">Prof Louise Baur</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Obesity in children &amp; adolescents is a serious problem with
                immediate and future complications. My vision is to lead an interdisciplinary
                program of research in preventing obesity in childhood and providing safe, effective
                treatments to children and adolescents living with obesity. My work will result in
                recommendations for targeting early childhood obesity prevention, personalised
                approaches to obesity treatment, and models of care &amp; costings for paediatric
                obesity treatment in Australia.</description>
            <description type="fundingAmount">$1,750,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009047</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009047</identifier>
            <identifier type="nhmrc">2009047</identifier>
            <name type="primary">
                <namePart>Alleviating anaemia in mothers and babies worldwide</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">anaemia</subject>
            <subject type="local">iron deficiency</subject>
            <subject type="local">nutrition</subject>
            <subject type="local">randomised controlled trial (RCT)</subject>
            <subject type="local">translational research</subject>
            <description type="Chief Investigator">A/Prof Sant-Rayn Pasricha</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Anaemia can cause fatigue, lethargy, and impair health outcomes
                during pregnancy and in children, and affects over 1.7 billion people. I will
                develop and test innovative new solutions to reduce anaemia in children and pregnant
                mothers, and use samples from these studies to drive new discoveries that will
                inform development of next generation improved treatments. Finally, I lead the WHO
                Collaborating Centre on anaemia control, enabling our findings to be quickly
                translated into practice.</description>
            <description type="fundingAmount">$2,398,844.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009050</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009050</identifier>
            <identifier type="nhmrc">2009050</identifier>
            <name type="primary">
                <namePart>Personalising colorectal cancer prevention strategies with a risk
                    stratification tool</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">cancer epidemiology</subject>
            <subject type="local">public health</subject>
            <subject type="local">dietary lifestyle</subject>
            <subject type="local">colorectal cancer prevention</subject>
            <subject type="local">health surveillance</subject>
            <description type="Chief Investigator">Dr Molla Wassie</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Bowel cancer is the second leading cause of cancer death in
                Australia. People who are at increased risk for this cancer are recommended to have
                colonoscopies every 3-5 years, with minimal personalisation to the individual’s risk
                factors (such as age, diet and lifestyle). This study will develop a computerised
                risk factor tool to personalise cancer prevention strategies for this high-risk
                subgroup of the population thereby utilising colonoscopy resources more
                efficiently.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009062</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009062</identifier>
            <identifier type="nhmrc">2009062</identifier>
            <name type="primary">
                <namePart>Mining the Molecular Machinery of Cell Death for Novel Drug
                    Targets</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">apoptosis</subject>
            <subject type="local">cell death</subject>
            <subject type="local">structural biology</subject>
            <subject type="local">X-ray crystallography</subject>
            <subject type="local">electron microscopy</subject>
            <description type="Chief Investigator">A/Prof Peter Czabotar</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Programmed cell death is a process the body uses to kill cells
                that are no longer needed, damaged or dangerous, e.g. those that have become
                cancerous or infected with viruses. Our studies have shown that the pathways that
                control cell death are targets for therapy, e.g. in cancer. We will continue to
                uncover the molecular details of how these pathways are regulated to provide new
                strategies for the development of therapeutic agents to treat diseases characterised
                by cell death malfunction.</description>
            <description type="fundingAmount">$2,472,570.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009075</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009075</identifier>
            <identifier type="nhmrc">2009075</identifier>
            <name type="primary">
                <namePart>Inflammasome inhibitors as new first-in-class anti-inflammatory
                    therapies</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">caspases</subject>
            <subject type="local">anti-inflammatory agents</subject>
            <subject type="local">innate immunity</subject>
            <subject type="local">macrophage biology</subject>
            <subject type="local">chronic inflammation</subject>
            <description type="Chief Investigator">Prof Kate Schroder</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Inflammation drives many devastating human diseases, and there
                are currently no effective treatments for many such diseases. My research program
                aims to leverage my validated discovery and development pipeline to deliver new
                first-in-class anti-inflammatory drugs to treat devastating diseases such as chronic
                liver disease and inflammatory bowel disease.</description>
            <description type="fundingAmount">$2,872,570.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009079</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009079</identifier>
            <identifier type="nhmrc">2009079</identifier>
            <name type="primary">
                <namePart>Harnessing genetics to halt the sneak thief of sight.</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01nfmeh72</identifier>
                <title>University of Tasmania</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">glaucoma</subject>
            <subject type="local">complex genetic disease</subject>
            <subject type="local">adult stem cells</subject>
            <subject type="local">genetic association</subject>
            <subject type="local">genetic susceptibility</subject>
            <description type="Chief Investigator">Prof Alex Hewitt</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Glaucoma is the leading cause of irreversible blindness
                worldwide. In the early stages it is asymptomatic, and as such many people present
                at advanced stages of the disease when irreversible vision loss has already
                occurred. This research will reduce blindness and visual impairment from glaucoma
                through an improved prediction of high-risk individuals for developing glaucoma, and
                by the development of new therapies stemming from a better understanding of the
                molecular mechanisms of this disease.</description>
            <description type="fundingAmount">$2,072,570.00</description>
            <coverage>
                <spatial type="text">TAS</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009096</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009096</identifier>
            <identifier type="nhmrc">2009096</identifier>
            <name type="primary">
                <namePart>Fall prevention: innovation and translation</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">accidental falls</subject>
            <subject type="local">exercise</subject>
            <subject type="local">aged health</subject>
            <subject type="local">multiple sclerosis (MS)</subject>
            <subject type="local">Parkinson disease</subject>
            <description type="Chief Investigator">Prof Stephen Lord</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Falls are a major health care problem for older adults and
                people with neurodegenerative disorders. This program will evaluate novel fall
                prevention interventions in older people and people with multiple sclerosis and
                Parkinson’s disease. By developing software, diagnostic tools and balance training
                systems, my program intends to improve the health and wellbeing of older people and
                clinical populations with balance impairments.</description>
            <description type="fundingAmount">$2,352,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009136</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009136</identifier>
            <identifier type="nhmrc">2009136</identifier>
            <name type="primary">
                <namePart>Personalised Melanoma Risk Score: Development and Evaluation of a
                    Co-Designed Toolkit for Nation-Wide Implementation</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">genetic counselling</subject>
            <subject type="local">genomics</subject>
            <subject type="local">polygenic diseases</subject>
            <subject type="local">melanoma</subject>
            <subject type="local">communications/social research</subject>
            <description type="Chief Investigator">Dr Tatiane Yanes</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Personalised risk prediction models that combined the effects
                of several genetic and non-genetic factors are rapidly being implemented in clinical
                practice. However, there is little implementation research on personalised risk, and
                data on the patient reported outcomes and risk management behaviour is scarce. For
                this study, I will develop a framework that provides guidance regarding optimal risk
                communication and a pathway for the successful translation of personalised risk
                information.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009152</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009152</identifier>
            <identifier type="nhmrc">2009152</identifier>
            <name type="primary">
                <namePart>Stereo-EEG and precision neuropsychology: optimising epilepsy surgery and
                    minimising neurocognitive risk</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">epilepsy</subject>
            <subject type="local">epilepsy surgery</subject>
            <subject type="local">electroencephalogram (EEG)</subject>
            <subject type="local">neuropsychology</subject>
            <subject type="local">neurophysiology</subject>
            <description type="Chief Investigator">Dr Andrew Neal</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">To guide safe and successful epilepsy surgery, many patients
                may require sensors to be placed in the brain to map seizures. Electrical impulses
                can also be delivered through these sensors to test the function of different brain
                regions so that important brain structures are not removed. However, we do not know
                the best way to test language and memory. This project will develop a new method to
                assess brain function in patients with epilepsy in order to improve surgical
                outcomes.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009163</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009163</identifier>
            <identifier type="nhmrc">2009163</identifier>
            <name type="primary">
                <namePart>Dissecting the impacts of the bacterial host versus plasmid on the AMR
                    burden</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">klebsiella</subject>
            <subject type="local">plasmids</subject>
            <subject type="local">antimicrobial resistance</subject>
            <subject type="local">bacterial evolution</subject>
            <subject type="local">genomics</subject>
            <description type="Chief Investigator">Dr Margaret Lam</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Plasmids, mobile DNA, transmit antimicrobial resistance (AMR).
                This project will use an innovative approach of experimental evolution and the
                latest DNA and RNA sequencing technology to study how AMR plasmids spread and evolve
                in multidrug-resistant Klebsiella pneumoniae strains within different clinical
                settings. Expected outcomes include enhanced knowledge in bacterial-plasmid
                co-evolution critically needed for targeted surveillance, detection and control
                strategies to curb the spread of AMR.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009177</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009177</identifier>
            <identifier type="nhmrc">2009177</identifier>
            <name type="primary">
                <namePart>Genetically defining and pharmacologically exploiting new oncogenic
                    dependencies in Myc-driven lymphoid cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">human malignant B-cell lymphoma</subject>
            <subject type="local">c-myc</subject>
            <subject type="local">multiple myeloma</subject>
            <subject type="local">epigenetics</subject>
            <subject type="local">targeted therapy</subject>
            <description type="Chief Investigator">A/Prof Jake Shortt</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">I will develop new treatments for blood cancers like multiple
                myeloma (MM) and B-cell lymphoma that share biological features associated with
                resistance to conventional treatments. By genetically editing the cancer-causing
                genes in MM and B-cell lymphoma, I have identified new (non-chemotherapy) drug
                targets that can overcome treatment resistance. My research will validate such drug
                targets and devise new therapies to improve patient outcomes.</description>
            <description type="fundingAmount">$1,228,048.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009203</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009203</identifier>
            <identifier type="nhmrc">2009203</identifier>
            <name type="primary">
                <namePart>Improving outcomes in patients with sepsis through precision
                    medicine</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">intensive care medicine</subject>
            <subject type="local">sepsis</subject>
            <subject type="local">systemic infection</subject>
            <subject type="local">genomics</subject>
            <subject type="local">corticosteroids</subject>
            <description type="Chief Investigator">Prof Bala Venkatesh</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Patients with life threatening infections may die or have major
                residual health issues. Previous attempts to treat such patients have focussed
                mainly on the infecting agent. It is now recognized that the genetic and biological
                make-up of the patient also plays a major role in the response to treatment. This
                work will improve the understanding of life threatening illnesses which will then be
                used to personalise patient treatments for improving outcomes with life threatening
                infections.</description>
            <description type="fundingAmount">$1,870,806.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009209</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009209</identifier>
            <identifier type="nhmrc">2009209</identifier>
            <name type="primary">
                <namePart>A National Wastewater Surveillance Program for Antimicrobial
                    Resistance</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">antimicrobial resistance</subject>
            <subject type="local">population health</subject>
            <subject type="local">epidemiology</subject>
            <subject type="local">chemistry</subject>
            <subject type="local">mass spectrometry</subject>
            <description type="Chief Investigator">Dr Jake O'Brien</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This fellowship aims to provide a world-class surveillance
                method for antimicrobial use and antimicrobial resistance genes in Australia's
                general population through wastewater-based epidemiology. Expected outcomes include
                building capacity to objectively measure antimicrobial use and antimicrobial
                resistance in the general population. Significant benefits expected include a cost
                effective, rapid surveillance tool to meet the emergent needs of bacterial disease
                outbreaks.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009216</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009216</identifier>
            <identifier type="nhmrc">2009216</identifier>
            <name type="primary">
                <namePart>Novel approaches to preventing perinatal death and disability from birth
                    asphyxia</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">fetal distress</subject>
            <subject type="local">fetal growth restriction</subject>
            <subject type="local">caesarean section</subject>
            <subject type="local">stillbirth</subject>
            <subject type="local">placental function</subject>
            <description type="Chief Investigator">Prof Sailesh Kumar</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Fetal distress is often caused by lack of oxygen because the
                poorly functioning placenta limits oxygen and nutrient supply to the baby. Lack of
                oxygen can cause brain injury and death. Sildenafil increases blood flow to the
                placenta potentially reducing this risk. The proposed body of work will address this
                problem and will develop tools to identify at-risk babies and evaluate if Sildenafil
                reduces the risk of injury related to birth asphyxia and rates of emergency
                caesarean section.</description>
            <description type="fundingAmount">$2,174,514.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009231</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009231</identifier>
            <identifier type="nhmrc">2009231</identifier>
            <name type="primary">
                <namePart>Inflammation and chronic infections in the pathogenesis of Alzheimer’s
                    disease: the role of amyloid cross-seeding.</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">Alzheimer disease</subject>
            <subject type="local">amyloid</subject>
            <subject type="local">inflammation</subject>
            <subject type="local">bacterial infection</subject>
            <subject type="local">fungal infection</subject>
            <description type="Chief Investigator">Dr Aleksandr Kakinen</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project seeks to evaluate the pathological role of
                inflammation and infections in the development and progression of Alzheimer’s
                disease, the most common cause of dementia. The knowledge generated in this study
                will guide future drug discovery and development approaches against Alzheimer’s
                disease, especially for people who have faced acute or chronic inflammations or have
                been affected by bacterial and fungal infections.</description>
            <description type="fundingAmount">$517,233.19</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009237</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009237</identifier>
            <identifier type="nhmrc">2009237</identifier>
            <name type="primary">
                <namePart>Neuroinflammation in schizophrenia</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">schizophrenia</subject>
            <subject type="local">neuropsychiatric disorders</subject>
            <subject type="local">molecular neuroscience</subject>
            <subject type="local">molecular biology</subject>
            <subject type="local">inflammation</subject>
            <description type="Chief Investigator">Prof Cynthia Shannon Weickert</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Schizophrenia is debilitating disorder in need of a cure.
                Inflammation along with macrophage invasion occurs in the brains of ~40-45% of the
                people with schizophrenia. I aim to block immune cell invasion and test if the
                symptoms of schizophrenia can be reversed. Through studies of the human brain, basic
                science studies and novel investigator initiated clinical trials, I will continue to
                develop strategies to dampen neuroinflammation and to prevent damaging immune cells
                entering the brain.</description>
            <description type="fundingAmount">$2,427,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009253</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009253</identifier>
            <identifier type="nhmrc">2009253</identifier>
            <name type="primary">
                <namePart>Strengthen the role of health economics in perinatal health to inform
                    priority setting and funding decisions</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">health economics</subject>
            <subject type="local">burden of disease</subject>
            <subject type="local">economic evaluation</subject>
            <subject type="local">disease modelling</subject>
            <subject type="local">cost-effectiveness</subject>
            <description type="Chief Investigator">Dr Xinyang Hua</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">My program will develop new health economics methods to guide
                government decisions and help achieve the best health outcomes for children through
                more efficient and fair health care services during pregnancy and the year after
                birth.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009254</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009254</identifier>
            <identifier type="nhmrc">2009254</identifier>
            <name type="primary">
                <namePart>Creating an active Australia through active systems: Co-production of
                    multi-sectoral population physical activity strategies</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">disease prevention</subject>
            <subject type="local">population health</subject>
            <subject type="local">health promotion</subject>
            <subject type="local">public health policy</subject>
            <subject type="local">physical activity</subject>
            <description type="Chief Investigator">Dr Ding Ding</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">To prevent chronic disease, Australians need to become more
                physically active. This proposed research examines the value of solutions that
                promote physical activity, including changes to urban planning and transport. The
                research combines scientific evidence and local expertise to develop a
                decision-making tool to help predict the health, economic and environmental impacts
                of different solutions. The findings will guide policymakers in adopting the best
                strategies to promote physical activity.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009264</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009264</identifier>
            <identifier type="nhmrc">2009264</identifier>
            <name type="primary">
                <namePart>Unravelling the Contributions of Sleep Dysfunction to Alzheimer’s Disease
                    and Dementia</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">dementia</subject>
            <subject type="local">Alzheimer disease</subject>
            <subject type="local">neurodegenerative disorders</subject>
            <subject type="local">sleep/wake patterns</subject>
            <subject type="local">longitudinal cohort study</subject>
            <description type="Chief Investigator">A/Prof Matthew Pase</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">My research program will determine whether poor sleep should be
                a therapeutic target for reducing dementia risk. Using longitudinal cohort studies,
                I will identify the changes in sleep that most strongly predict the risk of
                Alzheimer’s disease and dementia. Results will guide targeted sleep interventions to
                reduce dementia risk and help select at risk subjects for inclusion in dementia
                prevention trials.</description>
            <description type="fundingAmount">$1,306,096.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009278</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009278</identifier>
            <identifier type="nhmrc">2009278</identifier>
            <name type="primary">
                <namePart>Mathematical modelling to support policy decisions on COVID-19 vaccination
                    in Australia</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">COVID-19</subject>
            <subject type="local">vaccine strategy</subject>
            <subject type="local">mathematical modelling</subject>
            <subject type="local">population health</subject>
            <subject type="local">infectious diseases</subject>
            <description type="Chief Investigator">Dr Alexandra Hogan</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Vaccination against COVID-19 is underway globally. However,
                even as the virus is controlled by vaccination, it will be very difficult to
                eliminate COVID-19 completely, and we will need additional vaccine doses to boost
                protection against current and variant strains. I will use mathematical models to
                estimate the health benefit of COVID-19 vaccines, and to inform policy planning for
                longer-term, sustainable COVID-19 vaccine programs in Australia and
                regionally.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009280</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009280</identifier>
            <identifier type="nhmrc">2009280</identifier>
            <name type="primary">
                <namePart>Endovascular Neuromodulation</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">motor neuron disease (MND)</subject>
            <subject type="local">paralysis</subject>
            <subject type="local">artificial neural networks</subject>
            <subject type="local">biomedical engineering</subject>
            <subject type="local">stroke</subject>
            <description type="Chief Investigator">A/Prof Thomas Oxley</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The blood vessels provide access to regions of brain and nerves
                in the body that enable treatment with implantable devices. Interventional
                techniques enable a method of implanting a device while avoiding open brain surgery.
                Building off of work already achieved over a 6 year period, this grant progresses a
                body of world-first research that is proving the safety and efficacy of the first
                applications in paralysis and epilepsy in this new field of medicine.</description>
            <description type="fundingAmount">$443,109.73</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009283</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009283</identifier>
            <identifier type="nhmrc">2009283</identifier>
            <name type="primary">
                <namePart>Reducing Resuscitation Errors</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">resuscitation</subject>
            <subject type="local">traumatic injury</subject>
            <subject type="local">surgical procedures</subject>
            <subject type="local">decision support techniques</subject>
            <subject type="local">computer-based decision support</subject>
            <description type="Chief Investigator">Prof Mark Fitzgerald</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Error-free decisions made during resuscitation are fundamental
                to the subsequent recovery of the critically ill. A computer-assisted, resuscitation
                decision support system has already been shown to reduce clinical errors and improve
                outcomes during the resuscitation of the severely injured. This project will
                research and develop the system to include cardiac, stroke, sepsis, pediatric,
                toxidrome and obstetric emergencies and ascertain the effectiveness in these domains
                as well..</description>
            <description type="fundingAmount">$1,500,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009287</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009287</identifier>
            <identifier type="nhmrc">2009287</identifier>
            <name type="primary">
                <namePart>Defining a novel waste disposal mechanism that aids vascular homeostasis
                    and prevents inflammation</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">autophagy</subject>
            <subject type="local">inflammation</subject>
            <subject type="local">endothelial cells</subject>
            <subject type="local">cell biology</subject>
            <subject type="local">inflammatory diseases</subject>
            <description type="Chief Investigator">Dr Georgia Atkin-Smith</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">The survival of our cellular building blocks is crucial to
                prevent disease. One way in which our cells maintain their health is through
                disposing of cellular waste. This project will investigate a new waste disposal
                system employed by key cells that line the vascular system. Through advanced mouse
                models and imaging techniques, this project will determine how our cells survive
                under healthy and disease conditions, and how disposing of their waste correctly can
                prevent harmful inflammation.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009288</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009288</identifier>
            <identifier type="nhmrc">2009288</identifier>
            <name type="primary">
                <namePart>Reproductive bodies across borders: Enhancing fertility management among
                    culturally and linguistically diverse women in Australia.</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03t52dk35</identifier>
                <title>University of Western Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">refugee health</subject>
            <subject type="local">migrant health</subject>
            <subject type="local">contraception</subject>
            <subject type="local">qualitative methods</subject>
            <subject type="local">women's health</subject>
            <description type="Chief Investigator">Dr Alexandra Hawkey</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project will explore CALD women’s perception and
                experiences of fertility control, focusing on fertility decision-making,
                contraception, and management of unplanned pregnancies, areas that have previously
                been underexplored. It will address CALD women’s health literacy and fertility
                control support needs through the co-design and evaluation of an online health
                educational resource, a knowledge translation exhibition and recommendations for
                health promotion and healthcare provision.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009295</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009295</identifier>
            <identifier type="nhmrc">2009295</identifier>
            <name type="primary">
                <namePart>Translating lifestyle-based mental health care into practice</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02czsnj07</identifier>
                <title>Deakin University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">lifestyle</subject>
            <subject type="local">mental disorder</subject>
            <subject type="local">dietary factors</subject>
            <subject type="local">exercise</subject>
            <subject type="local">quality of care</subject>
            <description type="Chief Investigator">A/Prof Adrienne O'Neil</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We now know that providing clinical care to people with mental
                health problems that improves their diet, physical activity and sleep, while
                reducing their smoking, drug and alcohol use is highly beneficial for their mental
                health as well as their physical health. Yet this type of care is not typically
                offered as part of routine mental health care. My research will produce evidence
                that addresses this gap to improve the lives of individuals with mental health
                concerns in Australia and beyond.</description>
            <description type="fundingAmount">$1,567,933.24</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009303</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009303</identifier>
            <identifier type="nhmrc">2009303</identifier>
            <name type="primary">
                <namePart>Improving outcomes in peritoneal dialysis through patient-centred clinical
                    trials</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">nephrology</subject>
            <subject type="local">kidney disease</subject>
            <subject type="local">consumers</subject>
            <subject type="local">patient safety</subject>
            <subject type="local">collaboration</subject>
            <description type="Chief Investigator">A/Prof Yeoung-Jee Cho</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Globally, the number of people living with kidney disease
                requiring dialysis or transplantation is growing. Peritoneal dialysis (PD), a form
                of home-based therapy, has been promoted by the international community as a
                solution to overcome this crisis. Yet, globally only 11% of patients on dialysis
                receive PD and the number of people choosing PD therapy for their kidney disease is
                declining. My research program is focussed on patient-important outcomes to directly
                address these deficiencies.</description>
            <description type="fundingAmount">$1,342,072.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009306</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009306</identifier>
            <identifier type="nhmrc">2009306</identifier>
            <name type="primary">
                <namePart>Safeguarding the next generation: Using data to map and address
                    injury-related harm in adolescence</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">accidental injury</subject>
            <subject type="local">rural and remote health</subject>
            <subject type="local">adolescence</subject>
            <subject type="local">alcohol</subject>
            <subject type="local">injury prevention</subject>
            <description type="Chief Investigator">Dr Amy Peden</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Globally, injury is a preventable cause of harm. This research
                focuses on preventing injury among adolescents and aims to assess and benchmark data
                on adolescent injury in Australia and the Western Pacific region, while also
                expanding understanding of the impact of remoteness and alcohol on adolescent fatal
                and non-fatal injury in urban and rural New South Wales, informing a pilot co-design
                process to develop an alcohol and injury prevention intervention for rural dwelling
                adolescents.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009308</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009308</identifier>
            <identifier type="nhmrc">2009308</identifier>
            <name type="primary">
                <namePart>Harnessing T cell immunity to boost vaccine efficacy</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">CD4</subject>
            <subject type="local">vaccine</subject>
            <subject type="local">antibody</subject>
            <subject type="local">Coronavirus</subject>
            <subject type="local">T cell response</subject>
            <description type="Chief Investigator">Dr Jennifer Juno</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The recent SARS-CoV-2 pandemic has highlighted the need for
                rapid, large-scale vaccine development. This research program will study how
                specific types of T cells can be activated in order to improve the immune response
                to vaccines, with the goal of identifying new vaccine platforms that can be
                successfully deployed in future pandemics. This work will advance our knowledge of
                vaccine-related immunology and significantly improve human health.</description>
            <description type="fundingAmount">$1,320,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009309</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009309</identifier>
            <identifier type="nhmrc">2009309</identifier>
            <name type="primary">
                <namePart>Deciphering the impact of non-coding mutations in congenital heart
                    disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">enhancer</subject>
            <subject type="local">comparative genomics</subject>
            <subject type="local">heart development</subject>
            <subject type="local">functional genomics</subject>
            <subject type="local">control of gene expression</subject>
            <description type="Chief Investigator">Dr Emily Wong</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Enhancers are non-coding regions of genomic DNA that play a
                crucial role in determining cellular identity. They are over-represented at genetic
                variants associated with disease. The goal of this proposal is to identify enhancers
                causal to human disease using in vivo high-throughput imaging and quantitative
                biology. The focus is to uncover the functional consequences of human enhancer
                variants in congenital heart disease.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009322</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009322</identifier>
            <identifier type="nhmrc">2009322</identifier>
            <name type="primary">
                <namePart>Safer anaesthesia for children - optimizing perioperative outcomes by
                    advancing and translating knowledge into clinical practice using an
                    international, interdisciplinary approach</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">anaesthesia</subject>
            <subject type="local">paediatric</subject>
            <subject type="local">patient outcomes</subject>
            <subject type="local">complications</subject>
            <subject type="local">adverse events</subject>
            <description type="Chief Investigator">Prof Britta Regli-von
                Ungern-Sternberg</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">One in 20 children in Australia undergoes surgery each year.
                Children are particularly at risk of breathing problems during and after
                anaesthesia. I am investigating methods to predict, prevent and treat these
                problems. I am investigating ways to minimise the effects of anaesthesia on the
                developing brains of babies and improving the clinical tools available to paediatric
                anaesthetists. My goal is to ensure that when a child needs a vital operation, it is
                as safe and pain-free as possible.</description>
            <description type="fundingAmount">$1,874,277.50</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009323</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009323</identifier>
            <identifier type="nhmrc">2009323</identifier>
            <name type="primary">
                <namePart>Restoring the Fair Go: which policies and practices are likely to reverse
                    growing health inequities in Australia post-COVID-19</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">equity</subject>
            <subject type="local">social determinants of health</subject>
            <subject type="local">policy analysis</subject>
            <subject type="local">social disadvantage</subject>
            <subject type="local">social justice</subject>
            <description type="Chief Investigator">Prof Fran BAUM</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Australia has become a less equal society. My ‘Restoring the
                Fair Go’ program will analyse the underlying economic and health inequity trends,
                assess the policies that have contributed to these inequalities and determine how
                these can be reversed. The program will explore Australian policymaker and citizens
                perspectives on inequality and draw comparisons to other OECD countries. Practical
                policy proposals will be developed to help Australia build back from
                COVID-19.</description>
            <description type="fundingAmount">$2,245,987.59</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009324</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009324</identifier>
            <identifier type="nhmrc">2009324</identifier>
            <name type="primary">
                <namePart>Alcohol use during pregnancy: Understanding and improving health outcomes
                    in offspring</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">fetal alcohol syndrome</subject>
            <subject type="local">mental health</subject>
            <subject type="local">multi-generation study</subject>
            <subject type="local">alcohol</subject>
            <subject type="local">brain development</subject>
            <description type="Chief Investigator">Ms Briana Lees</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The aim of this research is to gain understanding of how small
                amounts of alcohol during pregnancy can impact child development across the first
                two decades of life and to test the effectiveness of a program that aims to reduce
                some of this burden. The world's largest datasets for examining prenatal alcohol
                exposure will be used to provide concrete evidence of the impacts. It is anticipated
                the findings will provide critical new insights important for families,
                practitioners, and policy-makers.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009326</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009326</identifier>
            <identifier type="nhmrc">2009326</identifier>
            <name type="primary">
                <namePart>Implementation research: Delivering impact at the interface between
                    reproductive and metabolic women’s health</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">implementation</subject>
            <subject type="local">women's health</subject>
            <subject type="local">endocrine</subject>
            <subject type="local">overweight/obesity</subject>
            <subject type="local">public health</subject>
            <description type="Chief Investigator">Prof Helena Teede</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">As an active clinician, academic and leader, I bring an
                exemplary track record, team and research program aiming to generate and translate
                new knowledge to improve women's health internationally, during the reproductive
                years and beyond. My research program addresses patient and clinician priorities,
                links to international guidelines and has far reaching translation programs to
                directly improve women's health. Target conditions include polycystic ovary
                syndrome, early menopause and pregnancy.</description>
            <description type="fundingAmount">$1,870,806.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009336</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009336</identifier>
            <identifier type="nhmrc">2009336</identifier>
            <name type="primary">
                <namePart>Harnessing tissue-resident regulatory T cells to fight cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rxfrp27</identifier>
                <title>La Trobe University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">regulatory T cells</subject>
            <subject type="local">tissue factor</subject>
            <subject type="local">adipose tissue</subject>
            <subject type="local">cancer immunology</subject>
            <subject type="local">stromal cells</subject>
            <description type="Chief Investigator">Dr Ajithkumar Vasanthakumar</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Specialised immune cells called regulatory T cells (Tregs)
                reside in almost all organs of the body where they play a central role in preventing
                autoimmunity and inflammation. Tregs, however, aggravate cancer by antagonising the
                activity of beneficial, cancer killing immune cells and limiting cancer
                immunotherapy. This proposal aims to discover mechanisms utilized by Tregs to
                populate distinct tissues and tumours. These mechanisms will be harnessed to target
                Tregs for the treatment of cancer.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009339</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009339</identifier>
            <identifier type="nhmrc">2009339</identifier>
            <name type="primary">
                <namePart>Harnessing CD4+ Regulatory T Cells to Enhance Formation of Protective
                    Immunity Against Human Viruses</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">regulatory T cells</subject>
            <subject type="local">cellular immunity</subject>
            <subject type="local">viral immunology</subject>
            <subject type="local">T cell memory</subject>
            <subject type="local">gut immunity</subject>
            <description type="Chief Investigator">Dr Laura Cook</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">In order to fight off infection we need specialised white blood
                cells, called helper T cells, to activate immune responses. A specialised helper T
                cell, called a regulatory T cell, are key orchestrators of immune memory, which
                protect against re-infection. This study will explore the role for regulatory T
                cells in generating protective immunity, which is the foundation of vaccine
                efficacy. This information will aid the design of better treatments and vaccines for
                infectious diseases.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009340</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009340</identifier>
            <identifier type="nhmrc">2009340</identifier>
            <name type="primary">
                <namePart>Personalised Nutrition Support</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">nutrition</subject>
            <subject type="local">nutritional support techniques</subject>
            <subject type="local">dietary intervention</subject>
            <subject type="local">dietary intake</subject>
            <subject type="local">chronic diseases</subject>
            <description type="Chief Investigator">Prof Clare Collins</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">My research program in precision and personalised nutrition
                technologies will generate new knowledge on cost-effective models of care to reduce
                diet-related health risks, especially for under-served groups based on life-stage,
                socio-economic status or geographic location. My research findings will improve
                health and well-being for those at elevated diet-related chronic disease risk and be
                rapidly translated to lower the healthcare burden related to poor
                nutrition.</description>
            <description type="fundingAmount">$3,927,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009380</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009380</identifier>
            <identifier type="nhmrc">2009380</identifier>
            <name type="primary">
                <namePart>Addressing racialised health inequities in cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">cervical cancer</subject>
            <subject type="local">equity</subject>
            <subject type="local">cancer prevention</subject>
            <subject type="local">cancer screening</subject>
            <subject type="local">implementation</subject>
            <description type="Chief Investigator">A/Prof Lisa Whop</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cervical cancer can be eliminated by vaccination, screening and
                treatment (three pillars of elimination). Aboriginal and Torres Strait Islander
                women experience rates of cervical cancer comparable with less developed regions of
                the world despite other Australian women having the lowest rates in the world. This
                Indigenous led research program will focus on overcoming racial inequities via
                strategic culturally safe interventions focused on the three pillars of
                elimination.</description>
            <description type="fundingAmount">$1,581,120.00</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009389</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009389</identifier>
            <identifier type="nhmrc">2009389</identifier>
            <name type="primary">
                <namePart>Improving outcomes for people with Multiple Sclerosis</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01nfmeh72</identifier>
                <title>University of Tasmania</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">multiple sclerosis (MS)</subject>
            <subject type="local">adult stem cells</subject>
            <subject type="local">patient outcomes</subject>
            <subject type="local">complex genetic disease</subject>
            <subject type="local">clinical epidemiology</subject>
            <description type="Chief Investigator">Prof Bruce Taylor</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Multiple sclerosis is a disabling neurological condition with a
                profound impact on the community. This proposal builds on years of successful MS
                research to develop a "human" model to study MS. Using advanced genetic techniques
                to understand why MS is more common in families. To understand how genes, the
                environment, and personal behaviours influence MS risk and progression. How
                information can be used to improve MS and how to translate discoveries into
                meaningful outcomes rapidly.</description>
            <description type="fundingAmount">$2,335,378.22</description>
            <coverage>
                <spatial type="text">TAS</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009408</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009408</identifier>
            <identifier type="nhmrc">2009408</identifier>
            <name type="primary">
                <namePart>Using modelling to guide the control of hepatitis C as a public health
                    threat</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05ktbsm52</identifier>
                <title>Burnet Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">mathematical modelling</subject>
            <subject type="local">economic analysis</subject>
            <subject type="local">population health</subject>
            <subject type="local">hepatitis C virus</subject>
            <subject type="local">infectious diseases</subject>
            <description type="Chief Investigator">Dr Nick Scott</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">During this grant I will use epidemic and economic modelling to
                guide health policy responses to hepatitis C in Australia and internationally. My
                findings will inform decisions by national governments and global health
                organisations on how to best find and cure people with hepatitis C. I will leverage
                my own and my collaborators’ memberships on global panels to ensure that lives are
                saved around the world because approaches to hepatitis C elimination are
                evidence-based and cost-effective.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009409</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009409</identifier>
            <identifier type="nhmrc">2009409</identifier>
            <name type="primary">
                <namePart>Mitochondria live imaging in mammalian preimplantation embryos</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">embryonic development</subject>
            <subject type="local">imaging</subject>
            <subject type="local">confocal microscopy</subject>
            <subject type="local">mitochondria</subject>
            <subject type="local">microtubules</subject>
            <description type="Chief Investigator">Dr Jennifer Zenker</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">One type of organelle, mitochondria, are in the spotlight to
                improve pregnancy success of women suffering reduced fertility. This project will
                provide insights into mitochondrial integrity using cutting-edge non-invasive live
                imaging of the preimplantation embryo. We will uncover in real-time how mitochondria
                move, being sorted in subpopulations and how the parental mitochondrial heritage
                plays a role. Our findings will open new ways to refine mitochondrial therapies in
                reproductive medicine.</description>
            <description type="fundingAmount">$1,270,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009419</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009419</identifier>
            <identifier type="nhmrc">2009419</identifier>
            <name type="primary">
                <namePart>Reducing the harms of inappropriate medicalisation of women's reproductive
                    health</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">harm minimisation</subject>
            <subject type="local">fertility</subject>
            <subject type="local">public health costs</subject>
            <subject type="local">assisted reproductive technology (ART)</subject>
            <subject type="local">communication</subject>
            <description type="Chief Investigator">Dr Tessa Copp</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Women’s reproductive health is an under-researched area with
                many areas of uncertainty, increasing the risk of inappropriate medicalisation and
                harm. The recent explosion of technology-based products focused on women’s health is
                expanding this issue on a massive scale. Using mixed methods and involving key
                stakeholders, this research program aims to a) understand the impacts of three
                increasingly popular technologies on women and b) find ways to reduce inappropriate
                medicalisation and harm.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009432</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009432</identifier>
            <identifier type="nhmrc">2009432</identifier>
            <name type="primary">
                <namePart>NextGen evidence synthesis to maximise data utility and improve health
                    outcomes</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">meta-analysis</subject>
            <subject type="local">overweight/obesity</subject>
            <subject type="local">neonatology</subject>
            <subject type="local">databases</subject>
            <subject type="local">epidemiological research methods</subject>
            <description type="Chief Investigator">Dr Anna Lene Seidler</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">To bring together results from different studies, researchers
                would traditionally extract results from journal articles. Often, not all required
                information is available in these articles. New methods bring together full datasets
                of previous studies. This research program will develop these methods, looking at
                how to 1) best share data and 2) find and exclude fraudulent or low-quality studies.
                The program will also apply these methods looking at 1) babies born too early and 2)
                childhood obesity.</description>
            <description type="fundingAmount">$600,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009447</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009447</identifier>
            <identifier type="nhmrc">2009447</identifier>
            <name type="primary">
                <namePart>Biomimetic nanoparticles as a gene delivery platform for combinational
                    brain tumour treatment</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">nanotechnology</subject>
            <subject type="local">drug delivery systems</subject>
            <subject type="local">brain tumours</subject>
            <subject type="local">biomaterials</subject>
            <subject type="local">controlled release</subject>
            <description type="Chief Investigator">Dr Yan Zou</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Gene engineering shows exciting potential in biomedical
                applications including cancer therapies. However, effective therapies for brain
                tumour remain limited due to the cascade brain delivery challenges, which markedly
                limits their translational potential. This project aims to develop a new treatment
                strategy for the delivery of state-of-the-art gene therapies directly into the
                brain, which may provide a new effective and safe therapy for brain tumour
                patients.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009464</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009464</identifier>
            <identifier type="nhmrc">2009464</identifier>
            <name type="primary">
                <namePart>Decoding the drivers of food choices towards sustainable self-management
                    of obesity</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">obesity</subject>
            <subject type="local">decision making</subject>
            <subject type="local">cognition</subject>
            <subject type="local">behavioural intervention</subject>
            <subject type="local">neuroimaging</subject>
            <description type="Chief Investigator">Prof Antonio Verdejo-Garcia</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Excessive eating of caloric foods is increasing the number of
                people who suffer obesity. Available treatments focus too much on personal efforts
                to reduce eating, and do not pay enough attention to the joint role of mental
                states, attractive foods and overwhelming marketing. I will use new research tools,
                such as brain scans taken while eating, mathematical algorithms made to reveal
                subconscious aspects of behaviour and virtual reality to assist people with obesity
                to change food choices.</description>
            <description type="fundingAmount">$2,248,555.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009476</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009476</identifier>
            <identifier type="nhmrc">2009476</identifier>
            <name type="primary">
                <namePart>Predictive biomarkers of response, resistance and toxicity with
                    immunotherapy in melanoma</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">melanoma</subject>
            <subject type="local">immunotherapy</subject>
            <subject type="local">drug resistance</subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">drug toxicity</subject>
            <description type="Chief Investigator">A/Prof Alexander Menzies</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Immunotherapy has activity across many cancers, none more so
                than melanoma where approximately half the patients with metastatic disease may be
                cured. Half the patients do not benefit, however, and the drugs can cause toxicity
                and are expensive. At present, clinicians have little ability to predict who will
                and will not respond to therapy or get toxicity, nor the mechanisms underlying this.
                Improving this understanding will improve patient outcomes and reduce costs to the
                healthcare system.</description>
            <description type="fundingAmount">$1,342,072.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009504</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009504</identifier>
            <identifier type="nhmrc">2009504</identifier>
            <name type="primary">
                <namePart>Ribosome biogenesis and disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">Ribosome biogenesis</subject>
            <subject type="local">cancer cell biology</subject>
            <subject type="local">drug development</subject>
            <subject type="local">chromatin structure</subject>
            <subject type="local">cell growth</subject>
            <description type="Chief Investigator">Prof Ross Hannan</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Ribosomes are macromolecular machines that synthesise all
                cellular proteins and their catalytic core, the ribosomal RNAs, are synthesised from
                hundreds of ribosomal genes in a sub-nuclear body termed the nucleolus. This
                application continues my work on developing drugs that target the nucleolus for
                cancer therapies and ribosomopathies and investigate new non-ribosomal functions of
                the nucleolus that we believe are important for normal cellular development and
                which are dysregulated in disease.</description>
            <description type="fundingAmount">$1,927,015.00</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009507</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009507</identifier>
            <identifier type="nhmrc">2009507</identifier>
            <name type="primary">
                <namePart>Heat and Health: Building resilience to a warming planet across the human
                    lifespan</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">heat stress</subject>
            <subject type="local">thermoregulation</subject>
            <subject type="local">hyperthermia</subject>
            <subject type="local">dehydration</subject>
            <subject type="local">climate change</subject>
            <description type="Chief Investigator">Prof Ollie Jay</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Each year peak temperature records are repeatedly broken around
                the world. We already know the health effects of extreme heat can be potentially
                devastating, from pregnancy through to older age. This investigator grant will
                explore different ways to increase our resilience to a warming world across the
                entire lifespan in way that is sustainable for the future, protects the most
                vulnerable, and helps reduce the risk of other diseases that are aggravated by heat
                stress.</description>
            <description type="fundingAmount">$2,098,555.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009529</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009529</identifier>
            <identifier type="nhmrc">2009529</identifier>
            <name type="primary">
                <namePart>Optimising palliative care services to deliver better value health care
                    for older people</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03pnv4752</identifier>
                <title>Queensland University of Technology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">palliative care</subject>
            <subject type="local">health services</subject>
            <subject type="local">outcomes research</subject>
            <subject type="local">aged care</subject>
            <subject type="local">nursing</subject>
            <description type="Chief Investigator">Prof Patsy Yates</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The recent report from the Royal Commission into Aged Care
                Quality and Safety in Australia highlighted substandard palliative care in
                Australia’s aged care system. This research will transform the way in which
                palliative care services are delivered for older people by designing and evaluating
                new approaches to ensure quality palliative and end of life services in the
                residential and community aged care system.</description>
            <description type="fundingAmount">$1,500,000.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009548</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009548</identifier>
            <identifier type="nhmrc">2009548</identifier>
            <name type="primary">
                <namePart>Advancing Australian human challenge trials for priority
                    pathogens</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">Streptococcus pyogenes</subject>
            <subject type="local">group A streptococcal disease</subject>
            <subject type="local">Streptococcus pneumoniae</subject>
            <subject type="local">vaccine</subject>
            <subject type="local">pharyngitis</subject>
            <description type="Chief Investigator">Dr Joshua Osowicki</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">In human challenge models, healthy volunteers are given a
                carefully monitored infection, with healthcare support, to learn how diseases work
                and how to stop them. I built the world’s only strep throat human model and will use
                it to test vaccines to stop Strep A diseases, which affect ~1 billion people and
                kill &gt;500,000 annually. I will build challenge models for other important
                diseases (like pneumonia) and work with the public and participants to maximise the
                impact of this kind of research.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009550</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009550</identifier>
            <identifier type="nhmrc">2009550</identifier>
            <name type="primary">
                <namePart>Risk and resilience in Alzheimer's pathogenesis, cognitive decline and
                    clinical disease progression</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">Alzheimer disease</subject>
            <subject type="local">cognitive assessment</subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">risk factors</subject>
            <subject type="local">resilience</subject>
            <description type="Chief Investigator">A/Prof Yen Ying Lim</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Alzheimer’s disease is the most common form of dementia, and
                the number of people living with it will triple by 2050. There is currently no cure
                for Alzheimer’s disease, and the only means of slow the growing epidemic is to delay
                onset. My research program aims to identify risk and resilience factors of
                Alzheimer’s disease. This will uncover novel disease-modifying strategies, improve
                clinical trial design, and develop algorithms that will predict individuals’ rate of
                disease progression.</description>
            <description type="fundingAmount">$1,306,096.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009551</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009551</identifier>
            <identifier type="nhmrc">2009551</identifier>
            <name type="primary">
                <namePart>Modulating protein-protein interactions in disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">medicinal chemistry</subject>
            <subject type="local">peptides</subject>
            <subject type="local">protease-activated receptors</subject>
            <subject type="local">G protein-coupled receptors</subject>
            <subject type="local">drug design</subject>
            <description type="Chief Investigator">Prof David Fairlie</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Healthy lives are powered by countless interactions between
                proteins that induce normal body functions. Infections, mutations, physical/chemical
                damage wear down our immune defences and lead to disease. This program will create
                new knowledge and approaches to discover new medicines, larger than conventional
                drugs but smaller than antibodies. They will modulate protein-protein interactions
                on or in cells to suppress inflammatory/metabolic diseases in rodents, on a path to
                clinical trials.</description>
            <description type="fundingAmount">$3,927,015.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009554</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009554</identifier>
            <identifier type="nhmrc">2009554</identifier>
            <name type="primary">
                <namePart>Targeting Follicular Helper T cells to Boost Protective Humoral
                    Immunity</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">B cells</subject>
            <subject type="local">T cells</subject>
            <subject type="local">antibody production</subject>
            <subject type="local">vaccination</subject>
            <subject type="local">lymphocyte differentiation</subject>
            <description type="Chief Investigator">Prof Di Yu</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">After vaccination, the immune system is activated and acquires
                the ability to secret antibodies that recognise and destroy pathogens. However,
                vaccines don’t always induce sufficient immunity. The interactions between different
                types of immune cells play an essential role in regulating the generation of
                high-quality antibody immunity. This research will investigate the mechanisms
                governing this process. The new knowledge will have broad applications for infection
                control or vaccine design.</description>
            <description type="fundingAmount">$3,098,844.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009564</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009564</identifier>
            <identifier type="nhmrc">2009564</identifier>
            <name type="primary">
                <namePart>Advancing peptide-based drug design</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">peptides</subject>
            <subject type="local">structure-based drug design</subject>
            <subject type="local">protein structure</subject>
            <subject type="local">drug design</subject>
            <subject type="local">drug discovery</subject>
            <description type="Chief Investigator">Prof David Craik</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">I will use molecules called peptides to make safer, more
                effective medicines. These next-generation drugs will have fewer side effects than
                existing drugs due to their highly specific interactions with their target sites in
                the body. In the past pharmaceutical companies have not been able to utilise
                peptides because of technical challenges associated with their synthesis and
                delivery. My work has led to solutions to these problems that will be exploited to
                develop new drugs for pain and cancer.</description>
            <description type="fundingAmount">$3,177,015.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009572</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009572</identifier>
            <identifier type="nhmrc">2009572</identifier>
            <name type="primary">
                <namePart>Novel methods for analysing causal pathways to disease in longitudinal
                    studies</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">statistics</subject>
            <subject type="local">biostatistics</subject>
            <subject type="local">epidemiological research methods</subject>
            <subject type="local">longitudinal study</subject>
            <subject type="local">biomarkers</subject>
            <description type="Chief Investigator">Dr Margarita Moreno-Betancur</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Health research studies obtain increasingly detailed data from
                participant biosamples that could in principle provide key insights into disease
                causality. However, the analytical tools and expertise for realising this potential
                are lacking. This program aims to develop, disseminate and apply novel data analysis
                methods that address this gap, as well as building biostatistical capacity in this
                area. Program outcomes will be urgently needed tools, expertise and new knowledge
                for improving health.</description>
            <description type="fundingAmount">$1,442,004.49</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009577</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009577</identifier>
            <identifier type="nhmrc">2009577</identifier>
            <name type="primary">
                <namePart>Tackling multimorbidity in women across the life course: Building the
                    evidence for improved prevention strategies and care pathways</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">women's health</subject>
            <subject type="local">chronic diseases</subject>
            <subject type="local">comorbidity</subject>
            <subject type="local">multiple risk factors</subject>
            <subject type="local">reproductive health</subject>
            <description type="Chief Investigator">Prof Gita Mishra</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Multimorbidity, where a person has two or more chronic
                conditions, is increasing and is more common among women than men. Women also face
                different risks for multimorbidity, and some can have conditions that interact and
                require complex care plans. My research addresses gaps in our understanding of how
                multimorbidity develops in women and of the corresponding care plans. The new
                knowledge will inform more personalised and co-ordinated care for prevention and
                management of multimorbidity.</description>
            <description type="fundingAmount">$2,350,314.03</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009612</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009612</identifier>
            <identifier type="nhmrc">2009612</identifier>
            <name type="primary">
                <namePart>Improving evidence synthesis methods to enhance decision making about
                    public health and policy interventions</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">evidence-based health care</subject>
            <subject type="local">meta-analysis</subject>
            <subject type="local">intervention study</subject>
            <subject type="local">statistics</subject>
            <subject type="local">methodology</subject>
            <description type="Chief Investigator">A/Prof Joanne McKenzie</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Systematic reviews synthesize available research to determine
                whether policy, health service delivery, and public health interventions are
                effective. Statistical methods underpin the validity of the findings in systematic
                reviews. This research will evaluate and develop statistical methods for systematic
                reviews with the aim of improving the quality of reviews and ensuring healthcare
                decisions are based on reliable research syntheses.</description>
            <description type="fundingAmount">$2,248,555.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009633</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009633</identifier>
            <identifier type="nhmrc">2009633</identifier>
            <name type="primary">
                <namePart>Reducing medication-related harm in people living with dementia in
                    residential aged care</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">dementia</subject>
            <subject type="local">aged care</subject>
            <subject type="local">residential care</subject>
            <subject type="local">pharmacy</subject>
            <subject type="local">adverse drug reactions</subject>
            <description type="Chief Investigator">Dr Amanda Cross</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">People who live in aged care facilities, particularly those
                living with dementia, often take multiple medications and are at increased risk of
                medication-related harm. My research aims to reduce medication-related harm by
                addressing key steps in the medication-management cycle where errors and harm can
                occur. I will work with consumers, aged care providers and health care professionals
                to ensure my findings are translated into practice to improve quality of life for
                people living with dementia.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009642</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009642</identifier>
            <identifier type="nhmrc">2009642</identifier>
            <name type="primary">
                <namePart>Targeting skeletal muscle for the treatment of insulin
                    resistance</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">proteomics</subject>
            <subject type="local">muscle physiology</subject>
            <subject type="local">mouse models</subject>
            <subject type="local">signal transduction</subject>
            <subject type="local">muscle metabolism</subject>
            <description type="Chief Investigator">Dr Benjamin Parker</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Insulin resistance is a condition that leads to high-blood
                glucose and poor muscle function. It is the fastest growing chronic disease in
                Australia and the major contributor to type-2 diabetes and sarcopenia. We urgently
                need new treatment strategies. We have identified a series of novel therapeutic
                targets for the treatment of insulin resistance. This project will analyse these
                therapeutic targets in preclinical models and improve our understanding of the
                molecular events of insulin resistance.</description>
            <description type="fundingAmount">$1,470,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009670</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009670</identifier>
            <identifier type="nhmrc">2009670</identifier>
            <name type="primary">
                <namePart>Improving outcomes in advanced lung and gynaecological cancers through
                    innovations in clinical trials</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">medical oncology</subject>
            <subject type="local">molecular oncology</subject>
            <subject type="local">lung cancer</subject>
            <subject type="local">gynaecological cancers</subject>
            <subject type="local">clinical trial</subject>
            <description type="Chief Investigator">A/Prof Chee Khoon Lee</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Lung and ovarian cancers are major causes of cancer-related
                deaths in Australia and worldwide. Improving outcomes for these cancers is a
                national priority. The overall aim of this project is to better personalise patient
                treatment and improve their cancer outcomes. The specific objectives are to develop
                new therapies and strategies for combination treatment, identify new biomarkers,
                evaluate benefits and harms from treatments, and improve selection of patients for
                more appropriate therapies.</description>
            <description type="fundingAmount">$1,799,422.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009675</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009675</identifier>
            <identifier type="nhmrc">2009675</identifier>
            <name type="primary">
                <namePart>Using clonal multi-omics to better understand haematopoiesis</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">haematopoiesis</subject>
            <subject type="local">dendritic cell lineages</subject>
            <subject type="local">biotechnology</subject>
            <subject type="local">haematopoietic stem cells</subject>
            <subject type="local">monocyte/macrophage differentiation</subject>
            <description type="Chief Investigator">Dr Shalin Naik</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Our body must continually produce white blood cells to fight
                infection. When this production goes wrong it can lead to too few cells (immune
                deficiency) or too many (leukemia). We will examine this process using cutting edge
                single cell technologies to trace the developmental origins and pathways of
                individual cells as they mature. In this way, we will learn how to treat these
                diseases and inform new ways to boost immunity or treat immune and inflammatory
                diseases.</description>
            <description type="fundingAmount">$2,348,555.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009707</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009707</identifier>
            <identifier type="nhmrc">2009707</identifier>
            <name type="primary">
                <namePart>Reconstructing ancestral viruses to fight current and future flavivirus
                    outbreaks</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">molecular virology</subject>
            <subject type="local">virology</subject>
            <subject type="local">structural biology</subject>
            <subject type="local">viral proteins</subject>
            <subject type="local">viral vaccines</subject>
            <description type="Chief Investigator">Dr Natalee Newton</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">I am a co-inventor of a powerful toolset combining advanced
                structural biology and rapid virus engineering that enables the investigation of
                flavivirus structure and immune response at the molecular level. This project
                integrates these approaches to resurrect ancient flaviviruses and explore the
                structural evolution of non-human primate flaviviruses, which will be used to
                understand viral evolution, improve outbreak preparedness and design safer and more
                effective vaccines.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009711</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009711</identifier>
            <identifier type="nhmrc">2009711</identifier>
            <name type="primary">
                <namePart>Driving rational improvement of vaccines against respiratory
                    viruses</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">B cells</subject>
            <subject type="local">vaccination immunology</subject>
            <subject type="local">vaccine development</subject>
            <subject type="local">respiratory viruses</subject>
            <subject type="local">humoral immunity</subject>
            <description type="Chief Investigator">Dr Hyon Xhi Tan</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Respiratory viruses, such as influenza and human coronaviruses,
                impose a significant burden on human health and present major pandemic risks. There
                is a critical need for highly effective vaccines to protect susceptible human
                populations. This research program will expand our understanding of fundamental
                drivers of protective immunity against respiratory viruses and integrate these
                insights in the design and testing of novel vaccine concepts that produce durable
                and efficacious immunity.</description>
            <description type="fundingAmount">$600,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009726</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009726</identifier>
            <identifier type="nhmrc">2009726</identifier>
            <name type="primary">
                <namePart>Reducing sex disparities in stroke through a deeper understanding of risks
                    and management patterns</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">sex differences</subject>
            <subject type="local">stroke</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">cohort study</subject>
            <subject type="local">cost-effectiveness</subject>
            <description type="Chief Investigator">Dr Cheryl Carcel</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Each year, 11,000 Australians die from one of the biggest
                killers in Australia and globally, stroke. There is high demand for effective
                prevention and treatment strategies. However, published evidence suggests that women
                and men experience the disease and its medical care differently. My research aims to
                better understand why such differences exist and how to provide sex-specific,
                strategies to improve survival from stroke.</description>
            <description type="fundingAmount">$575,578.71</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009727</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009727</identifier>
            <identifier type="nhmrc">2009727</identifier>
            <name type="primary">
                <namePart>Developing a community-led coordination and response guide for a syphilis
                    outbreak in Aboriginal communities</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">syphilis</subject>
            <subject type="local">Aboriginal health</subject>
            <subject type="local">surveillance</subject>
            <subject type="local">community participation</subject>
            <subject type="local">community health care</subject>
            <description type="Chief Investigator">Dr Simon Graham</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">My program of research has two phases. Phase 1 will evaluate
                the how the World Health Organization establishes and deploying outbreak teams to
                different countries. Phase 2 aims to 1) evaluate Australia National Notifiable
                Surveillance System with a focus on the identification of Aboriginal people and
                alerts for potential outbreaks and 2) to develop a community-based coordination
                guide for syphilis outbreaks that includes Aboriginal leadership, governance and our
                biggest strength, our culture.</description>
            <description type="fundingAmount">$1,581,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009730</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009730</identifier>
            <identifier type="nhmrc">2009730</identifier>
            <name type="primary">
                <namePart>Addressing evidence gaps to improve adolescent the sexual and reproductive
                    health</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">adolescent health</subject>
            <subject type="local">sexual health</subject>
            <subject type="local">reproductive health</subject>
            <subject type="local">evidence-based health care</subject>
            <subject type="local">population health</subject>
            <description type="Chief Investigator">Dr Zohra Lassi</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">My research focuses on identifying opportunities to improve the
                sexual and reproductive health of adolescents living in Australia and other parts of
                the world. This involves working with adolescents and health services to co-design
                and test new strategies to deliver sexual and reproductive health that is
                specifically focussed on the needs of young people.</description>
            <description type="fundingAmount">$1,560,435.77</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009732</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009732</identifier>
            <identifier type="nhmrc">2009732</identifier>
            <name type="primary">
                <namePart>Developing a multi-omics platform for the diagnosis of mitochondrial
                    disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">mitochondrial disease</subject>
            <subject type="local">proteomics</subject>
            <subject type="local">functional genomics</subject>
            <subject type="local">mitochondrial function</subject>
            <subject type="local">systems biology</subject>
            <description type="Chief Investigator">Dr David Stroud</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Mitochondrial Diseases (MDs) are the most common inherited
                metabolic disorders. They can be caused by changes in more than 300 different genes
                and affect any or all of our organ systems. New genomic (DNA) technologies have
                increased our ability to diagnose MDs from less than a quarter of patients to about
                a half. DNA is the blueprint for protein. This study seeks to further improve the
                diagnostic rate by using new “proteomic” technologies that can detect changes in
                thousands of proteins at once.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009736</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009736</identifier>
            <identifier type="nhmrc">2009736</identifier>
            <name type="primary">
                <namePart>Translating precision antibiotic dosing into better outcomes for severe
                    infections</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">antibiotic therapy</subject>
            <subject type="local">sepsis</subject>
            <subject type="local">pharmacokinetics</subject>
            <subject type="local">antibiotic resistance</subject>
            <subject type="local">critical care medicine</subject>
            <description type="Chief Investigator">Prof Jason Roberts</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Millions of people die from infections around the world each
                year, in part, from inadequate antimicrobial use. Antimicrobial dosing is an aspect
                of therapy which clinicians can control and improve if given sufficient information.
                My research program will explore the benefits of using a dose that is optimised for
                an individual patient, to ensure the patient is cured from that infection, and not
                contribute to the emergence of antimicrobial resistant bacteria.</description>
            <description type="fundingAmount">$2,772,570.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009750</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009750</identifier>
            <identifier type="nhmrc">2009750</identifier>
            <name type="primary">
                <namePart>Macrophage Biology in Health and Disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">macrophage biology</subject>
            <subject type="local">colony stimulating factors (CSF)</subject>
            <subject type="local">gene transcription</subject>
            <subject type="local">transgenic animals</subject>
            <subject type="local">regenerative medicine</subject>
            <description type="Chief Investigator">Prof David Hume</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Macrophages are cells of the innate immune system. They are
                found in every organ and act as the body's waste disposal system and contribute to
                repair of damaged tissue. In many diseases, their functions are out of control and
                they contribute to injury and symptoms. In this project we aim to understand how
                macrophages are made and controlled and to exploit that knowledge to develop new
                therapies in regenerative medicine.</description>
            <description type="fundingAmount">$3,427,015.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009765</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009765</identifier>
            <identifier type="nhmrc">2009765</identifier>
            <name type="primary">
                <namePart>Mitigating the consequence of preeclampsia for mother and child</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">pre-eclampsia</subject>
            <subject type="local">antioxidant therapy</subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">placental insufficiency</subject>
            <subject type="local">clinical trial</subject>
            <description type="Chief Investigator">Dr Kirsten Palmer</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Preeclampsia, a condition unique to pregnancy, is a major cause
                for premature birth, death and disability for both mother and baby. No treatment
                exists that can control the disease to reduce these risks. This research assesses a
                promising new therapy derived from broccoli sprouts that could prolong pregnancy,
                reducing the risk of preterm birth. New approaches to diagnosing preeclampsia
                earlier and to prevent women from poor health outcomes in the years that follow will
                also be explored.</description>
            <description type="fundingAmount">$1,285,060.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009767</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009767</identifier>
            <identifier type="nhmrc">2009767</identifier>
            <name type="primary">
                <namePart>Improving assisted reproductive technology outcomes - a personalised
                    approach</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">infertility</subject>
            <subject type="local">evidence-based health care</subject>
            <subject type="local">individualising management</subject>
            <subject type="local">in vitro fertilisation (IVF)</subject>
            <subject type="local">assisted reproductive technology (ART)</subject>
            <description type="Chief Investigator">Dr Rui Wang</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">One in seven couples have problems conceiving. Assisted
                reproductive technology (ART) is the last resort for all couples with prolonged
                unresolved infertility. There is a lack of personalised evidence-based guidance on
                choosing the best treatment strategies during ART. I will systematically evaluate
                the effectiveness and safety of treatment options in multiple steps during ART and
                provide a personalised treatment pathway to improve ART outcomes in couples with
                infertility.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009771</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009771</identifier>
            <identifier type="nhmrc">2009771</identifier>
            <name type="primary">
                <namePart>Addressing Health Inequality Experienced by People with Intellectual
                    Disability</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">intellectual disability</subject>
            <subject type="local">burden of disease</subject>
            <subject type="local">neurodevelopmental disorders</subject>
            <subject type="local">health service utilisation</subject>
            <subject type="local">health services</subject>
            <description type="Chief Investigator">Prof Julian Trollor</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">People with intellectual disability face stark health
                inequalities, die prematurely from potentially avoidable causes and experience poor
                access to preventative health care. This project will find out why there are gaps in
                health care for people with intellectual disability, determine how these gaps affect
                people and develop better responses in healthcare for people with intellectual
                disability.</description>
            <description type="fundingAmount">$2,372,570.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009776</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009776</identifier>
            <identifier type="nhmrc">2009776</identifier>
            <name type="primary">
                <namePart>Increasing the value of evidence from nutritional epidemiology</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">nutrition</subject>
            <subject type="local">epidemiology</subject>
            <subject type="local">public health</subject>
            <subject type="local">cardiovascular health</subject>
            <subject type="local">methodology</subject>
            <description type="Chief Investigator">Dr Yohannes Adama Melaku</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">In nutrition research, observational studies are fundamental
                sources of evidence as it is often impossible or unethical to conduct randomized
                controlled trials. Unfortunately, many nutritional epidemiological studies fail to
                provide useful evidence due to poor data analysis methods. My research will improve
                the quality of evidence from nutritional epidemiology by developing practical
                solutions to the challenges of dietary data analysis by advancing analysis methods
                and tools.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009782</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009782</identifier>
            <identifier type="nhmrc">2009782</identifier>
            <name type="primary">
                <namePart>Lost in translation: Accelerating the implementation of digital
                    interventions in youth mental health</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">mental health</subject>
            <subject type="local">internet service delivery</subject>
            <subject type="local">implementation</subject>
            <subject type="local">young adults</subject>
            <subject type="local">intervention</subject>
            <description type="Chief Investigator">Dr Jennifer Nicholas</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Mental ill-health affects one in four young Australians.
                Digital interventions can deliver high-quality accessible mental health care to
                those in need, however, they currently sit disconnected from our overburdened,
                antiquated mental health system. My research program will address this historic
                failure of research translation, by refining, evaluating, and disseminating a
                blueprint for digital mental health implementation – propelling Australian youth
                mental health care into the 21st century.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009783</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009783</identifier>
            <identifier type="nhmrc">2009783</identifier>
            <name type="primary">
                <namePart>Super-Responders and Super-Survivors – how to dramatically improve cancer
                    outcomes</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">translational research</subject>
            <subject type="local">ovarian cancer</subject>
            <subject type="local">immune response</subject>
            <subject type="local">cancer biology</subject>
            <subject type="local">genomics</subject>
            <description type="Chief Investigator">Prof Clare Scott</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Ovarian cancer and other rare cancer types have low survival
                rates. My program will study women who achieve very long remissions
                (“Super-Responders”) following PARP inhibitor + immune therapy and
                “Super-survivors”, individuals who develop three or more cancers. The underlying
                genetic mechanisms for this are poorly understood. By studying both, we expect to
                discover key molecular and immune pathways that should underpin effective therapies
                to prevent cancer recurrence.</description>
            <description type="fundingAmount">$2,372,570.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009798</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009798</identifier>
            <identifier type="nhmrc">2009798</identifier>
            <name type="primary">
                <namePart>Innovative public health interventions to control the global burden of
                    Strep A disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">Streptococcus pyogenes</subject>
            <subject type="local">scabies</subject>
            <subject type="local">rheumatic heart disease</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">vaccine</subject>
            <description type="Chief Investigator">Prof Andrew Steer</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Strep A causes over 500,000 deaths in the world each year,
                especially due to rheumatic heart disease. Scabies is a major driver of Strep A skin
                infection in our region. I propose to tackle the problem with 2 innovative
                approaches. First, I will test new vaccines using a human model of Strep A infection
                and in a large clinical trial. Second, I will investigate how mass treatment for
                scabies can impact on Strep A skin infection and rheumatic heart disease, and I will
                test new drugs and diagnostics.</description>
            <description type="fundingAmount">$2,299,438.96</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009800</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009800</identifier>
            <identifier type="nhmrc">2009800</identifier>
            <name type="primary">
                <namePart>Innovations in Clinical Trials Research: from personalised medicine to
                    population health</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">clinical epidemiology</subject>
            <subject type="local">oncology</subject>
            <subject type="local">cardiovascular disease</subject>
            <subject type="local">perinatal</subject>
            <description type="Chief Investigator">Prof John Simes</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Well-designed clinical trials including translational research
                are critical for real advances in healthcare. The proposed research involves major
                clinical trials evaluating new treatments and strategies in cancer, cardiovascular
                disease and perinatal medicine; novel methods for better trials; and integrating
                evidence for better decision-making in healthcare. The aim is to integrate clinical
                research into routine care and use translational science to optimise treatment for
                individual patients.</description>
            <description type="fundingAmount">$2,727,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009808</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009808</identifier>
            <identifier type="nhmrc">2009808</identifier>
            <name type="primary">
                <namePart>Improving back pain care in Australia</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">musculoskeletal disorders</subject>
            <subject type="local">back pain</subject>
            <subject type="local">health policy evaluation</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">health services research</subject>
            <description type="Chief Investigator">Dr Giovanni Ferreira</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Over the next five years, this research program will improve
                the care provided for back pain in Australia, the number one cause of disability. To
                accomplish that goal, a series of health policy evaluations at the national and
                state level, a randomised trial to reduce unnecessary lumbar surgeries and improve
                return to work, and two studies to investigate barriers and enablers of the right
                care for back pain will be conducted.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009820</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009820</identifier>
            <identifier type="nhmrc">2009820</identifier>
            <name type="primary">
                <namePart>Nicotinamide adenine dinucleotide as a novel target for ageing and
                    dementia</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">Alzheimer disease</subject>
            <subject type="local">oxidative stress</subject>
            <subject type="local">nutritional therapy</subject>
            <subject type="local">cognition</subject>
            <subject type="local">bioenergetics</subject>
            <description type="Chief Investigator">Dr Nady Braidy</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">A better understanding of novel molecular targets of disease to
                use in diagnostics and therapeutics for age-related cognitive impairment and
                dementia is urgently needed. My research program will test the hypothesis that
                raising intracellular NAD+ levels can (1) slow down the onset of dementia-related
                neuropathology; (2) alter dementia biomarker trajectories; and (3) moderate
                behavioural/cognitive deficits, in established in animal models and humans
                cohorts.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009840</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009840</identifier>
            <identifier type="nhmrc">2009840</identifier>
            <name type="primary">
                <namePart>Development of clinical tests to improve treatment for ovarian cancer
                    patients</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">ovarian cancer</subject>
            <subject type="local">genomics</subject>
            <subject type="local">prognostic markers</subject>
            <subject type="local">differential gene expression</subject>
            <subject type="local">clinical decision making</subject>
            <description type="Chief Investigator">Prof Susan Ramus</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The aim of this program is to improve ovarian cancer survival.
                In other cancers, tumour tests at diagnosis are used to guide treatment. I will
                utilise the resources of the international Ovarian Tumour Tissue Analysis (OTTA)
                consortium, that I lead, to develop tumour tests to determine the best treatment for
                each patient. This will include; if they should have surgery before chemotherapy, if
                they need an alternative to the commonly used chemotherapy, and predicting response
                to new treatments.</description>
            <description type="fundingAmount">$3,427,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009843</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009843</identifier>
            <identifier type="nhmrc">2009843</identifier>
            <name type="primary">
                <namePart>Tau - A diagnostic and therapeutic target in Alzheimer's
                    Disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">Alzheimer disease</subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">dementia</subject>
            <subject type="local">diagnosis</subject>
            <description type="Chief Investigator">A/Prof Nawaf Yassi</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Toxic forms of ‘tau’ protein in the brain are part of the cause
                of Alzheimer’s disease. This condition is difficult to diagnose, and there are no
                treatments to stop progression. My research focuses on developing a blood test
                measuring the levels of toxic tau in patients attending Australian memory clinics.
                The program will also undertake a world-first clinical trial of an oral drug (SAMe)
                that targets the tau protein to understand whether this can slow the progression of
                Alzheimer’s disease.</description>
            <description type="fundingAmount">$1,280,217.88</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009852</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009852</identifier>
            <identifier type="nhmrc">2009852</identifier>
            <name type="primary">
                <namePart>Lipid trafficking and storage: from cell biology to novel therapies
                    against diseases</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">cell biology</subject>
            <subject type="local">membrane trafficking</subject>
            <subject type="local">protein trafficking</subject>
            <subject type="local">membrane lipids</subject>
            <subject type="local">phospholipids</subject>
            <description type="Chief Investigator">Prof Hongyuan Yang</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Lipids represent a major class of molecules in life. They are
                associated with many common human diseases such as obesity, diabetes, heart disease
                and cancer. A major gap in knowledge is how our cells store and transport important
                lipids such as cholesterol. This proposal aims to investigate mechanisms governing
                the storage and trafficking of lipids, and to also apply the new knowledge to
                developing novel compounds/therapies against cancer and other
                diseases.</description>
            <description type="fundingAmount">$2,927,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009866</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009866</identifier>
            <identifier type="nhmrc">2009866</identifier>
            <name type="primary">
                <namePart>Health Risk Assessment of Bushfire Smoke on Children and Pregnancy
                    Outcomes</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">environmental epidemiology</subject>
            <subject type="local">air pollution</subject>
            <subject type="local">climate change</subject>
            <subject type="local">exposure assessment</subject>
            <subject type="local">child</subject>
            <description type="Chief Investigator">Dr Shanshan Li</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This Investigator Grant program will fill the knowledge gaps in
                whether bushfire smoke have impacts on children and pregnancy outcomes using new
                technology, novel approaches and big data analyses. The outcomes will result in
                improved environmental exposure assessment and reduced hazard of bushfire smoke,
                leading to substantial gains in population and environmental health. Importantly,
                this work will enhance capacity building and advance the development of bushfire
                epidemiology.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009873</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009873</identifier>
            <identifier type="nhmrc">2009873</identifier>
            <name type="primary">
                <namePart>A Global Programme on Epidemiology, Early Detection and Intervention for
                    Children with Cerebral Palsy in Low- and Middle-Income Countries</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/023q4bk22</identifier>
                <title>Central Queensland University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cerebral palsy</subject>
            <subject type="local">cerebral palsy treatments</subject>
            <subject type="local">early diagnosis</subject>
            <subject type="local">early intervention</subject>
            <subject type="local">disease prevention</subject>
            <description type="Chief Investigator">Prof Gulam Khandaker</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cerebral palsy (CP) is the leading cause of childhood
                disability with an estimated 50 million people affected globally. However, majority
                of the children with CP living in low- and middle-income countries (LMICs) do not
                receive timely diagnosis and intervention. I propose a global research programme
                across Asia, Africa and South America to study the burden, causes and suitable
                approaches for early detection and intervention for children with CP in LMICs to
                improve their lives.</description>
            <description type="fundingAmount">$1,342,072.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009878</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009878</identifier>
            <identifier type="nhmrc">2009878</identifier>
            <name type="primary">
                <namePart>Personalised medicine to improve outcomes for men with prostate cancer
                    through seamless integration of novel imaging and targeted therapy
                    (theranostics)</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">prostate cancer</subject>
            <subject type="local">nuclear medicine</subject>
            <subject type="local">radiology</subject>
            <subject type="local">medical oncology</subject>
            <subject type="local">clinical trial</subject>
            <description type="Chief Investigator">Prof Michael Hofman</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This grant will enable me as a clinician-scientist to improve
                outcomes for men with prostate cancer, a disease resulting in more than 3000 deaths
                in Australia annually, by using a technology called theranostics. Theranostics uses
                radioactive tumour seeking molecules to integrate whole body imaging and a targeted
                treatment. I will develop clinical trials with global impact and use artificial
                intelligence image interpretation to better define patient prognosis and select
                optimal therapy.</description>
            <description type="fundingAmount">$1,863,610.68</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009885</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009885</identifier>
            <identifier type="nhmrc">2009885</identifier>
            <name type="primary">
                <namePart>Deciphering the heterogeneity of chronic breathlessness: implications for
                    more personalised management of the symptom</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03f0f6041</identifier>
                <title>University of Technology Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">breathlessness</subject>
            <subject type="local">palliative care</subject>
            <subject type="local">assessment</subject>
            <subject type="local">neurophysiology</subject>
            <subject type="local">phenotype</subject>
            <description type="Chief Investigator">Prof David Currow</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Chronic breathlessness is a debilitating symptom affecting
                &gt;300,000 Australians with chronic, progressive conditions. This innovative
                program combines epidemiological, basic science and health services research to
                generate a world-first classification of clinical sub-types of chronic
                breathlessness. This will provide more personalised symptom management, and
                ultimately deliver improved health outcomes and independence, and directly inform
                clinical practice and reduce health service use.</description>
            <description type="fundingAmount">$1,500,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009940</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009940</identifier>
            <identifier type="nhmrc">2009940</identifier>
            <name type="primary">
                <namePart>Translating oocyte biology discoveries to clinical practice</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">reproductive biology</subject>
            <subject type="local">in vitro maturation of oocytes</subject>
            <subject type="local">assisted reproductive technology (ART)</subject>
            <subject type="local">ovary</subject>
            <subject type="local">translational research</subject>
            <description type="Chief Investigator">Prof Robert Gilchrist</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">I am reproductive biologist studying factors that regulate the
                intrinsic quality of unfertilised eggs. I have produced and patented the use of
                unique growth factors produced by the egg that enhance egg quality in women.
                Bringing together industry and world-leading clinics, I am developing new forms of
                hormone-free infertility treatment for cancer and infertile patients, which I will
                apply in widespread clinical practice over the next 5 years.</description>
            <description type="fundingAmount">$2,827,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009957</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009957</identifier>
            <identifier type="nhmrc">2009957</identifier>
            <name type="primary">
                <namePart>Developing new therapies targeting innate immune mediated inflammation in
                    neurodegenerative disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">complement</subject>
            <subject type="local">neurodegeneration</subject>
            <subject type="local">motor neuron disease (MND)</subject>
            <subject type="local">neuroinflammation</subject>
            <subject type="local">drug development</subject>
            <description type="Chief Investigator">Prof Trent Woodruff</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Brain diseases such as Parkinson’s disease and motor neuron
                disease remain a burden on society with few effective treatments. Recent studies
                have documented a key role for the immune system and inflammation in accelerating
                neurodegenerative disease progression. This project will identify new drugs that can
                tame the inflammation cascade in the brain, to help treat these diseases. It will
                assist in the progression of these drugs into human clinical trials to ultimately
                improve patient outcomes.</description>
            <description type="fundingAmount">$3,372,570.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009965</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009965</identifier>
            <identifier type="nhmrc">2009965</identifier>
            <name type="primary">
                <namePart>Integrating lipidomic, metabolomic and genomic studies to define causal
                    metabolic pathways in cardiometabolic disease: Delivering precision medicine
                    solutions for Australia.</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03rke0285</identifier>
                <title>Baker Heart and Diabetes Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">lipid metabolism</subject>
            <subject type="local">genomics</subject>
            <subject type="local">bioinformatics</subject>
            <subject type="local">risk prediction</subject>
            <subject type="local">population studies</subject>
            <description type="Chief Investigator">Prof Peter Meikle</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Our metabolism plays a central role in the development type 2
                diabetes, cardiovascular disease, age related dementia and some cancers. We plan to
                use new technology (genomics and metabolomics) to understand how our genes and
                environment combine to influence our metabolism and our health. We will use this new
                information to develop new tests for risk assessment and early detection and develop
                new treatments to maintain health and to prevent, attenuate or treat these common
                metabolic diseases.</description>
            <description type="fundingAmount">$2,427,015.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009982</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009982</identifier>
            <identifier type="nhmrc">2009982</identifier>
            <name type="primary">
                <namePart>Building a foundation for equitable population-scale genomic
                    medicine</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">genetics</subject>
            <subject type="local">genomics</subject>
            <subject type="local">sequencing</subject>
            <subject type="local">bioinformatics</subject>
            <subject type="local">population genetics</subject>
            <description type="Chief Investigator">Dr Daniel MacArthur</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Genomic technologies, such as whole-genome sequencing, are
                already transforming our ability to diagnose, predict, and treat many diseases.
                However, to ensure that genomic medicine is accessible and useful to everyone, we
                need more powerful tools for analysis, new databases representing all Australian
                communities, and new approaches to identify targets for therapeutic drugs. My
                program will develop methods and resources to establish the foundations for
                equitable population-scale genomic medicine.</description>
            <description type="fundingAmount">$3,427,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009991</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009991</identifier>
            <identifier type="nhmrc">2009991</identifier>
            <name type="primary">
                <namePart>Role of Gut-Bacteria in Dementia and Implications for Future
                    Nanomedicine</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">amyloid beta-protein</subject>
            <subject type="local">protein aggregation</subject>
            <subject type="local">bacterial biofilm</subject>
            <subject type="local">nanotechnology</subject>
            <subject type="local">microbial pathogenesis</subject>
            <description type="Chief Investigator">Dr Ibrahim Javed</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">My research and recent clinical evidence indicate the
                involvement of gut-bacteria in the early-onset and accelerated progression of
                dementia in Alzheimer's Disease. This project will investigate the molecular
                mechanisms for this toxic communication between gut-bacteria and the brain, and
                develop a nanotechnology-based approach to block this communication. It will open
                new therapeutic opportunities to control the progression and inhibit the early-onset
                of dementia in Alzheimer’s Disease.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009998</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009998</identifier>
            <identifier type="nhmrc">2009998</identifier>
            <name type="primary">
                <namePart>Harnessing the power of diverse data to model population impacts of injury
                    and inform health and social policy</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">injury epidemiology</subject>
            <subject type="local">traumatic injury</subject>
            <subject type="local">data linkage</subject>
            <subject type="local">data analysis</subject>
            <subject type="local">disability</subject>
            <description type="Chief Investigator">Prof Belinda Gabbe</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This investigator grant program will transform thinking about
                the long-term impacts of injury and the complex interplay between health and social
                sectors. The program will establish cross-sectoral data platforms with the
                real-world capacity to fundamentally change how we use data to characterise injury
                and its impacts. The findings will drive evidence-informed public health and social
                policy planning and investment to reduce the population impacts of
                injury.</description>
            <description type="fundingAmount">$1,885,378.22</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010008</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010008</identifier>
            <identifier type="nhmrc">2010008</identifier>
            <name type="primary">
                <namePart>Reducing the impact and burden of substance use on mental
                    health</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">epidemiology</subject>
            <subject type="local">substance use</subject>
            <subject type="local">substance use disorders</subject>
            <subject type="local">alcohol use disorders</subject>
            <subject type="local">comorbidity</subject>
            <description type="Chief Investigator">Dr Janni Leung</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Substance use and mental health are both major public health
                issues that commonly occur together. The relationship between them is not well
                understood. This work will use advanced statistical models to quantify the
                relationship, predict how much harm substance use is causing to mental health, and
                identify how much harm could be prevented by better policy. The knowledge gained
                will inform policies on how to reduce disease burden caused by substance use on
                mental health in Australia and overseas.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010037</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010037</identifier>
            <identifier type="nhmrc">2010037</identifier>
            <name type="primary">
                <namePart>Defining the mechanisms that drive cell competition and plasticity in
                    stomach cancer.</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">adult stem cells</subject>
            <subject type="local">gastric cancer</subject>
            <subject type="local">mesenchymal signals</subject>
            <subject type="local">epithelial biology</subject>
            <subject type="local">cell-cell communication</subject>
            <description type="Chief Investigator">Dr Dustin Flanagan</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cancers of the upper digestive tract (stomach) are composed of
                a diverse mixture of cell types that function differently depending on the stage of
                cancer progression. Understanding exactly how the different cell types interact with
                each other to promote cancer growth at various stages of disease (early,
                intermediate and late-stage) is crucial in order to develop better cancer therapies
                to extend patient survival.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010051</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010051</identifier>
            <identifier type="nhmrc">2010051</identifier>
            <name type="primary">
                <namePart>Mitigating the impacts of infectious disease emergencies</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">informed decision making</subject>
            <subject type="local">policy development</subject>
            <subject type="local">disease transmission</subject>
            <subject type="local">social epidemiology</subject>
            <subject type="local">emerging diseases</subject>
            <description type="Chief Investigator">Dr Freya Shearer</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">While public health and social measures have been central to
                the COVID-19 response and saved lives, many uncertainties remain as to their optimal
                use. Governments have been repeatedly required to balance the consequences of an
                uncontrolled outbreak against the social and economic costs of interventions. Over
                the next five years, I will use modelling and decision science to support the
                development of more tailored and adaptive response policies for COVID-19 and
                inevitable future pandemics.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010053</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010053</identifier>
            <identifier type="nhmrc">2010053</identifier>
            <name type="primary">
                <namePart>Designing and translating novel therapies for diabetes and kidney
                    disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">type 1 diabetes mellitus (insulin-dependent diabetes
                mellitus)</subject>
            <subject type="local">kidney disease</subject>
            <subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes
                mellitus)</subject>
            <subject type="local">drug therapy</subject>
            <subject type="local">indigenous health</subject>
            <description type="Chief Investigator">Prof Josephine Forbes</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Four million individuals die from diabetes each year and half
                of these are less than 50 years old. Individuals with earlier onset diabetes in
                Australia and their families are personally impacted by diabetes specific health
                issues such as kidney disease. During this five year program of research we aim to
                better understand the factors responsible, and to progress therapies which may
                reduce diabetes and kidney disease if made available to these individuals including
                Indigenous Australians.</description>
            <description type="fundingAmount">$2,372,570.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010055</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010055</identifier>
            <identifier type="nhmrc">2010055</identifier>
            <name type="primary">
                <namePart>Health workforce investment to incentivise universal health
                    coverage</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">health economics</subject>
            <subject type="local">economic analysis</subject>
            <subject type="local">incentives</subject>
            <subject type="local">workforce policy</subject>
            <subject type="local">community health care</subject>
            <description type="Chief Investigator">Dr Blake Angell</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Health workers including doctors, nurses and community health
                workers are crucial to population health and a major driver of healthcare costs. In
                low- and middle-income nations, there has been little attention to the most
                effective way to finance and organise health workers despite the large costs in lost
                health and wasted expenditure caused by investing in ineffective care. This
                Fellowship will generate economic evidence to drive rational healthcare investment
                in low- and middle-income nations.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010063</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010063</identifier>
            <identifier type="nhmrc">2010063</identifier>
            <name type="primary">
                <namePart>Improving the mental health of trans and gender diverse young
                    people</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">mental health</subject>
            <subject type="local">gender</subject>
            <subject type="local">youth</subject>
            <subject type="local">psychological</subject>
            <subject type="local">psychiatric</subject>
            <description type="Chief Investigator">A/Prof Ashleigh Lin</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The aim of this research program is to improve the mental
                health of trans and gender diverse (henceforth trans) children and young people. One
                stream will be dedicated to better understanding the experiences of trans young
                people where gaps in knowledge still exist. The other stream will focus on the
                development of novel interventions to improve the mental health of trans children
                and young people at the individual and family levels.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010064</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010064</identifier>
            <identifier type="nhmrc">2010064</identifier>
            <name type="primary">
                <namePart>Bridging the clinico-pathological divide: improving neuroimaging analysis
                    and applications in dementia</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">frontotemporal dementia</subject>
            <subject type="local">neuroimaging</subject>
            <subject type="local">differential diagnosis</subject>
            <subject type="local">atrophy</subject>
            <subject type="local">disease progression</subject>
            <description type="Chief Investigator">Dr Ramon Landin-Romero</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Dementias are a group of incurable and fatal disorders caused
                by progressive deterioration of the brain function. This program will identify the
                gradual brain changes that cause symptoms of dementia (e.g., problems with thinking,
                language, behaviour and everyday skills) to develop. Greater understanding of how
                the brain changes throughout the disease course will lead to better diagnosis of
                dementia and contribute to develop medical treatments to stop the progression of the
                underlying disease.</description>
            <description type="fundingAmount">$1,570,120.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010070</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010070</identifier>
            <identifier type="nhmrc">2010070</identifier>
            <name type="primary">
                <namePart>Improving outcomes for men with advanced prostate cancer through
                    innovative clinical trials and biomarker development.</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">prostate cancer</subject>
            <subject type="local">novel therapies</subject>
            <subject type="local">radiopharmaceuticals</subject>
            <subject type="local">immunotherapy</subject>
            <subject type="local">biomarkers</subject>
            <description type="Chief Investigator">A/Prof Shahneen Sandhu</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Prostate cancer (PC) is a common disease and the median
                survival advantage from novel androgen receptor targeted agents for men with
                castration resistant disease is measured in months and is not cumulative due to
                underlying cross-resistance. My research program aims to understand the biology of
                aggressive forms of PC, define new immune and molecular targets and undertake novel
                biomarker driven clinical trials that will co-develop new combinations and
                biomarkers for optimal patient selection.</description>
            <description type="fundingAmount">$2,023,988.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010072</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010072</identifier>
            <identifier type="nhmrc">2010072</identifier>
            <name type="primary">
                <namePart>RetinaAGE as a novel biomarker for ageing and cardiovascular
                    risk</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sqdef20</identifier>
                <title>Centre for Eye Research Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">retina</subject>
            <subject type="local">ageing</subject>
            <subject type="local">chronic diseases</subject>
            <subject type="local">artificial neural networks</subject>
            <subject type="local">risk prediction</subject>
            <description type="Chief Investigator">Dr Zhuoting Zhu</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">The back of the eye (retina) is a window to our blood vessels
                and nervous system and can be easily imaged. I have developed and pilot tested an AI
                algorithm that can accurately predict age using retinal photos. The gap between age
                predicted by the algorithm and chronological age, known as RetinaAGE, can predict
                premature death and cardiovascular events. This project will test RetinaAGE in
                individuals of different ethnicities and translate this AI into a system that will
                be tested in clinics.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010084</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010084</identifier>
            <identifier type="nhmrc">2010084</identifier>
            <name type="primary">
                <namePart>Molecular and genomic profiling of rogue lymphocytes in autoimmune disease
                    using single-cell genomics</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">autoimmune disease</subject>
            <subject type="local">genomics</subject>
            <subject type="local">immune tolerance</subject>
            <subject type="local">bioinformatics</subject>
            <subject type="local">autoantibodies</subject>
            <description type="Chief Investigator">Dr Mandeep Singh</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Autoimmune disease occurs when the immune system turns "rogue"
                and attacks tissues within the body. The exact cause of human autoimmune diseases
                are unknown. A major hurdle in autoimmune disease research is identifying the rogue
                disease-causing immune cells from normal immune cells. I have developed novel
                technology capable of identifying and characterising rogue immune cells which will
                advance our understanding of how these cells arise and persist, and help develop
                more targeted therapies.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010088</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010088</identifier>
            <identifier type="nhmrc">2010088</identifier>
            <name type="primary">
                <namePart>Tailoring implementation for forgotten populations in chronic disease
                    management</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">implementation</subject>
            <subject type="local">evidence-based health care</subject>
            <subject type="local">mechanisms</subject>
            <subject type="local">translational research</subject>
            <subject type="local">chronic diseases</subject>
            <description type="Chief Investigator">Dr Aidan Cashin</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Using evidence in clinical practice is challenging when the
                evidence does not describe how the treatment works or include participants from the
                population of interest. The aim of this fellowship is to extend research evidence by
                identifying how treatments for chronic conditions work, and whether they apply to
                under-served populations in Australia. This information will improve the use of
                evidence in clinical practice and the uptake of evidence-based treatments for
                forgotten populations.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010091</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010091</identifier>
            <identifier type="nhmrc">2010091</identifier>
            <name type="primary">
                <namePart>Research generating evidence to optimise pneumococcal disease
                    prevention</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">vaccine</subject>
            <subject type="local">epidemiology</subject>
            <subject type="local">public health</subject>
            <subject type="local">epidemiological research methods</subject>
            <subject type="local">vaccine-preventable diseases</subject>
            <description type="Chief Investigator">Dr Sanjay Jayasinghe Wadanambi
                Arachchige</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This research program aims to develop an in-depth understanding
                of various streptococcus pneumoniae (SP) infections that could be serious and even
                life threatening. Antibiotic resistance and how COVID-19 and influenza could make
                people vulnerable to SP infections will be two key areas explored. This research is
                expected to feed directly in to practice and policy relating to pneumococcal disease
                surveillance and optimizing prevention using vaccinations during COVID-19 pandemic
                and beyond.</description>
            <description type="fundingAmount">$450,370.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010100</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010100</identifier>
            <identifier type="nhmrc">2010100</identifier>
            <name type="primary">
                <namePart>Developing an Oral Nanoformulation for Preventing Cancer
                    Recurrence</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">anticancer drug</subject>
            <subject type="local">nanotechnology</subject>
            <subject type="local">breast cancer prevention</subject>
            <subject type="local">copper transport</subject>
            <subject type="local">chemoprevention</subject>
            <description type="Chief Investigator">Dr Yannan Yang</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Triple negative breast cancer (TNBC) is a highly aggressive
                disease with high recurrence rate following primary treatment. This project aims to
                develop an oral nanoformulation for preventing TNBC recurrence by reducing systemic
                copper level. This formulation is based on an advanced nanobiotechnology which is
                expected to enable primarily localised copper depletion in the intestine and reduce
                systemic exposure, thereby minimising adverse off-target effects and improving
                therapeutic outcomes.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010110</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010110</identifier>
            <identifier type="nhmrc">2010110</identifier>
            <name type="primary">
                <namePart>Improving Outcomes after Extracorporeal Membrane Oxygenation</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">critical care medicine</subject>
            <subject type="local">heart failure</subject>
            <subject type="local">acute respiratory distress syndrome (ARDS)</subject>
            <subject type="local">mechanical ventilation</subject>
            <subject type="local">critical illness</subject>
            <description type="Chief Investigator">Dr Aidan Burrell</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Extracorporeal membrane oxygenation is a potentially lifesaving
                support for patients with severe cardiac or respiratory failure, but the underlying
                evidence base remains limited. Over the last 7 years, i have build leading program
                of research, which has led to the development of a national ECMO registry and a
                large RCT of ECMO for cardiac failure. With this fellowship, i will extend this work
                to generate new high quality knowledge in major evidence gaps, including a new
                clinical trial.</description>
            <description type="fundingAmount">$450,370.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010124</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010124</identifier>
            <identifier type="nhmrc">2010124</identifier>
            <name type="primary">
                <namePart>Improving Neonatal Resuscitation</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">neonatal intensive care (NICU)</subject>
            <subject type="local">resuscitation</subject>
            <subject type="local">neonatal respiratory distress syndrome</subject>
            <subject type="local">perinatal</subject>
            <subject type="local">neonatal survival</subject>
            <description type="Chief Investigator">Dr Douglas Blank</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Over 5% of all babies worldwide need help breathing in the
                seconds after birth. Failing to breath kills more than 1 baby every minute. My grant
                will investigate simple ideas that may make birth safer for the baby, including:
                understanding how the baby begins breathing air after birth, augmenting the
                respiratory drive of premature babies to spontaneously breathe after birth, and
                helping babies breathe before cutting the umbilical cord so that they are still
                being supported by their mother.</description>
            <description type="fundingAmount">$450,370.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010128</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010128</identifier>
            <identifier type="nhmrc">2010128</identifier>
            <name type="primary">
                <namePart>Improving care for low back pain</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">low back pain</subject>
            <subject type="local">chronic pain</subject>
            <subject type="local">clinical research</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">implementation</subject>
            <description type="Chief Investigator">Prof James McAuley</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Low back pain is the number-one cause of disability worldwide,
                affecting an estimated 540 million people at any one time. The disease burden due to
                low back pain has increased by 54% since 1990, threatening the sustainability of
                health care systems globally. My research will address the growing burden of low
                back pain by providing new knowledge on the effect of analgesic medicines and on
                works to improve the research translation of evidence into care.</description>
            <description type="fundingAmount">$2,111,089.24</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010134</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010134</identifier>
            <identifier type="nhmrc">2010134</identifier>
            <name type="primary">
                <namePart>Revealing how tolerance checkpoints fail in human autoimmune diseases and
                    how to target therapy</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">autoimmune disease</subject>
            <subject type="local">immunological tolerance</subject>
            <subject type="local">cellular immunology</subject>
            <subject type="local">somatic mutation</subject>
            <subject type="local">differential gene expression</subject>
            <description type="Chief Investigator">Prof Christopher Goodnow</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Prof Goodnow will lead a program of research defining the root
                cause of human autoimmune diseases and using these discoveries to guide better
                targetted treatment for these important, chronic diseases. The research employs new
                single cell genomic technologies to pinpoint the DNA and other molecular
                abnormalities that allow rare cells within the immune system to escape the body’s
                normal control processes, and instead attack one or other part of the body to cause
                autoimmunity.</description>
            <description type="fundingAmount">$2,500,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010136</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010136</identifier>
            <identifier type="nhmrc">2010136</identifier>
            <name type="primary">
                <namePart>Preventing stillbirths and improving care after loss</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">antenatal care</subject>
            <subject type="local">stillbirth</subject>
            <subject type="local">prevention</subject>
            <subject type="local">bereavement</subject>
            <subject type="local">neonatal</subject>
            <description type="Chief Investigator">Prof Vicki Flenady</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">In Australia, over 2000 families suffer the tragedy of
                stillbirth each year. By building on my achievements in rapidly translating new
                research into maternity care, I will lead my outstanding team to reduce stillbirth
                rates by 20% and reconcile inequities in stillbirth rates by Australia by 2025. I
                also anticipate a reduction in adverse neonatal outcomes. When stillbirth or
                neonatal death does occur, my research aims to ensure all women and families receive
                optimal care.</description>
            <description type="fundingAmount">$3,372,570.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010141</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010141</identifier>
            <identifier type="nhmrc">2010141</identifier>
            <name type="primary">
                <namePart>Understanding the role of predictive coding in visual processing: from
                    neural circuits to whole brain systems</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">visual attention</subject>
            <subject type="local">visual system</subject>
            <subject type="local">neuropsychological impairments</subject>
            <subject type="local">electroencephalogram (EEG)</subject>
            <subject type="local">functional magnetic resonance imaging (fMRI)</subject>
            <description type="Chief Investigator">Prof Jason Mattingley</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The simple act of perceiving an object in the world depends not
                only on the incoming sensory information, but also on the brain’s predictions about
                the object’s likely identity. This research will characterise the neural mechanisms
                responsible for predictive coding of visual information. I will combine brain
                imaging and analogous visual tasks in humans and animal models, and apply novel
                computational methods to reveal a common code for perception in whole brain systems
                and individual neurons.</description>
            <description type="fundingAmount">$2,527,015.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010149</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010149</identifier>
            <identifier type="nhmrc">2010149</identifier>
            <name type="primary">
                <namePart>Understanding complex I assembly for better diagnosis and future
                    treatment</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">mitochondria</subject>
            <subject type="local">membrane protein</subject>
            <subject type="local">protein complexes</subject>
            <subject type="local">mitochondrial disease</subject>
            <subject type="local">proteomics</subject>
            <description type="Chief Investigator">Dr Luke Formosa</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Almost all cells in the human body need to produce energy so
                they can survive and grow. This is achieved by tiny generators in the cell called
                Mitochondria. When Mitochondria are unable to produce the energy the cell needs it
                dies and this leads to Mitochondrial Disease, which affects 1 in 2000 people. This
                project aims to understand one of the biggest contributors to Mitochondrial Disease-
                called Complex I Deficiency. This will lead to better diagnosis of patients and
                treatments in the future.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010154</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010154</identifier>
            <identifier type="nhmrc">2010154</identifier>
            <name type="primary">
                <namePart>Gold Electronic Skins for Remote Biodiagnostics</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">biosensor</subject>
            <subject type="local">biomonitoring</subject>
            <subject type="local">remote</subject>
            <subject type="local">diagnosis</subject>
            <subject type="local">nanotechnology</subject>
            <description type="Chief Investigator">Prof Wenlong Cheng</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This interdisciplinary Eng-IT-Med research program aims to
                develop artificial intelligence-powered soft gold electronic skins for ‘health’
                monitoring of living organisms, including cells, tissues, organoids whenever one
                wants wherever one wants by a wireless smartphone. It is expected that this program
                will generate groundbreaking knowledge/technologies in remote monitoring of
                biological systems, deliver translational outcomes in industries and train a large
                cohort of workforces.</description>
            <description type="fundingAmount">$2,348,555.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010156</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010156</identifier>
            <identifier type="nhmrc">2010156</identifier>
            <name type="primary">
                <namePart>Decoding the epigenome of the tumour microenvironment for improved patient
                    outcomes in prostate cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">epigenetics</subject>
            <subject type="local">prostate cancer</subject>
            <subject type="local">microenvironment</subject>
            <subject type="local">DNA methylation</subject>
            <subject type="local">clinical decision making</subject>
            <description type="Chief Investigator">Dr Ruth Pidsley</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Just as people in big cities rely on a complex infrastructure
                network for their daily lives, cancer cells depend on the surrounding tumour
                microenvironment. Studying the behaviour and interactions of the neighbouring cells
                is crucial to understanding how a tumour develops and progresses. I will scrutinize
                the molecular information in prostate tumour microenvironment cells to learn how
                they emerge and function to promote cancer, and to identify new molecular markers to
                guide treatment decisions.</description>
            <description type="fundingAmount">$650,740.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010203</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010203</identifier>
            <identifier type="nhmrc">2010203</identifier>
            <name type="primary">
                <namePart>Building heart muscle to treat cardiomyopathies</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">congestive heart failure</subject>
            <subject type="local">coronary artery disease</subject>
            <subject type="local">cardiomyopathy</subject>
            <subject type="local">regeneration</subject>
            <subject type="local">cell cycle regulation</subject>
            <description type="Chief Investigator">Prof Bob Graham</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cardiovascular disease is our major societal and economic
                health burden. Many types of heart disease are due to a lack of functioning heart
                muscle cells either resulting from the massive loss of these cells following a heart
                attack or to the toxic effects of certain drugs in adults, or to inadequate heart
                growth in children; causing heart failure or death. This study aims to stimulate
                heart muscle cells to divide, thereby building heart muscle to improve heart
                function, well-being and survival.</description>
            <description type="fundingAmount">$2,352,015.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010212</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010212</identifier>
            <identifier type="nhmrc">2010212</identifier>
            <name type="primary">
                <namePart>Behavioural and social science to close gaps in vaccination
                    coverage</namePart>
            </name>
            <name type="alternative">
                <namePart>Investigator Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">behavioural intervention</subject>
            <subject type="local">communications/social research</subject>
            <subject type="local">vaccination policy</subject>
            <subject type="local">implementation</subject>
            <subject type="local">primary care</subject>
            <description type="Chief Investigator">Prof Julie Leask</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">COVID-19 has cost trillions in economic loss globally and
                devastated entire nations. The pandemic now has the capacity to be much better
                controlled with vaccination. But the best vaccines - those against COVID-19 and
                other diseases - are of no use if the public will not, or cannot, take them. This
                research will help countries to gather a better understanding of why people don't
                vaccinate and what to do about it.</description>
            <description type="fundingAmount">$2,372,570.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2000367</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2000367</identifier>
            <identifier type="nhmrc">2000367</identifier>
            <name type="primary">
                <namePart>Combination immune therapy for type 1 diabetes</namePart>
            </name>
            <name type="alternative">
                <namePart>Clinical Trials and Cohort Studies Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04z4kmw33</identifier>
                <title>Melbourne Health</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">type 1 diabetes mellitus (insulin-dependent diabetes mellitus) </subject>
            <subject type="local">autoimmune disease </subject>
            <subject type="local">immune modulation </subject>
            <subject type="local">metabolic control </subject>
            <subject type="local">immune tolerance</subject>
            <description type="Chief Investigator">A/Pr John Wentworth</description>
            <description type="Date Announced">2021-09-14T00:00:00</description>
            <description type="Sector">Health</description>
            <description type="full">This clinical trial will test whether a combination of two safe
                therapies, abatacept and nasal insulin, can stop the immune attack that causes type
                1 diabetes. Sixty-two children and young adults with recently-diagnosed type 1
                diabetes will receive either abatacept and nasal insulin or abatacept and nasal
                placebo for one year to determine if combined immune therapy preserves pancreas
                function and decreases the need for insulin therapy.</description>
            <description type="fundingAmount">$1,803,801.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009677</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009677</identifier>
            <identifier type="nhmrc">2009677</identifier>
            <name type="primary">
                <namePart>Mining the host-pathogen interface to deliver a drug pipeline for treating
                    intractable and emerging infections</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">drug discovery</subject>
            <subject type="local">medicinal chemistry</subject>
            <subject type="local">therapeutic agents</subject>
            <subject type="local">innate immunity</subject>
            <subject type="local">host/pathogen interaction</subject>
            <description type="Chief Investigator">Prof Kate Schroder</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Emerging viruses and antibiotic-resistant superbugs are the
                most important challenge to human health in the 21st century. New viruses such as
                SARS-CoV2 and Zika, as well as antibiotic resistant superbugs, emerge regularly and
                rapidly, urgently requiring new therapies. Our multidisciplinary Synergy team has
                demonstrated success in drug development and will create new drugs to avert the
                imminent global health disaster posed by emerging viruses and
                superbugs.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009851</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009851</identifier>
            <identifier type="nhmrc">2009851</identifier>
            <name type="primary">
                <namePart>Linking clinical and basic science discovery to find new treatments for
                    alcohol use disorder</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">alcohol dependence</subject>
            <subject type="local">pharmacotherapy</subject>
            <subject type="local">animal model</subject>
            <subject type="local">neuroimaging</subject>
            <subject type="local">alcohol use disorders</subject>
            <description type="Chief Investigator">Prof Paul Haber</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">More than a million Australians meet criteria for an alcohol
                use disorder, making it a leading cause of death, injury and many diseases. Current
                treatment is often ineffective and research receives limited attention with no new
                medications in 20 years. We will create a program for treatment development. We will
                test new medications and new behavioural treatment in experimental animals before
                moving to human trials. The approach links outstanding basic science and clinical
                research groups.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009923</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009923</identifier>
            <identifier type="nhmrc">2009923</identifier>
            <name type="primary">
                <namePart>Roadmap Options for Melanoma Screening in Australia
                    (Melanoma-ROSA)</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">melanoma</subject>
            <subject type="local">non-melanoma skin cancer</subject>
            <subject type="local">behaviour change</subject>
            <subject type="local">cancer screening</subject>
            <subject type="local">early detection</subject>
            <description type="Chief Investigator">Prof Monika Janda</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Melanoma is Australia’s third most common cancer and the
                earlier a melanoma is diagnosed the better the patient outcomes. Our program will
                co-design with consumers a blueprint for a NEW nationwide strategy for effective
                melanoma screening to inform practice and policy. We anticipate our program will
                generate evidence that will translate into a targeted melanoma screening program
                that is equitable in its reach, trustworthy for patients and clinicians, and
                cost-effective to the system.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010268</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010268</identifier>
            <identifier type="nhmrc">2010268</identifier>
            <name type="primary">
                <namePart>Tackling Australia’s low screening participation to prevent bowel cancer
                    morbidity and deaths</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">bowel cancer screening</subject>
            <subject type="local">participation</subject>
            <subject type="local">colorectal cancer prevention</subject>
            <subject type="local">controlled trial</subject>
            <subject type="local">behaviour change</subject>
            <description type="Chief Investigator">Prof Mark Jenkins</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Fifteen years after rollout, participation in our national
                bowel cancer screening program continues to lag behind comparable programs globally.
                We have not yet cracked even 50% participation despite the program’s world class
                free postal test kit and national registry. Current methods at getting people to
                screen are not working for most people. We content this due to failure to assess
                novel interventions in randomised controlled trials within the NBCSP.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010275</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010275</identifier>
            <identifier type="nhmrc">2010275</identifier>
            <name type="primary">
                <namePart>Improving outcomes for lung cancer patients: Discovering targetable
                    vulnerabilities in lung cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">lung cancer</subject>
            <subject type="local">mouse models</subject>
            <subject type="local">cancer biology</subject>
            <subject type="local">targeted therapy</subject>
            <subject type="local">cancer immunotherapy</subject>
            <description type="Chief Investigator">Assoc Prof Kate Sutherland</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Lung cancer is the leading cause of cancer-related mortality.
                One major hurdle faced in the clinic is that many patients fail to respond to
                currently available anti-cancer drugs. We will leverage the expertise of a diverse
                team of scientists and clinicians to tease apart the processes that can cause lung
                cancer to become refractory to current treatments. The discoveries made in this
                proposal will catalyse translational programs that will lead to improved ways to
                detect and treat lung cancer.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010287</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010287</identifier>
            <identifier type="nhmrc">2010287</identifier>
            <name type="primary">
                <namePart>Defining the role and therapeutic manipulation of the gut-lung axis in
                    respiratory disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03f0f6041</identifier>
                <title>University of Technology Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">respiratory diseases</subject>
            <subject type="local">gastroenterology</subject>
            <subject type="local">microbial ecology</subject>
            <subject type="local">metabolites</subject>
            <subject type="local">treatment</subject>
            <description type="Chief Investigator">Prof Philip Hansbro</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Emphysema is an enormous clinical issue that needs effective
                treatment. Gut diseases cause lung inflammation. We show that gut bacteria (the
                microbiome) are altered and can be modified with targeted dietary interventions. We
                will define these changes and rapidly screen new diet for effectiveness in the lab
                and then test the most effective in clinical trials in patients. We will define how
                the new therapies work and progress new interventions to human
                treatment.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010290</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010290</identifier>
            <identifier type="nhmrc">2010290</identifier>
            <name type="primary">
                <namePart>Interventions for better life-time mental health outcomes for young
                    Australians with disability</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">disability</subject>
            <subject type="local">young adults</subject>
            <subject type="local">health sociology</subject>
            <subject type="local">employment</subject>
            <subject type="local">community participation</subject>
            <description type="Chief Investigator">Prof Anne Kavanagh</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This research program brings together academic researchers from
                multiple disciplines to address the entrenched social, economic and mental health
                disadvantage experienced by Australian youth with disability. In partnership with
                advocacy groups and government, we will generate new evidence about interventions,
                including policy reforms, that can reduce the gap in mental health and wellbeing
                between young people with disability and their non-disabled peers.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010562</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010562</identifier>
            <identifier type="nhmrc">2010562</identifier>
            <name type="primary">
                <namePart>"Integrative-omics" for precision medicine in the epilepsies</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">epilepsy</subject>
            <subject type="local">genetics</subject>
            <subject type="local">paediatric</subject>
            <subject type="local">data analysis</subject>
            <subject type="local">molecular biology</subject>
            <description type="Chief Investigator">Prof Ingrid Scheffer</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Epilepsy affects 4% of the population, with an estimated annual
                cost of $12.3 billion in Australia in 2019. This is largely due to devastating
                epilepsies known as Developmental and Epileptic Encephalopathies (DEEs). Patients
                have uncontrolled seizures, developmental impairment and a high risk of early death.
                We will bring computational expertise to integrate multiple biological measurements
                from patients with DEEs to reveal underlying disease dynamics and target new
                treatment approaches.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010716</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010716</identifier>
            <identifier type="nhmrc">2010716</identifier>
            <name type="primary">
                <namePart>STopping Acute Rheumatic Fever Infections to Strengthen Health
                    (STARFISH)</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">rheumatic fever</subject>
            <subject type="local">aboriginal health</subject>
            <subject type="local">streptococcal disease</subject>
            <subject type="local">immunology</subject>
            <subject type="local">environmental health</subject>
            <description type="Chief Investigator">Prof Jonathan Carapetis</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Rheumatic Heart Disease (RHD) is a serious disease caused by
                preventable Strep A infections, disproportionately affecting Indigenous Australians.
                Knowledge gaps remain on how to eliminate RHD, and preventing acute rheumatic fever
                (ARF, the step before RHD) is key. In a global first STARFISH brings together a
                diverse team of experts to tackle the root causes – social determinants – providing
                evidence as to how environmental health and housing interventions can stop Strep A
                spread and prevent ARF.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010736</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010736</identifier>
            <identifier type="nhmrc">2010736</identifier>
            <name type="primary">
                <namePart>Cerebral Palsy SYNERGY Network to Protect, Repair and improve
                    Outcomes</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cerebral palsy treatments</subject>
            <subject type="local">neuroplasticity</subject>
            <subject type="local">neuroprotection</subject>
            <subject type="local">consumer participation</subject>
            <subject type="local">clinical trial</subject>
            <description type="Chief Investigator">Prof Roslyn Boyd</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cerebral Palsy (CP) is a life-long condition that affects
                movement and learning due to early brain injury. Recent research has reduced the
                number of infants being born with CP by 30 percent and now 70 percent of children
                will now walk. Our CP Synergy Network will develop new early tests to detect CP,
                treatments to prevent CP and repair and rehabilitate those with early brain injury
                that leads to Cerebral Palsy guided by a national consumer network and a diverse
                multidisciplinary clinical team.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010766</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010766</identifier>
            <identifier type="nhmrc">2010766</identifier>
            <name type="primary">
                <namePart>SERPICO Stroke: Synergistic Enhancement of Research design with Precision
                    analytics to Improve Clinical Outcomes in Stroke.</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">stroke</subject>
            <subject type="local">ischaemic stroke</subject>
            <subject type="local">haemorrhage</subject>
            <subject type="local">stroke outcome</subject>
            <subject type="local">post-stroke dementia</subject>
            <description type="Chief Investigator">Prof Mark Parsons</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Our Stroke synergy brings a diverse and revitalised
                cross-disciplinary team to harness our data infrastructure and pursue a whole new
                research direction for stroke. We will conduct a suite of new clinical trials with
                advanced statistical designs to improve trial efficiency. We will also develop
                completely new brain function and physical frailty measures to predict stroke
                outcome with embed cost-effectiveness analysis across all our activities to identify
                new ways to help patients.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010849</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010849</identifier>
            <identifier type="nhmrc">2010849</identifier>
            <name type="primary">
                <namePart>Rational design of novel CARs for safe and effective brain cancer
                    immunotherapy</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">protein engineering</subject>
            <subject type="local">t cell immunotherapy</subject>
            <subject type="local">brain neoplasms</subject>
            <subject type="local">cd8 t cells</subject>
            <subject type="local">cancer immunotherapy</subject>
            <description type="Chief Investigator">Assoc Prof Misty Jenkins</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Glioblastoma is a deadly brain cancer with &lt;5% survival, 5
                years after diagnosis. There are no curative treatments so novel approaches are
                urgently required. This project will improve therapy options for brain cancer by
                using immunotherapy, an approach showing great clinical promise. Using genetically
                engineered blood cells designed to specifically kill cancer cells, this project will
                use cutting edge technology to make new cell therapies and test them in preclinical
                models of brain cancer.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011100</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011100</identifier>
            <identifier type="nhmrc">2011100</identifier>
            <name type="primary">
                <namePart>Improving patient outcomes through implementation of digital and
                    diagnostic innovations for infections in cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">immunocompromised</subject>
            <subject type="local">clinical patient management</subject>
            <subject type="local">health information management</subject>
            <subject type="local">surveillance</subject>
            <subject type="local">infectious diseases</subject>
            <description type="Chief Investigator">Prof Monica Slavin</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Fever and sepsis complicate the management of cancer and occur
                in up to 90% of patients receiving treatment for certain types of cancer, and in
                some cases infection is the leading cause of early mortality. Gaps in the management
                of infection in cancer include lack of access to diagnostic tests and specialist
                care. This project will incorporate new technologies to deliver life saving care
                pathways for these vulnerable patients on a national scale.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011139</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011139</identifier>
            <identifier type="nhmrc">2011139</identifier>
            <name type="primary">
                <namePart>Understanding and averting blood cancer resistance to therapy</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">acute leukaemia</subject>
            <subject type="local">human malignant b-cell lymphoma</subject>
            <subject type="local">chronic lymphocytic leukaemia (cll)</subject>
            <subject type="local">drug resistance</subject>
            <subject type="local">targeted therapy</subject>
            <description type="Chief Investigator">Prof Andrew Roberts</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Blood cancers account for one-sixth of all cancer deaths. To
                substantially reduce this we need to establish why current treatments, including new
                targeted and immune therapies, fail. We are bringing together experts in different
                areas of science (biology, bioinformatics, imaging, immunology) and medicine
                (molecular diagnosis, treatment) to dissect why leukaemias and lymphomas become
                resistant to new therapies and design strategies to either prevent resistance
                occurring or to overcome it.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011204</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011204</identifier>
            <identifier type="nhmrc">2011204</identifier>
            <name type="primary">
                <namePart>IMPACT: IMplementation of x-ray PhAse-Contrast Tomography to transform
                    cancer diagnosis</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cancer detection</subject>
            <subject type="local">diagnostic imaging</subject>
            <subject type="local">computed tomography</subject>
            <subject type="local">medical physics</subject>
            <subject type="local">health services research</subject>
            <description type="Chief Investigator">Prof Patrick Brennan</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Techniques used for breast and lung cancer imaging miss 20-40%
                of cancers and use unnecessary radiation. We will clinically implement a novel
                technique called propagation-based phase-contrast computed tomography (PB-CT) which
                will exploit X-ray refraction in addition to X-ray absorption. PB-CT increases image
                signal, offering significantly improved cancer detection and reduced radiation dose.
                This work will transform cancer diagnosis in Australia and
                internationally.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011277</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011277</identifier>
            <identifier type="nhmrc">2011277</identifier>
            <name type="primary">
                <namePart>Respecting the Gift - Empowering Indigenous Communities in Genomic
                    Medicine</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03e3kts03</identifier>
                <title>South Australian Health and Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">genetics</subject>
            <subject type="local">aboriginal health</subject>
            <subject type="local">community participation</subject>
            <subject type="local">bioethics</subject>
            <subject type="local">access to health care</subject>
            <description type="Chief Investigator">Prof Alex Brown</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Genomic medicine represents a step change in medical sciences.
                Yet Indigenous Australians are not represented in, engaged with, nor have equitable
                access to the benefits of genomic research. Our national consortium will build
                Indigenous leadership in genomics through Empowering Communities; data sciences;
                understanding genomic variation; uncovering multi-omic signatures of disease; and
                translate these findings to health care, ensuring Indigenous peoples can lead
                genomic research on their terms.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011329</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011329</identifier>
            <identifier type="nhmrc">2011329</identifier>
            <name type="primary">
                <namePart>National Precision Health Research Translation for Breast and Prostate
                    Cancer Prevention and Early Detection</namePart>
            </name>
            <name type="alternative">
                <namePart>Synergy Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cancer genetics</subject>
            <subject type="local">breast cancer prevention</subject>
            <subject type="local">prostate cancer</subject>
            <subject type="local">economic evaluation</subject>
            <subject type="local">clinical genetics</subject>
            <description type="Chief Investigator">Prof Melissa Southey</description>
            <description type="Date Announced">2021-10-22T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This program will make the next benchmark advance in saving
                lives from breast and prostate cancer by i) expanding our understanding of the
                genomic risk factors and improving individualised risk prediction, ii) extending our
                understanding of Australian attitudes, views and preferences on returning clinically
                actionable genomic information and iii) enabling an informed pilot study to
                demonstrate the feasibility of population genomic testing in the Australian
                setting.</description>
            <description type="fundingAmount">$5,000,000.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010310</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010310</identifier>
            <identifier type="nhmrc">2010310</identifier>
            <name type="primary">
                <namePart>Impaired mucociliary clearance drives Bronchiectasis
                    progression</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">bronchiectasis </subject>
            <subject type="local">mucociliary clearance</subject>
            <subject type="local">airway epithelium</subject>
            <subject type="local">sequencing</subject>
            <subject type="local">molecular biology</subject>
            <description type="Chief Investigator">Assoc Prof Christopher Grainge</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">How bronchiectasis develops and progresses in the lung remains
                a mystery. One of the key features of bronchiectasis is the inability to clear mucus
                from the airways which leads to mucus stagnation. We have a identified a defect in
                production of the cells critical to moving mucus in the airways in samples taken
                from patients with bronchiectasis. By identifying the causes of this defect we may
                be able to reverse it and restore healthy mucus clearance in patients that suffer
                with bronchiectasis.</description>
            <description type="fundingAmount">$909,817.40</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010319</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010319</identifier>
            <identifier type="nhmrc">2010319</identifier>
            <name type="primary">
                <namePart>OPN as an Immune Checkpoint in KRAS Mutant Colorectal Cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/004y8wk30</identifier>
                <title>QIMR Berghofer Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">colon cancer </subject>
            <subject type="local">cancer therapy</subject>
            <subject type="local">molecular oncology</subject>
            <subject type="local">molecular pathology</subject>
            <subject type="local">medical genomics</subject>
            <description type="Chief Investigator">Assoc Prof Vicki Whitehall</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Bowel cancer is a very common disease that will be diagnosed in
                1/12 Australians living to age 85 and leads to over 4000 deaths annually.
                Subgrouping of colorectal cancers based on gene changes can predict response to
                therapy. Our research project specifically focuses on bowel cancers with a KRAS
                mutation that are usually resistant to currently available therapies. We are using
                cutting edge technology to identify novel approaches to therapy that will improve
                outcomes for these patients.</description>
            <description type="fundingAmount">$689,561.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010330</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010330</identifier>
            <identifier type="nhmrc">2010330</identifier>
            <name type="primary">
                <namePart>SPARC as a key regulator of breast cancer metastasis and resistance to
                    therapy</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">extracellular matrix </subject>
            <subject type="local">stroma</subject>
            <subject type="local">cancer metastasis</subject>
            <subject type="local">matrix proteins</subject>
            <subject type="local">breast cancer metastases</subject>
            <description type="Chief Investigator">Assoc Prof Thomas Cox</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">` The extracellular matrix or 'matrix' surrounds all cells and
                is very important in regulating cell behaviour. In cancer, the matrix is
                dramatically altered, typically making the cancer more aggressive. We recently
                developed new ways to study the matrix in breast cancer and in particular during
                cancer cell spread to other organs. We have uncovered exciting new matrix targets
                associated with breast cancer metastasis, and this project will validate their
                potential as novel therapeutic targets.</description>
            <description type="fundingAmount">$798,196.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010332</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010332</identifier>
            <identifier type="nhmrc">2010332</identifier>
            <name type="primary">
                <namePart>Programmable correction of mitochondrial DNA mutations</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">mitochondrial disease </subject>
            <subject type="local">mitochondria</subject>
            <subject type="local">mitochondrial function</subject>
            <subject type="local">mitochondrial respiration</subject>
            <subject type="local">gene expression</subject>
            <description type="Chief Investigator">Prof Aleksandra Filipovska</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Mitochondrial diseases (MD) may occur at any age, affect any
                body organ, and may result in severe disability and often death. The prognosis for
                children with mitochondrial disease is especially grim and devastating for families.
                There are no known cures and it is not possible to predict the future of a child
                with mitochondrial disease. We have created unique RNA editing tools that can
                reverse mutations in cells and potentially improve energy metabolism in patient and
                in vivo models of MD.</description>
            <description type="fundingAmount">$760,442.50</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010336</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010336</identifier>
            <identifier type="nhmrc">2010336</identifier>
            <name type="primary">
                <namePart>Preclinical evaluation of a streptococcal peptide based specific
                    diagnostic for rheumatic fever and the identification of proteins responsible
                    for the pathogenesis of rheumatic heart disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02n2ava60</identifier>
                <title>University of New England</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">rheumatic heart disease </subject>
            <subject type="local">diagnostic test</subject>
            <subject type="local">bacterial pathogenesis</subject>
            <subject type="local">autoimmunity initiation</subject>
            <subject type="local">indigenous health</subject>
            <description type="Chief Investigator">Prof Natkunam Ketheesan</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Rheumatic Heart Disease (RHD) is the commonest heart disease in
                children and young adults. While efforts have been made to control Strep infections
                that lead to RHD they are ineffective as NO SPECIFIC TEST for timely diagnosis is
                available. We have identified immune antibodies produced in RHD that can help the
                development of a new cost effective SPECIFIC test. During this project we will also
                identify the pathways that lead to heart damage and train and mentor three
                Indigenous Research Cadets.</description>
            <description type="fundingAmount">$485,134.90</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010382</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010382</identifier>
            <identifier type="nhmrc">2010382</identifier>
            <name type="primary">
                <namePart>Machine learning models for personalised epilepsy management</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">epilepsy </subject>
            <subject type="local">antiepileptic drugs</subject>
            <subject type="local">artificial neural networks</subject>
            <subject type="local">risk prediction</subject>
            <subject type="local">health service decision making</subject>
            <description type="Chief Investigator">Prof Patrick Kwan</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We will use clinical and genetic information to develop machine
                learning models to help clinician to select the most effective drug for individual
                epilepsy patients, and to identify patients likely has drug-resistant epilepsy at
                the time of diagnosis. These models will be validated in a new multicentre cohort of
                patients with newly diagnosed epilepsy in Australia.</description>
            <description type="fundingAmount">$781,017.60</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010384</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010384</identifier>
            <identifier type="nhmrc">2010384</identifier>
            <name type="primary">
                <namePart>Changing the paradigm to improve outcomes for Aboriginal children in
                    out-of-home care</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">indigenous health </subject>
            <subject type="local">aboriginal child</subject>
            <subject type="local">aboriginal health</subject>
            <subject type="local">aboriginal mental health</subject>
            <subject type="local">culturally appropriate methodology</subject>
            <description type="Chief Investigator">Dr Brad Farrant</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The evidence is clear that increasing the fit between service
                provision (research, policy, practice and resources), and the culture, values and
                needs of Aboriginal families and children is key to improving health and wellbeing
                outcomes. Building on the solid foundation of our previous work, this project will
                change the paradigm and co-design a personalised intervention support program to
                improve the health and wellbeing outcomes for Aboriginal children in out-of-home
                care and their families.</description>
            <description type="fundingAmount">$1,312,382.40</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010390</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010390</identifier>
            <identifier type="nhmrc">2010390</identifier>
            <name type="primary">
                <namePart>Dual-function ribonucleases: unexpected agents of antibiotic
                    resistance</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">antibiotic resistance </subject>
            <subject type="local">enzymes</subject>
            <subject type="local">molecular evolution</subject>
            <subject type="local">bioinformatics</subject>
            <subject type="local">genomics</subject>
            <description type="Chief Investigator">Prof Philip Hugenholtz</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Bacterial pathogens use a group of enzymes called
                metallo-ß-lactamases (or MBLs) that enable them to be multi-drug resistant. Our
                project aims to determine how MBLs have evolved from harmless and widespread
                ribonucleases, both deep in the past and potentially very recently in response to
                modern use of antibiotics. These insights will provide valuable functional and
                structural information that will enable the development of urgently needed
                strategies to combat ß-lactam antibiotic resistance.</description>
            <description type="fundingAmount">$739,593.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010400</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010400</identifier>
            <identifier type="nhmrc">2010400</identifier>
            <name type="primary">
                <namePart>Harnessing structural insights to block pneumococcal manganese
                    uptake</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">streptococcus pneumoniae </subject>
            <subject type="local">manganese</subject>
            <subject type="local">membrane transport</subject>
            <subject type="local">metals</subject>
            <subject type="local">ion transport</subject>
            <description type="Chief Investigator">Prof Christopher McDevitt</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Streptococcus pneumoniae is the world’s foremost bacterial
                pathogen. In Australia, bacterial infections are responsible for more than 9,000
                deaths every year, and the economic burden associated with treating diseases due to
                S. pneumoniae infections is more than $1 billion annually. This proposal aims to
                define how manganese, an essential trace element, is scavenged by S. pneumoniae
                during infection and then use a novel antimicrobial therapeutic strategy to block
                this pathway and prevent disease.</description>
            <description type="fundingAmount">$998,822.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010405</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010405</identifier>
            <identifier type="nhmrc">2010405</identifier>
            <name type="primary">
                <namePart>Genotype Imputation Resources for Productive Genetic Disease Studies of
                    Indigenous Oceanic Sub-Populations</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">population genetics </subject>
            <subject type="local">genomics</subject>
            <subject type="local">indigenous health</subject>
            <subject type="local">human genome project</subject>
            <subject type="local">genetic epidemiology</subject>
            <description type="Chief Investigator">Dr Sathish Periyasamy</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Indigenous Oceanic sup-populations are perhaps the
                least-represented of any population in genetic studies. We are proposing productive
                applications to conduct genetic disease studies by deploying the Indigenous Oceanic
                genetic analysis resources to promote complex genetic disease studies in these
                sub-populations. The outcomes will lead to improved disease diagnosis,
                interventions, treatments, and understanding the interplay of genetic and
                environmental factors in diseases of IO sub-populations.</description>
            <description type="fundingAmount">$2,512,857.80</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010464</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010464</identifier>
            <identifier type="nhmrc">2010464</identifier>
            <name type="primary">
                <namePart>The role of Piezo1 and TRPM4 ion channels in pathophysiology of cardiac
                    mechano-electric coupling</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">mechanotransduction </subject>
            <subject type="local">ion channels</subject>
            <subject type="local">cardiac hypertrophy</subject>
            <subject type="local">calcium imaging</subject>
            <subject type="local">electrophysiology</subject>
            <description type="Chief Investigator">Prof Boris Martinac</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Heart hypertrophy is an important risk factor for premature
                death from a heart disease. In this project we propose to study a new cellular
                signalling pathway causing heart hypertrophy due to systemic increase in blood
                pressure. The biological molecules central to this new cellular pathway are the
                Piezo1 and TRPM4 ion channels underlying contractions of the heart muscle. This
                project aims to establish a novel paradigm in our understanding of the molecular
                origins of heart hypertrophy.</description>
            <description type="fundingAmount">$1,207,705.25</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010522</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010522</identifier>
            <identifier type="nhmrc">2010522</identifier>
            <name type="primary">
                <namePart>Using renewal theory to develop personalised classification and treatment
                    for atrial fibrillation</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">atrial fibrillation </subject>
            <subject type="local">computer simulation</subject>
            <subject type="local">cardiac electrophysiology</subject>
            <subject type="local">applied statistics</subject>
            <subject type="local">cardiovascular physiology</subject>
            <description type="Chief Investigator">Assoc Prof Anand Ganesan</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Atrial fibrillation is the most common disorder of heart rhythm
                in the Australian community. It is characterised by disordered electrical waves, and
                mini-tornadoes of electricity called rotors. We have recently developed equations
                which can accurately predict the number and population distribution of rotors. Here,
                we will harness this discovery to perform a combination of clinical, experimental,
                simulation and technology development projects to develop personalised approaches to
                AF treatment.</description>
            <description type="fundingAmount">$1,166,529.20</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010530</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010530</identifier>
            <identifier type="nhmrc">2010530</identifier>
            <name type="primary">
                <namePart>Prediction of preterm birth using vaginal microbiology</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">very preterm birth </subject>
            <subject type="local">diagnostic test</subject>
            <subject type="local">molecular microbiology</subject>
            <subject type="local">aboriginal health</subject>
            <subject type="local">preventive medicine</subject>
            <description type="Chief Investigator">Dr Matthew Payne</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Recently, our team developed a vaginal microbial DNA test that
                successfully predicted up to 45% of spontaneous preterm birth (sPTB) cases in
                mid-gestation pregnant women, the majority of whom were Caucasian (75%). Our next
                steps are to maximise the tests’ ability to predict sPTB in Aboriginal women, whose
                vaginal microbiology differs, and to use pre-pregnancy vaginal microbiology to
                predict sPTB risk in all Australian women prior to conception.</description>
            <description type="fundingAmount">$2,073,045.00</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010532</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010532</identifier>
            <identifier type="nhmrc">2010532</identifier>
            <name type="primary">
                <namePart>A new model of ß-Spectrin function: understanding how the skin protects
                    neurons from damage</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">molecular neuroscience </subject>
            <subject type="local">axonal degeneration</subject>
            <subject type="local">cytoskeleton</subject>
            <subject type="local">peripheral nerve damage</subject>
            <subject type="local">neuroprotection</subject>
            <description type="Chief Investigator">Dr Sean Coakley</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The spectrin cytoskeleton is thought to function like a spring
                within neurons to allow them to bend and stretch – protecting them from damage
                induced by mechanical stress. Human mutations in spectrins cause severe neurological
                disorders with debilitating symptoms. We propose that spectrins function in tissue
                surrounding neurons to protect them from damage, and not within them as previously
                thought. This could revolutionise our understanding of disorders associated with
                spectrin dysfunction.</description>
            <description type="fundingAmount">$682,448.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010551</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010551</identifier>
            <identifier type="nhmrc">2010551</identifier>
            <name type="primary">
                <namePart>Resolving prostate cancer health disparities through population-scale
                    genomic interrogation</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">genomics </subject>
            <subject type="local">prostate cancer</subject>
            <subject type="local">population genetics</subject>
            <subject type="local">mutation analysis</subject>
            <subject type="local">bioinformatics</subject>
            <description type="Chief Investigator">Prof Vanessa Hayes</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Geography (environment) and ethnicity (genetics) are
                significant predictors of prostate cancer (PCa) mortality, specifically Africa or
                African ancestry. This project harnesses the power of whole genome interrogation and
                an intercontinental (Australia and Africa) and interethnic (European, African and
                Asian) study design, to distinguish the genetic and non-genetic factors contributing
                to PCa disparities. The hypothesis, non-genetic forces leave a ‘hallmark of DNA
                damage’ in the evolving tumour.</description>
            <description type="fundingAmount">$1,314,996.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010571</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010571</identifier>
            <identifier type="nhmrc">2010571</identifier>
            <name type="primary">
                <namePart>Heterochromatin instability as a molecular driver of haematopoietic
                    ageing</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">chromatin structure </subject>
            <subject type="local">ageing</subject>
            <subject type="local">haematopoiesis</subject>
            <subject type="local">immune dysfunction</subject>
            <subject type="local">epigenetics</subject>
            <description type="Chief Investigator">Dr Christine Keenan</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Ageing of the blood and immune system leaves elderly people
                more susceptible to infections and blood cancers. Given our ageing population,
                strategies that can either rejuvenate or slow this process are urgently needed. We
                have identified an epigenetic pathway that controls blood system ageing. This
                proposal will provide a comprehensive understanding of this epigenetic pathway in
                blood system ageing, and determine whether activating this pathway can slow-down or
                reverse the ageing process.</description>
            <description type="fundingAmount">$949,007.90</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010593</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010593</identifier>
            <identifier type="nhmrc">2010593</identifier>
            <name type="primary">
                <namePart>Preparing Australia for the next pandemic: Managing controversy; promoting
                    trust.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00jtmb277</identifier>
                <title>University of Wollongong</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">outbreak </subject>
            <subject type="local">public health policy</subject>
            <subject type="local">communications/social research</subject>
            <subject type="local">communicable disease</subject>
            <subject type="local">social and cultural issues</subject>
            <description type="Chief Investigator">Dr Christopher Degeling</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project addresses the question: how can we better prepare
                our institutions and Australian society for the next pandemic? COVID-19 has been
                characterised by uncertainties about transmission risks and the effectiveness of
                precautionary strategies, undermining confidence in experts and authorities. This
                project will develop guidance and practical resources to improve social preparedness
                for the next pandemic, and promote greater trust within and between expert groups
                and the broader community.</description>
            <description type="fundingAmount">$840,775.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010600</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010600</identifier>
            <identifier type="nhmrc">2010600</identifier>
            <name type="primary">
                <namePart>Targeting Renal Energy Metabolism in Kidney Injury and Disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00ymae584</identifier>
                <title>Institute for Breathing and Sleep</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">kidney disease </subject>
            <subject type="local">fatty acid metabolism</subject>
            <subject type="local">amp-activated protein kinase</subject>
            <subject type="local">kidney failure</subject>
            <subject type="local">obesity</subject>
            <description type="Chief Investigator">Assoc Prof Peter Mount</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Short-term acute kidney injury and permanent chronic kidney
                disease affects 1 in 10 Australians. It is unknown how these diseases are
                interlinked and related to obesity. A lack of energy supply in kidney cells could be
                the shared link and we will test this theory by targeting energy proteins in the
                kidney with a new drug O304. We anticipate knowledge generated by our innovative
                project will catalyse the development of new targeted treatments to improve kidney
                patient care and quality of life.</description>
            <description type="fundingAmount">$887,862.20</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010610</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010610</identifier>
            <identifier type="nhmrc">2010610</identifier>
            <name type="primary">
                <namePart>New approaches to cancer treatment through mRNA display</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">gene regulation </subject>
            <subject type="local">transcriptional regulation</subject>
            <subject type="local">protein structure</subject>
            <subject type="local">epigenetics</subject>
            <subject type="local">drug discovery</subject>
            <description type="Chief Investigator">Prof Joel Mackay</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This proposal will pioneer the development of a new class of
                molecules that will block the activity of proteins that regulate gene expression and
                have been shown to be promising targets for a range of diseases, predominantly
                cancer. These molecules have the potential to be much more selective and potent than
                existing molecules and to also open up new directions for cancer therapy by allowing
                previously intractable molecular targets to be addressed.</description>
            <description type="fundingAmount">$829,494.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010611</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010611</identifier>
            <identifier type="nhmrc">2010611</identifier>
            <name type="primary">
                <namePart>A gene-editing strategy for telomere-related bone marrow
                    failure</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">telomeres </subject>
            <subject type="local">telomerase</subject>
            <subject type="local">haematological disorders</subject>
            <subject type="local">gene therapy</subject>
            <subject type="local">haematopoietic stem cells</subject>
            <description type="Chief Investigator">Prof Tracy Bryan</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">A subset of inherited bone marrow failure (BMF) syndromes is
                caused by mutations in genes that protect the ends of chromosomes, or telomeres. The
                only curative therapy for BMF is bone marrow transplant, which has a high rate of
                mortality and complications. We will use the latest developments in gene editing of
                bone marrow stem cells to develop a strategy for correcting mutations in
                telomere-related genes in the patient’s own cells, providing a potentially curative
                therapy for inherited BMF.</description>
            <description type="fundingAmount">$617,992.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010632</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010632</identifier>
            <identifier type="nhmrc">2010632</identifier>
            <name type="primary">
                <namePart>Novel Hormone Analogues as an Innovative Endocrinological Intervention for
                    the Anaemia of Chronic Disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02sc3r913</identifier>
                <title>Griffith University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">hormones </subject>
            <subject type="local">hormone action</subject>
            <subject type="local">endocrine</subject>
            <subject type="local">endocrine disease</subject>
            <subject type="local">endocrine factors</subject>
            <description type="Chief Investigator">Prof Des Richardson</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Anaemia of chronic disease (ACD) is a severe cause of morbidity
                &amp;amp; mortality in millions of people with cancer or inflammatory diseases. ACD
                is due to excessive levels of hepcidin, a hormone that prevents gut iron uptake,
                which inhibits the use of iron for making red blood cells. Thus, excessive hepcidin
                leads to debilitating anaemia. This proposal will develop innovative Null Hepcidin
                Analogues that have no hormonal activity, but lead to excretion of excessive
                hepcidin, thereby curing the anaemia</description>
            <description type="fundingAmount">$638,288.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010647</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010647</identifier>
            <identifier type="nhmrc">2010647</identifier>
            <name type="primary">
                <namePart>Alternative splicing: A novel target to improve outcomes in acute myeloid
                    leukaemia</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">alternative splicing </subject>
            <subject type="local">acute myeloid leukaemia (aml)</subject>
            <subject type="local">cancer cell biology</subject>
            <subject type="local">cancer genetics</subject>
            <subject type="local">mouse models</subject>
            <description type="Chief Investigator">Dr Justin Wong</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">In 2013, we made a breakthrough discovery that certain parts of
                genes, previously considered “Junk DNA”, are actually carrying signals to control
                the amount of proteins produced in cells. Our preliminary work now suggests these
                signals controlling protein levels can be faulty in cancers. Here, we wish to
                determine if these faulty signals could be exploited to better manage a deadly blood
                cancer called acute myeloid leukaemia (AML). Our work will spur the development of
                novel therapy for AML.</description>
            <description type="fundingAmount">$1,111,376.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010654</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010654</identifier>
            <identifier type="nhmrc">2010654</identifier>
            <name type="primary">
                <namePart>Building an Evidence-Base to inform Post-Traumatic Stress Disorder (PTSD)
                    Treatment for Culturally and Linguistically Diverse Communities</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">posttraumatic stress disorder (ptsd) </subject>
            <subject type="local">mental health</subject>
            <subject type="local">trauma</subject>
            <subject type="local">culture</subject>
            <subject type="local">cross-cultural</subject>
            <description type="Chief Investigator">Dr Laura Jobson</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">How someone appraises trauma and deals with emotion is core to
                treating posttraumatic stress disorder (PTSD). Yet these treatments are based on
                research emphasising Western values. There is an urgent need to examine what
                appraisals and emotion regulation should be targeted in PTSD treatments for trauma
                survivors from other cultural backgrounds. This research examines cultural
                influences on appraisals and emotion regulation in PTSD to improve treatment
                outcomes for culturally diverse Australians.</description>
            <description type="fundingAmount">$738,149.20</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010701</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010701</identifier>
            <identifier type="nhmrc">2010701</identifier>
            <name type="primary">
                <namePart>Driving quality in delirium care through a patient-centred monitoring
                    system in palliative care</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02stey378</identifier>
                <title>University of Notre Dame Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">palliative care </subject>
            <subject type="local">delirium</subject>
            <subject type="local">health systems</subject>
            <subject type="local">clinical practice</subject>
            <subject type="local">psychological distress</subject>
            <description type="Chief Investigator">Assoc Prof Annmarie Hosie</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Delirium - sudden confusion and difficulty thinking related to
                illness, injury or medical treatment - is serious, distressing, and often not
                addressed for people in hospital at end of life. We will develop and test a new way
                to monitor delirium in palliative care that involves patients, their family, and
                staff. The system will align with national quality initiatives, tackle a complex and
                long-standing clinical issue, and be a key step forward for global quality
                improvement in palliative care.</description>
            <description type="fundingAmount">$503,477.30</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010704</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010704</identifier>
            <identifier type="nhmrc">2010704</identifier>
            <name type="primary">
                <namePart>Epithelial mechanics and the fate of cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">epithelium </subject>
            <subject type="local">cytoskeleton</subject>
            <subject type="local">cell adhesion</subject>
            <subject type="local">cell transformation</subject>
            <subject type="local">cancer cell biology</subject>
            <description type="Chief Investigator">Prof Alpha Yap</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Many common cancers originate in epithelial tissues, such as
                the breast, lung, colon and skin. All such cancers first begin as one cancer
                (transformed) cell within its epithelial tissue of origin, and these can be
                potentially eliminated by the epithelium to protect against cancer. This research
                proposal tests how abnormal function of the host epithelium can increase the risk of
                a newly-transformed cell being retained in the body to progress into a clinically
                significant tumor.</description>
            <description type="fundingAmount">$1,187,084.40</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010711</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010711</identifier>
            <identifier type="nhmrc">2010711</identifier>
            <name type="primary">
                <namePart>Modelling intellectual disability caused by mutations in
                    chromatin-modifying enzymes to develop ameliorating treatments</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">epigenetics </subject>
            <subject type="local">developmental genetics</subject>
            <subject type="local">chromatin</subject>
            <subject type="local">developmental disorders</subject>
            <subject type="local">transcriptional regulation</subject>
            <description type="Chief Investigator">Assoc Prof Tim Thomas</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Intellectual disability is a condition that affects speech,
                motor-coordination and emotional interactions. In cases where it is caused by a
                reduction in enzyme activity, it may be possible to improve patient outcome by
                providing more substrate for the enzymatic reaction or by inhibiting the opposing
                enzymatic activity. We propose to model human genetic disorders in mice to study new
                treatment options.</description>
            <description type="fundingAmount">$920,050.64</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010717</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010717</identifier>
            <identifier type="nhmrc">2010717</identifier>
            <name type="primary">
                <namePart>Global analysis of metabolic targets in Leishmania parasites</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">leishmania </subject>
            <subject type="local">metabolomics</subject>
            <subject type="local">microbial infections</subject>
            <subject type="local">drug discovery</subject>
            <subject type="local">cell metabolism</subject>
            <description type="Chief Investigator">Prof Malcolm McConville</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">There is an urgent need to develop new drugs to treat human
                leishmaniasis, a disease that causes debilitating and life-threatening diseases in
                millions of people worldwide. This project will systematically investigate the
                function of all metabolic enzymes in Leishmania pathogens using newly developed
                genetic and analytical tools. The findings of this study will be used to triage
                Leishmania metabolic enzymes for drug development, with the view of generating more
                effective anti-parasitics.</description>
            <description type="fundingAmount">$1,224,328.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010743</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010743</identifier>
            <identifier type="nhmrc">2010743</identifier>
            <name type="primary">
                <namePart>Immune mechanisms underpinning remission of allergy</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">food allergy </subject>
            <subject type="local">specific allergen immunotherapy</subject>
            <subject type="local">paediatric</subject>
            <subject type="local">systems biology</subject>
            <subject type="local">immunological intervention</subject>
            <description type="Chief Investigator">Prof Mimi Tang</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">There is no cure for food allergy. Treatments in development
                have been shown to induce remission of allergy. This can be transient or
                long-lasting. We will employ state-of-the-art approaches to characterise the immune
                changes underpinning remission, particularly whether remission is persistent
                (long-lasting) or transient. This knowledge would enable the development of more
                effective long-term treatments for food allergy by providing new targets for
                intervention, possibly offering a cure.</description>
            <description type="fundingAmount">$870,143.80</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010757</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010757</identifier>
            <identifier type="nhmrc">2010757</identifier>
            <name type="primary">
                <namePart>COVID-19-induced vascular complications: mechanisms and potential
                    therapies</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">endothelial dysfunction </subject>
            <subject type="local">vascular pathologies</subject>
            <subject type="local">inflammatory cytokines</subject>
            <subject type="local">covid-19</subject>
            <subject type="local">coagulation</subject>
            <description type="Chief Investigator">Dr Emma Gordon</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The coronavirus SARS-CoV-2 is responsible for the disease
                COVID-19, which causes significant lung dysfunction. Importantly, reports have
                observed COVID-19 symptoms that are not associated with the lungs, such as blood
                clots, vessel inflammation and leakage of fluid from vessels into tissues. These
                virus-induced vessel defects can lead to the death of patients. Here, we aim to
                understand exactly how these vessel defects occur to develop treatments for patients
                with acute and long term disease.</description>
            <description type="fundingAmount">$717,305.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010763</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010763</identifier>
            <identifier type="nhmrc">2010763</identifier>
            <name type="primary">
                <namePart>Brain injury in intimate partner violence: Insight into a silent
                    pandemic</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">mild traumatic brain injury </subject>
            <subject type="local">domestic violence</subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">brain trauma</subject>
            <subject type="local">brain imaging</subject>
            <description type="Chief Investigator">Assoc Prof Sandy Shultz</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Intimate partner violence (IPV) is a worldwide problem that
                primarily affects women. Although &amp;gt;90% of IPV survivors report symptoms
                consistent with traumatic brain injury (mTBI), how IPV-related TBI contributes to
                the lived experience of IPV victims has been remarkably understudied. This
                translational project will characterise the effects of IPV-related TBI. By doing
                this, we will be able to development interventions, and change practice and policy,
                to improvement the well-being of IPV victims.</description>
            <description type="fundingAmount">$1,924,134.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010778</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010778</identifier>
            <identifier type="nhmrc">2010778</identifier>
            <name type="primary">
                <namePart>Are nicotine replacement therapy and varenicline safe and effective for
                    women trying to quit smoking during pregnancy?</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">smoking cessation </subject>
            <subject type="local">pregnancy</subject>
            <subject type="local">pharmacoepidemiology</subject>
            <subject type="local">drug safety</subject>
            <subject type="local">effectiveness</subject>
            <description type="Chief Investigator">Dr Alys Havard</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project will measure the safety and effectiveness of two
                quit smoking medicines during pregnancy. It will use routinely collected data from
                Australia, New Zealand and the Nordic countries, for over 400,000 women who smoked
                during pregnancy. Women who used nicotine replacement therapy or varenicline during
                pregnancy will be compared to women who smoked but did not use these medicines in
                relation to quitting and adverse birth outcomes and neurodevelopmental problems
                among their children.</description>
            <description type="fundingAmount">$904,422.30</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010781</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010781</identifier>
            <identifier type="nhmrc">2010781</identifier>
            <name type="primary">
                <namePart>Engineering of novel insulin analogues for improved management of
                    diabetes</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">peptides </subject>
            <subject type="local">peptide synthesis</subject>
            <subject type="local">synthetic peptides</subject>
            <subject type="local">insulin</subject>
            <subject type="local">type 1 diabetes mellitus (insulin-dependent diabetes
                mellitus)</subject>
            <description type="Chief Investigator">Prof John Wade</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Diabetes is a major global health condition affecting nearly
                0.5 billion people. Insulin is an essential treatment for Type 1 and, increasingly,
                Type 2 diabetes. However, it is difficult to both manufacture and handle as it
                aggregates rapidly in solution making storage and accurate dosing difficult. We will
                develop novel modified insulins that are biologically active, long-acting,
                aggregate-free and which self-respond to increases in glucose levels therefore
                greatly improving diabetes therapy.</description>
            <description type="fundingAmount">$1,098,388.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010784</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010784</identifier>
            <identifier type="nhmrc">2010784</identifier>
            <name type="primary">
                <namePart>Mapping B-cell fate to improve humoral immunity to malaria</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">b cells </subject>
            <subject type="local">t cells</subject>
            <subject type="local">cellular interactions</subject>
            <subject type="local">genomics</subject>
            <subject type="local">humoral immunity</subject>
            <description type="Chief Investigator">Dr Ashraful Haque</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Malaria killed half a million people in 2019. While ~60
                vaccines exist against viral or bacterial diseases, no effective vaccines exist
                against malaria-causing parasites. Immunity to malaria can be mediated by
                antibodies. This depends on immune cells called B- and T-cells, conducting a
                choreographed series of interactions in immune organs. This process appears
                defective in malaria for reasons unknown. We will determine these reasons, and
                provide new ways for boosting immunity to malaria.</description>
            <description type="fundingAmount">$1,548,906.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010795</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010795</identifier>
            <identifier type="nhmrc">2010795</identifier>
            <name type="primary">
                <namePart>Oncofetal ecosystem in advanced Hepatocellular Carcinoma: Implications for
                    Identifying Immunotherapy response</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02n415q13</identifier>
                <title>Curtin University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">liver cancer </subject>
            <subject type="local">hepatocellular carcinoma</subject>
            <subject type="local">cancer immunotherapy</subject>
            <subject type="local">genomics</subject>
            <subject type="local">macrophages</subject>
            <description type="Chief Investigator">Dr Ankur Sharma</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Each year ~1800 Australians succumb to hepatocellular carcinoma
                (HCC). The lack of effective treatment options is a major contributing factor to the
                poor outcomes. A new immunotherapy treatment which activates the body's immune
                system, has demonstrated significant efficacy. However, this treatment does not work
                for all patients. Therefore, we will identify which patients will benefit from this
                treatment and provide biomarkers, with the overall purpose of guiding clinical
                decision making.</description>
            <description type="fundingAmount">$1,195,455.00</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010804</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010804</identifier>
            <identifier type="nhmrc">2010804</identifier>
            <name type="primary">
                <namePart>Measuring healthy ageing: finding an autophagy biomarker for a scalable
                    clinical test</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03e3kts03</identifier>
                <title>South Australian Health and Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">autophagy </subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">plasma proteins</subject>
            <subject type="local">lysosome biology</subject>
            <subject type="local">ageing</subject>
            <description type="Chief Investigator">Dr Timothy Sargeant</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">The cells of our bodies possess a powerful recycling system
                that removes damaged material that accumulates with age and causes diseases such as
                dementia and atherosclerosis. Although scientists know how to increase this
                recycling system in laboratory models, we cannot easily measure this function in
                humans. This study aims to develop easy methods to measure cell recycling in humans
                so that we can increase the activity of this recycling system to support healthy
                ageing.</description>
            <description type="fundingAmount">$818,964.40</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010812</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010812</identifier>
            <identifier type="nhmrc">2010812</identifier>
            <name type="primary">
                <namePart>Mechanisms underlying cortical hyperexcitability in amyotrophic lateral
                    sclerosis</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">amyotrophic lateral sclerosis </subject>
            <subject type="local">motor cortex</subject>
            <subject type="local">motor neuron disease (mnd)</subject>
            <subject type="local">transcranial magnetic stimulation (tms)</subject>
            <subject type="local">dementia</subject>
            <description type="Chief Investigator">Prof Ostoja Vucic</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The current research grant will use novel neurophysiological
                tools to study brain activity in patients with motor neuron disease/amyotrophic
                lateral sclerosis. We anticipate that excessive brain activity, called cortical
                hyperexcitability, will be caused by reduction in activity of cortical inhibitory
                nerves, increase in activity of cortical excitatory nerves and increase in
                persistent sodium currents. Treatments, targeting the abnormal brain processes, are
                likely to be developed.</description>
            <description type="fundingAmount">$1,009,316.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010813</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010813</identifier>
            <identifier type="nhmrc">2010813</identifier>
            <name type="primary">
                <namePart>Metabolic and molecular protection against mtDNA mutations</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">dna damage </subject>
            <subject type="local">cell metabolism</subject>
            <subject type="local">mitochondrial dna (mtdna)</subject>
            <subject type="local">mitochondria</subject>
            <subject type="local">cell biology</subject>
            <description type="Chief Investigator">Dr Steven Zuryn</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Mitochondria are powerhouses of the cell. Their assembly and
                function are encoded by a small mitochondrial genome. Mutations in the mitochondrial
                genome can cause devastating metabolic disorders and have been linked to many common
                age-related diseases. This project will reveal how cells invoke protective measures
                to overcome these mutations, thus revealing new mechanisms that can be exploited to
                combat mitochondria-associated disease.</description>
            <description type="fundingAmount">$782,369.60</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010841</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010841</identifier>
            <identifier type="nhmrc">2010841</identifier>
            <name type="primary">
                <namePart>Coxiella pathogenesis and Effector-Effector Interplay</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">bacterial virulence factors </subject>
            <subject type="local">coxiella burnetii</subject>
            <subject type="local">bacterial pathogenesis</subject>
            <subject type="local">autophagy</subject>
            <subject type="local">protein interactions</subject>
            <description type="Chief Investigator">Assoc Prof Hayley Newton</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Coxiella causes the human infection Q fever. Coxiella has a
                cohort of virulence proteins that interfere with the human cell. This research will
                uncover how these proteins function, and interact with each other, to cause disease.
                This will contribute important new knowledge of pathogenesis that will highlight
                novel intervention targets. We will also learn how these virulence proteins
                manipulate human cell functions which are involved in a range of human
                diseases.</description>
            <description type="fundingAmount">$572,643.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010899</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010899</identifier>
            <identifier type="nhmrc">2010899</identifier>
            <name type="primary">
                <namePart>Neuropharmacology of decision-making: causal brain network modelling
                    across species</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">decision making </subject>
            <subject type="local">electroencephalogram (eeg)</subject>
            <subject type="local">functional magnetic resonance imaging (fmri)</subject>
            <subject type="local">neuropharmacology</subject>
            <subject type="local">dopamine</subject>
            <description type="Chief Investigator">Prof Mark Bellgrove</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Decision making is a critical aspect of human cognition that is
                frequently impaired in clinical disorders. This project will identify the
                fundamental brain processes governing decision making by studying both monkeys and
                humans while they perform the same cognitive task. We will identify the critical
                brain networks that allow organisms to efficiently make decisions and the chemicals
                which modulate these networks. Our knowledge will inform treatment of clinical
                disorders of decision making.</description>
            <description type="fundingAmount">$2,018,154.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010901</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010901</identifier>
            <identifier type="nhmrc">2010901</identifier>
            <name type="primary">
                <namePart>Investigating myristic acid as key mediator of memory via
                    myristoylation</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">memory </subject>
            <subject type="local">lipid</subject>
            <subject type="local">mass spectrometry</subject>
            <subject type="local">synaptic plasticity</subject>
            <subject type="local">phospholipases</subject>
            <description type="Chief Investigator">Prof Frederic Meunier</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Despite the fact the that human brain is made of nearly 60
                percent fat, the vast majority of studies on the mechanism of memory and
                neurodegeneration primarily focused on protein and genetic changes. Here, we
                discovered that myristic acid production derived from brain cell phospholipids
                correlates with memory acquisition. Using state-of-the-art mass spectrometry and
                super-resolution microscopy, we will establish the role of myristic acid in learning
                and how it is affected during ageing.</description>
            <description type="fundingAmount">$978,361.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010917</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010917</identifier>
            <identifier type="nhmrc">2010917</identifier>
            <name type="primary">
                <namePart>Targeting neuropilin in SARS-Cov-2 neuronal uptake and
                    transport</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">covid-19 </subject>
            <subject type="local">sars-cov-2</subject>
            <subject type="local">endocytosis</subject>
            <subject type="local">axonal transport</subject>
            <subject type="local">central nervous system (cns) diseases</subject>
            <description type="Chief Investigator">Prof Frederic Meunier</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">COVID-19 is associated with a variety of neurological symptoms,
                ranging from a transient loss of smell and taste to headaches to severe ischaemic
                damage in fatal cases. The long-term consequences of potential interactions of the
                causative virus, SARS-CoV-2, with brain cells are currently unknown but could be
                linked to intractable neuronal degeneration as previously found with the 1918
                influenza pandemic. We will investigate the uptake and transport of the virus and
                find ways to block infection.</description>
            <description type="fundingAmount">$904,308.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010919</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010919</identifier>
            <identifier type="nhmrc">2010919</identifier>
            <name type="primary">
                <namePart>Detecting Referable Glaucoma Using Artificial Intelligence</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03f0f6041</identifier>
                <title>University of Technology Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">glaucoma </subject>
            <subject type="local">artificial neural networks</subject>
            <subject type="local">computer-assisted diagnosis</subject>
            <subject type="local">retinal vessels</subject>
            <subject type="local">image analysis</subject>
            <description type="Chief Investigator">Dr Mojtaba Golzan</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Glaucoma is a leading cause of blindness worldwide affecting
                over 300,000 Australians. While treatments are available to delay vision loss, no
                cure for glaucoma exists, making early identification of at-risk individuals an
                utmost priority. We have developed a model that can accurately detect early
                glaucoma-specific changes in the eye. In this project, we will evaluate the
                performance of our model in comparison to assessments made by glaucoma specialists
                to determine its efficacy.</description>
            <description type="fundingAmount">$379,061.20</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010939</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010939</identifier>
            <identifier type="nhmrc">2010939</identifier>
            <name type="primary">
                <namePart>Molecular mechanisms underlying the pathogenesis of complex I dysfunction
                    and mitochondrial disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">mitochondria </subject>
            <subject type="local">mitochondrial disease</subject>
            <subject type="local">mitochondrial respiration</subject>
            <subject type="local">protein complexes</subject>
            <subject type="local">molecular basis of disease</subject>
            <description type="Chief Investigator">Prof Michael Ryan</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Mitochondria are the powerhouses of our cells that produce the
                chemical ATP for functions such as muscle contraction and triggering of nerves.
                Mitochondrial Complex I is a molecular motor that helps to make this ATP and defects
                in this motor cause mitochondrial disease, resulting in early childhood death. In
                this project we will study how Complex I is assembled and determine how defects in
                this assembly pathway leads to disease. New insights into therapeutic approaches
                will be investigated.</description>
            <description type="fundingAmount">$1,370,808.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010955</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010955</identifier>
            <identifier type="nhmrc">2010955</identifier>
            <name type="primary">
                <namePart>Investigating complement C5a receptor 2 as a therapeutic target for
                    diabetic kidney disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">diabetic complications </subject>
            <subject type="local">diabetic nephropathy</subject>
            <subject type="local">complement activation</subject>
            <subject type="local">complement c5a</subject>
            <subject type="local">kidney disease</subject>
            <description type="Chief Investigator">Dr Sih Min Tan</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Kidney disease is a serious and common complication of diabetes
                and the leading cause of kidney failure worldwide. We have found that the complement
                system, which is a normal part of the immune system, is overactivated in diabetes
                and leads to kidney injury. We propose studies to not only understand how complement
                leads to kidney disease in diabetes, but also to identify novel therapeutic targets
                to enable the development of new treatments for diabetic kidney
                disease.</description>
            <description type="fundingAmount">$855,469.60</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010979</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010979</identifier>
            <identifier type="nhmrc">2010979</identifier>
            <name type="primary">
                <namePart>A novel antibody-based treatment for polymicrobial sepsis.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rxfrp27</identifier>
                <title>La Trobe University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">apoptosis </subject>
            <subject type="local">acute inflammation</subject>
            <subject type="local">bacterial infection</subject>
            <subject type="local">receptors</subject>
            <subject type="local">biomarkers</subject>
            <description type="Chief Investigator">Assoc Prof Hamsa Puthalakath</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Sepsis or blood poisoning kills more than 7000 Australians
                every year and there is no cure for this disease. Using the CRISPR gene editing
                technology, we identified and characterized the receptor protein responsible death
                during sepsis in mice. We also have developed antibodies against the human
                counterparts of this receptor. We propose to test these antibodies in mice and human
                sepsis patients. We also propose to test a diagnostic marker for sepsis-associated
                mortality in sepsis patients.</description>
            <description type="fundingAmount">$653,115.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010992</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010992</identifier>
            <identifier type="nhmrc">2010992</identifier>
            <name type="primary">
                <namePart>Targeting a novel epigenetic regulator of Hodgkin lymphoma, H2A.B, for
                    treament of cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">drug discovery </subject>
            <subject type="local">tumour-specific targeting</subject>
            <subject type="local">nuclear transport</subject>
            <subject type="local">protein targeting</subject>
            <subject type="local">enzyme inhibition</subject>
            <description type="Chief Investigator">Dr Tatiana Soboleva</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We have identified a novel key regulator of Hodgkin Lymphoma,
                epigenetic factor, histone H2A.B. This proposal aims to develop novel therapeutic
                tools that would target H2A.B and potentially provide a more specific and less toxic
                treatment for Hodgkin Lymphoma patients. We will use Modular Nanotransporters, a
                highly specific intracellular delivery system, to target H2A.B for degradation and
                we will use the small molecule kinase inhibitors for functional inactivation of
                H2A.B.</description>
            <description type="fundingAmount">$1,041,337.40</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010998</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010998</identifier>
            <identifier type="nhmrc">2010998</identifier>
            <name type="primary">
                <namePart>Targeting metabolism to improve healthy ageing</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">mitochondria </subject>
            <subject type="local">healthy ageing</subject>
            <subject type="local">ageing</subject>
            <subject type="local">metabolism</subject>
            <subject type="local">longevity</subject>
            <description type="Chief Investigator">Assoc Prof Kyle Hoehn</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Ageing is the largest risk factor for chronic diseases that
                account for most of the financial burden of disease and 90% of deaths in Australia.
                The goal of this project is to test a new small molecule drug in mouse models of
                ageing to test the hypothesis that it will improve healthy ageing by decreasing
                age-related organ deterioration. Success of this project would provide support for
                clinical translation that could benefit individuals and society by decreasing
                disease incidence.</description>
            <description type="fundingAmount">$858,203.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011004</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011004</identifier>
            <identifier type="nhmrc">2011004</identifier>
            <name type="primary">
                <namePart>Targeting caloric efficiency to treat obesity-related diabetes</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">diabetes mellitus </subject>
            <subject type="local">obesity</subject>
            <subject type="local">glucose homeostasis</subject>
            <subject type="local">insulin resistance</subject>
            <subject type="local">endocrinology</subject>
            <description type="Chief Investigator">Assoc Prof Kyle Hoehn</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Diabetes is a major unmet medical need in Australia. We have
                recently discovered a new class of drug that reverses obesity and pre-diabetes in
                mice. The objectives of this project are to determine whether this drug is effective
                in a mouse model of very severe obesity-related diabetes, and to determine if new
                drug coatings will improve drug exposure so that it can be taken orally once per
                day. Success of this project will provide vital data needed to support clinical
                translation.</description>
            <description type="fundingAmount">$586,751.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011010</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011010</identifier>
            <identifier type="nhmrc">2011010</identifier>
            <name type="primary">
                <namePart>Elucidating the function of host-derived cysteine in bacterial
                    virulence</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">helicobacter pylori </subject>
            <subject type="local">oxidative stress</subject>
            <subject type="local">x-ray crystallography</subject>
            <subject type="local">host colonisation</subject>
            <subject type="local">molecular microbiology</subject>
            <description type="Chief Investigator">Assoc Prof Anna Roujeinikova</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Our immune system responds to stomach infection with
                Helicobacter pylori by producing high levels of defence molecules called reactive
                oxygen species (ROS). However, H. pylori can withstand ROS, and they fail to clear
                the infection, but in the long term, ROS damage the stomach lining resulting in
                disease. This project tests the hypothesis that H. pylori uses amino acids cysteine
                and cystine available in the stomach lining to combat ROS. The outcomes will aid
                future design of new antimicrobials.</description>
            <description type="fundingAmount">$300,922.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011020</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011020</identifier>
            <identifier type="nhmrc">2011020</identifier>
            <name type="primary">
                <namePart>Cytotoxic T cell granules – a matter of life and death</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">lysosome biology </subject>
            <subject type="local">lysosomal storage disorder</subject>
            <subject type="local">cytotoxic t lymphocytes (ctl)</subject>
            <subject type="local">protein trafficking</subject>
            <subject type="local">apoptosis</subject>
            <description type="Chief Investigator">Assoc Prof Ilia Voskoboinik</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Humans are protected from infections and cancer by a subset of
                immune cells called cytotoxic lymphocytes, which can recognised and kill rogue
                cells. Despite an enormous clinical interest, how these cells mature from a naive
                inactive to a fully activated state is poorly understood. The aim of the current
                proposal is to investigate that process, and thus provide a better understanding of
                how the immune system works and how it can be better utilised to treat cancer and
                other diseases.</description>
            <description type="fundingAmount">$1,386,960.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011033</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011033</identifier>
            <identifier type="nhmrc">2011033</identifier>
            <name type="primary">
                <namePart>ComBATing lethal prostate cancer with combination Bipolar Androgen
                    Therapy</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">testosterone </subject>
            <subject type="local">steroid hormones</subject>
            <subject type="local">androgen receptor</subject>
            <subject type="local">hormone-dependent cancers</subject>
            <subject type="local">prostate</subject>
            <description type="Chief Investigator">Dr Mitchell Lawrence</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">For 80 years, the main way to treat advanced prostate cancer
                has been to cut off the supply of male hormones. Unfortunately, this only works
                temporarily and it compromises quality of life. Surprisingly, new clinical trials
                show that the opposite approach – supplying excess testosterone – is effective and
                improves quality of life. Our novel idea is to boost the efficacy of testosterone
                therapy, and ensure more patients benefit, by combining it with a second
                drug.</description>
            <description type="fundingAmount">$952,194.20</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011042</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011042</identifier>
            <identifier type="nhmrc">2011042</identifier>
            <name type="primary">
                <namePart>Establishing a new bone pathologic pathway and solving problems of
                    diagnosis in chronic orthopaedic infections</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">chronic infection </subject>
            <subject type="local">orthopaedic surgery</subject>
            <subject type="local">antibiotic therapy</subject>
            <subject type="local">medicinal chemistry</subject>
            <subject type="local">staphylococcus</subject>
            <description type="Chief Investigator">Prof Gerald Atkins</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Orthopaedic and other bone infections are difficult to
                diagnose, treat and cure. Hard bone is a unique niche for host-pathogen interaction
                that provides both serious treatment challenges and new opportunities for improving
                patient outcomes. Using analysis of human patients, unique animal and human models
                of bone infection, our proposal will revolutionise diagnosis and understanding of
                complex infections such as periprosthetic joint infection and diabetic foot
                infection.</description>
            <description type="fundingAmount">$893,115.80</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011044</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011044</identifier>
            <identifier type="nhmrc">2011044</identifier>
            <name type="primary">
                <namePart>COMBAT - A Combination B-and T-Cell Epitope Vaccine to Futureproof
                    COVID-19 Vaccine</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02sc3r913</identifier>
                <title>Griffith University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">covid-19 </subject>
            <subject type="local">vaccine</subject>
            <subject type="local">synthetic peptides</subject>
            <subject type="local">humoral immunity</subject>
            <subject type="local">cellular immunity</subject>
            <description type="Chief Investigator">Dr Manisha Pandey</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We are proposing a vaccine that contains only safe components
                of the SARS-CoV-2 virus, yet effectively elicits protective immunity. The vaccine
                works by inducing antibodies capable of preventing the virus from attaching to lung
                cells, and killer T cells that destroy virus-infected cells. This highly innovative
                approach will generate a much needed safe and prophylactic 2nd generation modular
                vaccine, ideal for “vaccine update” that will have a major impact on health and
                society more generally.</description>
            <description type="fundingAmount">$1,211,033.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011047</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011047</identifier>
            <identifier type="nhmrc">2011047</identifier>
            <name type="primary">
                <namePart>Immunoglobulin A degradation by the gut microbiome</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">microbial ecology </subject>
            <subject type="local">immunoglobulin a (iga)</subject>
            <subject type="local">ulcerative colitis</subject>
            <subject type="local">protease</subject>
            <subject type="local">microbial pathogenesis</subject>
            <description type="Chief Investigator">Assoc Prof Nadeem Kaakoush</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The antibody immunoglobulin A (IgA) plays an important role in
                the immune response to microbial species at mucosal surfaces. Pathogenic bacterial
                species are known to degrade IgA in the gut to aid their virulence; however, little
                is known about this activity in commensal bacteria. Here, we aim to study a novel
                protein identified in a gut commensal bacterium that can potentially degrade IgA,
                and determine if this protein activity has downstream consequences to disease
                susceptibility.</description>
            <description type="fundingAmount">$647,333.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011083</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011083</identifier>
            <identifier type="nhmrc">2011083</identifier>
            <name type="primary">
                <namePart>Mapping the Beneficial Effects of Exercise in humans using Personalised
                    Phosphoproteomics</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">exercise </subject>
            <subject type="local">cell signalling</subject>
            <subject type="local">insulin action</subject>
            <subject type="local">glucose metabolism</subject>
            <subject type="local">muscle metabolism</subject>
            <description type="Chief Investigator">Dr Sean Humphrey</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Exercise has major health benefits and can prevent many
                diseases. For example, it is very effective in diabetes by improving insulin action.
                However, exercise is poorly tolerated by many creating a need to define the
                mechanism for these benefits. Using cutting-edge technologies we have identified a
                new lead that might underpin exercise effects on insulin action. This project will
                characterise this novel pathway in humans, bringing us a step closer to finding a
                drug that mimics exercise.</description>
            <description type="fundingAmount">$1,348,941.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011115</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011115</identifier>
            <identifier type="nhmrc">2011115</identifier>
            <name type="primary">
                <namePart>Defining the inflammatory T cell landscape in ankylosing
                    spondylitis</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03pnv4752</identifier>
                <title>Queensland University of Technology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">rheumatic diseases </subject>
            <subject type="local">musculoskeletal disorders</subject>
            <subject type="local">chronic inflammation</subject>
            <subject type="local">cd8 t cells</subject>
            <subject type="local">antigen</subject>
            <description type="Chief Investigator">Assoc Prof Tony Kenna</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Ankylosing spondylitis, or AS for short, is a common
                inflammatory arthritis that affects joints of the spine and pelvis. There is no cure
                for AS. Cells of the immune system called T cells are known to be important in AS
                but the details of how these cells work in the disease are unclear. Our work will
                define exactly how T cells work in AS. This world-first knowledge will permit design
                of new treatments focused specifically on preventing harmful aspects of T cell
                function that contribute to AS.</description>
            <description type="fundingAmount">$986,267.20</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011119</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011119</identifier>
            <identifier type="nhmrc">2011119</identifier>
            <name type="primary">
                <namePart>Legumain at the cutting edge of oral cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">protease </subject>
            <subject type="local">protease inhibitors</subject>
            <subject type="local">cancer metastasis</subject>
            <subject type="local">cancer pain</subject>
            <subject type="local">head and neck cancer</subject>
            <description type="Chief Investigator">Dr Laura Edgington-Mitchell</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Oral cancer patients suffer from profound pain and the survival
                rate is low due to the spread of the cancer. Effective therapies to treat oral
                cancer pain and prevent its spread are currently lacking. We have identified an
                enzyme that promotes cancer pain, and drugs that block its activity are effective at
                relieving pain. We will test the contribution of this enzyme to cancer spread and
                determine whether drugs blocking its activity are effective at preventing spread and
                alleviating pain.</description>
            <description type="fundingAmount">$588,593.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011120</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011120</identifier>
            <identifier type="nhmrc">2011120</identifier>
            <name type="primary">
                <namePart>When sporadic disease is not sporadic - exploiting cryptic relatedness to
                    unravel MND genetics</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">motor neuron disease (mnd) </subject>
            <subject type="local">genetic linkage</subject>
            <subject type="local">phenotype-genotype correlation</subject>
            <subject type="local">genomics</subject>
            <subject type="local">gene discovery</subject>
            <description type="Chief Investigator">Dr Kelly Williams</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Amyotrophic lateral sclerosis (ALS) is a devastating
                neurodegenerative disease with a significant genetic component underlying both the
                hereditary and sporadic forms of disease. Using a global cohort of ~10,000 ALS
                cases, we aim to uncover unrecognised ancestral relationships between patients in
                order to detect new genes that cause ALS or influence the progression of the
                disease. We will also harness the power of artificial intelligence to predict
                prognosis and inform clinical care.</description>
            <description type="fundingAmount">$1,165,925.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011129</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011129</identifier>
            <identifier type="nhmrc">2011129</identifier>
            <name type="primary">
                <namePart>Vaccine nonspecific effects of live and non-live vaccines: understanding
                    the mechanisms and potential consequences.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">systems biology </subject>
            <subject type="local">genomics</subject>
            <subject type="local">innate immunity</subject>
            <subject type="local">vaccine biology</subject>
            <subject type="local">bacterial infection</subject>
            <description type="Chief Investigator">Prof David Lynn</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Increasing evidence suggests that in addition to protecting us
                against specific diseases, vaccines can also confer nonspecific effects that are
                defined as effects on health unrelated to the disease targeted by the vaccine. In
                this proposal, we will investigate how different vaccines may shape how our innate
                immune system responds to subsequent infections.</description>
            <description type="fundingAmount">$883,314.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011143</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011143</identifier>
            <identifier type="nhmrc">2011143</identifier>
            <name type="primary">
                <namePart>Evaluating anti-fibrotic drugs for intracochlear fibrosis</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">fibrosis </subject>
            <subject type="local">transforming growth factor beta (tgf-beta)</subject>
            <subject type="local">fibroblasts</subject>
            <subject type="local">cochlear implant</subject>
            <subject type="local">animal model</subject>
            <description type="Chief Investigator">Assoc Prof Cecilia Prele</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cochlear implantation is currently the best method for hearing
                restoration and has been shown to improve speech understanding in the majority of
                patients. The acute and long-term outcomes of cochlear implantation remain variable
                and can be unpredictable. One reason for this variability is the formation of scar
                tissue around the electrode which, in some cases can lead to device failure. In this
                study we will determine if anti-fibrotic drugs can reduce the formation of this scar
                tissue.</description>
            <description type="fundingAmount">$1,108,813.80</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011172</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011172</identifier>
            <identifier type="nhmrc">2011172</identifier>
            <name type="primary">
                <namePart>A new role for gut pH in blood pressure regulation</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">blood pressure </subject>
            <subject type="local">heart disease</subject>
            <subject type="local">intestine</subject>
            <subject type="local">g protein-coupled receptors</subject>
            <subject type="local">nutritional therapy</subject>
            <description type="Chief Investigator">Assoc Prof Francine Marques</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">High blood pressure continues to be a major, poorly controlled
                but modifiable risk factor for cardiovascular death. Diets high in fibre are
                associated with lower blood pressure via the production of substances as a result of
                fibre digestion by gut microbes. We found that these same substances lower gut pH.
                This new mechanism could have major implications for the management of hypertension
                in the future.</description>
            <description type="fundingAmount">$998,801.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011193</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011193</identifier>
            <identifier type="nhmrc">2011193</identifier>
            <name type="primary">
                <namePart>Development of a nociceptive measuring device capable of differentiating
                    chronic pain states</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">peripheral nervous system (pns) diseases </subject>
            <subject type="local">pain measurement</subject>
            <subject type="local">dorsal root ganglia</subject>
            <subject type="local">calcium imaging</subject>
            <subject type="local">transcriptional regulation</subject>
            <description type="Chief Investigator">Dr Dusan Matusica</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Pain measurement is an essential element in any medical
                assessment, including diagnosis, monitoring of disease progress and evaluation of
                treatment effectiveness, but there is no common or easy method of objective pain
                measurement. This study aims to create an biosensor "neuron-on-chip" cell-based
                device with the machine learning driven capacity to measure and discriminate between
                various chronic types by analysing serum samples from animal models of chronic pain
                and human patients.</description>
            <description type="fundingAmount">$777,495.20</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011200</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011200</identifier>
            <identifier type="nhmrc">2011200</identifier>
            <name type="primary">
                <namePart>Novel therapies for slowing vision loss caused by retinal
                    degeneration</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">retinal degeneration </subject>
            <subject type="local">autophagy</subject>
            <subject type="local">proteasome</subject>
            <subject type="local">photoreceptors</subject>
            <subject type="local">drug screening</subject>
            <description type="Chief Investigator">Dr Kirstan Vessey</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Death of the light sensitive cells of the eye, the
                photoreceptors, is one of the leading causes of visual impairment in Australia. Our
                data indicate accumulation of intracellular waste within photoreceptors is a
                critical driver of their death. The aims of this project are to define the molecular
                pathways causing waste accumulation and find treatments that enhance waste recycling
                in photoreceptors to slow the devastating progression of vision loss.</description>
            <description type="fundingAmount">$735,066.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011209</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011209</identifier>
            <identifier type="nhmrc">2011209</identifier>
            <name type="primary">
                <namePart>Mapping sex differences in the journey of an individual with coronary
                    heart disease through the healthcare system</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02czsnj07</identifier>
                <title>Deakin University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">coronary heart disease (chd) </subject>
            <subject type="local">data linkage</subject>
            <subject type="local">sex differences</subject>
            <subject type="local">health service utilisation</subject>
            <subject type="local">health outcomes</subject>
            <description type="Chief Investigator">Prof Rachel Huxley</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">A general practice visit is often the first point of contact
                with the health system and a gateway to other specialist health services. However,
                data from different services are not easily ‘joined up’ making it difficult to look
                across the patient’s care journey. This project will join all health attendances for
                patients with heart related symptoms. This high-quality ‘joined up’ research will
                contribute to improvements in the provision of health services and patient outcomes
                in Australia.</description>
            <description type="fundingAmount">$843,258.40</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011217</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011217</identifier>
            <identifier type="nhmrc">2011217</identifier>
            <name type="primary">
                <namePart>TARGETING DEREGULATED EPIGENETIC MECHANISMS IN LYMPHOMA</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">lymphoma </subject>
            <subject type="local">epigenetics</subject>
            <subject type="local">b cells</subject>
            <subject type="local">dna targeted drugs</subject>
            <subject type="local">immune modulation</subject>
            <description type="Chief Investigator">Dr Maria del Pilar Dominguez
                Rodriguez</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Diffuse large B-cell lymphomas (DLBCL) are aggressive tumors,
                with 40% patients not responding to the conventional chemotherapy treatment or
                relapsing after treatment. In this proposal, we will evaluate new epigenetic
                therapies to treat these lymphomas, targeting the non-inherited environmental
                factors that control the function of genes. We predict that the results from this
                project will drive new clinical trials for DLBCL patients with TET2 or CREBBP
                mutations, which represent 1 in 3 patients.</description>
            <description type="fundingAmount">$1,111,760.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011220</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011220</identifier>
            <identifier type="nhmrc">2011220</identifier>
            <name type="primary">
                <namePart>Regenerative surgery for liver disease using human iPSC-derived liver
                    organoids</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02k3cxs74</identifier>
                <title>St Vincents Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">liver regeneration </subject>
            <subject type="local">stem cell therapy</subject>
            <subject type="local">stem cells</subject>
            <subject type="local">liver disease</subject>
            <subject type="local">tissue engineering</subject>
            <description type="Chief Investigator">Assoc Prof Geraldine Mitchell</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">This project will develop a new treatment for liver disease.
                Using a patient’s own stem cells, we will generate the key components of liver
                tissue and combine this into mini-liver units called organoids. Organoids will be
                transplanted into the body (in the groin), for initial development around a major
                artery/vein, forming a “second liver” in the body. We will then remove diseased
                liver tissue and replace this with the second liver, in a surgical procedure similar
                to liver transplantation.</description>
            <description type="fundingAmount">$1,184,911.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011299</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011299</identifier>
            <identifier type="nhmrc">2011299</identifier>
            <name type="primary">
                <namePart>Deciphering incomplete penetrance of subfertility</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02k3cxs74</identifier>
                <title>St Vincents Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">meiosis </subject>
            <subject type="local">recombination</subject>
            <subject type="local">sexual recombination</subject>
            <subject type="local">dna repair</subject>
            <subject type="local">dna replication</subject>
            <description type="Chief Investigator">Assoc Prof Wayne Crismani</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Infertility is one of the most common chronic health issues
                involving young adults. Infertility has many causes and is associated with other
                conditions including elevated risk of type 2 diabetes, heart disease and mental
                health issues such as anxiety and depression. The goal of the project is to discover
                genes that influence female fertility levels. This work is crucial to bridge the gap
                between accurately predicting who is at risk of infertility and how best to treat
                patients as individuals.</description>
            <description type="fundingAmount">$1,360,955.20</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011314</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011314</identifier>
            <identifier type="nhmrc">2011314</identifier>
            <name type="primary">
                <namePart>Generating a higher order kidney by understanding and controlling nephron
                    connectivity</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">kidney development </subject>
            <subject type="local">stem cell biology</subject>
            <subject type="local">regenerative medicine</subject>
            <subject type="local">kidney disease</subject>
            <subject type="local">tissue engineering</subject>
            <description type="Chief Investigator">Prof Melissa Little</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Engineering replacement kidney tissue for the treatment of
                chronic kidney disease has the potential to revolutionise kidney disease treatment.
                We previously used human stem cells to generate many nephrons, the filtering units
                of the kidney. In this project, we will focus on how to induce connections between
                these nephrons to ensure a common path for urine exit. This will bring us one stem
                closer to a stem-cell derived replacement kidney.</description>
            <description type="fundingAmount">$1,455,804.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011334</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011334</identifier>
            <identifier type="nhmrc">2011334</identifier>
            <name type="primary">
                <namePart>Can psychedelics treat anorexia nervosa? Insights into the therapeutic
                    effects of psilocybin in an animal model</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">anorexia nervosa </subject>
            <subject type="local">animal model</subject>
            <subject type="local">novel therapeutic agents</subject>
            <subject type="local">cognitive behaviour</subject>
            <subject type="local">serotonin</subject>
            <description type="Chief Investigator">Dr Claire Foldi</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Anorexia nervosa (AN) is a debilitating disorder which is
                currently untreatable. Phase 1 clinical trials of psilocybin are underway in
                patients with AN, however the biological mechanisms of psilocybin remain
                inadequately understood. This project, which will inform patient selection to avoid
                unfavourable effects, utilises the activity-based anorexia rat model combined with
                sophisticated techniques to furnish an understanding of psilocybin’s actions on
                weight loss, cognition and brain function.</description>
            <description type="fundingAmount">$770,855.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011342</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011342</identifier>
            <identifier type="nhmrc">2011342</identifier>
            <name type="primary">
                <namePart>Novel modelling of childhood obesity to improve decision making and close
                    the gap</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">overweight/obesity </subject>
            <subject type="local">modelling</subject>
            <subject type="local">health economics</subject>
            <subject type="local">early prevention</subject>
            <subject type="local">indigenous health</subject>
            <description type="Chief Investigator">Assoc Prof Alison Hayes</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Children from Aboriginal and Torres Strait Islander, other
                culturally and linguistically diverse groups, and socioeconomically disadvantaged
                groups are most affected by obesity. We will use novel modelling methods to assess
                childhood obesity prevention programs for future savings in healthcare costs,
                improvements in quality of life and impacts on inequalities. We will work with
                relevant stakeholders to ensure that resources are prioritised for the best and
                fairest obesity prevention programs.</description>
            <description type="fundingAmount">$367,556.20</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011344</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011344</identifier>
            <identifier type="nhmrc">2011344</identifier>
            <name type="primary">
                <namePart>Elucidating the impact of oxidative stress on the early development of
                    human placental villi using human stem cell derived placentoids</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/016gb9e15</identifier>
                <title>University of the Sunshine Coast</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">trophoblast </subject>
            <subject type="local">placenta</subject>
            <subject type="local">embryonic stem cells</subject>
            <subject type="local">fetal growth restriction</subject>
            <subject type="local">oxidative stress</subject>
            <description type="Chief Investigator">Dr Georgia Kafer</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The placenta supports the life of the baby. Nutrients, waste
                and oxygen cross special placental cells (trophoblasts) at the boundary between
                fetal and maternal circulation. Early in pregnancy, trophoblasts may experience
                premature rises in oxygen levels that can damage the placenta and risk maternal and
                fetal health. A newly developed experimental system will be used to study how oxygen
                fluxes impact trophoblast health to better understand the cause of placental defects
                at the cellular level.</description>
            <description type="fundingAmount">$393,481.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011355</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011355</identifier>
            <identifier type="nhmrc">2011355</identifier>
            <name type="primary">
                <namePart>New strategy to safely and effectively reduce diabetic kidney
                    disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">renal fibrosis </subject>
            <subject type="local">tubulointerstitial inflammation</subject>
            <subject type="local">transforming growth factor beta (tgf-beta)</subject>
            <subject type="local">protein interactions</subject>
            <subject type="local">peptide inhibitors</subject>
            <description type="Chief Investigator">Dr Zhonglin Chai</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Diabetic kidney disease (DKD) is a catastrophic disease with no
                effective treatment to reduce scarring and inflammation, the major pathological
                features of DKD. We have found a new target and generated a prototype drug, CHA-061,
                to safely inhibit this target, which led to concurrent inhibition of inflammation
                and fibrosis in animal models of DKD. This grant will study the structure-activity
                relationship of this prototype inhibitor in order to generate a more effective
                therapy to combat DKD.</description>
            <description type="fundingAmount">$1,162,198.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011391</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011391</identifier>
            <identifier type="nhmrc">2011391</identifier>
            <name type="primary">
                <namePart>Developing novel CAR T cell therapy approaches to treat prostate
                    cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">prostate cancer </subject>
            <subject type="local">cancer therapy</subject>
            <subject type="local">pre-clinical studies</subject>
            <subject type="local">cancer cell biology</subject>
            <subject type="local">immunotherapy</subject>
            <description type="Chief Investigator">Assoc Prof Renea Taylor</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Prostate cancer is the most common cancer in Australian men and
                second leading cause of death. The major clinical challenge is to offer more
                effective treatments for men with advanced prostate cancer, particularly those who
                have failed all available therapies. This project will provide preclinical evidence
                that CAR T cell immunotherapy is effective for prostate cancer and will inform
                future clinical trial development.</description>
            <description type="fundingAmount">$1,744,586.40</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011398</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011398</identifier>
            <identifier type="nhmrc">2011398</identifier>
            <name type="primary">
                <namePart>Development of a defective interfering RNA based antiviral approach to
                    treat infections by SARS-CoV-2 and emerging variants</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/004y8wk30</identifier>
                <title>QIMR Berghofer Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">viral infection </subject>
            <subject type="local">virus-like particle</subject>
            <subject type="local">nanotechnology</subject>
            <subject type="local">rna</subject>
            <subject type="local">antiviral agents</subject>
            <description type="Chief Investigator">Assoc Prof David Harrich</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Specific therapy for severe disease caused by SARS-CoV-2 is
                limited. The ability of viruses to become resistant to a therapy may be obstacle for
                antiviral development. This project develops a unique platform, using virus-specific
                antiviral RNA, as a unique and possibly “antiviral-resistance” proof approach that
                could be deployed as a therapeutic for COVID-19 and also help to solve the challenge
                of viral pandemics from known and unknown viruses, especially other human pathogenic
                coronaviruses.</description>
            <description type="fundingAmount">$815,219.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011447</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011447</identifier>
            <identifier type="nhmrc">2011447</identifier>
            <name type="primary">
                <namePart>A novel single treatment for two serious complications of allogeneic stem
                    cell transplantation: acute graft-versus-host disease and sinusoidal obstruction
                    syndrome.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">graft versus host disease (gvhd) </subject>
            <subject type="local">allogeneic transplantation</subject>
            <subject type="local">novel therapeutic agents</subject>
            <subject type="local">liver disease</subject>
            <subject type="local">antibody therapy</subject>
            <description type="Chief Investigator">Prof Harshal Nandurkar</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Acute graft versus host disease (GVHD) is a frequent and
                devastating complication of allogeneic stem cell transplantation, which is the use
                of stem cells from a donor related or unrelated to the patient who is the recipient.
                It is mediated by immune activation and inflammation. We have developed a new drug
                (Anti-VCAM-CD39) that has anti-inflammatory and immune suppressive properties. We
                will test the efficacy of this drug to simultaneously treat GVHD.</description>
            <description type="fundingAmount">$1,863,376.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011462</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011462</identifier>
            <identifier type="nhmrc">2011462</identifier>
            <name type="primary">
                <namePart>The role of memory engrams in the cortex</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">memory </subject>
            <subject type="local">memory disorders</subject>
            <subject type="local">neuron</subject>
            <subject type="local">dendrites</subject>
            <subject type="local">synaptic plasticity</subject>
            <description type="Chief Investigator">Assoc Prof Lucy Palmer</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Memory formation is one of the great mysteries of the brain.
                Memories are not only crucial for survival, but they make us who we are. This
                project will address where, and how, memories are formed in the brain and provide
                insight into new targets to treat disorders of memory.</description>
            <description type="fundingAmount">$996,007.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011467</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011467</identifier>
            <identifier type="nhmrc">2011467</identifier>
            <name type="primary">
                <namePart>Defining the impact of chronic lung disease on COVID-19 and developing
                    effective therapies</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">covid-19 </subject>
            <subject type="local">lung inflammation</subject>
            <subject type="local">chronic obstructive pulmonary disease (copd)</subject>
            <subject type="local">tuberculosis</subject>
            <subject type="local">anti-inflammatory agents</subject>
            <description type="Chief Investigator">Emer Prof Warwick Britton</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">COVID-19 disease is driven by virus-induced, hyper-inflammation
                that damages the lungs. Patients with chronic lung disease, such as chronic
                obstructive pulmonary disease (COPD) and tuberculosis (TB), have increased severity
                of COVID-19 disease. Using our models of TB and smoking-induced COPD, we will define
                how chronic lung disease increases the severity of COVID-19, how CoV2 infection
                exacerbates TB and COPD, and identify effective drugs that suppress this
                inflammatory damage to the lung.</description>
            <description type="fundingAmount">$896,784.20</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011471</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011471</identifier>
            <identifier type="nhmrc">2011471</identifier>
            <name type="primary">
                <namePart>Optogenetic restoration of high-sensitivity vision with ChRmine, a novel
                    Type I opsin</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">gene therapy </subject>
            <subject type="local">retinal degeneration</subject>
            <subject type="local">retina</subject>
            <subject type="local">vision</subject>
            <subject type="local">retinal dystrophy</subject>
            <description type="Chief Investigator">Assoc Prof Matthew Simunovic</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Inherited retinal disease (IRD) is the commonest cause of
                blindness in people of working age. Sight loss in IRD is due to the loss of
                light-sensitive cells inside the eye called the rods and cones. However, the
                light-insensitive nerve cells in the eye, which normally relay information from the
                rods and cones to the brain, persist. This project aims to introduce a new, highly
                light-sensitive protein called ChRmine into these cells to make them
                light-sensitive, thereby restoring vision.</description>
            <description type="fundingAmount">$634,081.60</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011481</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011481</identifier>
            <identifier type="nhmrc">2011481</identifier>
            <name type="primary">
                <namePart>Characterisation of novel genetic variants in Hyperekplexia and Dravet
                    Syndrome: Identifying the Unknown Knowns</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">clinical diagnosis </subject>
            <subject type="local">neurodevelopmental disorders</subject>
            <subject type="local">epilepsy</subject>
            <subject type="local">clinical genetics</subject>
            <subject type="local">gene mutations</subject>
            <description type="Chief Investigator">Assoc Prof SEO-KYUNG CHUNG</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">All people carry 3 million points-of-variation (variants) in
                their individual genetic code which can be accurately read but only partially
                interpreted. This study, with collective world-wide efforts of neurologists and
                scientists, will enhance our interpretation of variants that are overlooked in
                routine clinical genetic testing. Outcomes of this study will improve our
                understanding of neurological disorders and provide a methodological pathway to
                rapidly detect the splicing variant defects.</description>
            <description type="fundingAmount">$585,714.50</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011513</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011513</identifier>
            <identifier type="nhmrc">2011513</identifier>
            <name type="primary">
                <namePart>Intraneuronal Immunotherapy to treat Alzheimer’s Disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">molecular neuroscience </subject>
            <subject type="local">dementia</subject>
            <subject type="local">drug development</subject>
            <subject type="local">antibody therapy</subject>
            <subject type="local">antibody engineering</subject>
            <description type="Chief Investigator">Dr Ole Tietz</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Dementia is the single greatest cause of disability in older
                Australians and the second leading cause of death. At present, dementia can only be
                managed through symptomatic treatment with limited therapeutic effects. Current
                immunotherapies for dementia are limited to the small amount of toxic protein
                accessible outside neurons. This project will develop new immunotherapeutics that
                clear problematic proteins inside neurons in order to halt and reverse the course of
                dementia.</description>
            <description type="fundingAmount">$972,072.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011540</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011540</identifier>
            <identifier type="nhmrc">2011540</identifier>
            <name type="primary">
                <namePart>Development of multifaceted glucose-plus therapies - A focus on
                    Hexosaminidase A (HEXA)</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes mellitus) </subject>
            <subject type="local">fatty liver disease</subject>
            <subject type="local">endocrine factors</subject>
            <subject type="local">lipid bilayers</subject>
            <subject type="local">lipid metabolism</subject>
            <description type="Chief Investigator">Dr Magdalene Montgomery</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Type 2 diabetes (T2D) is a cause of heart attacks, stroke, and
                kidney failure. Patients with T2D also commonly suffer from liver disease and
                increased blood lipids. We have recently identified Hexosaminidase A (HEXA) as a
                protein secreted by the liver that reduces high blood glucose levels and blood
                lipids, and improves insulin sensitivity and liver disease in diabetic mice. This
                project will investigate if HEXA is a useful therapeutic target for the treatment of
                metabolic disease.</description>
            <description type="fundingAmount">$1,087,328.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011547</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011547</identifier>
            <identifier type="nhmrc">2011547</identifier>
            <name type="primary">
                <namePart>Human pain genes as a window into pain mechanisms and modern pain
                    management</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">pain </subject>
            <subject type="local">epigenetics</subject>
            <subject type="local">chronic pain</subject>
            <subject type="local">cell biology</subject>
            <subject type="local">molecular basis of disease</subject>
            <description type="Chief Investigator">Prof Graham Neely</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Chronic pain affects ~20% of the adult population at any one
                time, most people will suffer from chronic pain at some stage in their lives, and
                available pain treatments do not help the majority of pain patients. In this project
                we use new genomic knowledge and techniques to gain basic insight into pain biology
                and develop new gene editing therapies to treat extreme untreatable chronic
                pain.</description>
            <description type="fundingAmount">$832,476.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011557</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011557</identifier>
            <identifier type="nhmrc">2011557</identifier>
            <name type="primary">
                <namePart>A microRNA NanoChip Technology for Predicting Childhood Type 1 Diabetes
                    Risk</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03t52dk35</identifier>
                <title>University of Western Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">microrna </subject>
            <subject type="local">nanotechnology</subject>
            <subject type="local">risk prediction</subject>
            <subject type="local">autoantibodies</subject>
            <subject type="local">diabetes</subject>
            <description type="Chief Investigator">Assoc Prof Anandwardhan Hardikar</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Type 1 diabetes (T1D) involves destruction of insulin-producing
                cells. Current clinical tests, although useful to diagnose T1D, cannot accurately
                predict future T1D as they measure blood-based molecules that arise following the
                destruction of insulin producing cells. Through this study, we use a novel test
                (like a pregnancy test) that offers the capacity to measure a different class of
                blood-based molecules, which can help identifying T1D progression. Early detection
                can help prevent diabetes.</description>
            <description type="fundingAmount">$390,166.90</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011558</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011558</identifier>
            <identifier type="nhmrc">2011558</identifier>
            <name type="primary">
                <namePart>Investigation of novel immune pathways for improving cancer
                    immunotherapy</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rxfrp27</identifier>
                <title>La Trobe University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">colorectal cancer </subject>
            <subject type="local">mucosal immunity</subject>
            <subject type="local">gastrointestinal disease</subject>
            <subject type="local">cytokine biology</subject>
            <subject type="local">transcriptional regulation</subject>
            <description type="Chief Investigator">Dr Lisa Mielke</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The epithelium of the gastrointestinal tract separates our body
                from the intestinal content. Its barrier function is crucially promoted by immune
                cells named intraepithelial lymphocytes (IELs) that sense cellular stress and
                recognise microbial agents. We show that IELs play a critical role in preventing
                bowel cancer progression. We will discover new genes and molecular pathways that
                promote the anti-cancer functions of IELs, leading to discovery of novel drug
                targets to treat bowel cancer.</description>
            <description type="fundingAmount">$781,419.40</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011560</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011560</identifier>
            <identifier type="nhmrc">2011560</identifier>
            <name type="primary">
                <namePart>Breast Cancer Dormancy - Mechanisms and Development of Rational New
                    Therapies</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rxfrp27</identifier>
                <title>La Trobe University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">breast cancer </subject>
            <subject type="local">metastatic progression</subject>
            <subject type="local">minimal residual disease</subject>
            <subject type="local">targeted therapy</subject>
            <subject type="local">cancer immunotherapy</subject>
            <description type="Chief Investigator">Prof Robin Anderson</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Over 85% of breast cancer deaths are caused by the spread of
                the cancer cells to vital organs, leading to organ failure and death. Once these
                secondary tumours establish, our current therapies are not effective, at best, they
                delay the growth and further spread of the cancer. Tumour cells can lie dormant for
                up to 20 years before relapse. The aim of this project is to test novel therapies
                for their ability to kill these dormant tumour cells before they can grow into new
                tumours.</description>
            <description type="fundingAmount">$768,784.40</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011584</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011584</identifier>
            <identifier type="nhmrc">2011584</identifier>
            <name type="primary">
                <namePart>Targeting necroptosis in the race to treat acute and chronic
                    inflammation</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">cell death </subject>
            <subject type="local">pro-inflammatory alleles</subject>
            <subject type="local">inflammatory diseases</subject>
            <subject type="local">sepsis</subject>
            <subject type="local">animal model</subject>
            <description type="Chief Investigator">Dr Joanne Hildebrand</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Necroptosis, a form of programmed cell death, is an important
                weapon used by our bodies to prevent the spread of viruses, bacteria and even
                cancer. We have discovered that many populations have developed genetic changes that
                may enhance necroptosis and increase inflammation in the body. We propose that these
                changes are the key to understanding why only some people develop severe life
                threatening symptoms to infections, and the key to designing more effective
                therapies for inflammatory diseases.</description>
            <description type="fundingAmount">$1,237,965.20</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011590</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011590</identifier>
            <identifier type="nhmrc">2011590</identifier>
            <name type="primary">
                <namePart>Glioblastoma - inhibition of P2X7R as a potential therapeutic target for
                    treatment of this aggressive cancer.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">glioma </subject>
            <subject type="local">brain</subject>
            <subject type="local">anticancer drug</subject>
            <subject type="local">purinergic receptors</subject>
            <subject type="local">drug therapy</subject>
            <description type="Chief Investigator">Dr Mastura Monif</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Glioblastoma is a highly fatal human brain cancer generally
                affecting young adults, with survival time of only 12 months after diagnosis despite
                treatment. Our work is showing very promising results where inhibiting a particular
                cell membrane protein, P2X7R (with a particular drug AZ10606120) can significantly
                reduce tumour proliferation. AZ10606120 was better than the currently available
                chemotherapy, Temozolomide. This is very exciting and warrants urgent further study
                via this Ideas grant.</description>
            <description type="fundingAmount">$842,094.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011592</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011592</identifier>
            <identifier type="nhmrc">2011592</identifier>
            <name type="primary">
                <namePart>Normative reference ranges for brain phenotypes in psychiatry</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">magnetic resonance imaging (mri) </subject>
            <subject type="local">neuroimaging</subject>
            <subject type="local">neuropsychiatry</subject>
            <subject type="local">brain imaging</subject>
            <subject type="local">psychiatry</subject>
            <description type="Chief Investigator">Assoc Prof Andrew Zalesky</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Psychiatry is one of the few remaining fields in medicine where
                biological tests are seldom used to inform treatments and guide diagnoses. We aim to
                improve the utility of brain imaging in psychiatry through the development and
                provision of healthy reference ranges for measurements of brain structure extracted
                from a patient's MRI scan. This project charts a way forward towards personalised
                brain medicine in psychiatry.</description>
            <description type="fundingAmount">$596,602.80</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011595</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011595</identifier>
            <identifier type="nhmrc">2011595</identifier>
            <name type="primary">
                <namePart>Prolonging survival in glioblastoma through quiescence
                    inhibition</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/004y8wk30</identifier>
                <title>QIMR Berghofer Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">adult stem cells </subject>
            <subject type="local">glioma</subject>
            <subject type="local">combination therapy</subject>
            <subject type="local">cell proliferation</subject>
            <subject type="local">chemotherapy</subject>
            <description type="Chief Investigator">Dr Lachlan Harris</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Most people diagnosed with the brain cancer glioblastoma die
                within 15-months. The cancer is so deadly because it rapidly returns after therapy.
                Glioblastoma returns because of slowly dividing cancer stem cells that resist
                treatment. Our strategy is to eliminate these cells by forcing them to divide
                quickly during chemotherapy. This project will test targeted molecules in organoid
                and pre-clinical animal models of the disease to establish an evidence base for
                Phase 1 trials.</description>
            <description type="fundingAmount">$571,687.60</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011627</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011627</identifier>
            <identifier type="nhmrc">2011627</identifier>
            <name type="primary">
                <namePart>The Single Cell Basis for the Emergence of Drug Resistance during
                    Azacitidine Therapy in Myelodysplastic Syndromes and Acute Myeloid
                    Leukemia</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">myelodysplasia </subject>
            <subject type="local">haematopoietic stem cells</subject>
            <subject type="local">epigenetics</subject>
            <subject type="local">bone marrow stroma</subject>
            <subject type="local">immune modulation</subject>
            <description type="Chief Investigator">Prof John Pimanda</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Myelodysplasia and acute myeloid leukemia are blood cancers
                that arise in abnormal blood stem cells in the bone marrow. Azacitidine (AZA) is a
                drug that helps re-establish blood cell production in ~50% of patients. It is
                ineffective in the remainder. We will test whether AZA works in responders by
                improving the fitness of abnormal blood stem cells and their surrounding cells and
                modulating immune cells that help eliminate abnormal blood cells. This will guide
                drug discovery for non-responders.</description>
            <description type="fundingAmount">$1,200,569.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011633</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011633</identifier>
            <identifier type="nhmrc">2011633</identifier>
            <name type="primary">
                <namePart>Novel pathways to abstinence from alcohol seeking</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">drug relapse </subject>
            <subject type="local">neural pathways</subject>
            <subject type="local">brain</subject>
            <subject type="local">alcohol and behaviour</subject>
            <subject type="local">animal model</subject>
            <description type="Chief Investigator">Prof Gavan McNally</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Relapse to drinking after a period of treatment remains a
                fundamental problem for sufferers of alcohol-use disorders. This project uses a
                suite of state of the art technologies in a well validated pre-clinical animal model
                to identify how the brain gates this propensity to relapse. It will provide critical
                new knowledge on which cells in which brain circuits to target as well as when to
                target them in order to prevent relapse and promote abstinence from
                drinking.</description>
            <description type="fundingAmount">$1,104,880.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011634</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011634</identifier>
            <identifier type="nhmrc">2011634</identifier>
            <name type="primary">
                <namePart>Understanding Brain Cleaning in Obstructive Sleep Apnoea</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">obstructive sleep apnoea </subject>
            <subject type="local">sleep disturbance</subject>
            <subject type="local">amyloid beta-protein</subject>
            <subject type="local">haemodynamics</subject>
            <subject type="local">dynamic process modelling</subject>
            <description type="Chief Investigator">Assoc Prof Craig Phillips</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">During deep sleep, blood pressure falls and the brain rests.
                Production of toxic waste also slows while its removal increases. This brain
                cleaning process during sleep is thought to be crucial for preventing dementia.
                Obstructive Sleep Apnoea (OSA) is a common condition characterised by marked sleep
                and blood pressure disturbances. People with OSA have an increased risk for
                dementia. This study aims to investigate how sleep and blood pressure disturbances
                affect brain cleaning in people with OSA</description>
            <description type="fundingAmount">$658,233.80</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011728</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011728</identifier>
            <identifier type="nhmrc">2011728</identifier>
            <name type="primary">
                <namePart>Targeting metastatic triple-negative breast cancer with a selective
                    oncogenic JNK inhibitor</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">c-jun/jnk kinase </subject>
            <subject type="local">protein-protein interaction</subject>
            <subject type="local">signal transduction</subject>
            <subject type="local">cytoskeleton</subject>
            <subject type="local">breast cancer</subject>
            <description type="Chief Investigator">Assoc Prof David Croucher</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">While JNK is a potent oncogene in TNBC, there are no effective
                JNK-targeting therapies due to the fact that this signalling pathway regulates
                numerous cellular functions. Leveraging a recent screen of 114,000 compounds, we
                have identified a novel molecule, called K12, that specifically inhibits the tumour
                promoting activity of JNK. Now, we will further the preclinical evaluation of K12,
                to generate a world-first drug capable of preventing metastatic outgrowth in
                TNBC</description>
            <description type="fundingAmount">$674,218.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011730</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011730</identifier>
            <identifier type="nhmrc">2011730</identifier>
            <name type="primary">
                <namePart>Improving the pipeline for translation of therapies for serious
                    complications of pregnancy</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">pregnancy complications </subject>
            <subject type="local">fetal growth restriction</subject>
            <subject type="local">pre-eclampsia</subject>
            <subject type="local">drug therapy</subject>
            <subject type="local">placental insufficiency</subject>
            <description type="Chief Investigator">Assoc Prof Natalie Hannan</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Preeclampsia and fetal growth restriction are deadly
                complications of pregnancy, without current therapies for either. Development of
                treatments is seriously limited, pregnant women are excluded from drug trials, due
                to concerns for both mother and baby. We have developed a dedicated pipeline for
                drug discovery for pregnancy; we will thoroughly test promising drug candidates and
                advanced delivery strategies. This proposal paves the way for much needed
                development of therapies for pregnant women.</description>
            <description type="fundingAmount">$965,933.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011733</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011733</identifier>
            <identifier type="nhmrc">2011733</identifier>
            <name type="primary">
                <namePart>The effects of early exposure to bushfires on adult brain structure and
                    function</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">monkey </subject>
            <subject type="local">bushfire</subject>
            <subject type="local">brain function</subject>
            <subject type="local">brain development</subject>
            <subject type="local">social and behavioural research</subject>
            <description type="Chief Investigator">Dr Farshad Mansouri</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The effects of bushfire smoke inhalation on brain structure and
                function remain unknown. We will conduct the first systematic study of this issue,
                based on a cohort of monkeys born during the 2019-2020 bushfire season. The effects
                of pre- and post-natal bushfire exposure will be investigated in adult brain, using
                functional and structural MRI, cognitive tests, and neuropathological examination.
                This project will gain vital scientific data that may help guide future government
                action.</description>
            <description type="fundingAmount">$1,326,234.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011747</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011747</identifier>
            <identifier type="nhmrc">2011747</identifier>
            <name type="primary">
                <namePart>Enabling early ovarian cancer diagnosis and prediction of platinum
                    resistance</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04ttjf776</identifier>
                <title>RMIT University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">ovarian cancer </subject>
            <subject type="local">early diagnosis</subject>
            <subject type="local">cisplatin resistance</subject>
            <subject type="local">biosensor</subject>
            <subject type="local">nanotechnology</subject>
            <description type="Chief Investigator">Prof Magdalena Plebanski</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Ovarian cancer often gets diagnosed late, and at that stage
                survival outcomes are poor. Here, we propose to use a simple drop of blood, to
                detect combinations of proteins and changes in genetic material originating from
                cancer and immune cells, to support earlier, more accurate diagnosis and predict
                platinum resistance to avoid delay of personalised treatment. We also develop
                easy-to-use, low-cost Lab-on-a Chip devices to enable routine testing and monitoring
                at the point-of-care.</description>
            <description type="fundingAmount">$999,428.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011753</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011753</identifier>
            <identifier type="nhmrc">2011753</identifier>
            <name type="primary">
                <namePart>Infiltrating central command to selectively alter autonomic
                    function</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">vagus nerve </subject>
            <subject type="local">amygdala</subject>
            <subject type="local">hypothalamus</subject>
            <subject type="local">central autonomic control</subject>
            <subject type="local">autonomic dysfunction</subject>
            <description type="Chief Investigator">Dr Stuart McDougall</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The brain controls blood pressure and other internal organ
                functions that are necessary for life. In disease, this control does not work
                properly. This can be the cause of diseases like hypertension, but it also seems to
                happen in neurological conditions. It is not known why. Using a genetically modified
                virus that we made, we hope to find out exactly which neurons control organ function
                and then modify their activity.</description>
            <description type="fundingAmount">$705,188.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011761</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011761</identifier>
            <identifier type="nhmrc">2011761</identifier>
            <name type="primary">
                <namePart>A novel regulator of interferon signalling</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">interferon (ifn) </subject>
            <subject type="local">suppressor of cytokine signalling (socs)</subject>
            <subject type="local">cytokine signalling</subject>
            <subject type="local">jak/stat pathway</subject>
            <subject type="local">innate immunity</subject>
            <description type="Chief Investigator">Assoc Prof Sandra Nicholson</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">We have identified a new role for a protein called ARAP2 in
                regulating the immune response to infection. We have generated unique experimental
                models and have access to immune cells from 25 patients carrying ARAP2 mutations
                which will enable us to understand the role of ARAP2 in infectious diseases such as
                TB or Covid-19. This project offers the potential to identify and treat individuals
                at high risk of life-threatening infections.</description>
            <description type="fundingAmount">$646,916.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011763</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011763</identifier>
            <identifier type="nhmrc">2011763</identifier>
            <name type="primary">
                <namePart>Harnessing a novel immune check point for cancer killing</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cancer genetics </subject>
            <subject type="local">cancer immunotherapy</subject>
            <subject type="local">mouse models</subject>
            <subject type="local">nuclear factor kappa-b (nf-kb)</subject>
            <subject type="local">cancer immunology</subject>
            <description type="Chief Investigator">Prof Shane Grey</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The Project Team aims to test the idea that a patients T cells
                can be ‘tuned’ to increase the ability of their own immune system to find,
                infiltrate, and kill pancreatic cancer cells.This may be beneficial as a stand alone
                therapy or most likely, work in synergy with emerging immune
                therapies.</description>
            <description type="fundingAmount">$924,922.20</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011767</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011767</identifier>
            <identifier type="nhmrc">2011767</identifier>
            <name type="primary">
                <namePart>Rewriting the dogma of chromatin compaction: a new pathway for
                    polycomb-mediated gene repression in development and disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">chromatin structure </subject>
            <subject type="local">epigenetics</subject>
            <subject type="local">structural biology</subject>
            <subject type="local">chromatin</subject>
            <subject type="local">gene regulation</subject>
            <description type="Chief Investigator">Assoc Prof Chen Davidovich</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Polycomb repressive complexes are enzymatic complexes that
                safeguard the genome by preventing repressed genes from becoming active. The
                proposed study aimed at identifying how different types of polycomb repressive
                complexes work together to maintain genes in a compacted state that prevent their
                expression. The project aims to determine the cascade of molecular events that lead
                to chromatin compaction and to visualize this process in high
                resolution.</description>
            <description type="fundingAmount">$849,323.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011768</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011768</identifier>
            <identifier type="nhmrc">2011768</identifier>
            <name type="primary">
                <namePart>Understanding and Treating Videogame Addiction in Young People</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03pnv4752</identifier>
                <title>Queensland University of Technology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">addiction treatment </subject>
            <subject type="local">behavioural intervention</subject>
            <subject type="local">randomised controlled trial (rct)</subject>
            <subject type="local">addictive behaviours</subject>
            <subject type="local">prospective cohort study</subject>
            <description type="Chief Investigator">Prof Daniel Johnson</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Excessive videogame play is causing harm to individuals and
                conflict among families. In the most severe cases players develop Internet Gaming
                Disorder. We will identify the factors that lead to addiction and based on this we
                will work with videogame players to design an intervention that will help people
                overcome IGD. The intervention will be based in software that videogame players are
                already using. We will evaluate the intervention and translate the knowledge we gain
                for use by others.</description>
            <description type="fundingAmount">$1,048,250.70</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011770</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011770</identifier>
            <identifier type="nhmrc">2011770</identifier>
            <name type="primary">
                <namePart>Upending the platelet paradigm: Targeting actin-driven membrane budding to
                    modulate platelet production in health and disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">platelets </subject>
            <subject type="local">thrombocytopenia</subject>
            <subject type="local">electron microscopy</subject>
            <subject type="local">bone marrow</subject>
            <subject type="local">actin cytoskeleton</subject>
            <description type="Chief Investigator">Dr Samir Taoudi</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Platelets are the cells in the blood responsible for blood
                clotting and also contribute to wound healing and fighting infection. In a world
                first, we discovered how the body produces platelets, overturning a 100-year-old
                dogma. We will capitalise on our breakthrough to understand the diseases of platelet
                production, develop new therapies to control platelet levels, and generate new
                knowledge to overcome scalability problems preventing laboratory-based production of
                platelets for clinical use.</description>
            <description type="fundingAmount">$1,953,814.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011806</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011806</identifier>
            <identifier type="nhmrc">2011806</identifier>
            <name type="primary">
                <namePart>Transforming genomic surveillance of foodborne Salmonella infections with
                    SalmonellaTracker: a standardised, high resolution and scalable
                    platform</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">salmonella </subject>
            <subject type="local">food safety</subject>
            <subject type="local">bacterial pathogen</subject>
            <subject type="local">bacterial gastroenteritis</subject>
            <subject type="local">molecular typing</subject>
            <description type="Chief Investigator">Prof Ruiting Lan</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Salmonella infections are a major health burden with over
                50,000 cases each year in Australia. Control of this disease requires rapid and
                accurate strain typing and tracking. In this project we will develop tools for
                national and international Salmonella genomic surveillance. These tools will
                facilitate the tracking, control and characterisation of Salmonella in both the
                human population and in the food production chain, reducing their global health
                burden.</description>
            <description type="fundingAmount">$865,336.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011845</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011845</identifier>
            <identifier type="nhmrc">2011845</identifier>
            <name type="primary">
                <namePart>A paradigm shift in lactational mastitis</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">lactation </subject>
            <subject type="local">breastfeeding</subject>
            <subject type="local">breast development</subject>
            <subject type="local">breast milk</subject>
            <subject type="local">milk synthesis</subject>
            <description type="Chief Investigator">Assoc Prof Wendy Ingman</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Lactation mastitis is a debilitating inflammatory breast
                disease occurring in 1 in 5 Australian breastfeeding women. The disease causes
                lactation insufficiency, localised pain and rapid onset of fever, muscle aches,
                chills and fatigue, leading many women to use supplementary formula or cease
                breastfeeding altogether. This project will address key gaps in our understanding of
                the biological causes of mastitis and lead to improved prevention and treatment of
                this disease.</description>
            <description type="fundingAmount">$946,417.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011853</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011853</identifier>
            <identifier type="nhmrc">2011853</identifier>
            <name type="primary">
                <namePart>Illumination of Immune Checkpoint Therapy of Cancer: Molecular Imaging of
                    Immunity with Copper Radiopharmaceuticals</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">chemistry </subject>
            <subject type="local">copper</subject>
            <subject type="local">molecular imaging</subject>
            <subject type="local">radiopharmaceuticals</subject>
            <subject type="local">diagnostic imaging</subject>
            <description type="Chief Investigator">Prof Paul Donnelly</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Exciting developments in the treatment of cancer have involved
                developing ways to reinvigorate a patient’s own immune system to attack their
                disease. This type of therapy, called immune checkpoint therapy, produces remarkable
                outcomes for some patients but some do not respond. This research will develop the
                chemistry required to produce imaging agents to enable clinicians to identify
                patients suitable for immune checkpoint therapies using non-invasive Positron
                Emission Tomography (PET) imaging.</description>
            <description type="fundingAmount">$515,103.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011883</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011883</identifier>
            <identifier type="nhmrc">2011883</identifier>
            <name type="primary">
                <namePart>Creating Health in a New Home: A transformative approach to building
                    evidence for refugee health across generations</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03f0f6041</identifier>
                <title>University of Technology Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">refugee health </subject>
            <subject type="local">health status</subject>
            <subject type="local">social determinants of health</subject>
            <subject type="local">ethnic health promotion</subject>
            <subject type="local">health services research</subject>
            <description type="Chief Investigator">Prof Angela Dawson</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Refugees experience serious health issues on arrival that
                demand specialised services. Little is known about refugee health after settlement
                and over generations and if tailored healthcare is needed. This study will deliver
                new evidence to plan appropriate cost-effective health services and programs. A
                roadmap will be designed with refugees to achieve health and evaluate outcomes. This
                innovative approach will empower refugees, placing them at the centre of their
                health decision making.</description>
            <description type="fundingAmount">$919,116.30</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011912</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011912</identifier>
            <identifier type="nhmrc">2011912</identifier>
            <name type="primary">
                <namePart>Communication training for mental health professionals: developing
                    cultural sensitivity and capability to improve Aboriginal and Torres Strait
                    Islander people mental health outcomes</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/004y8wk30</identifier>
                <title>QIMR Berghofer Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">patient/professional communication </subject>
            <subject type="local">aboriginal mental health</subject>
            <subject type="local">clinical practice</subject>
            <subject type="local">social and cultural issues</subject>
            <subject type="local">capacity building</subject>
            <description type="Chief Investigator">Mr Gregory Pratt</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">This interventional study will be led by Indigenous researchers
                and mental health professionals and engage with Indigenous consumers, communities,
                services providers and policy makers to co-design, deliver and evaluate a
                communication training package for non-Indigenous mental health professionals. The
                goal is to improve health outcomes for Indigenous patients and build an accountable,
                more knowledgeable and culturally sensitive mental health workforce.</description>
            <description type="fundingAmount">$2,813,401.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011940</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011940</identifier>
            <identifier type="nhmrc">2011940</identifier>
            <name type="primary">
                <namePart>CHIARI MALFORMATION: DEFINING PATHOPHYSIOLOGY AND TREATMENT
                    GOALS</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cerebellar disorders </subject>
            <subject type="local">headache</subject>
            <subject type="local">neurosurgery</subject>
            <subject type="local">cognition</subject>
            <subject type="local">magnetic resonance imaging (mri)</subject>
            <description type="Chief Investigator">Prof Marcus Stoodley</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Chiari I malformation is a complex neurological disorder that
                has a significant impact on a patient’s quality of life. We do not understand what
                causes many of the symptoms (debilitating headache &amp;amp; cognitive deficits) and
                complications (spinal cysts). Indications for surgery and surgical goals are also
                controversial. This project addresses these knowledge gaps using integrated human
                studies and machine learning and is expected to develop imaging guidelines for
                surgical indications and success.</description>
            <description type="fundingAmount">$729,270.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011953</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011953</identifier>
            <identifier type="nhmrc">2011953</identifier>
            <name type="primary">
                <namePart>Development of a novel glucose lowering medication targeting mTORC1 in
                    osteoblasts.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">glucoregulation </subject>
            <subject type="local">insulin resistance</subject>
            <subject type="local">osteoblast</subject>
            <subject type="local">obesity</subject>
            <subject type="local">bone biology</subject>
            <description type="Chief Investigator">Prof Andrew Zannettino</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">New medications to lower blood sugar levels are desperately
                needed to help treat the many millions of people at risk of developing chronic
                diseases associated with obesity and Type 2 diabetes (T2DM). Our group has
                identified a new drug target in bone forming cells. This target becomes
                over-activated in obesity and decreases the ability of insulin to stimulate sugar
                uptake. In this proposal, we will develop a novel inhibitor and test the inhibitor
                in a model system of diet-induced T2DM.</description>
            <description type="fundingAmount">$649,347.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011958</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011958</identifier>
            <identifier type="nhmrc">2011958</identifier>
            <name type="primary">
                <namePart>New insights for reducing Aboriginal stillbirth: Community-led, integrated
                    evidence for change</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02n415q13</identifier>
                <title>Curtin University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">aboriginal child </subject>
            <subject type="local">stillbirth</subject>
            <subject type="local">perinatal</subject>
            <subject type="local">health inequalities</subject>
            <subject type="local">indigenous health</subject>
            <description type="Chief Investigator">Assoc Prof Carrington Shepherd</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project will work in partnership with Aboriginal Elders,
                communities and service providers to undertake the first large-scale examination of
                stillbirth among Aboriginal peoples. It aims to enhance our understanding of the
                risks to Aboriginal stillbirth, explore Aboriginal community knowledge and awareness
                of stillbirth risks, and progress Aboriginal-specific intervention strategies to
                support stillbirth education and awareness.</description>
            <description type="fundingAmount">$1,462,378.90</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011959</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011959</identifier>
            <identifier type="nhmrc">2011959</identifier>
            <name type="primary">
                <namePart>A FRET-based protein sensor for RNA detection, localisation and
                    analysis</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">rna binding proteins </subject>
            <subject type="local">protein structure</subject>
            <subject type="local">biophysics</subject>
            <subject type="local">molecular biology</subject>
            <subject type="local">molecular design</subject>
            <description type="Chief Investigator">Prof Charles Bond</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The ability to detect specific RNA molecules is a key aspect of
                diagnosis and pathogenesis of a variety of diseases. Recent developments from
                synthetic biology have provided us with robust designer RNA-binding proteins which
                can be used as sophisticated tools for detecting specific RNA molecules to
                understand the molecular basis of numerous diseases. Applying cutting edge
                “single-molecule” techniques to prototype molecules we will develop these tools for
                application as RNA detecting biosensors.</description>
            <description type="fundingAmount">$765,196.00</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011963</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011963</identifier>
            <identifier type="nhmrc">2011963</identifier>
            <name type="primary">
                <namePart>Improving therapeutic delivery of RNA</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">nanotechnology </subject>
            <subject type="local">messenger rna (mrna)</subject>
            <subject type="local">endosomes</subject>
            <subject type="local">targeting</subject>
            <subject type="local">trafficking</subject>
            <description type="Chief Investigator">Dr Angus Johnston</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">RNA based therapies show tremendous promise for treating many
                important diseases, however an effective method of delivering these drugs to the
                correct compartment of cells has not yet been discovered. This project will
                investigate the barriers existing at the cellular level that hinder RNA delivery.
                This knowledge will be used to engineer nanoparticles to help translate RNA
                technologies from the laboratory into the clinic.</description>
            <description type="fundingAmount">$834,328.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011969</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011969</identifier>
            <identifier type="nhmrc">2011969</identifier>
            <name type="primary">
                <namePart>Modelling polycystic kidney disease in vitro</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">disease modelling </subject>
            <subject type="local">drug screening</subject>
            <subject type="local">kidney disease</subject>
            <subject type="local">stem cells</subject>
            <subject type="local">cell biology</subject>
            <description type="Chief Investigator">Dr Sara Howden</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Autosomal Recessive Polycystic Kidney Disease (ARPKD) causes
                kidney and liver failure in babies and children. One quarter of babies born with
                ARPKD will not survive after birth. We have recently developed a method to recreate
                human kidney tissue from stem cells. We will generate stem cells using patient blood
                samples and use these to make a model of the patient’s ARPKD disease in the
                laboratory. We will use these patient models to screen for new, personalised
                treatments for patients with ARPKD.</description>
            <description type="fundingAmount">$861,834.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011978</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011978</identifier>
            <identifier type="nhmrc">2011978</identifier>
            <name type="primary">
                <namePart>α1-adrenoceptor protein structures and selective tools: towards novel
                    treatments for heart failure and Alzheimer’s disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">adrenoceptors </subject>
            <subject type="local">rational drug design</subject>
            <subject type="local">antibody engineering</subject>
            <subject type="local">protein structure</subject>
            <subject type="local">protein engineering</subject>
            <description type="Chief Investigator">Assoc Prof Daniel Scott</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Heart failure and dementia are the top and fifth leading
                disease burdens in Australia respectively, highlighting the urgent need to identify
                new ways to treat and relieve the symptoms of these devastating diseases. Adrenaline
                receptors in our body called a1-adrenoceptors, have been implicated as playing an
                important role in heart failure and Alzheimer’s disease, but no suitable drugs exist
                to explore this further. This project will develop such tools using innovative
                approaches.</description>
            <description type="fundingAmount">$1,551,582.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011990</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011990</identifier>
            <identifier type="nhmrc">2011990</identifier>
            <name type="primary">
                <namePart>Pathogenic membranes as therapeutic drug targets</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">antimicrobial resistance </subject>
            <subject type="local">membrane lipids</subject>
            <subject type="local">peptides</subject>
            <subject type="local">antimicrobial therapy</subject>
            <subject type="local">biophysics</subject>
            <description type="Chief Investigator">Prof Marie-Isabel Aguilar</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Resistance of pathogens to drugs continues to emerge and
                intensify. While host defence peptides (HDPs) are a promising alternative to current
                drugs, many pathogens have also evolved resistance mechanisms through changes in
                their cell membrane. This application will apply a range of analytical tools to
                understand how bacteria change their cell walls in response to HDPs. The results
                will allow us to design new combination therapies to treat pathogenic
                infections.</description>
            <description type="fundingAmount">$1,269,456.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012006</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012006</identifier>
            <identifier type="nhmrc">2012006</identifier>
            <name type="primary">
                <namePart>Characterising the unique functional and pathological properties of a
                    novel extracellular RNA binding protein in Amyotrophic Lateral
                    Sclerosis</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">amyotrophic lateral sclerosis </subject>
            <subject type="local">motor neuron disease (mnd)</subject>
            <subject type="local">alternative splicing</subject>
            <subject type="local">neurodegeneration</subject>
            <subject type="local">rna binding proteins</subject>
            <description type="Chief Investigator">Prof Julie Atkin</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">'FUS' is an important protein that causes aggressive, juvenile
                types of motor neuron disease (MND). FUS is also implicated in the most common
                sporadic forms of MND (90% of cases), but the mechanisms involved are unclear. We
                have found a new form of FUS that is unique because it exists outside the cell,
                unlike all other MND proteins. Importantly we have found that in MND patients this
                protein is abnormal. Here we will examine its normal function outside the cell and
                its role in MND.</description>
            <description type="fundingAmount">$810,299.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012013</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012013</identifier>
            <identifier type="nhmrc">2012013</identifier>
            <name type="primary">
                <namePart>Improving the safety and efficacy of chimeric antigen receptor (CAR)-T
                    cell therapies</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">receptor signalling </subject>
            <subject type="local">cell surface receptor</subject>
            <subject type="local">t cell activation</subject>
            <subject type="local">t cell immunotherapy</subject>
            <subject type="local">cancer immunotherapy</subject>
            <description type="Chief Investigator">Dr Melissa Call</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Immunotherapy is the ‘fourth pillar’ of cancer treatment,
                alongside surgery, radiation and chemotherapy. We are investigating the manipulation
                of human immune cells to generate new and improved cancer treatments that ‘train’ a
                patient’s own immune cells to kill tumours. Preliminary results show potential for
                improved efficacy and patient safety compared to current immunotherapies. This grant
                will support further development of suitable ‘trained’ cells for potential use in
                human clinical trials.</description>
            <description type="fundingAmount">$1,106,418.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012029</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012029</identifier>
            <identifier type="nhmrc">2012029</identifier>
            <name type="primary">
                <namePart>Identifying brain pathways regulating sympathetic nervous outflow in human
                    hypertension</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/031rekg67</identifier>
                <title>Swinburne University of Technology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">sympathetic nervous system </subject>
            <subject type="local">hypertension</subject>
            <subject type="local">brain imaging</subject>
            <subject type="local">central nervous system (cns)</subject>
            <subject type="local">obesity</subject>
            <description type="Chief Investigator">Assoc Prof Elisabeth Lambert</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Hypertension is characterised by an increase in the activity of
                the sympathetic nerves. We will use magnetoencephalography, which records the
                magnetic field generated by brain neurones, coupled with simultaneous direct nerve
                recording to reveal which neurones in the brain are responsible for the generation
                of excess nervous activity in individuals with hypertension.</description>
            <description type="fundingAmount">$683,535.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012051</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012051</identifier>
            <identifier type="nhmrc">2012051</identifier>
            <name type="primary">
                <namePart>Development of a diagnostic platform for preventative wound
                    management</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01p93h210</identifier>
                <title>University of South Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">wound healing </subject>
            <subject type="local">diagnostic</subject>
            <subject type="local">diabetic complications</subject>
            <subject type="local">delayed wound repair</subject>
            <subject type="local">prognosis</subject>
            <description type="Chief Investigator">Prof Allison Cowin</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Early diagnosis, accurate evaluation, and appropriate wound
                management are vital to prevent the progression of a diabetic foot ulcer to the
                stage where amputation is required. Currently there are no effective biochemical
                tools to predict whether a patient will develop a chronic wound. We aim to develop a
                simple blood-based diagnostic/prognostic device that will provide an early
                indication of wound risk for people living with diabetes.</description>
            <description type="fundingAmount">$1,256,874.20</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012072</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012072</identifier>
            <identifier type="nhmrc">2012072</identifier>
            <name type="primary">
                <namePart>3D Nuclear Re-organisation Potentiates Genomic Structural Variations in
                    Prostate Cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">epigenetics </subject>
            <subject type="local">dna methylation</subject>
            <subject type="local">chromatin structure</subject>
            <subject type="local">dna replication</subject>
            <subject type="local">cancer cell biology</subject>
            <description type="Chief Investigator">Prof Susan Clark</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">When the cell divides not only does the DNA (genome) need to be
                replicated but so do the chemical modifications on top of the DNA called the
                ‘epigenome’. Here we ask how the genome and epigenome talk to each other during cell
                division and how this can go wrong in cancer. We will demonstrate that progressive
                alterations to our epigenome when the cell divides result in an increased risk of
                DNA rearrangements and the development of cancer. Our results will open new
                approaches for cancer strategies.</description>
            <description type="fundingAmount">$838,167.20</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012074</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012074</identifier>
            <identifier type="nhmrc">2012074</identifier>
            <name type="primary">
                <namePart>The ADEPT study: Adaptive Diagnostics for Emerging Pandemic Threats in
                    regional Australia</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">covid-19 </subject>
            <subject type="local">influenza</subject>
            <subject type="local">bacterial sepsis</subject>
            <subject type="local">diagnostic assay</subject>
            <subject type="local">regional health</subject>
            <description type="Chief Investigator">Assoc Prof Timothy Inglis</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project will develop regional diagnostic tests for serious
                infections, using technical advances made against COVID-19. We will apply these
                rapid, simple to operate technologies in regional Western Australia. This project
                will involve regional indigenous communities to reduce the physical, mental and
                cultural harm done when people are shipped out of country to run diagnostic tests
                for conditions that could be treated with confidence locally when an early, specific
                diagnosis is available.</description>
            <description type="fundingAmount">$3,434,419.60</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012119</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012119</identifier>
            <identifier type="nhmrc">2012119</identifier>
            <name type="primary">
                <namePart>Understanding the biology of adipose tissue regulatory T cells to treat
                    metabolic disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">regulatory t cells </subject>
            <subject type="local">adipose tissue</subject>
            <subject type="local">inflammatory cytokines</subject>
            <subject type="local">obesity</subject>
            <subject type="local">dietary intervention</subject>
            <description type="Chief Investigator">Dr Kevin Man</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Our lab has identified a unique population of immune cell found
                in abdominal fat (Tregs) that functions to regulate glucose metabolism and are
                anti-inflammatory. In this proposal we aim to characterize the genes and signals
                found in fat that influence the function of these cells and understand how these
                signals differ between sexes. We also aim to understand how Tregs communicate with
                other cells found in fat, which will help us formulate new therapies for obesity and
                metabolic diseases.</description>
            <description type="fundingAmount">$760,853.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012140</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012140</identifier>
            <identifier type="nhmrc">2012140</identifier>
            <name type="primary">
                <namePart>Myelin: wrapping up neural circuit function and behaviour</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01nfmeh72</identifier>
                <title>University of Tasmania</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">myelin </subject>
            <subject type="local">oligodendrocytes</subject>
            <subject type="local">neural plasticity</subject>
            <subject type="local">behaviour</subject>
            <subject type="local">neurobiology</subject>
            <description type="Chief Investigator">Dr Carlie Cullen</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Almost half of all Australians aged 16-85 will experience
                mental illness in their life, yet we do not understand the underlying biological
                processes that contribute to mental ill health. This project aims to show how brain
                insulation adapts to and regulates brain function and learn how inappropriate
                insulation could underpin symptoms of mental health disorders.</description>
            <description type="fundingAmount">$794,211.30</description>
            <coverage>
                <spatial type="text">TAS</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012142</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012142</identifier>
            <identifier type="nhmrc">2012142</identifier>
            <name type="primary">
                <namePart>Type 2 diabetes relief by UPR-mediated beta cell protection</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes mellitus) </subject>
            <subject type="local">insulin secretion</subject>
            <subject type="local">pancreatic beta cell</subject>
            <subject type="local">islets of langerhans</subject>
            <subject type="local">obesity</subject>
            <description type="Chief Investigator">Assoc Prof David Laybutt</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Type 2 diabetes (T2D) is caused by insulin deficiency, with
                obesity a strong risk factor. However, only a small fraction of obese individuals
                develops T2D. Usually the pancreatic ß-cells increase insulin release. This proposal
                will test the novel hypothesis that an adaptive response to stress helps ß-cells
                increase insulin release and protect against T2D by preventing the conversion of
                ß-cells to other pancreatic cell types. The studies are important for the
                development of novel therapy for T2D.</description>
            <description type="fundingAmount">$1,000,959.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012166</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012166</identifier>
            <identifier type="nhmrc">2012166</identifier>
            <name type="primary">
                <namePart>Enhancers as a new target for diagnosing disorders of sex
                    development.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">sex determination </subject>
            <subject type="local">enhancer elements</subject>
            <subject type="local">gene regulation</subject>
            <subject type="local">functional genomics</subject>
            <subject type="local">gonadal development</subject>
            <description type="Chief Investigator">Prof Andrew Sinclair</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Most human DNA is made up of regions that do not contain genes
                but instead carry important regulators that increase or decrease gene activity.
                Those that increase gene activity are called enhancers. This project aims to
                identify enhancers of genes that control testis or ovary development. We will
                determine whether disruption of these enhancers leads to a baby being born with a
                Disorder of Sex Development to improve diagnosis and clinical management of these
                patients.</description>
            <description type="fundingAmount">$756,178.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012196</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012196</identifier>
            <identifier type="nhmrc">2012196</identifier>
            <name type="primary">
                <namePart>A novel genetic barcoding approach to identify the vulnerabilities of
                    lethal breast cancer clones</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rxfrp27</identifier>
                <title>La Trobe University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">dna barcoding </subject>
            <subject type="local">cell lineage</subject>
            <subject type="local">sequencing</subject>
            <subject type="local">cancer biology</subject>
            <subject type="local">breast cancer metastases</subject>
            <description type="Chief Investigator">Dr Delphine Merino</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Metastasis is the primary cause of mortality for patients with
                breast cancer. There is an urgent need to better understand how breast cancer cells
                spread and resist standard therapy, to ?nd more effective ways to treat patients
                with metastatic disease. Our project aims at tracking the fate of thousands of human
                tumour cells during cancer progression to identify the genetic mechanisms
                responsible for the recurrence of the disease in vital organs.</description>
            <description type="fundingAmount">$715,225.80</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012211</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012211</identifier>
            <identifier type="nhmrc">2012211</identifier>
            <name type="primary">
                <namePart>On-Demand, Nanoparticle-Based Analgesia for Musculoskeletal
                    Pain</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">chronic pain </subject>
            <subject type="local">pain</subject>
            <subject type="local">pain management</subject>
            <subject type="local">musculoskeletal</subject>
            <subject type="local">bone disease</subject>
            <description type="Chief Investigator">Assoc Prof Jason Ivanusic</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Chronic pain associated with musculoskeletal disease causes a
                major burden on individuals and health care systems. In this study, we will assay
                changes in whole-animal pain behavior, and pain signaling, in response to
                therapeutic delivery of designer nanoparticles in models of osteoarthritis and bone
                cancer pain. This project is exciting because it will provide proof-of-principle for
                the use of nanoparticles for on-demand, site-specific analgesia for osteoarthritis
                and bone cancer pain.</description>
            <description type="fundingAmount">$893,856.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012225</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012225</identifier>
            <identifier type="nhmrc">2012225</identifier>
            <name type="primary">
                <namePart>Uncovering the pathway between gluten immunity and adverse symptoms in
                    coeliac disease and gluten sensitivity to define novel treatments and symptom
                    biomarkers</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">coeliac disease </subject>
            <subject type="local">mucosal immunology</subject>
            <subject type="local">gastrointestinal symptoms</subject>
            <subject type="local">clinical research</subject>
            <subject type="local">serotonin</subject>
            <description type="Chief Investigator">Dr Melinda Hardy</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Coeliac disease and gluten sensitivity are common illnesses in
                Australia often associated with unpleasant symptoms after gluten is consumed.
                Symptoms in some patients can be severe and impair quality of life. How gluten
                causes this is poorly understood. This study aims to understand the pathways that
                are important in the development of symptoms, the true triggers, and how gluten
                immunity is involved. This will enable targeted treatments to manage symptoms
                improving patient health and well-being.</description>
            <description type="fundingAmount">$1,100,483.60</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012233</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012233</identifier>
            <identifier type="nhmrc">2012233</identifier>
            <name type="primary">
                <namePart>Safeguarding health in International Investment Agreements</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">public health policy </subject>
            <subject type="local">policy analysis</subject>
            <subject type="local">policy development</subject>
            <subject type="local">preventive health</subject>
            <subject type="local">access to health care</subject>
            <description type="Chief Investigator">Assoc Prof Anne Marie Thow</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The ‘post COVID-19 world’ will require striking a balance
                between economic recovery and protection of population health. It is essential that
                International Investment Agreements (IIAs) do not undermine comprehensive and
                effective health regulation. This project will generate new evidence on 'best
                practice' health safeguards in IIAs, to prevent challenge to public health policy,
                and provide resources for the health and investment policy sectors to increase
                inclusion of strong health safeguards.</description>
            <description type="fundingAmount">$844,369.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012250</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012250</identifier>
            <identifier type="nhmrc">2012250</identifier>
            <name type="primary">
                <namePart>USING HUMAN EMBRYONIC TESTIS ORGANOIDS TO MODEL REPRODUCTIVE
                    DISORDERS</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">stem cells </subject>
            <subject type="local">sex determination</subject>
            <subject type="local">congenital urogenital abnormalities</subject>
            <subject type="local">reproductive biology</subject>
            <subject type="local">functional genomics</subject>
            <description type="Chief Investigator">Dr Katie Ayers</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Some babies are born with atypical reproductive organs meaning
                the sex of the baby is not clear. If the cause is unknown, doctors can be left
                guessing as to the best treatment. We have recently created a “human embryonic
                testis in a dish” model from stem cells. Here we will optimise its use to study
                genetic and environmental causes of reproductive disorders. Our findings will
                empower families and doctors to choose the right clinical care for these children,
                improving their health and wellbeing.</description>
            <description type="fundingAmount">$953,527.80</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012257</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012257</identifier>
            <identifier type="nhmrc">2012257</identifier>
            <name type="primary">
                <namePart>Phase-Contrast Neuroimaging for Early Detection of Brain Injury at
                    Birth</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">brain imaging </subject>
            <subject type="local">diagnostic imaging</subject>
            <subject type="local">brain development</subject>
            <subject type="local">brain injury</subject>
            <subject type="local">computed tomography</subject>
            <description type="Chief Investigator">Dr Marcus Kitchen</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Early detection of brain injury that can occur before, during
                and around the time of birth is critical for the prevention of lifelong intellectual
                and physical disabilities. However, current imaging techniques are not able to
                resolve these types of injuries whilst preventative actions can still be taken. We
                aim to develop novel imaging technologies that will enable subtle brain injuries to
                be detected early and accurately in order to improve lifelong outcomes for many
                infants.</description>
            <description type="fundingAmount">$1,066,590.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012263</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012263</identifier>
            <identifier type="nhmrc">2012263</identifier>
            <name type="primary">
                <namePart>TARGETING COLD TUMOURS WITH TRIPLE THERAPY</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">t cells </subject>
            <subject type="local">tumour cells</subject>
            <subject type="local">radiation</subject>
            <subject type="local">adeno-associated virus</subject>
            <subject type="local">gene therapy</subject>
            <description type="Chief Investigator">Assoc Prof Paul Neeson</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Patients with advanced metastatic disease have a very poor
                clinical outcome and are the main group of patients with an unmet clinical need. We
                know that very advanced cancers are resistant to the patient's immune system, and
                immune based therapies. In my program I will address these issues by (1) revealing
                how the patient's cancer avoids the immune system (2) create new types of T cells
                which will be resistant to the tumour immune evasion mechanisms (3) translate my
                findings into the clinic.</description>
            <description type="fundingAmount">$1,624,510.40</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012271</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012271</identifier>
            <identifier type="nhmrc">2012271</identifier>
            <name type="primary">
                <namePart>A molecular and biophysical characterisation of host cell contribution to
                    invasion by the Apicomplexan parasites</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">plasmodium falciparum </subject>
            <subject type="local">membrane biology</subject>
            <subject type="local">invasion biology</subject>
            <subject type="local">cytoskeleton</subject>
            <subject type="local">cryptosporidium</subject>
            <description type="Chief Investigator">Dr Kelly Rogers</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Disease causing Apicomplexan parasites, such as those causing
                malaria or cryptosporidiosis, must overcome the membrane barrier to infect their
                host cells. We have developed a novel 4D microscopy method to determine how these
                human pathogens penetrate the host membrane and how the host cell contributes to
                this process. Identifying which key factors are essential will improve current
                treatment strategies and give rise to a novel class of host directed therapies
                against this group of pathogens.</description>
            <description type="fundingAmount">$799,667.10</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012273</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012273</identifier>
            <identifier type="nhmrc">2012273</identifier>
            <name type="primary">
                <namePart>Adrenal-Targeted Nanobiotechnology: A Novel Therapy for Adrenal
                    Disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">adrenal endocrinology </subject>
            <subject type="local">androgens</subject>
            <subject type="local">congenital adrenal hyperplasia</subject>
            <subject type="local">nanotechnology</subject>
            <subject type="local">gene therapy</subject>
            <description type="Chief Investigator">Prof Lee Smith</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The adrenal gland produces hormones essential for life-long
                health. Conditions related to the disruption of these hormones affect 4 million
                Australians annually, at a cost of $2 Billion. Adrenal conditions require life-long
                drug replacement therapy, with no possibility of a cure. Through the use of a new
                adrenal specific delivery technology, we aim to develop novel drug treatments and
                single-injection cures for adrenal disease.</description>
            <description type="fundingAmount">$733,194.50</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012285</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012285</identifier>
            <identifier type="nhmrc">2012285</identifier>
            <name type="primary">
                <namePart>Eliminating hepatitis B in remote Indigenous settings: generating health
                    economic evidence</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01nfmeh72</identifier>
                <title>University of Tasmania</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">indigenous health </subject>
            <subject type="local">hepatitis b infection</subject>
            <subject type="local">health services</subject>
            <subject type="local">health economics</subject>
            <subject type="local">disease modelling</subject>
            <description type="Chief Investigator">Dr Barbara de Graaff</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Chronic infection with hepatitis B (CHB), which can cause liver
                disease including liver cancer, is common across NT Indigenous communities. Many
                people are unaware they have CHB and few engage in care. To address this, the NHMRC
                funded the HEP B PAST Project (2017) which aims to eliminate CHB from NT Indigenous
                communities. Results show a highly effective model of care. This new project will
                generate health economic evidence that is required to embed the HEP B PAST model
                into standard practice.</description>
            <description type="fundingAmount">$750,736.60</description>
            <coverage>
                <spatial type="text">TAS</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012286</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012286</identifier>
            <identifier type="nhmrc">2012286</identifier>
            <name type="primary">
                <namePart>Understanding the establishment and persistence of community associated
                    methicillin-resistant Staphylococcus aureus (CA-MRSA) in resource-limited,
                    high-burden settings: How can we reduce the burden of disease?</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04gsp2c11</identifier>
                <title>James Cook University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">staphylococcus aureus </subject>
            <subject type="local">skin infections</subject>
            <subject type="local">papua new guinea</subject>
            <subject type="local">antimicrobial resistance</subject>
            <subject type="local">multiply-resistant staphylococci</subject>
            <description type="Chief Investigator">Assoc Prof Paul Horwood</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Methicillin resistant Staphylococcus aureus (MRSA) strain ST93
                is a potentially dangerous pathogen of particular concern in resource-limited
                settings. Our research team has recently identified the highlands of Papua New
                Guinea as a hotspot for MRSA ST93 bone infections. Through this study we will
                determine the factors that enable the spread and persistence of ST93 in these
                settings and identify interventions to reduce the impact of ST93 in resource-limited
                communities.</description>
            <description type="fundingAmount">$603,908.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012287</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012287</identifier>
            <identifier type="nhmrc">2012287</identifier>
            <name type="primary">
                <namePart>Using Cerebrospinal Fluid Liquid Biopsy for Detection of Mosaic Brain
                    Mutations</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">neurogenetics </subject>
            <subject type="local">somatic mutation</subject>
            <subject type="local">focal epilepsy</subject>
            <subject type="local">seizures</subject>
            <subject type="local">cerebrospinal fluid</subject>
            <description type="Chief Investigator">Assoc Prof Michael Hildebrand</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Seizures can occur in patients with or without abnormalities in
                their brain. We have collected spinal fluid from a subset of these patients and we
                will use this precious resource to determine the contribution of genetic defects to
                the development of their seizures. The overall contribution of different types of
                genetic defects to seizures is not completely understood and this knowledge will
                improve outcomes for patients by ending their diagnostic odyssey and promoting new
                therapies.</description>
            <description type="fundingAmount">$909,172.80</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012290</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012290</identifier>
            <identifier type="nhmrc">2012290</identifier>
            <name type="primary">
                <namePart>The mesenchymal stromal cell paradox – living cell therapy or dying
                    therapeutic cell?</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">cell therapy </subject>
            <subject type="local">cell death</subject>
            <subject type="local">macrophages</subject>
            <subject type="local">immunomodulation</subject>
            <subject type="local">mechanism of action</subject>
            <description type="Chief Investigator">Assoc Prof Tracy Heng</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Mesenchymal stromal cells (MSCs) can dampen inflammation and
                aid tissue repair, but efforts to improve their clinical utility are hampered by our
                poor understanding of how they work. We have found that the therapeutic effects of
                MSCs depend on their cell death, which triggers immune suppression. Instead of
                focussing on viable MSCs, we will investigate how dying MSCs modify immune
                responses. Our discoveries will enable more effective cell therapies for a wide
                range of diseases.</description>
            <description type="fundingAmount">$957,031.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012301</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012301</identifier>
            <identifier type="nhmrc">2012301</identifier>
            <name type="primary">
                <namePart>Targeting the brain and sympathetic nervous system to improve outcomes in
                    cancer cachexia</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">cachexia </subject>
            <subject type="local">sympathetic nervous system</subject>
            <subject type="local">appetite regulation</subject>
            <subject type="local">hypothalamus</subject>
            <subject type="local">energy balance</subject>
            <description type="Chief Investigator">Dr Sarah Lockie</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cancer cachexia is the wasting of fat and muscle that occurs in
                late stages of a number of cancers. It is particularly prevalent in pancreatic
                cancer. One of the known causes for this wasting is increased activity of the
                sympathetic nervous system (SNS), also responsible for the 'fight or flight'
                response to danger. The SNS is under control of the brain, and this project will
                look at specific brain cells as therapeutic targets for treating cachexia in a mouse
                model of pancreatic cancer.</description>
            <description type="fundingAmount">$878,451.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012313</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012313</identifier>
            <identifier type="nhmrc">2012313</identifier>
            <name type="primary">
                <namePart>Investigating the role of cellular metabolism in regulating antigen
                    presentation and tumour immune escape</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">cell metabolism </subject>
            <subject type="local">cancer cell biology</subject>
            <subject type="local">antigen presentation</subject>
            <subject type="local">immune evasion</subject>
            <subject type="local">molecular mechanisms</subject>
            <description type="Chief Investigator">Dr Kristin Brown</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">In order to develop and progress, tumours must avoid
                elimination by the immune system. Understanding the mechanisms that allow tumours to
                evade the immune system is critical for developing strategies to overcome immune
                escape and enhance the efficacy of currently existing immunotherapies. This research
                will investigate the fundamental mechanisms by which aberrant cell metabolism
                contributes to immune evasion in cancer and identify strategies to restore tumour
                elimination by the immune system.</description>
            <description type="fundingAmount">$994,327.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012330</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012330</identifier>
            <identifier type="nhmrc">2012330</identifier>
            <name type="primary">
                <namePart>Enabling next generation radiotherapy for cancer: Development of novel
                    Quality Assurance instrumentation for Proton Therapy</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00jtmb277</identifier>
                <title>University of Wollongong</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">radiotherapy </subject>
            <subject type="local">proton therapy</subject>
            <subject type="local">instrumentation</subject>
            <subject type="local">quality assurance</subject>
            <subject type="local">medical physics</subject>
            <description type="Chief Investigator">Prof Anatoly Rozenfeld</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Proton Therapy is a new form of radiotherapy that has many
                benefits over conventional radiotherapy and is particularly useful for childhood
                cancers. To maximise the benefits of proton therapy, we need to develop instruments
                called microdosimeters to accurately measure the physical and biological dose of
                radiation received by the patient. Our research will develop and test a novel
                microdosimeter for proton therapy to coincide with the opening of the new Australian
                Bragg Centre for Proton Therapy</description>
            <description type="fundingAmount">$758,040.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012342</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012342</identifier>
            <identifier type="nhmrc">2012342</identifier>
            <name type="primary">
                <namePart>Does Chlamydia infection damage the ovary and compromise
                    fertility?</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">ovary </subject>
            <subject type="local">fertility</subject>
            <subject type="local">bacterial infection</subject>
            <subject type="local">oocyte</subject>
            <subject type="local">inflammation</subject>
            <description type="Chief Investigator">Assoc Prof Karla Hutt</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The ability of Chlamydia to infect and damage the ovary has
                never been investigated. We will determine exactly how Chlamydia infects and damages
                ovarian tissues by studying aspects of ovarian function including hormone
                production, egg health, and fertility in our unique mouse model, and a cohort of
                human samples. We will also assess whether antibiotics, and our newly developed
                Chlamydia vaccine, can protect against ovary damage.</description>
            <description type="fundingAmount">$1,057,446.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012351</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012351</identifier>
            <identifier type="nhmrc">2012351</identifier>
            <name type="primary">
                <namePart>Exploring the therapeutic potential of genetically engineering macrophages
                    with a Chimeric Signaling Switch Receptor in kidney diseases</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">kidney disease </subject>
            <subject type="local">anti-inflammatory</subject>
            <subject type="local">cell therapy</subject>
            <subject type="local">immunology</subject>
            <subject type="local">macrophage biology</subject>
            <description type="Chief Investigator">Dr Yiping Wang</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Kidney diseases are a major cause of death and morbidity
                worldwide. Current treatments to delay progression of kidney diseases are few and
                largely ineffective, so that new therapies are urgently needed. We have recently
                developed an innovative approach to genetically engineer immune cells (macrophages)
                to treat kidney diseases. This study will determine the effectiveness of this new
                cell therapy in kidney disease models and whether it can be used to treat human
                kidney diseases.</description>
            <description type="fundingAmount">$753,039.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012362</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012362</identifier>
            <identifier type="nhmrc">2012362</identifier>
            <name type="primary">
                <namePart>IS THE EVOLUTIONARY LOSS OF ACTN3 DETRIMENTAL IN MODERN
                    SOCIETY?</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">muscle </subject>
            <subject type="local">performance</subject>
            <subject type="local">overweight/obesity</subject>
            <subject type="local">genetic influences</subject>
            <subject type="local">knockout mouse</subject>
            <description type="Chief Investigator">Dr Peter Houweling</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Do you feel the cold or are you happiest in the depths of
                winter? A common null polymorphism in the skeletal muscle gene ACTN3 (R577X) has
                been described as a key gene during modern evolution due to its ability to improve
                muscle function and metabolism following cold exposure. We will explore the impacts
                of this gene further in modern humans by studying muscles from healthy and obese
                ACTN3 R577X mice and humans to determine how our ACTN3 genotype influences life in
                todays modern society.</description>
            <description type="fundingAmount">$1,215,355.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012370</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012370</identifier>
            <identifier type="nhmrc">2012370</identifier>
            <name type="primary">
                <namePart>Development and mechanistic analysis of novel inhibitors of the dengue
                    virus NS1 protein</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">dengue virus </subject>
            <subject type="local">antiviral agents</subject>
            <subject type="local">drug discovery</subject>
            <subject type="local">viral replication</subject>
            <subject type="local">proteomics</subject>
            <description type="Chief Investigator">Dr Nicholas Eyre</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Mosquito-borne flaviviruses such as dengue virus (DENV) cause
                significant morbidity and mortality in tropical and sub-tropical areas worldwide.
                The DENV NS1 protein is critical to multiple aspects of the viral life cycle and
                DENV pathogenesis, making it an appealing target of future antiviral therapies. In
                this project we will apply a rational multi-disciplinary approach to identify and
                mechanistically characterise unique NS1-targeting antiviral drugs and future
                NS1-related drug targets.</description>
            <description type="fundingAmount">$783,440.40</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012371</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012371</identifier>
            <identifier type="nhmrc">2012371</identifier>
            <name type="primary">
                <namePart>Targeting dysregulated transcription in cancer through
                    Cyclin-Dependent-Kinase 11</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">gene regulation </subject>
            <subject type="local">cancer cell biology</subject>
            <subject type="local">gene transcription</subject>
            <subject type="local">anticancer drug action</subject>
            <subject type="local">rna processing</subject>
            <description type="Chief Investigator">Dr Jennifer Devlin</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Many proteins cooperate to carefully control which genes are
                ‘on’ or ‘off’ in our cells. Defects in gene control that cause cells to grow faster
                and to live longer than normal give rise to cancer. I will investigate the activity
                of a group of proteins called Cyclin-dependent-kinases (CDKs), that are essential
                for ensuring proper gene control and are essential for cancer cells to survive. This
                will allow us to design better strategies to block the activity of CDKs to kill
                cancer cells.</description>
            <description type="fundingAmount">$849,454.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012373</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012373</identifier>
            <identifier type="nhmrc">2012373</identifier>
            <name type="primary">
                <namePart>Determining the role of Target of Rapamycin Complex 2 (TORC2) in cancer
                    cell proliferation</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">cell signalling </subject>
            <subject type="local">cell biology</subject>
            <subject type="local">cell growth</subject>
            <subject type="local">cell division</subject>
            <subject type="local">cancer cell biology</subject>
            <description type="Chief Investigator">Prof Janni Petersen</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">In normal cells, proliferation depends on the availability of
                nutrients. Tumour cells are usually ‘nutritionally stressed’ but survive despite
                this. This project aims to study the cell’s nutrient sensor — TOR Complex 2 — in
                order to elucidate how it facilitates cell division under nutrient stress. Better
                understanding of TORC2 signalling will improve future treatment strategies for
                patients with solid tumours.</description>
            <description type="fundingAmount">$491,420.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012382</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012382</identifier>
            <identifier type="nhmrc">2012382</identifier>
            <name type="primary">
                <namePart>Achieving benefit without harm: a next-generation glucocorticoid
                    replacement</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">glucocorticoids </subject>
            <subject type="local">rheumatology</subject>
            <subject type="local">chronic inflammation</subject>
            <subject type="local">drug discovery</subject>
            <subject type="local">systemic lupus erythematosus (sle)</subject>
            <description type="Chief Investigator">Dr Sarah Jones</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Over 2% of the world’s population takes long-term steroid
                therapy to control unwanted immune system activity, despite the predictable, harmful
                side effects of steroids. A natural anti-inflammatory protein, GILZ, is increased as
                a result of steroid treatment, which is an important way that steroids work. Our
                studies will lead to a strategy to develop a drug that increases GILZ without the
                use of steroids, bringing about the protective effects of steroids without the
                harmful side effects.</description>
            <description type="fundingAmount">$1,076,432.80</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012393</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012393</identifier>
            <identifier type="nhmrc">2012393</identifier>
            <name type="primary">
                <namePart>The contribution of the gut to bipolar disorder</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">bipolar disorder </subject>
            <subject type="local">serotonin</subject>
            <subject type="local">gut peptides</subject>
            <subject type="local">visceral afferents</subject>
            <subject type="local">mental health</subject>
            <description type="Chief Investigator">Prof Damien Keating</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Bipolar disorder is a severe mental illness affecting many
                Australians. We provide evidence that specific gut cells may trigger the mood
                fluctuations that are central in bipolar disorders. Activation of these cells can
                alter brain activity via a pathway called the gut brain axis. This project will
                focus on understanding how serotonin release from these cells affects brain function
                in bipolar disorder and how we can target these cells to create new treatments for
                this disease.</description>
            <description type="fundingAmount">$844,809.80</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012404</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012404</identifier>
            <identifier type="nhmrc">2012404</identifier>
            <name type="primary">
                <namePart>Removing mosquito populations by releasing incompatible males: a species
                    specific biocontrol for urban arbovirus vectors</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">arbovirus diseases </subject>
            <subject type="local">mosquito-borne disease</subject>
            <subject type="local">vector control</subject>
            <subject type="local">vector-borne disease</subject>
            <subject type="local">arbovirus</subject>
            <description type="Chief Investigator">Dr Nigel Beebe</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Two mosquitoes, Aedes aegypti and Aedes albopictus, drive the
                global expansion of arboviruses such as dengue and Zika; both threaten Australia.
                With no effective vaccines and extensive insecticide resistance, new mosquito
                control tools are vital. By releasing reproductively incompatible males (males don’t
                bite), we have successfully reduced aegypti populations in some Queensland towns by
                over 80% . We will now develop this technology into an efficient deployable product
                for Australia and beyond.</description>
            <description type="fundingAmount">$1,047,634.80</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012418</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012418</identifier>
            <identifier type="nhmrc">2012418</identifier>
            <name type="primary">
                <namePart>Applying reverse translation to the parkrun phenomenon to identify
                    effective, sustainable methods for scaling-up public health
                    interventions</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">physical activity </subject>
            <subject type="local">dissemination</subject>
            <subject type="local">preventive</subject>
            <subject type="local">social networks</subject>
            <subject type="local">social epidemiology</subject>
            <description type="Chief Investigator">Dr Anne Grunseit</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">parkrun is a free, weekly organised grass-roots mass physical
                activity event, which has spread across 23 countries with over six million
                registrants. It has succeeded where most researcher and government-led physical
                activity interventions have failed in terms of high participation, accessibility and
                sustainability. Our proposal analyses how parkrun has disseminated and been
                sustained throughout Australia and will derive models and principles to inform
                future public health interventions.</description>
            <description type="fundingAmount">$569,798.90</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012427</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012427</identifier>
            <identifier type="nhmrc">2012427</identifier>
            <name type="primary">
                <namePart>Studying the persisting glial dysfunction occurring after preterm brain
                    injury to uncover new therapeutic targets</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04ttjf776</identifier>
                <title>RMIT University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">neuroinflammation </subject>
            <subject type="local">very preterm birth</subject>
            <subject type="local">microglia</subject>
            <subject type="local">glucocorticoids</subject>
            <subject type="local">novel therapies</subject>
            <description type="Chief Investigator">Dr Bobbi Fleiss</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We cannot treat brain damage in prematurely born babies despite
                it often leading to permanent brain injury and disability. Cells called glia are
                vital for building the brain and keeping it healthy. After early-life brain injury,
                we are learning that glia cannot perform these tasks as they should for many months.
                In this project, we will test if helping glia 'get back to work’ in the weeks or
                months after injury might be a way to repair the damaging effects of preterm
                birth.</description>
            <description type="fundingAmount">$845,926.42</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012443</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012443</identifier>
            <identifier type="nhmrc">2012443</identifier>
            <name type="primary">
                <namePart>Improving respiratory support for preterm infants at birth</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">very preterm birth </subject>
            <subject type="local">neonatal respiratory distress syndrome</subject>
            <subject type="local">birth</subject>
            <subject type="local">fetal physiology</subject>
            <subject type="local">respiratory physiology</subject>
            <description type="Chief Investigator">Prof Stuart Hooper</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">In Australia, 92% of babies born very preterm need help to
                breathe at birth, which can injure their lungs and brains. While providing
                respiratory support with a face mask is the gentlest approach, it often fails
                because the baby’s vocal cords reflexly close if they stop breathing, which prevents
                air from entering their lungs. Our research focuses on helping these babies breathe
                at birth to improve the success of providing gentle respiratory
                support.</description>
            <description type="fundingAmount">$1,098,188.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012453</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012453</identifier>
            <identifier type="nhmrc">2012453</identifier>
            <name type="primary">
                <namePart>Communication via epigenetic mechanisms: cell cross-talk and male
                    fertility</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">spermatogenesis </subject>
            <subject type="local">cell-cell communication</subject>
            <subject type="local">control of gene expression</subject>
            <subject type="local">epigenetics</subject>
            <subject type="local">sertoli cell</subject>
            <description type="Chief Investigator">Dr Tatiana Soboleva</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Male infertility is on the rise in Western society but the
                processes that drive sperm production are still poorly understood. We discovered a
                new epigenetics-based process that involves the transfer of important information
                between different cell types in the testis that is critical for the production of
                viable sperm. We aim to uncover the molecular mechanism of this process, which will
                provide new insights into the causes of male infertility.</description>
            <description type="fundingAmount">$962,786.00</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012454</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012454</identifier>
            <identifier type="nhmrc">2012454</identifier>
            <name type="primary">
                <namePart>Engineering chimeric antigen receptor (CAR) T cells that induce host
                    anti-tumour immunity</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">t cell immunotherapy </subject>
            <subject type="local">t cell immunity</subject>
            <subject type="local">cd8 t lymphocytes</subject>
            <subject type="local">cancer immunotherapy</subject>
            <subject type="local">cancer immunology</subject>
            <description type="Chief Investigator">Dr Paul Beavis</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project will further enhance the therapeutic application
                of a gene-engineering based immune therapy involving a patients' own cells. To date
                this form of therapy has been effective in blood cancers but not solid tumours. We
                will aim to overcome this by developing technological and scientific advances which
                will make the immune cells more effective against solid tumours. These findings have
                the potential to provide treatment options for late stage solid tumour cancer
                patients.</description>
            <description type="fundingAmount">$984,101.60</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012463</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012463</identifier>
            <identifier type="nhmrc">2012463</identifier>
            <name type="primary">
                <namePart>Investigation of the structure of the influenza A virus genome and how it
                    directs reassortment to generate novel strains</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">influenza </subject>
            <subject type="local">influenza virus</subject>
            <subject type="local">viral replication</subject>
            <subject type="local">viral proteins</subject>
            <subject type="local">viral infection</subject>
            <description type="Chief Investigator">Dr Brad Gilbertson</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Pandemic influenza viruses acquire new properties through the
                swapping of gene segments known as reassortment. We will investigate the structure
                of the influenza A virus genome to dissect the molecular mechanism that enables
                specific genes to interact and be co-selected during reassortment. Our work will
                provide key insights into the probability of viruses with particular gene
                constellations emerging in the future, that will greatly benefit pandemic assessment
                and planning.</description>
            <description type="fundingAmount">$745,583.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012471</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012471</identifier>
            <identifier type="nhmrc">2012471</identifier>
            <name type="primary">
                <namePart>Eliminating HIV-infected macrophages; a neglected problem in HIV cure
                    research</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05ktbsm52</identifier>
                <title>Burnet Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">human immunodeficiency virus (hiv) </subject>
            <subject type="local">macrophages</subject>
            <subject type="local">latency</subject>
            <subject type="local">cytotoxicity</subject>
            <subject type="local">envelope protein</subject>
            <description type="Chief Investigator">Dr Anna Hearps</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">HIV cannot currently be cured due to the persistence of
                ‘silent’ sources of HIV hidden within certain cells which are not sensitive to
                anti-HIV drugs. One type of immune cell that HIV hides in are called macrophages,
                and these cells are very hard for the immune system to destroy. We will study HIV
                infection in macrophages and identify ways to ‘wake up’ silent HIV in these cells
                and weaken them so that they can be eliminated from the body.</description>
            <description type="fundingAmount">$708,501.10</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012474</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012474</identifier>
            <identifier type="nhmrc">2012474</identifier>
            <name type="primary">
                <namePart>Opening the pathway to large data-driven patient-specific diagnostics
                    using novel coronary angiogram analysis</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">haemodynamics </subject>
            <subject type="local">biomedical engineering</subject>
            <subject type="local">medical imaging</subject>
            <subject type="local">modelling</subject>
            <subject type="local">blood flow</subject>
            <description type="Chief Investigator">Dr Susann Beier</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This work will reform the medical practice of risk assessment
                for coronary artery disease and acute coronary artery syndrome by delivering the
                next generation of rapid, patient-specific, and high accuracy medical image-based
                risk assessment. Using innovative state-of-the-art engineering methods, including
                machine learning, large-scale computational modelling and image analysis, we will
                reveal new markers of cardiovascular risk in individuals for improved standard
                clinical care.</description>
            <description type="fundingAmount">$459,117.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012475</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012475</identifier>
            <identifier type="nhmrc">2012475</identifier>
            <name type="primary">
                <namePart>CRISPR Engineering of CAR T Cells to Enhance Efficacy in Solid
                    Tumours</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">immunology </subject>
            <subject type="local">t cell immunotherapy</subject>
            <subject type="local">cellular immunology</subject>
            <subject type="local">gene regulation</subject>
            <subject type="local">cd8 t lymphocytes</subject>
            <description type="Chief Investigator">Dr Paul Beavis</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project will further enhance the therapeutic application
                of a gene-engineering based immune therapy involving a patients' own cells. To date
                this form of therapy has been effective in blood cancers but not solid tumours. We
                will aim to overcome this by developing technological and scientific advances which
                will make the immune cells more effective against solid tumours. These findings have
                the potential to provide treatment options for late stage solid tumour cancer
                patients.</description>
            <description type="fundingAmount">$897,551.80</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012498</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012498</identifier>
            <identifier type="nhmrc">2012498</identifier>
            <name type="primary">
                <namePart>Pursuing IRF4 as a therapeutic opportunity for lymphoid
                    malignancies</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">b cells </subject>
            <subject type="local">lymphocyte differentiation</subject>
            <subject type="local">transcription factor</subject>
            <subject type="local">chronic lymphocytic leukaemia (cll)</subject>
            <subject type="local">structural immunology</subject>
            <description type="Chief Investigator">Assoc Prof Anselm Enders</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The molecule IRF4 is essential to the function of the immune
                system. In this application we investigate mouse models with mutations in IRF4 that
                are identical to those found in patients with cancers of the immune system. We will
                investigate how these mutations affect binding of IRF4 to the DNA and how changes in
                the IRF4-DNA binding domain lead to formation of tumours and how this interaction
                can be targeted therapeutically.</description>
            <description type="fundingAmount">$1,434,231.80</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012500</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012500</identifier>
            <identifier type="nhmrc">2012500</identifier>
            <name type="primary">
                <namePart>Mosquito-specific viruses: novel agents to control the transmission of
                    arboviral pathogens</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/004y8wk30</identifier>
                <title>QIMR Berghofer Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">arbovirus </subject>
            <subject type="local">mosquito transmission</subject>
            <subject type="local">mosquito-borne disease</subject>
            <subject type="local">flavivirus</subject>
            <subject type="local">ross river virus</subject>
            <description type="Chief Investigator">Dr Leon Hugo</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Insect-specific viruses are benign viruses that infect only
                insects and are transmitted from the insect to their offspring. We and others have
                shown that infection of mosquitoes with these benign viruses can inhibit infection
                of these mosquitoes by other viruses that cause human disease. In this grant, we
                plan to produce one or more strains of mosquitoes harboring these benign viruses for
                use in biological control programs against mosquito-borne diseases.</description>
            <description type="fundingAmount">$807,376.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012505</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012505</identifier>
            <identifier type="nhmrc">2012505</identifier>
            <name type="primary">
                <namePart>Using population-based data to improve maternal asthma management and
                    offspring health and development</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">asthma </subject>
            <subject type="local">pregnancy</subject>
            <subject type="local">pharmacoepidemiology</subject>
            <subject type="local">child development</subject>
            <subject type="local">data linkage</subject>
            <description type="Chief Investigator">Assoc Prof Luke Grzeskowiak</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Asthma affects more than 30,000 Australian pregnancies each
                year and has been associated with a range of adverse pregnancy outcomes. This
                project will utilise population-based data to examine the effects of maternal
                asthma, as well as the use of individual asthma treatments during pregnancy, on
                child health and development from birth to 14-years of age and will provide direct
                evidence to support improvements in policy and practice related to optimising asthma
                management during pregnancy.</description>
            <description type="fundingAmount">$979,886.40</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012513</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012513</identifier>
            <identifier type="nhmrc">2012513</identifier>
            <name type="primary">
                <namePart>Improving the Diagnosis of Barrett’s Oesophagus with Dysplasia</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02stey378</identifier>
                <title>University of Notre Dame Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">barrett's oesophagus </subject>
            <subject type="local">histopathology</subject>
            <subject type="local">lower oesophageal adenocarcinoma</subject>
            <subject type="local">endoscopy</subject>
            <subject type="local">biomarkers</subject>
            <description type="Chief Investigator">Prof Reginald Lord</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Some patients with Barrett’s oesophagus are at greatly
                increased risk of developing oesophageal adenocarcinoma, the most common form of
                oesophageal cancer in Australia. Unfortunately, the current examination method is
                unreliable for diagnosing these patients prior to cancer, or for accurately
                predicting cancer risk. We will investigate a molecular test and the potential to
                develop an antibody test to improve diagnosis and prediction of cancer risk, and
                possibly reduce healthcare costs.</description>
            <description type="fundingAmount">$1,001,895.20</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012523</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012523</identifier>
            <identifier type="nhmrc">2012523</identifier>
            <name type="primary">
                <namePart>A new way to see endometriosis</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04ttjf776</identifier>
                <title>RMIT University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">endometriosis </subject>
            <subject type="local">uterus</subject>
            <subject type="local">menstruation</subject>
            <subject type="local">embryo implantation</subject>
            <subject type="local">endometrium</subject>
            <description type="Chief Investigator">Prof Guiying Nie</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Endometriosis, a chronic and painful condition, affects ~10%
                women of reproductive age, and is characterized by growth of uterine-like cells
                outside the uterus such as the pelvis. However, why cells of the uterus end up in
                other parts of the body, and how they cause pain and other symptoms, are not well
                understood. This project will address these questions by studying the fundamental
                biology and function of uterine cells and exploring new diagnostic and therapeutic
                options for endometriosis.</description>
            <description type="fundingAmount">$1,197,867.40</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012530</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012530</identifier>
            <identifier type="nhmrc">2012530</identifier>
            <name type="primary">
                <namePart>Harnessing a novel insulin receptor binding mechanism to therapeutic
                    benefit</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">insulin </subject>
            <subject type="local">insulin receptor</subject>
            <subject type="local">insulin signalling</subject>
            <subject type="local">peptides</subject>
            <subject type="local">structure-function</subject>
            <description type="Chief Investigator">Prof Briony Forbes</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We aim to develop new insulin molecules that provide better
                blood glucose control to Type 1 and late stage Type 2 diabetic patients. A
                fascinating discovery from investigations of marine cone snail venom has provided
                the basis to develop a new class of diabetes therapeutics built on a cone snail
                derived "mini" insulin scaffold. This proposal outlines the steps required to
                translate our findings into the development of ultra fast acting insulin analogues
                for diabetes treatment.</description>
            <description type="fundingAmount">$727,642.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012535</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012535</identifier>
            <identifier type="nhmrc">2012535</identifier>
            <name type="primary">
                <namePart>iHSCs, repopulating haematopoietic stem cells derived from human
                    pluripotent stem cells</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">haematopoietic stem cells </subject>
            <subject type="local">stem cell biology</subject>
            <subject type="local">embryonic stem cells</subject>
            <subject type="local">developmental biology</subject>
            <subject type="local">cell differentiation</subject>
            <description type="Chief Investigator">Prof Andrew Elefanty</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">The ability to make blood stem cells from human pluripotent
                stem cells would be beneficial for patients with leukaemia or bone marrow failure
                who cannot find a matched donor. We will compare the blood stem cells that we can
                now make in the laboratory with stem cells present in umbilical cord blood and we
                will use these comparisons to inform improvements in our methods. Success in this
                project will accelerate the translation of these human stem cell derived blood
                therapies to the clinic.</description>
            <description type="fundingAmount">$1,375,597.60</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012552</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012552</identifier>
            <identifier type="nhmrc">2012552</identifier>
            <name type="primary">
                <namePart>Sex-differences in cellular aging and cardiovascular disease: Role of the
                    AngIV/IRAP axis</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">hypertension </subject>
            <subject type="local">senescence</subject>
            <subject type="local">end organ damage</subject>
            <subject type="local">pregnancy</subject>
            <subject type="local">kidney disease</subject>
            <description type="Chief Investigator">Prof Kate Denton</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">High blood pressure and ageing increase the risk of heart
                disease. Young women are protected from heart disease, but lose this protection with
                age. Senolytics are a new class of drug that remove damaged (senescent) cells from
                the body. Senescent cells lose the ability to self-repair and trigger a cascade of
                reactions to promote disease. We will determine if a novel enzyme insulin-regulated
                aminopeptidase (IRAP) causes cell damage and disease, and test the efficacy of IRAP
                inhibitors.</description>
            <description type="fundingAmount">$1,189,392.20</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012560</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012560</identifier>
            <identifier type="nhmrc">2012560</identifier>
            <name type="primary">
                <namePart>Multi-analyte liquid biopsy-based biomarkers for oropharyngeal
                    cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03pnv4752</identifier>
                <title>Queensland University of Technology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">saliva </subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">biosensor</subject>
            <subject type="local">biomedical engineering</subject>
            <subject type="local">cancer prognosis</subject>
            <description type="Chief Investigator">Assoc Prof Chamindie Punyadeera</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Throat cancer affects individuals at a relatively young age,
                who often go on to suffer from long-term treatment related morbidities. In addition,
                20% of throat cancers reoccur. There is a desire to reduce the intensity of
                treatment to lessen severe side effects as well as to monitor response to treatment
                . We propose to use non-invasive, novel biomarkers to address these unmet clinical
                needs, thereby improving quality of life for cancer patients and significantly
                cutting healthcare costs.</description>
            <description type="fundingAmount">$763,417.40</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012567</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012567</identifier>
            <identifier type="nhmrc">2012567</identifier>
            <name type="primary">
                <namePart>Pioneering novel therapeutic strategies to enhance an anti-tumour immune
                    response in Neuroblastoma</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">neuroblastoma </subject>
            <subject type="local">antibody cancer therapy</subject>
            <subject type="local">paediatric</subject>
            <subject type="local">adaptive immunity</subject>
            <subject type="local">metals</subject>
            <description type="Chief Investigator">Dr Orazio Vittorio</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Neuroblastoma has one of the lowest survival rates of all
                childhood cancers. Immunotherapy stimulates an immune response against cancer cells
                yet still works poorly in neuroblastoma. This suggests that understanding how
                neuroblastoma evade immune system is critical to improving such therapies. Our
                research has found that copper plays a key role in tumours to evade the immune
                response. We are currently developing new strategies to reduce copper and activate
                the anti-tumour immune responses.</description>
            <description type="fundingAmount">$721,983.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012569</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012569</identifier>
            <identifier type="nhmrc">2012569</identifier>
            <name type="primary">
                <namePart>Only a matter of time? A comparison of caloric restriction versus time
                    restriction of food intake.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">circadian rhythms </subject>
            <subject type="local">obesity</subject>
            <subject type="local">feeding and nutrition</subject>
            <subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes
                mellitus)</subject>
            <subject type="local">healthy ageing</subject>
            <description type="Chief Investigator">Assoc Prof Leonie Heilbronn</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The proposed study will compare the health benefits of limiting
                “when” vs “how much” is eaten on health in individuals at high risk of developing
                type 2 diabetes. The concept that marked improvements in health can be achieved by
                aligning food intake with circadian rhythms, without weight loss, is game changing.
                But we do not yet clearly understand how one performs against the other, or if both
                are required, in humans, since no trials have been performed.</description>
            <description type="fundingAmount">$1,189,927.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012579</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012579</identifier>
            <identifier type="nhmrc">2012579</identifier>
            <name type="primary">
                <namePart>Defining Chemotactic Signalling Networks to Identify New Anti-inflammatory
                    Targets</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">chemokine receptor </subject>
            <subject type="local">chemokines</subject>
            <subject type="local">signal transduction</subject>
            <subject type="local">proteomics</subject>
            <subject type="local">functional genomics</subject>
            <description type="Chief Investigator">Assoc Prof Martin Stone</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">A key feature of inflammatory diseases is infiltration of the
                affected tissues by white blood cells. White blood cell migration is controlled by
                “chemokine” proteins that are produced in the tissues and activate receptor proteins
                on the blood cells. This project will characterise the molecular events leading from
                receptor activation to white blood cell migration. The results will guide
                development of medicines to control inflammatory diseases, including atherosclerosis
                and rheumatoid arthritis.</description>
            <description type="fundingAmount">$1,152,153.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012582</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012582</identifier>
            <identifier type="nhmrc">2012582</identifier>
            <name type="primary">
                <namePart>A novel approach integrating genomics into the health economic modelling
                    of therapeutics</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">cost-effectiveness </subject>
            <subject type="local">cardiovascular disease prevention</subject>
            <subject type="local">modelling</subject>
            <subject type="local">early prevention</subject>
            <subject type="local">therapeutics</subject>
            <description type="Chief Investigator">Assoc Prof Zanfina Ademi</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Despite the increasing uptake of health economic models in
                practice, greater understanding of the impact of lifetime disease risk in costs and
                outcomes is fundamental for cardiovascular disease. This research project will
                utilise an innovative approach in health economic modelling that will provide
                evidence for the first time on the cost-effectiveness of new interventions. This in
                return will inform government policies, lead to efficient access to preventive
                therapeutics.</description>
            <description type="fundingAmount">$491,777.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012583</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012583</identifier>
            <identifier type="nhmrc">2012583</identifier>
            <name type="primary">
                <namePart>Targeted Delivery of Nucleic Acid Therapeutics for Preventing Preterm
                    Birth</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">pregnancy </subject>
            <subject type="local">premature birth</subject>
            <subject type="local">myometrium</subject>
            <subject type="local">nanotechnology</subject>
            <subject type="local">experimental therapeutics</subject>
            <description type="Chief Investigator">Dr Jonathan Paul</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Thousands of babies could be saved each year with a timely
                intervention for preterm birth. Current approaches are hampered by a lack of drug
                specificity. To address this, we first developed uterine-targeted nanocarriers for
                targeting interventions to the pregnant uterus. We now seek to leverage this
                platform for the targeted delivery of nucleic acid therapeutics. This bold strategy
                aims to modulate cellular phenotype in order to block the premature uterine
                contractions that cause preterm birth.</description>
            <description type="fundingAmount">$732,334.40</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012600</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012600</identifier>
            <identifier type="nhmrc">2012600</identifier>
            <name type="primary">
                <namePart>New pathways to improved stroke outcome: the importance of managing
                    intracranial pressure.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">ischaemic stroke </subject>
            <subject type="local">intracranial pressure</subject>
            <subject type="local">cerebrospinal fluid</subject>
            <subject type="local">molecular mechanisms</subject>
            <subject type="local">cardiovascular physiology</subject>
            <description type="Chief Investigator">Dr Kirsten Coupland</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Stroke is caused by a loss of blood supply that results in
                brain tissue death leading to disability. Delayed expansion of stroke injury can
                occur in the 24-48 hours after stroke. What causes this was previously unknown. We
                found that an increase in cerebrospinal fluid pressure that affects blood flow to
                the injury site is likely to blame. We have evidence that a change in the
                composition of cerebrospinal fluid drives this increase in pressure and we aim to
                design therapies to prevent it.</description>
            <description type="fundingAmount">$497,265.58</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012601</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012601</identifier>
            <identifier type="nhmrc">2012601</identifier>
            <name type="primary">
                <namePart>Leveraging innovative multi-omic approaches to understand and predict
                    myeloma disease development</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">multiple myeloma </subject>
            <subject type="local">proteomics</subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">microenvironment</subject>
            <subject type="local">cancer biology</subject>
            <description type="Chief Investigator">Prof Andrew Zannettino</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Multiple myeloma is a fatal bone marrow cancer which is
                universally preceded by a pre-cancerous stage known as MGUS. We currently have no
                way of identifying which MGUS patients will develop myeloma and no treatments to
                prevent this process. This study will develop clinical tools to identify which MGUS
                patients are at high risk of developing myeloma, and will identify new therapeutic
                targets, to revolutionise how we treat MGUS and myeloma and improve outcomes for
                these patients.</description>
            <description type="fundingAmount">$943,074.80</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012620</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012620</identifier>
            <identifier type="nhmrc">2012620</identifier>
            <name type="primary">
                <namePart>Defining a protective role for NLRC5 signalling in Helicobacter pylori
                    disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">helicobacter pylori </subject>
            <subject type="local">pathogenesis</subject>
            <subject type="local">host/pathogen interaction</subject>
            <subject type="local">chronic infection</subject>
            <subject type="local">mucosal inflammation</subject>
            <description type="Chief Investigator">Prof Richard Ferrero</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Helicobacter pylori infects the stomach of half the world’s
                population and is a major cause of human disease. The body fights H. pylori
                infection by mobilising white blood cells to the stomach lining, but these responses
                can lead to lymphoma. We have identified a host protein, NLRC5, as being important
                in the generation of immune responses that protect against the development of this
                disease. The project will determine how NLRC5 protects against stomach lymphoma due
                to H. pylori infection.</description>
            <description type="fundingAmount">$1,172,064.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012622</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012622</identifier>
            <identifier type="nhmrc">2012622</identifier>
            <name type="primary">
                <namePart>Location! Location! Location! Geospatial control of memory B cell
                    reactivation in vaccine-induced immunity</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">immunologic memory </subject>
            <subject type="local">vaccine</subject>
            <subject type="local">b cells</subject>
            <subject type="local">germinal centre</subject>
            <subject type="local">humoral immunity</subject>
            <description type="Chief Investigator">Prof Tri Phan</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Vaccines are one of the great public health achievements in the
                modern era. However, vaccinology remains an empirical art and there is an urgent
                need to advance the science to realize its full potential, particularly in the face
                of pandemics such as COVID-19 and the emergence of virus variants that require
                booster injections. Here we propose to track the cell fate trajectories of memory B
                cells to determine the factors that are critical to generating a potent immune
                response to vaccination.</description>
            <description type="fundingAmount">$684,360.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012657</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012657</identifier>
            <identifier type="nhmrc">2012657</identifier>
            <name type="primary">
                <namePart>A new frontier in receptor biology relevant to treatment of
                    disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">g protein-coupled receptors </subject>
            <subject type="local">molecular pharmacology</subject>
            <subject type="local">cell biology</subject>
            <subject type="local">gastrointestinal motility</subject>
            <subject type="local">autonomic nervous system</subject>
            <description type="Chief Investigator">Dr Sebastian Furness</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Disorders of colorectal function, especially constipation, are
                poorly responsive to drug therapy and are a substantial medical problem. This
                project should provide insights into the molecular basis for the voluntary
                defecation response that could provide the basis for novel therapeutic approaches to
                treat disorders of colorectal function.</description>
            <description type="fundingAmount">$699,712.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012661</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012661</identifier>
            <identifier type="nhmrc">2012661</identifier>
            <name type="primary">
                <namePart>Making peptide drugs orally bioavailable</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">peptides </subject>
            <subject type="local">drug design</subject>
            <subject type="local">drug delivery</subject>
            <subject type="local">oral administration</subject>
            <subject type="local">drug absorption</subject>
            <description type="Chief Investigator">Dr Richard Clark</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Bioactive peptides have exciting therapeutic potential however
                they are limited by the fact that that they generally can't be taken orally and they
                don't last very long in the body. The goal of this project is to develop an approach
                that solves both of these problems and to develop new drug leads for the treatment
                of chronic pain.</description>
            <description type="fundingAmount">$689,721.20</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012674</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012674</identifier>
            <identifier type="nhmrc">2012674</identifier>
            <name type="primary">
                <namePart>Submucosal glands as the origin of Barrett’s oesophagus and oesophageal
                    adenocarcinoma</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">barrett's oesophagus </subject>
            <subject type="local">progenitor cells</subject>
            <subject type="local">epithelial biology</subject>
            <subject type="local">oesophageal cancer</subject>
            <subject type="local">gastrointestinal tumourigenesis</subject>
            <description type="Chief Investigator">Prof Wayne Phillips</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Barrett’s oesophagus is a relatively common benign condition
                that arises as a consequence of acid reflux. In some patients, Barrett’s progresses
                to oesophageal cancer, for which treatments are largely ineffective and thus
                outcomes are poor. This project addresses a vital gap in our knowledge regarding the
                cell of origin of Barrett’s oesophagus, which will enable the future development of
                effective strategies for early intervention or prevention of oesophageal
                cancer.</description>
            <description type="fundingAmount">$1,115,454.40</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012689</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012689</identifier>
            <identifier type="nhmrc">2012689</identifier>
            <name type="primary">
                <namePart>Do patients with symptoms need a colonoscopy? A novel panel of
                    non-invasive biomarkers to determine need for diagnostic
                    investigation.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">colorectal cancer risk </subject>
            <subject type="local">colorectal cancer prevention</subject>
            <subject type="local">colonoscopy</subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">gastrointestinal symptoms</subject>
            <description type="Chief Investigator">Assoc Prof Erin Symonds</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Gastrointestinal symptoms can raise concern for bowel cancer,
                but as they are often non-specific, it is difficult to determine what type of
                further clinical investigations are needed. There is a need for simple tests to
                determine the need for colonoscopy. Our study will establish the use of blood and
                stool tests for identifying disease risk. This will ensure that all symptomatic
                patients are reviewed for bowel cancer risk with tests that are independent of their
                symptoms.</description>
            <description type="fundingAmount">$881,020.40</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012701</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012701</identifier>
            <identifier type="nhmrc">2012701</identifier>
            <name type="primary">
                <namePart>The role of resident and circulating CD8 T cell memory in the control of
                    liver infections</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">t cells </subject>
            <subject type="local">hepatocytes</subject>
            <subject type="local">infectious diseases</subject>
            <subject type="local">cytotoxic t lymphocytes (ctl)</subject>
            <subject type="local">memory t-cells</subject>
            <description type="Chief Investigator">Prof William Heath</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">CD8+ tissue-resident memory T (Trm) cells are a specialized
                population of immune cells that act as front-line defenders against pathogens in
                organs such as the liver. In this study we will investigate how these and other T
                cells recognise and destroy pathogens like malaria that infect liver cells, without
                damaging the remaining liver tissue, with the aim of designing better vaccines
                against liver infections.</description>
            <description type="fundingAmount">$920,958.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012704</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012704</identifier>
            <identifier type="nhmrc">2012704</identifier>
            <name type="primary">
                <namePart>Applying machine learning to develop a smart and engaging chatbot to
                    increase physical activity and improve health</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/023q4bk22</identifier>
                <title>Central Queensland University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">physical activity </subject>
            <subject type="local">health promotion</subject>
            <subject type="local">behavioural intervention</subject>
            <subject type="local">internet</subject>
            <subject type="local">behaviour change</subject>
            <description type="Chief Investigator">Prof Corneel Vandelanotte</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">As high levels of physical inactivity lead to a high disease
                burden in Australia, cost-effective population-based strategies are needed to
                increase activity levels. The main aim of this project is to develop a very
                sophisticated chatbot that applies artificial intelligence and machine learning to
                provide highly personalised physical activity advice, delivered just-in-time, based
                on real-time data (e.g., Fitbit, GPS, weather). Our project will enable 'precision
                medicine' for behavioural health.</description>
            <description type="fundingAmount">$1,497,468.80</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012718</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012718</identifier>
            <identifier type="nhmrc">2012718</identifier>
            <name type="primary">
                <namePart>Effectiveness of empirically based tackle technique intervention to reduce
                    the in-game risk of concussion</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">concussion </subject>
            <subject type="local">sports injury</subject>
            <subject type="local">indigenous australians</subject>
            <subject type="local">biomechanics</subject>
            <subject type="local">neurophysiology</subject>
            <description type="Chief Investigator">Dr Suzi Edwards</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Concussion in collision sports, is a prominent community health
                concern, occurring mostly during tackles. To make the sport safer for all players,
                our research will reveal how a rugby players’ tackles alters their head forces and
                how retraining their tackle technique can reduce their concussion risk. Our tackle
                coaching program will have an Indigenous focus as many players identify as
                Indigenous/Pasifika. We will use this information to develop new coaching guidelines
                to make the sport safer.</description>
            <description type="fundingAmount">$1,026,166.20</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012764</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012764</identifier>
            <identifier type="nhmrc">2012764</identifier>
            <name type="primary">
                <namePart>Chromatin defects in histone mutated brain cancers: from basic mechanisms
                    to novel therapeutic strategies</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">chromatin </subject>
            <subject type="local">chromatin structure</subject>
            <subject type="local">telomeres</subject>
            <subject type="local">chromosomal anomalies</subject>
            <subject type="local">atrx syndrome - alpha thalassemia-mental retardation of the
                x</subject>
            <description type="Chief Investigator">Assoc Prof Lee Wong</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Paediatric glioblastoma (pGBM) is the most aggressive kind of
                brain cancer affecting children. To develop treatments for this disease, the
                underlying molecular mechanisms leading to disease formation must first be
                understood. This study will investigate how mutations in two key regulators of the
                genome change DNA integrity and gene activity, leading to the development of pGBM.
                It will thereby identify new targets for therapeutic intervention
                strategies.</description>
            <description type="fundingAmount">$853,016.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012769</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012769</identifier>
            <identifier type="nhmrc">2012769</identifier>
            <name type="primary">
                <namePart>Harnessing the beneficial off-target effects of BCG vaccination to boost
                    protection against SARS-CoV-2</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">vaccination </subject>
            <subject type="local">vaccination immunology</subject>
            <subject type="local">sars-cov-2</subject>
            <subject type="local">immunomodulation</subject>
            <subject type="local">antiviral immunity</subject>
            <description type="Chief Investigator">Dr Nicole Messina</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Bacillus Calmette–Guérin(BCG), the vaccine that protects
                against tuberculosis, also protects against other diseases. This is thought to be
                because BCG can boost immunity. We will investigate how BCG boosts immune responses
                to SARS-CoV-2 and if this improves protection against COVID-19 and the effectiveness
                of COVID-19 vaccines. We will combine use of mouse models with use of samples from
                BRACE, our 6800 participant trial testing if BCG vaccination protects against
                COVID-19 in healthcare workers.</description>
            <description type="fundingAmount">$1,085,524.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012772</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012772</identifier>
            <identifier type="nhmrc">2012772</identifier>
            <name type="primary">
                <namePart>Inflammatory Cell Death, Circadian Rhythm &amp; Obesity: A Surprising
                    Triad</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">overweight/obesity </subject>
            <subject type="local">metabolic disorders</subject>
            <subject type="local">adipose tissue</subject>
            <subject type="local">macrophages</subject>
            <subject type="local">circadian rhythms</subject>
            <description type="Chief Investigator">Dr Denuja Karunakaran</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Obesity rates continue to soar despite decades of efforts to
                promote lifestyle changes. Our work points to an important role for the RIPK1 gene
                in obesity through adipose tissue inflammation and circadian clock disruption. Using
                unique mouse models, nanoparticle therapies and novel technologies to map genetic
                reprogramming, we will explore how RIPK1 pathways drive these processes in obesity
                and provide proof-of-concept for novel anti-obesity therapies.</description>
            <description type="fundingAmount">$1,274,091.08</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012793</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012793</identifier>
            <identifier type="nhmrc">2012793</identifier>
            <name type="primary">
                <namePart>Macrophage-driven lipid metabolism in health and disease – mechanisms and
                    therapeutic opportunities</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">macrophage biology </subject>
            <subject type="local">energy metabolism</subject>
            <subject type="local">fatty liver disease</subject>
            <subject type="local">adipose tissue</subject>
            <subject type="local">muscle</subject>
            <description type="Chief Investigator">Dr Katharine Irvine</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Macrophages are cells of the immune system that are abundant in
                every organ. We discovered that treating animals with a macrophage growth factor,
                Colony Stimulating Factor 1 (CSF1), reduces body fat mass and increases lean mass.
                This indicates that macrophages responding to CSF1 influence the cross-talk between
                metabolic tissues that controls energy metabolism and body composition. In this
                project we will investigate how this occurs and test CSF1 as a therapy for
                obesity-related complications.</description>
            <description type="fundingAmount">$656,972.40</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012805</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012805</identifier>
            <identifier type="nhmrc">2012805</identifier>
            <name type="primary">
                <namePart>Novel roles for NMDA receptors in cortical processing</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">cerebral cortex </subject>
            <subject type="local">n-methyl-d-aspartic acid (nmda) receptors</subject>
            <subject type="local">olfaction</subject>
            <subject type="local">patch clamp</subject>
            <subject type="local">calcium imaging</subject>
            <description type="Chief Investigator">Prof John Bekkers</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Major psychiatric disorders, like schizophrenia and depression,
                are thought to arise from subtle changes in brain circuits. A key player in these
                changes is a protein called the NMDA receptor, which is important for electrical
                signalling in the brain. This project will study how NMDA receptors normally work in
                mouse brains to enable the animal to make sense of its environment. The findings
                will help guide the development of new NMDA receptor-targeting drugs with fewer
                side-effects.</description>
            <description type="fundingAmount">$552,737.00</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012809</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012809</identifier>
            <identifier type="nhmrc">2012809</identifier>
            <name type="primary">
                <namePart>How the synergy between flavivirus protein and noncoding RNA defeats
                    antiviral response</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">flavivirus </subject>
            <subject type="local">rna</subject>
            <subject type="local">jak/stat pathway</subject>
            <subject type="local">host/pathogen interaction</subject>
            <subject type="local">molecular virology</subject>
            <description type="Chief Investigator">Prof Alexander Khromykh</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Flaviviruses represent a persistent threat with a devastating
                impact on human health. They have sophisticated mechanisms to subvert and control
                human antiviral response. One of them is by producing a noncoding RNA. In this
                project we will obtain an understanding of how these RNAs determine the ability of
                flaviviruses to evade immune response and establish infection in humans. The outcome
                will advance our understanding of flavivirus pathogenesis and inform future design
                of novel antivirals.</description>
            <description type="fundingAmount">$783,516.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012828</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012828</identifier>
            <identifier type="nhmrc">2012828</identifier>
            <name type="primary">
                <namePart>Circadian clock, sleep, and depression in adolescence: Modelling a novel
                    pathway</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">sleep </subject>
            <subject type="local">depression</subject>
            <subject type="local">mood disorders</subject>
            <subject type="local">circadian rhythms</subject>
            <subject type="local">adolescence</subject>
            <description type="Chief Investigator">Dr Bei Bei</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Body clock and sleep undergo significant changes during
                adolescence, a critical phase for the development of depression. In a large sample
                of adolescents, we propose to test how later timing of the body clock, shorter sleep
                duration, and irregular sleep timing, are associated with increased depressive
                symptoms. We will also test how light exposure patterns affect the shift in timing
                of the body clock. The study will inform the development of evidence-based sleep
                interventions for adolescents.</description>
            <description type="fundingAmount">$1,239,303.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012837</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012837</identifier>
            <identifier type="nhmrc">2012837</identifier>
            <name type="primary">
                <namePart>Single-cell intravital imaging guides anti-fibrotic therapy to improve
                    standard-of-care treatment in triple negative breast cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">cell biology </subject>
            <subject type="local">cancer cell biology</subject>
            <subject type="local">imaging</subject>
            <subject type="local">biosensor</subject>
            <subject type="local">cancer chemotherapy</subject>
            <description type="Chief Investigator">Dr David Herrmann</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Tissue fibrosis is a well-known risk factor for breast cancer
                initiation, progression and prognosis. It is commonly found in aggressive cancers,
                such as triple negative breast cancer (TNBC). Fibrosis is also known to protect
                cancer cells from treatment including chemotherapy, which is the standard-of-care in
                TNBC. In this proposal we will test the hypothesis that reducing tissue fibrosis can
                improve standard-of-care performance and outcomes in pre-clinical models of
                TNBC.</description>
            <description type="fundingAmount">$599,808.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012848</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012848</identifier>
            <identifier type="nhmrc">2012848</identifier>
            <name type="primary">
                <namePart>Revolutionising immunotherapy response prediction in non-small cell lung
                    cancer via longitudinal single-cell proteomic analysis of liquid biopsy derived
                    cancer and immune cells</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">cancer cell biology </subject>
            <subject type="local">computer-assisted diagnosis</subject>
            <subject type="local">non-small cell lung cancer</subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">immunocytochemistry</subject>
            <description type="Chief Investigator">Assoc Prof Therese Becker</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Lung cancer is leading personalised medicine (replacing “one
                medicine for all” with drugs targeting unique cancer characteristics), but that only
                applies to a small subset of lung cancers with certain characteristics (biomarkers).
                This proposal uses innovative methods to apply and thourougly test novel biomarkers
                for lung cancer patients, predicting response to immunotherapy, improving treatment
                and preventing deadly side-effects. This will transform treatment of Australia’s
                most deadly cancer.</description>
            <description type="fundingAmount">$1,356,196.80</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012860</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012860</identifier>
            <identifier type="nhmrc">2012860</identifier>
            <name type="primary">
                <namePart>Restoring anti-tumour immunity in melanoma</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">cutaneous melanoma </subject>
            <subject type="local">cancer immunotherapy</subject>
            <subject type="local">drug resistance</subject>
            <subject type="local">melanoma antigens</subject>
            <subject type="local">major histocompatibility complex (mhc)</subject>
            <description type="Chief Investigator">Prof Helen Rizos</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Melanoma is a major Australian health problem and a common
                cause of cancer death in young adults. Two recent types of therapies have
                revolutionised the treatment of patients with melanoma, and although patient
                survival has improved, most patients will eventually become resistant to treatment.
                This research explores how cancer cells evade treatment and reveals cancer
                vulnerabilities that can be exploited to re-sensitize melanoma to current and new
                therapies.</description>
            <description type="fundingAmount">$1,134,001.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012863</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012863</identifier>
            <identifier type="nhmrc">2012863</identifier>
            <name type="primary">
                <namePart>Dissecting the healthy and immunosuppressed, primary and secondary immune
                    responses within human lymph nodes following COVID-19 vaccination</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">covid-19 </subject>
            <subject type="local">vaccine efficacy</subject>
            <subject type="local">lymph node</subject>
            <subject type="local">t cell response</subject>
            <subject type="local">germinal centre</subject>
            <description type="Chief Investigator">Dr Cynthia Munier</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The dynamics of the immune response to vaccines in human lymph
                nodes are important in determining eventual vaccine responses but are poorly
                characterised. We will investigate the critical components of the immune response in
                human lymph nodes that lead to an effective neutralising antibody response to novel
                COVID-19 vaccines. Our findings will provide insights into the critical responses
                required for a successful vaccine and will inform the rational design of future
                vaccines.</description>
            <description type="fundingAmount">$982,669.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012882</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012882</identifier>
            <identifier type="nhmrc">2012882</identifier>
            <name type="primary">
                <namePart>MY Voice Library</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">motor speech disorders </subject>
            <subject type="local">cerebral palsy</subject>
            <subject type="local">dysarthria</subject>
            <subject type="local">communication</subject>
            <subject type="local">young children</subject>
            <description type="Chief Investigator">Dr Petra Karlsson</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">For children with cerebral palsy and speech impairment access
                to a communication device is imperative. Today, accessing their communication device
                is often challenging, resulting in 15-20 times slower communication rates compared
                to those who can speak. This application seeks funding to support the development of
                a world-first data-driven MY Voice Library, a foundation for research and
                development of innovative engineering of real-time communication solutions for
                children with cerebral palsy.</description>
            <description type="fundingAmount">$1,092,492.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012883</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012883</identifier>
            <identifier type="nhmrc">2012883</identifier>
            <name type="primary">
                <namePart>Predicting and preparing for the unfolding evolution of
                    SARS-CoV-2</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">covid-19 </subject>
            <subject type="local">molecular virology</subject>
            <subject type="local">host/pathogen interaction</subject>
            <subject type="local">viral vaccines</subject>
            <subject type="local">antiviral</subject>
            <description type="Chief Investigator">Prof Alexander Khromykh</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">One year on from the emergence of the COVID-19 pandemic,
                variants of SARS-CoV-2 have evolved to be more transmissible, pathogenic and less
                susceptible to immune responses from infection or vaccination. We propose utilising
                the deep mutational scanning method to examine the molecular pathogenesis and
                vaccine escape of SARS-CoV-2 at a single amino acid residue resolution and towards
                developing a universal vaccine candidate to neutralise all potential future
                SARS-CoV-2 variants.</description>
            <description type="fundingAmount">$999,836.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012895</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012895</identifier>
            <identifier type="nhmrc">2012895</identifier>
            <name type="primary">
                <namePart>Exploiting the neuroprotective effects of the gut microbiome for the
                    treatment of spinocerebellar ataxia-3 and related neurodegenerative
                    diseases</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">molecular microbiology </subject>
            <subject type="local">trinucleotide repeat disorder</subject>
            <subject type="local">metabolites</subject>
            <subject type="local">neurodegenerative disorders</subject>
            <subject type="local">autophagy</subject>
            <description type="Chief Investigator">Dr Angela Laird</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Spinocerebellar ataxia-3 (SCA3, also known as Machado Joseph
                disease) is a fatal neurodegenerative disease that causes coordination and mobility
                problems, leading to paralysis. There is currently no treatment for SCA3. This
                project will investigate whether the gut microbiome, bacteria that inhabit the gut,
                and levels of chemicals produced by these microbes are altered in SCA3 patients. We
                will also investigate a therapeutic strategy to correct the gut microbiome and its
                products to treat SCA3.</description>
            <description type="fundingAmount">$708,204.40</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012915</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012915</identifier>
            <identifier type="nhmrc">2012915</identifier>
            <name type="primary">
                <namePart>Artificial Intelligence to Understand and Predict Chronic Subdural
                    Haematoma Evolution</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">brain imaging </subject>
            <subject type="local">intracerebral haemorrhage</subject>
            <subject type="local">neurosurgery</subject>
            <subject type="local">computed tomography</subject>
            <subject type="local">artificial neural networks</subject>
            <description type="Chief Investigator">Dr Shalini Amukotuwa</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project tackles chronic subdural haematoma, a disease
                caused by bleeding on the brain’s surface that is increasing in incidence due to our
                ageing population. Artificial intelligence and advanced brain imaging will be used
                to predict and identify earlier those patients who are likely to need and benefit
                from treatment. This will personalize patient care, allowing proactive treatment to
                prevent progression and decrease the burden of disease.</description>
            <description type="fundingAmount">$1,236,630.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012929</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012929</identifier>
            <identifier type="nhmrc">2012929</identifier>
            <name type="primary">
                <namePart>Why do women overeat? Understanding the neural circuits driving
                    stress-related eating</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">binge eating </subject>
            <subject type="local">sub-clinical eating disorders</subject>
            <subject type="local">binge eating disorder</subject>
            <subject type="local">healthy eating</subject>
            <subject type="local">psychoemotional stress</subject>
            <description type="Chief Investigator">Dr Robyn Brown</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">For women negative emotions such as stress and loneliness are
                more likely to drive overeating compared to men. There is a dearth of literature
                detailing the brain circuits driving stress-induced binge eating, particularly in
                female subjects, as to date no suitable animal model exists. We have developed a
                highly translational model of stress-induced binge eating in female subjects, which
                enables us to determine for the first time the neurobiology underlying this specific
                form of eating behaviour.</description>
            <description type="fundingAmount">$793,515.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012936</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012936</identifier>
            <identifier type="nhmrc">2012936</identifier>
            <name type="primary">
                <namePart>Making a Niche: an in vitro human bone marrow organoid factory for
                    blood</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">haematopoietic stem cells </subject>
            <subject type="local">embryonic stem cells</subject>
            <subject type="local">bone marrow</subject>
            <subject type="local">bone development</subject>
            <subject type="local">stem cell biology</subject>
            <description type="Chief Investigator">Dr Elizabeth Ng</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">The bone marrow is the ‘factory’ where blood cells are made.
                The ability to recreate a human bone marrow organ from pluripotent stem cells in the
                laboratory would improve our ability to make blood stem cells for patients with
                leukaemia or bone marrow failure who cannot find a matched donor. We can now make
                all the individual components– blood cells, bone, cartilage, blood vessels and
                stromal cells. In this project we will assemble these into a functioning human bone
                marrow organ.</description>
            <description type="fundingAmount">$1,122,736.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012941</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012941</identifier>
            <identifier type="nhmrc">2012941</identifier>
            <name type="primary">
                <namePart>High-fidelity tumouroids: accelerating next generation personalised
                    medicine</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03f0f6041</identifier>
                <title>University of Technology Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">tissue engineering </subject>
            <subject type="local">cancer therapy</subject>
            <subject type="local">drug sensitivity</subject>
            <subject type="local">molecular oncology</subject>
            <subject type="local">expression profiling</subject>
            <description type="Chief Investigator">Assoc Prof David Gallego Ortega</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Anti-cancer drug testing using in vitro models are unable to
                recapitulate the complexity of human tumours, hindering the application of more
                effective therapeutic strategies. We have created ALTEN, a tissue-engineering system
                capable of preserving tumour biopsies maintaining their original environment. ALTEN
                allows parallel testing of different therapies on each patient’s biopsy, accurately
                identifying the most effective treatment for each patient, facilitating a
                personalised medicine approach.</description>
            <description type="fundingAmount">$510,388.50</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012943</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012943</identifier>
            <identifier type="nhmrc">2012943</identifier>
            <name type="primary">
                <namePart>Boosting cellular immunogenicity to combat metastatic cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">breast cancer metastases </subject>
            <subject type="local">hormone-refractory prostate cancer</subject>
            <subject type="local">cancer immunotherapy</subject>
            <subject type="local">immunogenicity</subject>
            <subject type="local">interferon (ifn)</subject>
            <description type="Chief Investigator">Assoc Prof Belinda Parker</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Spread (metastasis) to bone in breast and prostate cancer is
                painful and very difficult to treat. We have discovered that cancers growing in bone
                have developed changes to allow them to go undetected and escape immune control. In
                this proposal, we will discover ways to reverse these changes and increase response
                to radiotherapy and immune therapies to target deadly metastatic cancers. This work
                will offer a new avenue of therapy for bone metastasis that is built on strong
                biological discoveries.</description>
            <description type="fundingAmount">$658,031.60</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2012971</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2012971</identifier>
            <identifier type="nhmrc">2012971</identifier>
            <name type="primary">
                <namePart>A20 variants contribute to endemic kidney disease in Tiwi
                    Islanders</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">kidney disease </subject>
            <subject type="local">chronic inflammation</subject>
            <subject type="local">cardiovascular disease</subject>
            <subject type="local">indigenous australians</subject>
            <subject type="local">immunology</subject>
            <description type="Chief Investigator">Dr Simon Jiang</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Kidney disease is endemic amongst the Tiwi Islanders with the
                highest reported rates worldwide. It is thought that 60% of this risk comes from
                genetics. We have identified six gene variants in a gene likely to be important in
                controlling progression of kidney disease. These variants impair the ability of the
                gene to prevent kidney disease and offers a novel treatment target for the Tiwi
                Islanders.</description>
            <description type="fundingAmount">$453,680.00</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013024</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013024</identifier>
            <identifier type="nhmrc">2013024</identifier>
            <name type="primary">
                <namePart>Toward tailored excitation therapy for amyotrophic lateral
                    sclerosis</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01nfmeh72</identifier>
                <title>University of Tasmania</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">motor neuron disease (mnd) </subject>
            <subject type="local">excitotoxicity</subject>
            <subject type="local">transcranial magnetic stimulation (tms)</subject>
            <subject type="local">brain</subject>
            <subject type="local">spinal cord</subject>
            <description type="Chief Investigator">Dr Catherine Blizzard</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Motor neuron disease and associated dementia are significantly
                debilitating Australians and we have no effective cures. Our work has discovered
                that the way brain cells communicate in these diseases is disrupted. We propose to
                develop a new way of treating these diseases, tailored to the part of the brain that
                is affected. With this knowledge we will investigate new targeted therapies that
                could prevent brain cells from tipping over from proper brain function to too much
                excitation.</description>
            <description type="fundingAmount">$624,821.20</description>
            <coverage>
                <spatial type="text">TAS</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013027</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013027</identifier>
            <identifier type="nhmrc">2013027</identifier>
            <name type="primary">
                <namePart>Revealing how junctional neural tube defects arise</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">neural tube defects </subject>
            <subject type="local">embryo development</subject>
            <subject type="local">tissue development</subject>
            <subject type="local">tissue mechanics</subject>
            <subject type="local">abnormal embryogenesis</subject>
            <description type="Chief Investigator">Dr Melanie White</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The brain and spinal cord control are formed early in
                development from a common precursor called the neural tube. Each end of the neural
                tube forms by a different process and how these are united to form a single tube is
                unknown. Failures in this critical process cause severe birth defects in humans. We
                will use live imaging of transgenic quail embryos to understand how cells arrange
                into a continuous neural tube and what goes wrong when genes linked to human neural
                tube defects are mutated.</description>
            <description type="fundingAmount">$582,341.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013058</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013058</identifier>
            <identifier type="nhmrc">2013058</identifier>
            <name type="primary">
                <namePart>Understanding latent fate programming in T cells.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/031rekg67</identifier>
                <title>Swinburne University of Technology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">differentiation </subject>
            <subject type="local">cd8 t cells</subject>
            <subject type="local">cell cycle</subject>
            <subject type="local">developmental biology</subject>
            <subject type="local">t cell response</subject>
            <description type="Chief Investigator">Prof Sarah Russell</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Our immune response to infections and cancer involves
                amplification of T cells. Each of us has trillions of T cells, with only a handful
                specific for each infectious agent or cancer cell. What controls the effectiveness
                of their response is not yet known. In this project, we will use single cell
                approaches to describe what determines whether a T cell can yield an effective
                response. These studies will also provide a general framework to assess how fate is
                controlled in multicellular organisms.</description>
            <description type="fundingAmount">$802,328.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013115</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013115</identifier>
            <identifier type="nhmrc">2013115</identifier>
            <name type="primary">
                <namePart>Accelerating treatment for epilepsy in children with KIF1A-associated
                    neurological disorders.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">neurological diseases </subject>
            <subject type="local">seizures</subject>
            <subject type="local">genetic disorders</subject>
            <subject type="local">brain development</subject>
            <subject type="local">neurodegenerative disorders</subject>
            <description type="Chief Investigator">Dr Simranpreet Kaur</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Epilepsies are life threatening, where approximately 40%
                patients do not respond to current medications. Mutations in the KIF1A gene lead to
                a devastating form of epilepsy where patients die within first 5 years of life. We
                will use extremely innovative and physiologically relevant models such as stem cells
                and bioinformatic algorithms to identify novel therapies for KIF1A-related
                epilepsies.</description>
            <description type="fundingAmount">$776,019.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013129</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013129</identifier>
            <identifier type="nhmrc">2013129</identifier>
            <name type="primary">
                <namePart>A One Health/System Dynamics approach to reducing Clostridioides difficile
                    infection</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">antimicrobial resistance </subject>
            <subject type="local">disease transmission</subject>
            <subject type="local">public health impact</subject>
            <subject type="local">molecular epidemiology</subject>
            <subject type="local">zoonoses</subject>
            <description type="Chief Investigator">Prof Thomas Riley</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Clostridioides difficile infection is a major public health
                problem. While thought to be acquired in hospitals, evidence is growing that it can
                be acquired in the community. The bacteria have been found in food, households, farm
                animals and the environment, but we don’t understand what role this plays in human
                infection. We will use a novel approach using systems modelling to understand how
                people become exposed to C. difficile and, most importantly, what we can do to
                control the infection.</description>
            <description type="fundingAmount">$1,284,890.50</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013158</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013158</identifier>
            <identifier type="nhmrc">2013158</identifier>
            <name type="primary">
                <namePart>Polygenic mitochondrial dysfunction in heart failure and
                    neurodegeneration</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03rke0285</identifier>
                <title>Baker Heart and Diabetes Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">mitochondrial function </subject>
            <subject type="local">heart failure</subject>
            <subject type="local">population genetics</subject>
            <subject type="local">neurodegeneration</subject>
            <subject type="local">ageing</subject>
            <description type="Chief Investigator">Assoc Prof Brian Drew</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Mitochondria are the energy producing components of our cells.
                Genetics influences mitochondrial function, which influences risk for diseases such
                as heart failure and neurodegeneration. We don’t yet fully understand this genetic
                influence, however we propose that subtle, cumulative genetic (polygenic)
                differences may be liable. We will test this idea using unique mouse models, and use
                these findings to identify readily detectable measures for developing heart failure
                and neurodegeneration.</description>
            <description type="fundingAmount">$1,166,807.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013180</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013180</identifier>
            <identifier type="nhmrc">2013180</identifier>
            <name type="primary">
                <namePart>Harnessing artificial intelligence, spatial-omics and patient-derived
                    organoids to cure glioblastoma.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01p93h210</identifier>
                <title>University of South Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">metabolic stress </subject>
            <subject type="local">cell adhesion</subject>
            <subject type="local">microenvironment</subject>
            <subject type="local">glioblastoma</subject>
            <subject type="local">artificial neural networks</subject>
            <description type="Chief Investigator">Dr Guillermo Gomez</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This Proposal will investigate the mechanisms by which tumour
                cells reprogram healthy non-cancerous cells to support the tumour cells’ energy
                demands. Our results will lay the foundations of new anti-cancer approaches that
                will not only inhibit tumour cell source of energy (metabolism) but also prevent
                their metabolic compensation via recruitment and reprogramming of surrounding
                healthy cells.</description>
            <description type="fundingAmount">$1,999,371.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013189</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013189</identifier>
            <identifier type="nhmrc">2013189</identifier>
            <name type="primary">
                <namePart>Bioengineered skeletal muscle to discover therapies for age-related muscle
                    weakness</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/004y8wk30</identifier>
                <title>QIMR Berghofer Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">skeletal muscle </subject>
            <subject type="local">sarcopenia</subject>
            <subject type="local">exercise</subject>
            <subject type="local">skeletal muscle wasting</subject>
            <subject type="local">epigenetics</subject>
            <description type="Chief Investigator">Dr Richard Mills</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">As we grow older the positive effects of exercise training in
                muscle are reduced. This project will use 1000s of lab made mini-muscles, which act
                and function like real human skeletal muscle to understand changes that occur when
                we get older and how muscle responds to training. By understanding these changes we
                aim to identify new therapies to treat age-related muscle weakness, so that every
                Australian can be active and healthy in their older years.</description>
            <description type="fundingAmount">$950,516.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013215</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013215</identifier>
            <identifier type="nhmrc">2013215</identifier>
            <name type="primary">
                <namePart>Understanding how viruses overcome the nuclear pore complex, the
                    gatekeeper of genomic access</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">human immunodeficiency virus (hiv) </subject>
            <subject type="local">nuclear transport</subject>
            <subject type="local">encapsidation</subject>
            <subject type="local">viral proteins</subject>
            <subject type="local">antiviral agents</subject>
            <description type="Chief Investigator">Dr David Jacques</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">HIV remains an incurable disease. New ways of treating HIV
                infection are needed if we are to be ready for emerging strains that are resistant
                to current treatments. The viral shell, the ‘capsid’, has proven to be a good target
                for new drugs. We aim to understand how the capsid tricks immune cells into allowing
                HIV to enter their nuclei where it establishes infection. Understanding how HIV
                enters the nucleus will not only inform HIV therapies but also virus-inspired gene
                therapy technologies.</description>
            <description type="fundingAmount">$794,379.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013237</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013237</identifier>
            <identifier type="nhmrc">2013237</identifier>
            <name type="primary">
                <namePart>Overcoming chemoresistance in triple negative breast cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01p93h210</identifier>
                <title>University of South Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">protein kinase c (pkc) </subject>
            <subject type="local">protein phosphorylation</subject>
            <subject type="local">molecular modelling</subject>
            <subject type="local">breast cancer</subject>
            <subject type="local">chemotherapy</subject>
            <description type="Chief Investigator">Assoc Prof Yeesim Khew-Goodall</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Triple negative breast cancer (TNBC) is the most challenging
                breast cancer to treat. There is no reliable targeted therapy available and
                chemotherapy is the standard of care. About 20-25% of patients will become
                chemoresistant. For these patients, there are few viable treatment options available
                and their median survival is about 12 months. In this study, we aim to better
                understand the pathways to chemoresistance and to use a novel paradigm to develop
                new drugs to circumvent chemoresistance.</description>
            <description type="fundingAmount">$1,121,242.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013243</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013243</identifier>
            <identifier type="nhmrc">2013243</identifier>
            <name type="primary">
                <namePart>Top down cortical control of hypothalamic feeding circuits</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">appetite regulation </subject>
            <subject type="local">neural pathways</subject>
            <subject type="local">feeding disorders</subject>
            <subject type="local">acute stress</subject>
            <subject type="local">motivation</subject>
            <description type="Chief Investigator">Prof Zane Andrews</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Obesity continues to be a significant burden to public health
                shows no sign of slowing. A central part of the problem is the overconsumption
                calorically dense, highly palatable and innately rewarding foods. Although genetic
                evidence shows this overconsumption is driven by our brain, the precise way this
                occurs remain unknown. In this proposal, we will assess how the brain cortex
                communicates with the hypothalamus in order to control food intake, food motivation
                and the development of obesity.</description>
            <description type="fundingAmount">$895,804.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013260</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013260</identifier>
            <identifier type="nhmrc">2013260</identifier>
            <name type="primary">
                <namePart>A novel, dual-targeted therapeutic approach for reducing
                    diabetes-accelerated atherosclerosis</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">atherosclerosis </subject>
            <subject type="local">type 2 diabetes mellitus (non-insulin dependent diabetes
                mellitus)</subject>
            <subject type="local">inflammation</subject>
            <subject type="local">myeloperoxidase</subject>
            <subject type="local">peptides</subject>
            <description type="Chief Investigator">Prof Kerry-Anne Rye</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Patients with diabetes are in a pro-inflammatory state and many
                of them develop an aggressive form of heart disease. Blood levels of the
                pro-inflammatory enzyme myeloperoxidase (MPO) are also elevated in these patients.
                This project will determine whether treatment with peptides that have anti-diabetic
                and anti-inflammatory properties plus an MPO inhibitor reduces heart disease in
                these patients more effectively than the peptides alone or an MPO inhibitor
                alone.</description>
            <description type="fundingAmount">$1,566,077.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013278</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013278</identifier>
            <identifier type="nhmrc">2013278</identifier>
            <name type="primary">
                <namePart>Enhancing mitochondrial energetics to prevent age-associated muscle
                    weakness</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">skeletal muscle </subject>
            <subject type="local">skeletal muscle wasting</subject>
            <subject type="local">mitochondria</subject>
            <subject type="local">clinical pharmacology</subject>
            <subject type="local">ageing</subject>
            <description type="Chief Investigator">Dr Andrew Philp</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Sarcopenia is a recognized disease of ageing, describing the
                progressive decline in skeletal muscle mass and strength that occurs from midlife in
                humans. Recent research suggests that a decline in mitochondrial function, the
                energy producing cells in our body, precedes the development of sarcopenia. This
                project will test whether increasing mitochondrial energetics in skeletal muscle
                with the pharmacological compound BAM15 can prevent sarcopenia in mouse and human
                models of ageing.</description>
            <description type="fundingAmount">$799,706.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013281</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013281</identifier>
            <identifier type="nhmrc">2013281</identifier>
            <name type="primary">
                <namePart>Understanding the pathophysiology of Parkinson’s disease using cellular
                    genomics</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">parkinson disease </subject>
            <subject type="local">gene expression</subject>
            <subject type="local">genetic association</subject>
            <subject type="local">complex genetic disease</subject>
            <subject type="local">neurogenetics</subject>
            <description type="Chief Investigator">Dr Jacob Gratten</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Parkinson’s disease (PD) is a devastating neurodegenerative
                condition affecting 1% of Australians aged 60-years and over. Understanding the
                genetic basis of PD is critical to identifying new drug targets. We will apply
                powerful methods for measuring gene expression in single cells to identify specific
                genes that are altered in specific cell types in PD-related brain and gut regions.
                Our study will shed light on the cell type-specific molecular pathology of
                PD.</description>
            <description type="fundingAmount">$837,064.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013284</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013284</identifier>
            <identifier type="nhmrc">2013284</identifier>
            <name type="primary">
                <namePart>Transforming fertility treatment</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">ovary </subject>
            <subject type="local">female infertility</subject>
            <subject type="local">growth factor therapy</subject>
            <subject type="local">protein engineering</subject>
            <subject type="local">activin and inhibin</subject>
            <description type="Chief Investigator">Assoc Prof Craig Harrison</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">It is estimated that worldwide 186 million individuals live
                with infertility. Depending on the cause of infertility, treatment ranges from
                medications to stimulate ovulation through to more complex procedures, such as in
                vitro fertilisation (IVF). These fertility treatments have been quite successful;
                however, they all rely on decades-old medications that promote or suppress hormone
                activity. We will develop a new set of drugs that target ovarian growth factors to
                treat or prevent infertility.</description>
            <description type="fundingAmount">$846,531.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013285</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013285</identifier>
            <identifier type="nhmrc">2013285</identifier>
            <name type="primary">
                <namePart>Bionic-array Directed Gene Electrotransfer for Treating Focal Brain
                    Disorders</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">biomedical engineering </subject>
            <subject type="local">gene delivery</subject>
            <subject type="local">gene therapy</subject>
            <subject type="local">focal epilepsy</subject>
            <subject type="local">neurological disorders</subject>
            <description type="Chief Investigator">Prof Gary Housley</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">A platform for localized brain gene therapy, ‘Brain-BaDGE’,
                will be developed from proprietary UNSW electric field-focusing technology. This
                translational program will produce a first-for-human ‘needle-like’ medical device
                for electrotransfer of therapeutic DNA encoding a neuromodulator targeted to groups
                of neurons in the brain to suppress epileptic seizures of focal origin. This
                Brain-BaDGE platform will establish a translational pathway for gene therapies
                treating localized brain disorders.</description>
            <description type="fundingAmount">$1,941,007.20</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013305</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013305</identifier>
            <identifier type="nhmrc">2013305</identifier>
            <name type="primary">
                <namePart>Precursor neurons on standby fast track neural repair</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">neurodevelopment </subject>
            <subject type="local">adult neurogenesis</subject>
            <subject type="local">zebrafish</subject>
            <subject type="local">neural regeneration</subject>
            <subject type="local">acute inflammation</subject>
            <description type="Chief Investigator">Dr Jan Kaslin</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Brain and spinal cord injury are devastating events that has a
                life-long impact on the patient’s life with wide-reaching social and economic
                effects. This research program uses innovative regeneration models and screening
                approaches to identify how endogenous cells and molecules can be hoaxed to boost
                neural regeneration after injury or in disease. The work provides critical insight
                and hold keys to unlocking strategies for future restorative therapies in the brain
                or spinal cord.</description>
            <description type="fundingAmount">$814,423.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013323</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013323</identifier>
            <identifier type="nhmrc">2013323</identifier>
            <name type="primary">
                <namePart>Hospital trajectories for 15 million Australians</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">data analysis </subject>
            <subject type="local">applied statistics</subject>
            <subject type="local">hospitalisation</subject>
            <subject type="local">longitudinal study</subject>
            <subject type="local">health service utilisation</subject>
            <description type="Chief Investigator">Prof Louisa Jorm</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Patient segmentation, which divides a patient population into
                distinct groups with specific needs and characteristics, underpins a patient-centred
                approach to health care. We will use hospital records for the population of NSW and
                deep learning to identify clusters (segments) of patients who share patterns of
                hospital use, characterise and visualise these, and explore how they change over
                time. Our novel methods will have application in health service planning and
                delivery and research.</description>
            <description type="fundingAmount">$655,934.60</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013349</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013349</identifier>
            <identifier type="nhmrc">2013349</identifier>
            <name type="primary">
                <namePart>Building the mind: interplay of transcriptional and electrical activities
                    in the self-assembly of cortical circuits in vivo</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">early brain development </subject>
            <subject type="local">cerebral cortex</subject>
            <subject type="local">transcriptional regulation</subject>
            <subject type="local">neural coding</subject>
            <subject type="local">targeted gene delivery</subject>
            <description type="Chief Investigator">Dr Rodrigo Suarez</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The early impact of nature and nurture influences in human
                brain wiring remains poorly understood due to a lack of ways to study embryonic
                development in naturalistic live models. We have established advanced new methods in
                an Australian marsupial that allow, for the first time, mechanistic studies of how
                genes and electrical activity interact to form precise circuits in the cerebral
                cortex. These unique opportunities can revolutionise the way we understand brain
                wiring in health and disease.</description>
            <description type="fundingAmount">$887,243.20</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013362</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013362</identifier>
            <identifier type="nhmrc">2013362</identifier>
            <name type="primary">
                <namePart>Remodelling the ovary to extend female fertility and health</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">ovary </subject>
            <subject type="local">ageing</subject>
            <subject type="local">fibrosis</subject>
            <subject type="local">extracellular matrix</subject>
            <subject type="local">monocyte/macrophage</subject>
            <description type="Chief Investigator">Prof Rebecca Robker</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Female infertility is commonly caused by an inability to
                release an egg from the ovary, particularly in women who are middle-age or if they
                have obesity or PCOS. We discovered that these females also have fibrosis in the
                ovary; excess collagen deposited by cellular stress and inflammation that prevents
                the egg from being released. This project will identify strategies to combat the
                detrimental changes in the ovary that cause fibrosis in order to improve female
                health.</description>
            <description type="fundingAmount">$1,449,102.60</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013384</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013384</identifier>
            <identifier type="nhmrc">2013384</identifier>
            <name type="primary">
                <namePart>Establishment of novel, neuronal-cell based, therapeutic screens for
                    Alzheimer’s disease using patients stem cells</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">stem cells </subject>
            <subject type="local">alzheimer disease</subject>
            <subject type="local">neurons</subject>
            <subject type="local">secretory pathway</subject>
            <subject type="local">golgi</subject>
            <description type="Chief Investigator">Prof Paul Gleeson</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Alzheimer’s disease is the most common cause of dementia and a
                major cause of death in Australia. There is no effective treatment for this disease
                and there is an urgent need to develop treatments to target the cause of the
                Alzheimer’s disease. This project aims to use human neurons derived from patient’s
                stem cells to establish a powerful screening platform for the identification of
                targeted therapeutic drugs to rescue neuron defects to efficiently treat Alzheimer’s
                disease.</description>
            <description type="fundingAmount">$861,704.60</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013404</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013404</identifier>
            <identifier type="nhmrc">2013404</identifier>
            <name type="primary">
                <namePart>aSPOC – Commercialisable Aptamer-based Diagnostics for Sepsis Point of
                    Care</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00r4sry34</identifier>
                <title>Murdoch University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">sepsis </subject>
            <subject type="local">biotechnology</subject>
            <subject type="local">diagnostic techniques</subject>
            <subject type="local">molecular basis of disease</subject>
            <subject type="local">biomarkers</subject>
            <description type="Chief Investigator">Dr Andrew Currie</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Sepsis - bacterial blood infection - is a common cause of
                disease in babies and adults. Current diagnostic tests are too slow and often miss
                the sepsis diagnosis. We have identified blood markers that can improve sepsis
                diagnosis. Our team have developed a powerful system for making the molecular tools
                needed to rapidly detect these blood markers. We are working with science and
                manufacturing experts to make new sepsis tests that can be used easily by frontline
                staff in hospitals and GP clinics.</description>
            <description type="fundingAmount">$1,043,133.80</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013421</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013421</identifier>
            <identifier type="nhmrc">2013421</identifier>
            <name type="primary">
                <namePart>Inhibiting ASC with small molecules for treatment of inflammatory
                    diseases</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">anti-inflammatory agents </subject>
            <subject type="local">airway inflammation</subject>
            <subject type="local">drug discovery</subject>
            <subject type="local">cell biology</subject>
            <subject type="local">viral immunology</subject>
            <description type="Chief Investigator">Prof Avril Robertson</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">During flu infection inflammation causes significant morbidity
                there is therefore a need to reduce this inflammation while tackling the viral
                infection, we have special molecules that have this dual action. We will develop
                these molecules so they can become future drugs and explore their use in flu models
                combined with either asthma or obesity as these people are particularly vulnerable
                to the deadly effects of flu.</description>
            <description type="fundingAmount">$1,061,883.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013427</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013427</identifier>
            <identifier type="nhmrc">2013427</identifier>
            <name type="primary">
                <namePart>Do mitochondrial changes underlie insulin resistance induced by inadequate
                    sleep, and can this be prevented by prescribed exercise?</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rrz9s51</identifier>
                <title>Victoria University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">mitochondria </subject>
            <subject type="local">exercise</subject>
            <subject type="local">sleep</subject>
            <subject type="local">muscle metabolism</subject>
            <subject type="local">exercise training</subject>
            <description type="Chief Investigator">Prof David Bishop</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">More than 7.4 million Australians suffer from inadequate sleep.
                Sleep loss doesn't just make us tired; we have shown it also negatively affects
                mitochondria ("energy powerhouses") and glucose metabolism (increasing the risk of
                diabetes). Based on compelling data, this project will discover novel mechanisms
                responsible for the negative effects of sleep loss and test targeted exercise
                prescription as a cost-effective strategy to prevent metabolic problems arising from
                inadequate sleep.</description>
            <description type="fundingAmount">$813,502.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013451</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013451</identifier>
            <identifier type="nhmrc">2013451</identifier>
            <name type="primary">
                <namePart>ALPK1 dysfunction: revealing a novel pathogenic pathway in retinal
                    diseases</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">retinal disease </subject>
            <subject type="local">photoreceptors</subject>
            <subject type="local">vision loss</subject>
            <subject type="local">ocular disease</subject>
            <subject type="local">blindness</subject>
            <description type="Chief Investigator">Prof Robyn Jamieson</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Genetic retinal diseases are caused by changes in many
                different genes and lack effective therapy. This proposal aims to characterise and
                modulate a newly identified disease pathway in the retina. This holds promise for
                development of novel approaches to preserve vision in genetic and other forms of
                blinding retinal degeneration.</description>
            <description type="fundingAmount">$747,501.80</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013460</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013460</identifier>
            <identifier type="nhmrc">2013460</identifier>
            <name type="primary">
                <namePart>Exploiting a novel cell surface biomarker to defeat multiple
                    myeloma</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01p93h210</identifier>
                <title>University of South Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">multiple myeloma </subject>
            <subject type="local">cancer prognosis</subject>
            <subject type="local">cell adhesion molecule</subject>
            <subject type="local">bone marrow stroma</subject>
            <subject type="local">inhibitors</subject>
            <description type="Chief Investigator">Prof Claudine Bonder</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Multiple myeloma is an incurable aggressive cancer of the bone
                marrow. In Australia, ~2,500 new cases are diagnosed every year with a 5 year
                survival rate of ~50% and treatment costs exceeding $700,000 per patient. We have
                identified a single cell surface protein to be upregulated by ~20% of myeloma
                patients who are then 3 times more likely to die within 6 years of diagnosis. This
                study examines a new prognostic tool to rapidly identify poor prognosis patients and
                new a target to treat them.</description>
            <description type="fundingAmount">$908,658.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013468</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013468</identifier>
            <identifier type="nhmrc">2013468</identifier>
            <name type="primary">
                <namePart>Understanding the asymptomatic carriage of pathogens and antimicrobial
                    resistance (AMR) in the human gut microbiota</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03rke0285</identifier>
                <title>Baker Heart and Diabetes Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">antimicrobial resistance </subject>
            <subject type="local">bioinformatics</subject>
            <subject type="local">microbiology</subject>
            <subject type="local">microbial ecology</subject>
            <subject type="local">microbial infections</subject>
            <description type="Chief Investigator">Dr Guillaume Méric</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">The rise of microbial antibiotic resistance (AMR) and the lack
                of novel antibiotic compounds could soon be cancelling the effectiveness of current
                infectious disease therapies. Understanding and controlling the spread of AMR is a
                major challenge for public health, but we currently do not understand well if and
                how healthy people can carry and spread AMR genes. Here, we propose to study AMR
                dynamics in the gut microbiome of &amp;gt;20,000 healthy people, linking it with
                health and prescription records.</description>
            <description type="fundingAmount">$546,216.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013478</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013478</identifier>
            <identifier type="nhmrc">2013478</identifier>
            <name type="primary">
                <namePart>Identifying rational approaches to enhance the activity of BH3 mimetic
                    drugs in blood cancers</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">bcl-2 </subject>
            <subject type="local">leukaemia</subject>
            <subject type="local">lymphoma</subject>
            <subject type="local">apoptosis</subject>
            <subject type="local">therapeutic target</subject>
            <description type="Chief Investigator">Prof David Huang</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">It is now appreciated that normal cell death prevents cancers
                from developing; however, this could be undermined in blood cancers (e.g.,
                leukemias). This is often due to overactivity of BCL2 which allows the cancer cells
                to persist. Treating patients with a drug blocking BCL2 - venetoclax - is proving
                highly effective for such blood cancers. However, the disease will often eventually
                recur: this project seeks to understand why this is and to discover ways by which
                this can be prevented.</description>
            <description type="fundingAmount">$992,305.40</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013500</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013500</identifier>
            <identifier type="nhmrc">2013500</identifier>
            <name type="primary">
                <namePart>MicroRNA targeting to enhance haematopoietic stem cell function</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">mouse genetics </subject>
            <subject type="local">haematopoietic stem cells</subject>
            <subject type="local">microrna</subject>
            <subject type="local">stem cell biology</subject>
            <subject type="local">bone marrow transplantation</subject>
            <description type="Chief Investigator">Assoc Prof Edwina McGlinn</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The ability to transplant blood stem cells has dramatically
                improved outcomes for many blood diseases. However, there is a major limitation in
                the numbers of appropriate blood stem cells available for use. We have identified a
                gene family that represses the potential of blood stem cells to function after
                transplantation. Here, we aim to inhibit this gene family to enhance blood stem cell
                function.</description>
            <description type="fundingAmount">$992,474.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013511</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013511</identifier>
            <identifier type="nhmrc">2013511</identifier>
            <name type="primary">
                <namePart>The rogue germline: deciphering mechanisms of cancer testis antigen
                    reactivation in cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">epigenetics </subject>
            <subject type="local">germ cells</subject>
            <subject type="local">carcinogenesis</subject>
            <subject type="local">embryogenesis</subject>
            <subject type="local">genomics</subject>
            <description type="Chief Investigator">Assoc Prof Ozren Bogdanovic</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cancer testis antigens (CTAs) are proteins that are normally
                expressed in the germline of healthy individuals. During malignant transformation,
                CTAs become expressed in cancerous tissues, however their role in cancer formation
                is largely unknown. Given their tissue specificity, CTAs are being actively pursued
                as targets for cancer immunotherapy. This project aims to unravel the mechanisms of
                CTA reactivation and interrogate their contribution to cancer formation in
                vivo.</description>
            <description type="fundingAmount">$791,930.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013538</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013538</identifier>
            <identifier type="nhmrc">2013538</identifier>
            <name type="primary">
                <namePart>Increasing hematopoietic stem cell niches post transplantation through
                    enhancing bone marrow macrophage resilience and regeneration
                    mechanisms</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">macrophages </subject>
            <subject type="local">haematopoietic stem cell transplantation</subject>
            <subject type="local">bone marrow reconstitution</subject>
            <subject type="local">tissue regeneration</subject>
            <subject type="local">bone marrow stroma</subject>
            <description type="Chief Investigator">Prof Allison Pettit</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Bone marrow transplantation, a potential cure for blood cancers
                and used to enable high dose therapy in treatment resistant cancers, has a high-risk
                profile preventing treatment progression and high mortality. We will investigate a
                novel treatment to alleviate transplantation risk by improving the recovery of the
                recipient's bone marrow environment. It is expected that the efficiency of donor
                stem cell engraftment will be increased, and reconstitution of blood and immune
                cells accelerated.</description>
            <description type="fundingAmount">$935,616.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013563</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013563</identifier>
            <identifier type="nhmrc">2013563</identifier>
            <name type="primary">
                <namePart>Evaluating Systems Change for Health Equity: A Case Study of Australia’s
                    COVID-19 Policy Response</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">equity </subject>
            <subject type="local">social determinants of health</subject>
            <subject type="local">policy analysis</subject>
            <subject type="local">policy evaluation</subject>
            <subject type="local">policy making</subject>
            <description type="Chief Investigator">Dr Ashley Schram</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project will build new resources to evaluate the impact of
                policy reforms on changes to the underlying societal structures that shape health
                inequity. Using systems science we will study Australia’s COVID-19 policy response
                and the impact it will have on the rules, norms, power dynamics, and resource flows
                that stratify society and shape people’s health. This new evidence will be used to
                advocate for policy reform that better targets the roots of health inequity in
                Australia and abroad.</description>
            <description type="fundingAmount">$452,482.00</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013565</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013565</identifier>
            <identifier type="nhmrc">2013565</identifier>
            <name type="primary">
                <namePart>MACHINE LEARNING OF RANDOMISED CONTROLLED TRIALS: A major emerging
                    opportunity to advance precision oncology</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">risk prediction </subject>
            <subject type="local">cancer treatment</subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">clinical epidemiology</subject>
            <subject type="local">clinical pharmacology</subject>
            <description type="Chief Investigator">Prof Michael Sorich</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Individual patients can gain very different benefit from the
                same treatment. Immunotherapy for cancer is an important example of this - some
                patients have dramatic improvement in survival, whereas many others gain little or
                no benefit. Currently it is not possible to predict in advance who will benefit and
                who will not. We will evaluate of a new approach based on machine learning analysis
                of clinical trials to better distinguish patients who are unlikely to benefit from
                those who will benefit.</description>
            <description type="fundingAmount">$560,598.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013574</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013574</identifier>
            <identifier type="nhmrc">2013574</identifier>
            <name type="primary">
                <namePart>Reinforcing the cell identity network to improve the function of aged
                    cells</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">ageing </subject>
            <subject type="local">transcription factor</subject>
            <subject type="local">epigenetics</subject>
            <subject type="local">chromatin structure</subject>
            <subject type="local">gene regulation</subject>
            <description type="Chief Investigator">Dr Christian Nefzger</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">By 2055, one in four Australians will be aged over 65 and the
                frequency of age-related disorders will increase. In order to prevent unsustainable
                burdens for the health system and to reduce human suffering, innovative new
                therapies are needed to target the underlying causes of ageing. The proposal will
                provide the basis for new strategies to improve the function of aged cells by
                directly reinforcing youthful cell identity.</description>
            <description type="fundingAmount">$777,899.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013580</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013580</identifier>
            <identifier type="nhmrc">2013580</identifier>
            <name type="primary">
                <namePart>A dual approach to activate a tumour suppressor for breast cancer
                    therapy</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">protein phosphatase </subject>
            <subject type="local">tumour suppressor</subject>
            <subject type="local">protein-protein interaction</subject>
            <subject type="local">anticancer drug action</subject>
            <subject type="local">cell signalling</subject>
            <description type="Chief Investigator">Assoc Prof Nicole Verrills</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cancer is characterised by inactivation of proteins that
                inhibit cell growth and survival, called tumour suppressors. A rational way to treat
                cancer is to re-activate the tumour suppressors. Until recently this was not
                possible. However, we have developed drugs that can do this. Here, we will fully
                characterise how these drugs function in breast cancer, and use this knowledge to
                develop new anti-cancer therapies that could have wide reaching applicability for
                many cancer patients.</description>
            <description type="fundingAmount">$597,824.10</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013615</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013615</identifier>
            <identifier type="nhmrc">2013615</identifier>
            <name type="primary">
                <namePart>Interrogating the therapeutic potential of slow muscle programming in
                    cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">skeletal muscle </subject>
            <subject type="local">basic science</subject>
            <subject type="local">plasticity</subject>
            <subject type="local">exercise intolerance</subject>
            <subject type="local">cancer</subject>
            <description type="Chief Investigator">Prof Gordon Lynch</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Physical activity can improve cancer prognosis, but many
                patients cannot exercise because of treatment complications. Slow muscle programming
                could confer exercise-like benefits but its therapeutic potential to improve muscle
                health in cancer has not been interrogated. These studies will determine whether
                this strategy can preserve and promote muscle health in different cancer settings.
                The outcomes will inform development of new therapies for cancer patients throughout
                the continuum of care.</description>
            <description type="fundingAmount">$943,864.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013620</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013620</identifier>
            <identifier type="nhmrc">2013620</identifier>
            <name type="primary">
                <namePart>Do allergies start with the skin? A novel lipidomic analysis of early life
                    skin to identify “high risk” children and potential targets for preventive
                    interventions</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">atopic dermatitis </subject>
            <subject type="local">allergic disease</subject>
            <subject type="local">skin permeability</subject>
            <subject type="local">lipids</subject>
            <subject type="local">hypersensitivity</subject>
            <description type="Chief Investigator">Assoc Prof Adrian Lowe</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Eczema and food allergy are common conditions that cause a
                substantial burden for individuals and families. Impaired skin barrier in early life
                is believe to be critical in the development of these conditions, and skin lipids
                (fats) are the ‘mortar’ that holds the bricks of the skin barrier together. Using a
                non-invasive technique, we will test if the skin lipids can identify children who
                will develop eczema and food sensitisation, which may lead to novel preventive
                strategies.</description>
            <description type="fundingAmount">$299,752.80</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013621</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013621</identifier>
            <identifier type="nhmrc">2013621</identifier>
            <name type="primary">
                <namePart>Treating Cardiometabolic Disease by Targeting Mitochondrial
                    Defects</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">mitochondrial function </subject>
            <subject type="local">insulin resistance</subject>
            <subject type="local">reactive oxygen species (ros)</subject>
            <subject type="local">drug delivery</subject>
            <subject type="local">antioxidant</subject>
            <description type="Chief Investigator">Dr James Burchfield</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cardiometabolic disease is the leading cause of death and
                disability in the world. We have discovered that depletion of Coenzyme Q10 (a
                molecule essential for energy production) occurs in people with pre-diabetes and
                that boosting CoQ10 is a potential treatment for cardiometabolic disease. Here we
                seek to understand the underlying cause of CoQ10 depletion and how depletion causes
                disease. Finally, we will use our newly acquired understanding of the disease
                process to develop new treatments.</description>
            <description type="fundingAmount">$1,711,067.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013629</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013629</identifier>
            <identifier type="nhmrc">2013629</identifier>
            <name type="primary">
                <namePart>Positive allosteric modulation of anti-convulsant G protein-coupled
                    receptor signalling to treat drug-resistant epilepsy.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">g protein-coupled receptors </subject>
            <subject type="local">adenosine receptors</subject>
            <subject type="local">antiepileptic drugs</subject>
            <subject type="local">receptor signalling</subject>
            <subject type="local">drug discovery</subject>
            <description type="Chief Investigator">Dr Lauren May</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Epilepsy remains a significant health burden, with current
                antiseizure medications (ASM) providing inadequate seizure control for &amp;gt;30%
                of patients. Activation of adenosine A1 receptors, a protein expressed on neurons,
                can effectively abolish seizures animal models. We will apply multidisciplinary,
                innovative approaches to develop novel drug leads that can modulate adenosine A1
                receptor activity in a more selective and efficacious manner, developing a unique
                path for ASM discovery.</description>
            <description type="fundingAmount">$1,982,356.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013631</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013631</identifier>
            <identifier type="nhmrc">2013631</identifier>
            <name type="primary">
                <namePart>Dominant classes of tumour specific antigens in Melanoma</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">cancer vaccine </subject>
            <subject type="local">tumour antigens</subject>
            <subject type="local">proteomics</subject>
            <subject type="local">human leukocyte antigen (hla)</subject>
            <subject type="local">antigen presentation</subject>
            <description type="Chief Investigator">Prof Anthony Purcell</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We will explore new classes of antigens that can form targets
                of vaccines and immunotherapy in melanoma. In particular, we will compare the
                ability of small protein fragments that are generated via enzymatic modifications or
                through unusual proteolytic activities to stimulate patient immune responses to
                those protein fragments that contain cancer specific mutations. We anticipate that
                the inclusion of a broader variety of antigen classes will boost anti-cancer
                vaccines.</description>
            <description type="fundingAmount">$1,026,825.20</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013641</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013641</identifier>
            <identifier type="nhmrc">2013641</identifier>
            <name type="primary">
                <namePart>The development and potential of a malaria resistant mosquito for the
                    Southwest Pacific</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">malaria </subject>
            <subject type="local">mosquito-borne disease</subject>
            <subject type="local">mosquito transmission</subject>
            <subject type="local">population genetics</subject>
            <subject type="local">gene transfer</subject>
            <description type="Chief Investigator">Dr Nigel Beebe</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Malaria plagues the Southwest Pacific. With no vaccine,
                resistance to antimalarials growing, vector control is the mainstay in reducing
                malaria but mosquitoes are adapting to these tools. We are developing a malaria
                resistant mosquito in the lab with the capability to drive malaria resistant traits
                through populations. This project will permit the potential of this technology to be
                explored through population genomics and mathematical modelling to develop
                simulations of hypothetical releases.</description>
            <description type="fundingAmount">$739,220.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013650</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013650</identifier>
            <identifier type="nhmrc">2013650</identifier>
            <name type="primary">
                <namePart>Towards optimizing diabetes therapies for cardioprotection: Precision
                    approaches for women</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">diabetic cardiomyopathy </subject>
            <subject type="local">diastolic dysfunction</subject>
            <subject type="local">proteomics</subject>
            <subject type="local">mechanotransduction</subject>
            <subject type="local">cellular mechanisms</subject>
            <description type="Chief Investigator">Prof Leanne Delbridge</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Diabetes is an epidemic disease. A major cause of death in
                diabetic patients is due to heart damage &amp;amp; women are particularly
                vulnerable. No heart-specific therapies are available and current guidelines are not
                gender-targeted. The goal of this project is to understand why women have such high
                cardiac risk in diabetes, and to identify new treatment opportunities to maximise
                heart protection for diabetic women.</description>
            <description type="fundingAmount">$1,006,417.80</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013757</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013757</identifier>
            <identifier type="nhmrc">2013757</identifier>
            <name type="primary">
                <namePart>Developing a real-time machine learning rapid response and risk
                    stratification system for in hospital patients</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">health services research </subject>
            <subject type="local">emergency medicine</subject>
            <subject type="local">population health</subject>
            <subject type="local">health care delivery</subject>
            <subject type="local">health care evaluation</subject>
            <description type="Chief Investigator">Assoc Prof Jack Chen</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We intend to develop and implement a scalable and accurate
                patient-centred AI system based on the information derived during the whole patient
                journey for patients in a normal and pandemic setting so as to provide a clinical
                triage system for patients that match critical resources to patient needs and
                augment the current rapid response system (RRS) through more accurate and tailored
                risk predicting.</description>
            <description type="fundingAmount">$768,889.20</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013783</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013783</identifier>
            <identifier type="nhmrc">2013783</identifier>
            <name type="primary">
                <namePart>Promoting myelin repair in a refractory environment in vivo.</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">brain-derived neurotrophic factor (bdnf) </subject>
            <subject type="local">neurotrophins</subject>
            <subject type="local">demyelinating disease</subject>
            <subject type="local">oligodendrocytes</subject>
            <subject type="local">remyelination</subject>
            <description type="Chief Investigator">Assoc Prof Simon Murray</description>
            <description type="Date Announced">2021-11-04T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Many nerve cells in the brain are ensheathed in myelin. Myelin
                is critical for optimal brain function as it supports nerve cell function and
                survival. Damage to myelin, as occurs in multiple sclerosis and other
                neurodegenerative diseases leaves nerve cells vulnerable to degeneration. This
                proposal aims to identify whether a molecular target we have identified that
                promotes myelin repair can be optimised and promote myelin repair in a novel and
                more complex model of brain injury.</description>
            <description type="fundingAmount">$1,010,803.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008644</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008644</identifier>
            <identifier type="nhmrc">2008644</identifier>
            <name type="primary">
                <namePart>The Communicate Study: partnership across the Top End to improve
                    Aboriginal patients’ experience and outcomes of healthcare</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/006mbby82</identifier>
                <title>Menzies School of Health Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">communication </subject>
            <subject type="local">aboriginal health </subject>
            <subject type="local">doctor-patient interaction </subject>
            <subject type="local">patient/doctor communication </subject>
            <subject type="local">clinical competence / skills </subject>
            <description type="Chief Investigator">Prof Anna Ralph</description>
            <description type="Date Announced">2021-11-12T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Effective communication in healthcare improves patient
                outcomes. Aboriginal language interpreters should be used for around 50% of
                Aboriginal patients in Northern Territory Top End, but only around 18% of those in
                need are currently getting access. The Communicate Study, partnering Menzies with
                health and interpreter services aims to improve cultural safety in healthcare,
                focusing on improved uptake of Aboriginal interpreters and integration of Aboriginal
                Heath Practitioners into tertiary care.</description>
            <description type="fundingAmount">$1,499,896.70</description>
            <coverage>
                <spatial type="text">NT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010289</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010289</identifier>
            <identifier type="nhmrc">2010289</identifier>
            <name type="primary">
                <namePart>To Be Born Upon a Pandanus Mat (Yothuw gayatha dhäwal’
                    guyaŋa’nharaw)</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048zcaj52</identifier>
                <title>Charles Darwin University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">birth </subject>
            <subject type="local">indigenous health </subject>
            <subject type="local">midwifery </subject>
            <subject type="local">maternal and child health </subject>
            <subject type="local">health services research </subject>
            <description type="Chief Investigator">Prof Yvette Roe</description>
            <description type="Date Announced">2021-11-12T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We will establish and evaluate, Australia’s ‘Birthing on
                Country’ very remote, demonstration site in Galiwin’ku, Elcho Island, Northern
                Territory. We will redesign maternal and infant health services for Yolŋu
                (Aboriginal) families who currently have one of the highest proportions of babies
                being born too soon (preterm) in Australia (22% versus 7% non-Indigenous
                Australians). Djäkamirrs’ (Indigenous doulas) will increase support for women to
                modify risk factors and reduce preterm birth by 50%.</description>
            <description type="fundingAmount">$1,497,855.00</description>
            <coverage>
                <spatial type="text">NT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010493</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010493</identifier>
            <identifier type="nhmrc">2010493</identifier>
            <name type="primary">
                <namePart>Development and evaluation of a Child and Family eHub to improve access,
                    engagement and use of the existing community, social and mental health services
                    system</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">community child health </subject>
            <subject type="local">health care evaluation </subject>
            <subject type="local">access to health care </subject>
            <subject type="local">implementation </subject>
            <subject type="local">child behaviour </subject>
            <description type="Chief Investigator">Prof Sharon Goldfeld</description>
            <description type="Date Announced">2021-11-12T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Most Australian children with mental health concerns don’t get
                the right care at the right time. With COVID-19 this will only get worse. This
                project aims to improve access and engagement of existing services to address
                problems early, especially for disadvantaged families. We will co-develop and test a
                Child and Family eHub, overlaying existing systems with an easily accessible digital
                entry point to seek information, connect with services, and provide a care navigator
                for those most in need.</description>
            <description type="fundingAmount">$429,262.20</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2010866</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2010866</identifier>
            <identifier type="nhmrc">2010866</identifier>
            <name type="primary">
                <namePart>Optimising the implementation of an evidence-based school program to
                    engage adolescents in muscle-strengthening activities consistent with national
                    guidelines</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">physical activity </subject>
            <subject type="local">implementation </subject>
            <subject type="local">health promotion </subject>
            <subject type="local">translational research </subject>
            <subject type="local">school health promotion </subject>
            <description type="Chief Investigator">Prof David Lubans</description>
            <description type="Date Announced">2021-11-12T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">School-based physical activity interventions need to be
                ‘scaled-up’ to improve population health. The aim of this project is to study the
                effects of different implementation support models on the scale-up of an
                evidence-based physical activity program in NSW secondary schools. Expected outcomes
                include an optimal support model for scaling up school-based health promotion
                interventions, and population health benefits from participation in resistance
                training.</description>
            <description type="fundingAmount">$709,054.50</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011157</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011157</identifier>
            <identifier type="nhmrc">2011157</identifier>
            <name type="primary">
                <namePart>Promotion of evidence-based physical activity for older adults and people
                    with disabilities by health professionals</namePart>
            </name>
            <name type="alternative">
                <namePart>Partnership Projects</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">disability </subject>
            <subject type="local">ageing </subject>
            <subject type="local">exercise therapy </subject>
            <subject type="local">health promotion </subject>
            <subject type="local">physical activity </subject>
            <description type="Chief Investigator">Prof Catherine Sherrington</description>
            <description type="Date Announced">2021-11-12T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Promotion of physical activity by health services is part of
                the solution to global inactivity proposed in the WHO Global Action Plan on Physical
                Activity. Health professionals are an underutilised resource in the global fight
                against inactivity. This project aims to mobilise and empower Health professionals
                to encourage and support physical activity among patients by targeting
                implementation barriers identified at our Partnership health services.</description>
            <description type="fundingAmount">$1,440,374.50</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/GNT1078523</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/GNT1078523</identifier>
            <identifier type="nhmrc">GNT1078523</identifier>
            <name type="primary">
                <namePart>Psychosocial impact of genetic counselling and testing</namePart>
            </name>
            <name type="alternative">
                <namePart>Research Fellowship</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">psychology </subject>
            <subject type="local">public health </subject>
            <subject type="local">genetics </subject>
            <subject type="local">hereditary cancer </subject>
            <subject type="local">health psychology </subject>
            <description type="Chief Investigator">Prof Bettina Meiser</description>
            <description type="Date Announced">2021-11-15T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not applicable</description>
            <description type="fundingAmount">$131,769.60</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008937</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008937</identifier>
            <identifier type="nhmrc">2008937</identifier>
            <name type="primary">
                <namePart>Healthy Environments And Lives (HEAL) - National Research Network on Human
                    Health and Environmental Change</namePart>
            </name>
            <name type="alternative">
                <namePart>Special Initiative</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">environmental health </subject>
            <subject type="local">climate change adaption </subject>
            <subject type="local">environmental intervention </subject>
            <subject type="local">aboriginal health </subject>
            <subject type="local">environmental epidemiology</subject>
            <description type="Chief Investigator">Prof Sotiris Vardoulakis</description>
            <description type="Date Announced">2021-11-16T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">HEAL aims to strengthen the Australian community and health
                system’s resilience to changing environmental conditions, climate change and extreme
                weather events. This will be achieved by stimulating collaborative research that
                will improve the current understanding of the interactions between the climate, the
                natural and built environment and our health. HEAL will lead to more effective
                policies and measures that will protect and improve the health of the community and
                reduce inequalities.</description>
            <description type="fundingAmount">$10,000,000.00</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2011289</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2011289</identifier>
            <identifier type="nhmrc">2011289</identifier>
            <name type="primary">
                <namePart>Identification of metabolic alterations in cancer cachexia</namePart>
            </name>
            <name type="alternative">
                <namePart>Ideas Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">drosophila </subject>
            <subject type="local">developmental biology </subject>
            <subject type="local">cachexia </subject>
            <subject type="local">wasting syndromes </subject>
            <subject type="local">cell metabolism </subject>
            <description type="Chief Investigator">Assoc Prof Louise Cheng</description>
            <description type="Date Announced">2021-12-02T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cachexia is a metabolic disease where tumours cause muscle and
                fat to waste away. We established a Drosophila (fruit fly) model of cachexia-like
                wasting, opening up a novel opportunity to use its powerful genetic tools to better
                understand the genetic basis of cachexia-like wasting. This grant proposes to look
                at how organs can communicate with each other, and our findings will allow us to
                find potential new avenues for the development of treatment strategies for
                cachexia.</description>
            <description type="fundingAmount">$894,806.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013881</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013881</identifier>
            <identifier type="nhmrc">2013881</identifier>
            <name type="primary">
                <namePart>A First-In-Class Tumour Matrix Targeting Approach to Enhance Chemotherapy
                    in Pancreatic Cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">extracellular matrix</subject>
            <subject type="local">pancreatic cancer</subject>
            <subject type="local">fibrosis</subject>
            <subject type="local">stroma</subject>
            <subject type="local">fibroblasts</subject>
            <description type="Chief Investigator">Assoc Prof Thomas Cox</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Chemotherapy is the standard-of-care for pancreatic cancer
                patients. Whilst chemotherapy initially works, it quickly becomes ineffective and
                patients go on to relapse. One reason for this failure is chemotherapy-induced
                scarring (fibrosis) in and around the tumour. This scarring blunts the effectiveness
                of subsequent rounds of treatment. Our preliminary data show that our novel compound
                can block this scar formation offering a novel stromal targeting approach to improve
                chemotherapy efficacy.</description>
            <description type="fundingAmount">$827,500.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013899</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013899</identifier>
            <identifier type="nhmrc">2013899</identifier>
            <name type="primary">
                <namePart>Development of a Novel Photo-Angioplasty Device for the Treatment of
                    Occlusive Peripheral Vascular Disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">angioplasty</subject>
            <subject type="local">artery bypass graft failure</subject>
            <subject type="local">restenosis</subject>
            <subject type="local">epigenetics</subject>
            <subject type="local">photobiology</subject>
            <description type="Chief Investigator">Assoc Prof Anthony Dear</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We have designed and developed a new light-activated drug
                eluting balloon (DEB) angioplasty device termed Lumi-Solve, which targets drug
                delivery and activation specifically to the surface of a re-narrowed blood vessel,
                at the time of angioplasty balloon deployment, for the safer and more effective
                treatment of vascular disease. Our project aims to evaluate Lumi-Solve, in a large
                animal model with a view to commencing human trials shortly after completion of
                these studies.</description>
            <description type="fundingAmount">$808,505.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013973</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013973</identifier>
            <identifier type="nhmrc">2013973</identifier>
            <name type="primary">
                <namePart>Preventing reperfusion injury in stroke with an acutely dosed NK1R
                    antagonist prodrug</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">medicinal chemistry</subject>
            <subject type="local">pharmaceutical treatment</subject>
            <subject type="local">drug delivery</subject>
            <subject type="local">pharmacokinetics</subject>
            <subject type="local">ischaemic stroke</subject>
            <description type="Chief Investigator">Prof Jonathan Baell</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Stroke represents a major clinical and societal burden (on
                individuals and society) and is the primary cause of adult disability, second-most
                common cause of dementia, and third-leading cause of death. We will develop a novel
                and effective intravenous form of a compound known to act beneficially in these
                clinical settings. This form of administration will act quickly and more effectively
                with beneficial stroke victim outcomes.</description>
            <description type="fundingAmount">$653,527.20</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014002</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014002</identifier>
            <identifier type="nhmrc">2014002</identifier>
            <name type="primary">
                <namePart>Building Synthetic DNA Controls for Oxford Nanopore Sequencing.</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">sequencing</subject>
            <subject type="local">diagnosis</subject>
            <subject type="local">genomics</subject>
            <subject type="local">bioinformatics</subject>
            <subject type="local">cancer</subject>
            <description type="Chief Investigator">Assoc Prof Timothy Mercer</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The mutations that cause many cancers are often missed using
                current sequencing technologies because they are too large and complex. Our partner,
                Oxford Nanopore Technologies, developed a long-read sequencing method that can
                detect these complex mutations, but is too inaccurate and unreliable for use in
                clinical laboratories. We will build synthetic controls that improve the accuracy of
                long-read sequencing, and enable its use to diagnose mutations that are otherwise
                missed in cancer patients.</description>
            <description type="fundingAmount">$786,252.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014063</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014063</identifier>
            <identifier type="nhmrc">2014063</identifier>
            <name type="primary">
                <namePart>Developing HCK inhibitor drugs to improve immunotherapy</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rxfrp27</identifier>
                <title>La Trobe University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">immune modulation</subject>
            <subject type="local">solid tumours</subject>
            <subject type="local">therapy</subject>
            <subject type="local">src-family tyrosine kinases</subject>
            <subject type="local">inhibitors</subject>
            <description type="Chief Investigator">Prof Matthias Ernst</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Anti-tumour immune responses are modulated by a cell type
                called macrophages, which suppress the effects of immunotherapy. We identified a
                molecule called HCK, which induces macrophages to inhibit the anti-tumour immune
                response. In collaboration with SYNthesis and the Cancer Therapeutics CRC we will
                develop inhibitors for HCK. We will test these compounds in preclinical cancer
                models to identify the most effective combination with immunotherapies to provide
                the greatest patient benefits.</description>
            <description type="fundingAmount">$992,328.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014079</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014079</identifier>
            <identifier type="nhmrc">2014079</identifier>
            <name type="primary">
                <namePart>Targeting metabolism to correct fatty liver disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">fatty liver disease</subject>
            <subject type="local">energy metabolism</subject>
            <subject type="local">mitochondria</subject>
            <subject type="local">drug discovery</subject>
            <subject type="local">mouse models</subject>
            <description type="Chief Investigator">Assoc Prof Kyle Hoehn</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The severe form of fatty liver disease steatohepatitis affects
                ~40 million people worldwide and has no approved treatment. This project aims to
                identify new drugs and test them in mouse models to establish proof-of-concept that
                they safely reverse steatohepatitis. Success of this project will generate new drug
                candidates for human clinical testing.</description>
            <description type="fundingAmount">$621,083.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014095</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014095</identifier>
            <identifier type="nhmrc">2014095</identifier>
            <name type="primary">
                <namePart>Lung Ventilation Imaging: A new device to protect the lungs for cancer
                    treatment</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">medical physics</subject>
            <subject type="local">lung cancer</subject>
            <subject type="local">radiation oncology</subject>
            <subject type="local">medical imaging</subject>
            <subject type="local">oncology</subject>
            <description type="Chief Investigator">Prof Ricky O'Brien</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We will develop a device that gives clinicians insight into how
                their patients lungs are functioning. The information our technology will provide
                will allow radiotherapy plans to be shaped to minimise side effects for each
                individual patient, and allow surgeons to assess suitability for surgery in marginal
                patients with greater confidence. We will leverage the proven track record of our
                industry partner in complementary technologies to develop our device into a
                commercially ready product.</description>
            <description type="fundingAmount">$1,075,714.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014168</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014168</identifier>
            <identifier type="nhmrc">2014168</identifier>
            <name type="primary">
                <namePart>Development of a non-invasive mucosal integrity diagnostic and ingestible
                    capsule sampling tool targeting IBD gut health.</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">diagnostic assay</subject>
            <subject type="local">validation</subject>
            <subject type="local">inflammatory bowel disease (ibd)</subject>
            <subject type="local">proteome analysis</subject>
            <subject type="local">gastrointestinal disease</subject>
            <description type="Chief Investigator">Dr Valerie Wasinger</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Inflammatory Bowel Disease (IBD) affects many Australians and
                is a chronic condition requiring life-long management and intervention. Current
                technologies to manage the disease include invasive colonoscopy or non-specific lab
                tests. There is a need for non-invasive methods to improve the health and well-being
                of people suffering from IBD. We wish to develop a non-invasive diagnostic and
                ingestible sampling capsule that can determine gut-health and guide treatment for
                the long-term patients.</description>
            <description type="fundingAmount">$345,635.20</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014250</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014250</identifier>
            <identifier type="nhmrc">2014250</identifier>
            <name type="primary">
                <namePart>Developing a first-in-class therapeutic for chronic visceral pain using
                    venom derived peptides</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">chronic pain</subject>
            <subject type="local">irritable bowel syndrome (ibs)</subject>
            <subject type="local">nociception</subject>
            <subject type="local">analgesia</subject>
            <subject type="local">colon</subject>
            <description type="Chief Investigator">Prof Stuart Brierley</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Irritable Bowel Syndrome (IBS) is a leading cause of chronic
                pain, both world-wide and in Australia, but is without treatment. Chronic pain
                arises from nerve fibres in the colon which fail to "reset" back to normal following
                inflammation. Targeting these nerve endings with drugs is a key advance in IBS
                treatment. This project will identify specific voltage-gated sodium channel
                analogues that act at the level of the colon to numb pain sensing nerve fibres,
                providing efficacious pain relief in IBS</description>
            <description type="fundingAmount">$998,858.88</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014380</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014380</identifier>
            <identifier type="nhmrc">2014380</identifier>
            <name type="primary">
                <namePart>Retinal Implant with Closed-loop, Multichannel Stimulation to Improve
                    Visual Acuity</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">biomedical engineering</subject>
            <subject type="local">signal processing</subject>
            <subject type="local">retinitis pigmentosa</subject>
            <subject type="local">neuromodulation</subject>
            <subject type="local">vision loss</subject>
            <description type="Chief Investigator">Assoc Prof Hamish Meffin</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Previously we developed a retinal implant capable of restoring
                some vision to a group of patients blinded by the retinal disease, retinitis
                pigmentosa. However, the level of vision is relatively low. This project will
                develop a prototype retinal implant that aims to dramatically improve the level of
                vision provided. This would significantly increase the market of patients that could
                benefit from the implant.</description>
            <description type="fundingAmount">$1,141,581.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014388</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014388</identifier>
            <identifier type="nhmrc">2014388</identifier>
            <name type="primary">
                <namePart>Targeting the Achille’s heel of multi-drug resistant Neisseria gonorrhoeae
                    with drugs that disrupt metal homeostasis</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02sc3r913</identifier>
                <title>Griffith University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">neisseria gonorrhoeae</subject>
            <subject type="local">antibiotic resistance</subject>
            <subject type="local">treatment-resistant</subject>
            <subject type="local">drug development</subject>
            <subject type="local">microbiology</subject>
            <description type="Chief Investigator">Prof Mark von Itzstein</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Neisseria gonorrhoeae causes sexually transmitted disease
                gonorrhea. Most gonococcal infections are asymptomatic and can lead to pelvic
                disease, infertility and increasing risk of HIV co-transmission. Due to the recent
                emergence of multidrug resistant superbugs, N. gonorrhoeae is now classified as an
                immediate public-health threat. No vaccine is available. This ideas grant will
                generate new antibiotics to treat multidrug resistant gonorrhea
                infections.</description>
            <description type="fundingAmount">$1,116,524.60</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014395</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014395</identifier>
            <identifier type="nhmrc">2014395</identifier>
            <name type="primary">
                <namePart>A novel RNA-based therapeutic for liver cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">microrna</subject>
            <subject type="local">liver cancer</subject>
            <subject type="local">toxicology</subject>
            <subject type="local">mouse models</subject>
            <subject type="local">novel therapeutic agents</subject>
            <description type="Chief Investigator">Prof Peter Leedman</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The outlook for patients with liver cancer is poor. A new form
                of RNA-based treatment offers promise. An exciting development is the addition of a
                molecular hook to the RNA, which specifically targets the RNA-drug to the liver. We
                have modified our drug, miR-7, to make it more effective in the body and also to
                specifically target the liver. In this project we will evaluate how effective the
                new drug is and develop some of the essential data needed to progress it to a
                clinical trial.</description>
            <description type="fundingAmount">$482,632.00</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014398</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014398</identifier>
            <identifier type="nhmrc">2014398</identifier>
            <name type="primary">
                <namePart>RESCUING CONE PHOTORECEPTORS IN RETINITIS PIGMENTOSA WITH LASER-DELIVERED
                    PHOTOBIOMODULATION</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">photobiology</subject>
            <subject type="local">retinitis pigmentosa</subject>
            <subject type="local">photoreceptors</subject>
            <subject type="local">laser</subject>
            <subject type="local">neuroprotection</subject>
            <description type="Chief Investigator">Prof Robert Casson</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This proposal develops a new laser to treat the blinding eye
                condition, retinitis pigmentosa. The low energy laser rescues the light-sensitive
                film at the back of the eye and preserves central vision preventing complete
                blindness.</description>
            <description type="fundingAmount">$525,106.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014416</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014416</identifier>
            <identifier type="nhmrc">2014416</identifier>
            <name type="primary">
                <namePart>Development of a novel topical serine protease inhibitor for tissue repair
                    and inflammatory skin disease</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">wound healing</subject>
            <subject type="local">chronic inflammation</subject>
            <subject type="local">skin disease</subject>
            <subject type="local">burn injury</subject>
            <subject type="local">atopic dermatitis</subject>
            <description type="Chief Investigator">Assoc Prof Mark Fear</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Slow tissue repair, excessive scarring and many skin diseases
                are driven by the body’s inappropriate or excessive immune response to the injury or
                environmental trigger. A key enzyme that causes this excessive response is Granzyme
                B. We will develop a new drug that can target Granzyme B. We will generate the data
                to support the first in human trials of the drug at the end of this study to support
                translation to better treat patients with scarring, fibrosis and inflammatory skin
                disease.</description>
            <description type="fundingAmount">$590,264.40</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014427</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014427</identifier>
            <identifier type="nhmrc">2014427</identifier>
            <name type="primary">
                <namePart>Development of a potent and fast acting antimalarial that is orally
                    efficacious in vivo</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">malaria</subject>
            <subject type="local">antimalarial</subject>
            <subject type="local">drug discovery</subject>
            <subject type="local">medicinal chemistry</subject>
            <subject type="local">drug development</subject>
            <description type="Chief Investigator">Dr Brad Sleebs</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Malaria is a devastating disease that causes 420,000 deaths
                worldwide annually. Critically malaria parasites have become resistant to nearly all
                currently used drug classes, and therefore there is an urgent need to develop new
                therapies. We have identified a highly active antimalarial class with a known
                mechanism of action and all the prerequisites required to advance this antimalarial
                class into human clinic trials in partnership with Medicines for Malaria Venture and
                Janssen Pharmaceuticals.</description>
            <description type="fundingAmount">$1,002,769.20</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014512</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014512</identifier>
            <identifier type="nhmrc">2014512</identifier>
            <name type="primary">
                <namePart>Developing FXIIa inhibitors as next-generation anticoagulants</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">thrombosis</subject>
            <subject type="local">anticoagulants</subject>
            <subject type="local">protease inhibitors</subject>
            <subject type="local">synthetic lipopeptides</subject>
            <subject type="local">drug development</subject>
            <description type="Chief Investigator">Prof David Craik</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">We have designed a new potential drug to inhibit
                disease-related blood clotting without interfering with normal clotting processes.
                The new molecule is promising because it is effective at stopping clotting, but to
                develop it into a drug we need to generate additional data confirming its safety and
                stability, then test it in animal models of thrombosis as a precursor to human
                trials. This project aims to generate these data and to optimise the lead molecule
                to make it suitable for such trials.</description>
            <description type="fundingAmount">$698,512.40</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014538</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014538</identifier>
            <identifier type="nhmrc">2014538</identifier>
            <name type="primary">
                <namePart>Development of a novel blood test that accurately predicts response to
                    checkpoint therapy in cancer patients</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cancer immunotherapy</subject>
            <subject type="local">lung cancer</subject>
            <subject type="local">flow cytometry</subject>
            <subject type="local">clinical test</subject>
            <subject type="local">cancer immunology</subject>
            <description type="Chief Investigator">Prof Barbara Fazekas de St Groth</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">New cancer therapies that target the patient’s immune system
                can cure patients whose cancers are resistant to all other therapies. However these
                new immune targeting treatments are effective in only a minority of patients, can
                cause significant toxicity and are very expensive. This application will meet the
                urgent need for a blood test that can accurately predict which patients will respond
                before therapy is started.</description>
            <description type="fundingAmount">$571,216.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014544</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014544</identifier>
            <identifier type="nhmrc">2014544</identifier>
            <name type="primary">
                <namePart>Novel long-acting and orally delivered conotoxin-based peptides with both
                    analgesic efficacy and disease modifying potential.</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">peptides</subject>
            <subject type="local">peptide synthesis</subject>
            <subject type="local">rational drug design</subject>
            <subject type="local">chronic pain</subject>
            <subject type="local">neuropathic pain</subject>
            <description type="Chief Investigator">Dr Richard Clark</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Chronic pain is a common and debilitating condition and there
                is a significant need for new analgesics to treat this pain. We have designed
                conotoxin (small peptides from marine cone snail venom) analogues with potent
                analgesic effects and the objective of this project is the preclinical development
                of these molecules as novel long-acting treatments of chronic pain.</description>
            <description type="fundingAmount">$948,644.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014584</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014584</identifier>
            <identifier type="nhmrc">2014584</identifier>
            <name type="primary">
                <namePart>c-FIND: Diagnosis of infections in minutes</namePart>
            </name>
            <name type="alternative">
                <namePart>Development Grants</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">infectious diseases</subject>
            <subject type="local">diagnostic</subject>
            <subject type="local">molecular design</subject>
            <subject type="local">antimicrobial resistance</subject>
            <subject type="local">paediatric</subject>
            <description type="Chief Investigator">Prof Marc Pellegrini</description>
            <description type="Date Announced">2021-12-27T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Diagnostic tests dictate treatment algorithms for infectious
                diseases which has become incredibly complex due antibiotic resistance. The
                inability to diagnose infections or lengthy delays in diagnosis result in patients
                being unable to access appropriate, timely or effective treatment. WEHI has been
                using a gene technology called CRISPR for over a decade and we have adapted this to
                accurately detect infections in patients within minutes to inform management at the
                point of care.</description>
            <description type="fundingAmount">$868,752.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013798</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013798</identifier>
            <identifier type="nhmrc">2013798</identifier>
            <name type="primary">
                <namePart>Understanding response and resistance to immunotherapy in
                    immunocompromised patients with cutaneous squamous cell carcinomas</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">immunotherapy </subject>
            <subject type="local">non-melanoma skin cancer</subject>
            <subject type="local">immunocompromised</subject>
            <subject type="local">molecular oncology</subject>
            <subject type="local">drug resistance</subject>
            <description type="Chief Investigator">Dr Luke McLean</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cutaneous squamous cell carcinoma (CSCC) is common in those
                with impaired immune systems and these patients have been excluded from the major
                immunotherapy trials. This research looks at CSCC that has improved or worsened on
                immunotherapy so we can better understand why some tumours respond and others do
                not. This will help assess who will benefit from immunotherapy, how we can fight
                resistance and improve treatment outcomes for vulnerable immunosuppressed
                patients.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013800</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013800</identifier>
            <identifier type="nhmrc">2013800</identifier>
            <name type="primary">
                <namePart>Using twin studies to investigate epilepsy aetiology and antiepileptic
                    drug-induced birth defects</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">epilepsy </subject>
            <subject type="local">genetics</subject>
            <subject type="local">twin studies</subject>
            <subject type="local">antiepileptic drugs</subject>
            <subject type="local">seizures</subject>
            <description type="Chief Investigator">Dr Yew Li Dang</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">By measuring and comparing the degree of similarity in a trait
                or disease between identical and non-identical twins, we can understand how much of
                the difference in a trait or disease between people is attributable to genes. This
                project will use twins to study the genetic contributions to epilepsy and to birth
                defects seen in babies born to mothers taking antiepileptic medications in
                pregnancy. The results will improve patient management and lead to the development
                of better treatments.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013809</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013809</identifier>
            <identifier type="nhmrc">2013809</identifier>
            <name type="primary">
                <namePart>Understanding the genetics and mechanisms of spontaneous coronary artery
                    dissection</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">acute coronary syndromes </subject>
            <subject type="local">coronary heart disease (chd)</subject>
            <subject type="local">transgenic animals</subject>
            <subject type="local">women's health</subject>
            <subject type="local">computed tomography</subject>
            <description type="Chief Investigator">Dr Lucy McGrath-Cadell</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">SCAD occurs in young women as a bleed into the wall of an
                artery of the heart, resulting in a heart attack. Cause(s) are not known but there
                is a genetic link in some cases. I plan to: (1) use advanced heart imaging to define
                differences between heart arteries of affected and unaffected people; (2) use animal
                models to correlate the observed characteristics (phenotype) and genetics (genotype)
                of SCAD; (3) sequence DNA from people with SCAD and selected relatives to identify
                causative genes.</description>
            <description type="fundingAmount">$97,640.33</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013816</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013816</identifier>
            <identifier type="nhmrc">2013816</identifier>
            <name type="primary">
                <namePart>The Pregnancy in Crohn's and Colitis - Observations, Levels and Outcomes
                    Extension (PICCOLO - X) study</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">inflammatory bowel disease (ibd) </subject>
            <subject type="local">reproductive immunology</subject>
            <subject type="local">reproductive health</subject>
            <subject type="local">infant health</subject>
            <subject type="local">biological therapy</subject>
            <description type="Chief Investigator">Dr Ralley Prentice</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Poorly controlled IBD has been shown to negatively affect
                outcomes for mother and baby. As newer medications become available to treat IBD, it
                is increasingly important to determine: 1. How disease activity can be accurately
                and non-invasively monitored in pregnancy. 2. To what degree medications cross the
                placenta into the baby. 3. For how long medications remain detectable in the baby
                after delivery. 4. The effect on the baby’s brain and immune system development.
                PICCOLO-X will address these.</description>
            <description type="fundingAmount">$101,376.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013817</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013817</identifier>
            <identifier type="nhmrc">2013817</identifier>
            <name type="primary">
                <namePart>Harnessing the power of Patient Reported Outcomes (PROs): demonstrating
                    novel applications of PROs in the care of oncology patients</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">melanoma </subject>
            <subject type="local">health services research</subject>
            <subject type="local">patient/doctor communication</subject>
            <subject type="local">medical oncology</subject>
            <subject type="local">patient outcomes</subject>
            <description type="Chief Investigator">Dr Julia Lai-Kwon</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Patient-reported outcomes (PROs) empower patients to
                communicate their symptoms and needs to clinicians. Understanding the impact of
                treatment from a patient’s perspective is vital to ensure their concerns are
                addressed and to inform improvements to cancer care. This study will examine new
                ways of using PROs to understand the patient experience, enable treatment side
                effects to be captured and communicated with patients, and promote the collection of
                PROs in clinical registries.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013821</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013821</identifier>
            <identifier type="nhmrc">2013821</identifier>
            <name type="primary">
                <namePart>Long-term Outcomes of Surgery for Diseases of the Aortic Valve in
                    Children</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">congenital heart disease </subject>
            <subject type="local">cardiac surgery</subject>
            <subject type="local">aortic valve</subject>
            <subject type="local">paediatric</subject>
            <subject type="local">surgical outcomes research</subject>
            <description type="Chief Investigator">Dr Michael Zhu</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Over 2400 children in Australia are born with a heart defect
                annually. Up to 7% will have an abnormal aortic heart valve and need open-heart
                surgery in order to survive. Although surgery is often successful, affected children
                will need multiple heart operations throughout their life and face heart
                complications and premature death. This study will investigate the long-term
                outcomes of aortic valve surgery in children and aim to identify strategies to
                minimise complications and maximise survival.</description>
            <description type="fundingAmount">$116,321.17</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013829</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013829</identifier>
            <identifier type="nhmrc">2013829</identifier>
            <name type="primary">
                <namePart>Negative Symptoms of Psychosis</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">psychiatry </subject>
            <subject type="local">neuroscience</subject>
            <subject type="local">neuroimaging</subject>
            <subject type="local">psychophysics</subject>
            <subject type="local">functional magnetic resonance imaging (fmri)</subject>
            <description type="Chief Investigator">Dr Jayson Jeganathan</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Impairments in facial expressivity, motivation, and sociality –
                the ‘negative symptoms’ - are the most debilitating features of psychotic disorders,
                yet they are inadequately treated. In this study, I will use facial emotion
                detection algorithms, functional brain imaging, and novel tasks including real-time
                facial feedback and heart rate feedback, to discover the changes in the brain’s
                emotional circuits that underlie negative symptoms.</description>
            <description type="fundingAmount">$93,904.17</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013831</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013831</identifier>
            <identifier type="nhmrc">2013831</identifier>
            <name type="primary">
                <namePart>Evolution of Streptococcal pathovars</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">streptococcal disease </subject>
            <subject type="local">bacterial genetics</subject>
            <subject type="local">bacterial evolution</subject>
            <subject type="local">bacterial virulence factors</subject>
            <subject type="local">antigenic variation</subject>
            <description type="Chief Investigator">Dr Ouli Xie</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Streptococcus dysgalactiae subspecies equisimilis (group C/G
                Streptococcus) is a bacterium that is increasingly recognised as a cause of serious
                human disease. It shares genes and disease manifestations with the closely related
                bacteria, Streptococcus pyogenes (group A Streptococcus). We aim to analyse a global
                streptococcal genetic database to identify common drivers of disease and potential
                shared vaccine targets to inform public health and vaccine approaches to combat
                streptococcal disease.</description>
            <description type="fundingAmount">$123,793.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013839</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013839</identifier>
            <identifier type="nhmrc">2013839</identifier>
            <name type="primary">
                <namePart>Towards the understanding of the immunopathogenesis of
                    autoantibody-mediated systemic diseases: new approaches to old
                    problems</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b3dvp57</identifier>
                <title>Garvan Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">autoantibodies </subject>
            <subject type="local">autoimmune disease</subject>
            <subject type="local">b cells</subject>
            <subject type="local">diagnostic</subject>
            <subject type="local">lupus</subject>
            <description type="Chief Investigator">Dr Adrian Lee</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Autoantibodies and white cells called B cells are found in
                systemic autoimmune diseases such as lupus. These are normally present in healthy
                individuals but a series of failed checkpoints enable them to go “rogue”, damage
                host tissue and cause debilitating symptoms. Understanding their molecular
                signatures will allow me to understand the processes that occur that lead to
                autoimmunity. This will help create personalised therapies for patients to
                “eliminate” these rogue populations.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013842</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013842</identifier>
            <identifier type="nhmrc">2013842</identifier>
            <name type="primary">
                <namePart>Meeting an unmet need in systemic sclerosis: defining the burden of
                    arrhythmia and sudden cardiac death</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">scleroderma </subject>
            <subject type="local">muscle disease</subject>
            <subject type="local">cardiomyopathy</subject>
            <subject type="local">risk factors</subject>
            <subject type="local">treatment</subject>
            <description type="Chief Investigator">Dr Jessica Fairley</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Scleroderma is an autoimmune condition which damages multiple
                organs. Scleroderma patients are at risk of heart rhythm abnormalities which can
                result in sudden death. We do not understand why some people develop heart problems,
                or how to identify patients at greatest risk of rhythm abnormalities. We aim to
                determine how often heart rhythm problems occur in scleroderma, to understand how to
                predict risk of heart rhythm disturbances and potentially prevent them from
                occurring.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013844</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013844</identifier>
            <identifier type="nhmrc">2013844</identifier>
            <name type="primary">
                <namePart>Randomised Evaluation of the Impact of Catheter Ablation versus Medical
                    Therapy on Psychological Distress and Neurocognitive Function in Atrial
                    Fibrillation</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04z4kmw33</identifier>
                <title>Melbourne Health</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">atrial fibrillation </subject>
            <subject type="local">psychological distress</subject>
            <subject type="local">cognitive dysfunction</subject>
            <subject type="local">randomised controlled trial (rct)</subject>
            <subject type="local">quality of life</subject>
            <description type="Chief Investigator">Dr Michael Lim</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Health</description>
            <description type="full">Atrial fibrillation (AF), a type of arrhythmia, is a risk
                factor for both psychological distress and cognitive decline. This study aims to
                determine if potentially curative catheter ablation procedures result in a greater
                improvement in markers of psychological distress and neurocognitive function
                compared to ongoing anti-arrhythmic drugs. We will also assess if catheter ablation
                procedures lead to reduced AF burden and hospitalisations as well as improved
                quality of life and cardiac function.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013845</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013845</identifier>
            <identifier type="nhmrc">2013845</identifier>
            <name type="primary">
                <namePart>Advancing the prevention and early intervention for co-occurring anxiety
                    and alcohol use disorders</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">alcohol abuse </subject>
            <subject type="local">anxiety disorders</subject>
            <subject type="local">youth</subject>
            <subject type="local">cognitive behaviour therapy</subject>
            <subject type="local">addiction prevention</subject>
            <description type="Chief Investigator">Ms Tara Guckel</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Alcohol use disorders often occur together with anxiety
                disorders, especially among youth. When these two occur together, individuals can
                have worse symptoms and treatment outcomes. This study will enhance the prevention
                and early intervention between anxiety and hazardous alcohol use by identifying key
                underlying mechanisms driving their relationship, and optimising interventions which
                address both conditions simultaneously.</description>
            <description type="fundingAmount">$93,056.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013862</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013862</identifier>
            <identifier type="nhmrc">2013862</identifier>
            <name type="primary">
                <namePart>Targeting immune resistance mechanisms to enhance anti-tumour immunity in
                    Non-Small Cell Lung Cancer</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">lung cancer </subject>
            <subject type="local">immune surveillance</subject>
            <subject type="local">cancer immunotherapy</subject>
            <subject type="local">non-small cell lung cancer</subject>
            <subject type="local">cancer immunology</subject>
            <description type="Chief Investigator">Dr Adithya Balasubramanian</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Lung cancer remains the leading cause of cancer related death
                globally. Treatments designed to unleash the immune system’s brakes
                (‘immunotherapy’) have resulted in significantly improved long-term survival in only
                a minority of patients. Tumour cells evolve to escape the immune system by silencing
                signals that allow their recognition by immune cells. We will identify means to
                reactivating these signals could enable immunotherapy to work in these otherwise
                resistant tumours.</description>
            <description type="fundingAmount">$97,640.33</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013877</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013877</identifier>
            <identifier type="nhmrc">2013877</identifier>
            <name type="primary">
                <namePart>Risk factors for and burden of low back pain in elite athletes.</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rxfrp27</identifier>
                <title>La Trobe University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">sports medicine </subject>
            <subject type="local">injury epidemiology</subject>
            <subject type="local">injury prevention</subject>
            <subject type="local">athlete training programs</subject>
            <subject type="local">spinal health</subject>
            <description type="Chief Investigator">Dr Larissa Trease</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Despite being in peak physical condition, athletes experience
                low back pain (LBP) at a higher rate than other members of our community. The
                reasons for this are not well understood and the advice to "keep active" that is
                given to non-athletic patients is less appropriate for athletes. This project will
                recruit and follow 300 elite athletes for one year to identify risk factors for
                athlete LBP. The project will also measure the cost of LBP in terms of episodes of
                pain and training time lost.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013894</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013894</identifier>
            <identifier type="nhmrc">2013894</identifier>
            <name type="primary">
                <namePart>Young people with old knees: The role of matrix metalloproteinase 3 and
                    type 2 collagen C-telopeptide fragments in predicting post traumatic
                    osteoarthritis after anterior cruciate ligament reconstruction</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rxfrp27</identifier>
                <title>La Trobe University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">knee reconstruction </subject>
            <subject type="local">knee cartilage</subject>
            <subject type="local">knee osteoarthritis</subject>
            <subject type="local">cartilage</subject>
            <subject type="local">ligament</subject>
            <description type="Chief Investigator">Dr Lachlan Batty</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Anterior cruciate ligament (ACL) injuries are common in young
                and active people. The development of knee arthritis after ACL injury and ACL
                surgery is a concern because it can lead to a situation were a young patient has an
                "old knee". This scenario is a major cause of disability and is very challenging to
                treat. This research is important in identifying patients at risk of premature
                arthritis and to facilitate prevention, treatment and better outcomes for this young
                patient group.</description>
            <description type="fundingAmount">$101,376.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013908</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013908</identifier>
            <identifier type="nhmrc">2013908</identifier>
            <name type="primary">
                <namePart>Validation and implementation of smartphone-based digital biomarkers in
                    multiple sclerosis to define subclinical progression and treatment failure: the
                    ACTIVE MS study</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">multiple sclerosis (ms) </subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">disease progression</subject>
            <subject type="local">patient participation</subject>
            <subject type="local">quantitative magnetic resonance imaging (mri)</subject>
            <description type="Chief Investigator">Dr Yi Chao Foong</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Multiple sclerosis (MS) is a leading cause of disability
                amongst young Australian adults. To date, only 2 effective treatments for
                progressive MS has been found. Current treatment is limited by the lack of accurate
                tools to detect disease progression, which leads to inefficient clinical trials for
                progressive MS. This project aims to establish smartphone-based apps as a tool to
                monitor disease activity and detect subtle clinical progression, thereby empowering
                patients in their own care.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013928</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013928</identifier>
            <identifier type="nhmrc">2013928</identifier>
            <name type="primary">
                <namePart>Comorbid Mental Health and Drug and Alcohol Use Among Sexuality and Gender
                    Diverse Young People in Australia</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">sexuality </subject>
            <subject type="local">gender</subject>
            <subject type="local">adolescent</subject>
            <subject type="local">substance use</subject>
            <subject type="local">mental health</subject>
            <description type="Chief Investigator">Miss Sophia Garlick Bock</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This study aims to fill a gap in current literature around
                existing rates of comorbid mental ill-health and drug and alcohol use among young
                sexuality and gender diverse people (aged 14-25). Existing literature has
                demonstrated that this population have higher rates of mental ill-health and drug
                and alcohol use compared to their heterosexual and cisgender peers. I will examine
                the rates and risk and protective factors of comorbidity among this group, using
                nationally representative datasets.</description>
            <description type="fundingAmount">$93,056.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013946</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013946</identifier>
            <identifier type="nhmrc">2013946</identifier>
            <name type="primary">
                <namePart>Hypertension with low renin - new insights into prevalence,
                    pathophysiology and management</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">hypertension </subject>
            <subject type="local">aldosterone</subject>
            <subject type="local">mineralocorticoid receptor</subject>
            <subject type="local">renin-angiotensin system (ras)</subject>
            <subject type="local">cardiovascular disease</subject>
            <description type="Chief Investigator">Dr Sonali Shah</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">High blood pressure is a major cause of death affecting over 6
                million Australians, yet two-thirds of patients have poor control. Many of these
                patients may have a type of hypertension that will respond well to a cheap and
                widely available medicine called an aldosterone blocker. We will test this drug
                against currently recommended hypertension treatments to find out if our approach
                will improve blood pressure control and the overall health of
                patients.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013949</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013949</identifier>
            <identifier type="nhmrc">2013949</identifier>
            <name type="primary">
                <namePart>Maternal and Child Health Nursing: A golden opportunity to integrate
                    screening for reproductive coercion and increase effective contraception
                    use?</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rxfrp27</identifier>
                <title>La Trobe University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">maternal and child health </subject>
            <subject type="local">nursing</subject>
            <subject type="local">reproductive health</subject>
            <subject type="local">domestic violence</subject>
            <subject type="local">contraception in female</subject>
            <description type="Chief Investigator">Ms Desiree LaGrappe</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This research will create and test a short set of questions
                about behaviours used to control the pregnancy choices of another person. We aim to
                help health care workers talk to clients about making a safety plan and planning a
                pregnancy. The questions will be tested in the Victorian Maternal Child Health
                Service where nurses currently ask about domestic and family violence. Researchers
                will also review research papers and talk to nurses, their clients and experts to
                learn about their opinions.</description>
            <description type="fundingAmount">$101,541.92</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013951</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013951</identifier>
            <identifier type="nhmrc">2013951</identifier>
            <name type="primary">
                <namePart>Preventing infectious disease and reducing associated harms among people
                    who inject drugs</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">injecting drug use </subject>
            <subject type="local">vaccination</subject>
            <subject type="local">blood-borne communicable diseases</subject>
            <subject type="local">infectious diseases</subject>
            <subject type="local">sexually-transmitted infections (sti)</subject>
            <description type="Chief Investigator">Ms Olivia Price</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">People who inject drugs (PWID) are an understudied population
                and there are gaps in our understanding of their experience with infectious disease.
                This project will produce crucial evidence on: 1) vaccination rates and barriers; 2)
                rates of infection; 3) service utilisation after infection; and 4) effect of drug
                dependence treatment on infectious disease-related outcomes. These data will inform
                interventions to prevent and treat infectious disease, improving health outcomes of
                PWID.</description>
            <description type="fundingAmount">$93,056.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013953</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013953</identifier>
            <identifier type="nhmrc">2013953</identifier>
            <name type="primary">
                <namePart>The impact of COVID-19 and associated health policies on access to allied
                    healthcare, care quality, and health outcomes in Australian residential aged
                    care facilities</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">aged care </subject>
            <subject type="local">residential care</subject>
            <subject type="local">health care utilisation</subject>
            <subject type="local">covid-19</subject>
            <subject type="local">health outcomes</subject>
            <description type="Chief Investigator">Ms Isabelle Meulenbroeks</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This PhD seeks to explore care quality, health outcomes, and
                allied healthcare delivery in residential aged care facilities pre and during
                COVID-19. This PhD uses electronic medical record data from a large aged care
                provider. Findings will be used to inform care practices and policy during future
                RACF lockdowns which occur regularly for conditions like influenza. The results also
                address key policy areas in care quality, e.g., falls, restraint use, and access to
                allied healthcare.</description>
            <description type="fundingAmount">$101,541.92</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013961</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013961</identifier>
            <identifier type="nhmrc">2013961</identifier>
            <name type="primary">
                <namePart>Genomic architecture of skin in the vicinity of previous melanoma in
                    photodamaged and non-photodamaged areas</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">melanoma </subject>
            <subject type="local">skin</subject>
            <subject type="local">photocarcinogenesis</subject>
            <subject type="local">genomics</subject>
            <subject type="local">gene transcription</subject>
            <description type="Chief Investigator">Ms Katie Lee</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">UV damage is a cause of melanoma-associated mutations, but
                recent work shows that even normal skin is awash with mutations. Why do some sites
                become melanoma, but not in nearby, equally UV-damaged sites? I will identify
                genomic aberrations, that are markers of melanoma-prone sites, by assessing skin
                from UV-damaged sites near melanomas, UV-damaged sites away from melanomas, and
                sun-protected sites with spatial profiling technology that will enable a molecular
                map of aberrations across the skin.</description>
            <description type="fundingAmount">$77,630.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013970</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013970</identifier>
            <identifier type="nhmrc">2013970</identifier>
            <name type="primary">
                <namePart>High-risk lymphoproliferative malignancies in the era of novel therapies:
                    Infection risk, surveillance and prophylaxis</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">antifungal </subject>
            <subject type="local">fungal infection</subject>
            <subject type="local">bacterial infection</subject>
            <subject type="local">haematological malignancy</subject>
            <subject type="local">novel therapies</subject>
            <description type="Chief Investigator">Dr Gemma Reynolds</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Opportunistic infection risk in lymphoma patients is
                incompletely understood, especially amongst heavily pre-treated patients receiving
                novel cellular therapies. This project will explore infection epidemiology,
                prediction and prophylaxis strategies amongst lymphoma patients. Retrospective
                cohort analysis, immune-profiling, multivariate analysis of infection risk and
                national audit of prophylaxis strategies will be conducted, informing future
                infection prevention and treatment strategies.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013981</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013981</identifier>
            <identifier type="nhmrc">2013981</identifier>
            <name type="primary">
                <namePart>Developing and evaluating an evidence-based training program for improving
                    labour and childbirth care in India.</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05ktbsm52</identifier>
                <title>Burnet Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">maternal health </subject>
            <subject type="local">health care worker education</subject>
            <subject type="local">public health impact</subject>
            <subject type="local">labour</subject>
            <subject type="local">program evaluation</subject>
            <description type="Chief Investigator">Dr Elizabeth Armari</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Prolonged labour is a major cause of stillbirth and maternal
                haemorrhage. The WHO Labour Care Guide (LCG) is a labour-monitoring tool which
                assists nurses, midwives and doctors provide early and effective interventions to
                prevent these complications. In my PhD, I will develop a LCG training program and
                evaluate its effects on LCG use within four hospitals in India. By optimizing LCG
                use, we expect the quality of maternity care and women's childbirth experiences to
                improve.</description>
            <description type="fundingAmount">$101,376.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2013987</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2013987</identifier>
            <identifier type="nhmrc">2013987</identifier>
            <name type="primary">
                <namePart>Responsible pre-operative Opioid use for Hip and knee ArthropLasTy
                    (OpioidHALT) study</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">opioid analgesia </subject>
            <subject type="local">total hip replacement</subject>
            <subject type="local">knee replacement</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">qualitative study</subject>
            <description type="Chief Investigator">Shania Liu</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Opioids are medicines used to manage strong pain, but are
                associated with significant side effects. Opioids are often prescribed
                inappropriately for osteoarthritis and, when used before surgery, lead to worse pain
                and longer hospital stay. We propose an intervention where pharmacists educate
                patients on pain self-management and help with lowering opioid doses before surgery.
                This research is projected to save $5 million from safer opioid use and reduced
                hospital costs.</description>
            <description type="fundingAmount">$81,985.42</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014022</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014022</identifier>
            <identifier type="nhmrc">2014022</identifier>
            <name type="primary">
                <namePart>Revolutionising System Reform in Mental Health: Addressing Gaps in the
                    System through Big Data and Data Linkage</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">mental health services </subject>
            <subject type="local">health services research</subject>
            <subject type="local">data analysis</subject>
            <subject type="local">data linkage</subject>
            <subject type="local">access to health care</subject>
            <description type="Chief Investigator">Dr Anthony Hew</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The current mental health system in Australia is not providing
                the care to those that need it the most. This program of research aims to understand
                how the mental health system is failing these individuals though an internationally
                unique approach of analysing population-level ambulance and healthcare records to
                provide insights into how to improve and re-develop the system.</description>
            <description type="fundingAmount">$116,321.17</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014024</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014024</identifier>
            <identifier type="nhmrc">2014024</identifier>
            <name type="primary">
                <namePart>Identifying and addressing the needs and priorities of patients with
                    genetic kidney disease and their families</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">kidney disease </subject>
            <subject type="local">genetic disorders</subject>
            <subject type="local">clinical epidemiology</subject>
            <subject type="local">patient education</subject>
            <subject type="local">service delivery</subject>
            <description type="Chief Investigator">Dr Noa Amir</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Chronic kidney disease has a genetic cause in 10% of affected
                adults and up to 70% of children. A diagnosis of genetic kidney disease (GKD) can
                bring about a complex emotional response, this psychological burden if not addressed
                leads to frustration, and distress. I aim to describe patient and clinician
                experiences of genetic testing, and of GKD, determine patient priorities for genetic
                testing and models of care in GKD, and develop and implement patient resources to
                improve care in GKD.</description>
            <description type="fundingAmount">$97,640.33</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014035</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014035</identifier>
            <identifier type="nhmrc">2014035</identifier>
            <name type="primary">
                <namePart>Personalising Pain Relief for People With Cancer: The Right Opioid For the
                    Right Person at the Right Time</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cancer pain </subject>
            <subject type="local">pharmacogenomics</subject>
            <subject type="local">palliative care</subject>
            <subject type="local">clinical decision making</subject>
            <subject type="local">biomarkers</subject>
            <description type="Chief Investigator">Dr Aaron Kee Yee Wong</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Cancer pain is common and distressing. There is no scientific
                method to predict which opioid will work for which person. The same opioid may treat
                one person’s pain well, but cause confusion, or be ineffective for another. This
                multi-phase project aims to transform pain management.It will consolidate the
                evidence, and evaluate the impact and feasibility of using gene testing to
                personalise opioid prescribing for cancer, so that the right opioid is prescribed to
                the right person at the right time</description>
            <description type="fundingAmount">$93,904.17</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014036</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014036</identifier>
            <identifier type="nhmrc">2014036</identifier>
            <name type="primary">
                <namePart>Biomarker profiles in Indigenous Australians with systemic lupus
                    erythematosus</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">systemic lupus erythematosus (sle) </subject>
            <subject type="local">indigenous australians</subject>
            <subject type="local">biomarkers</subject>
            <subject type="local">genomics</subject>
            <subject type="local">proteomics</subject>
            <description type="Chief Investigator">Dr Laura Eades</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Lupus is a serious, incurable illness which reduces quality of
                life and life expectancy. Indigenous Australians have more frequent and severe lupus
                than the general population, although the reasons for this are unclear. I aim to
                analyse proteins in the blood of Indigenous and non-Indigenous lupus patients, to
                determine if there are biochemical differences which explain these disparities. This
                may help us select better treatments for Indigenous lupus patients in the
                future.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014037</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014037</identifier>
            <identifier type="nhmrc">2014037</identifier>
            <name type="primary">
                <namePart>Treatments to expand regulatory T cells and/or deplete autoantibody
                    production in primary membranous nephropathy</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">experimental glomerulonephritis </subject>
            <subject type="local">glomerulonephritis</subject>
            <subject type="local">regulatory t cells</subject>
            <subject type="local">cell therapy</subject>
            <subject type="local">autoimmunity</subject>
            <description type="Chief Investigator">Dr Edmund Chung</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Primary membranous nephropathy (pMN) is a kidney disease caused
                by antibodies that attack the kidney (autoantibody) and is often difficult to treat.
                We propose research into treatments in a rat model of pMN that target
                autoantibody-producing immune cells or promote regulatory immune cells, using
                manufactured immune cells and protein vaccination. We will also compare the immune
                cells in humans with pMN and healthy individuals to identify specific immune cells
                targetable using our new treatments.</description>
            <description type="fundingAmount">$97,640.33</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014038</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014038</identifier>
            <identifier type="nhmrc">2014038</identifier>
            <name type="primary">
                <namePart>Towards vaginal microbiota stability: new treatment paradigm for bacterial
                    vaginosis</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rxfrp27</identifier>
                <title>La Trobe University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">bacteriophage </subject>
            <subject type="local">bacteria</subject>
            <subject type="local">microbial ecology</subject>
            <subject type="local">disease mechanisms</subject>
            <subject type="local">gynaecology</subject>
            <description type="Chief Investigator">Dr Hiu Tat Chan</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Bacterial vaginosis (BV) is very common in reproductive aged
                women. Current therapies are not very effective. However bacterial vaginosis is
                linked with poor reproductive health outcomes in women. New therapies are needed.
                Phages are viruses that attack bacteria, and CPR bacteria are a group of
                little-known bacteria that parasitise other bacteria. This research will investiage
                how phages and CPR bacteria affect vaginal health and develop new BV therapies based
                on phages and CPR bacteria.</description>
            <description type="fundingAmount">$97,640.33</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014056</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014056</identifier>
            <identifier type="nhmrc">2014056</identifier>
            <name type="primary">
                <namePart>Using mathematical models to generate evidence to support Australia’s
                    COVID-19 responses and prepare for future pandemics</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05ktbsm52</identifier>
                <title>Burnet Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">epidemiology </subject>
            <subject type="local">infectious diseases</subject>
            <subject type="local">information systems/decision support systems</subject>
            <subject type="local">health systems</subject>
            <subject type="local">mathematical modelling</subject>
            <description type="Chief Investigator">Mr Dominic Delport</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">My PhD will utilise mathematical modelling to generate evidence
                to support COVID-19 responses in Australia and prepare for future
                epidemics/pandemics. The main objectives are to address current COVID-19 policy
                questions (e.g. vaccination strategies), learn lessons from deep analysis of
                previous COVID-19 outbreaks in Australia, and produce generalisable and impactful
                guidelines for future pandemic responses.</description>
            <description type="fundingAmount">$93,056.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014074</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014074</identifier>
            <identifier type="nhmrc">2014074</identifier>
            <name type="primary">
                <namePart>Economic evaluation of strategies to increase kidney donation and
                    transplantation</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">health economics </subject>
            <subject type="local">economic evaluation</subject>
            <subject type="local">quality of life</subject>
            <subject type="local">equity</subject>
            <subject type="local">health policy evaluation</subject>
            <description type="Chief Investigator">Mr Karan Shah</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">I will investigate value and harm of changing the way organ
                donation is managed in Australia using health economic approaches. I will use data
                from a large trial to look at how quality of life changes over time as people wait
                for a transplant. By linking health datasets together I will look at whether the
                transplant program in Australia treats everyone fairly.</description>
            <description type="fundingAmount">$80,201.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014086</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014086</identifier>
            <identifier type="nhmrc">2014086</identifier>
            <name type="primary">
                <namePart>Improving Syphilis diagnosis and management in the community</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">syphilis </subject>
            <subject type="local">public health</subject>
            <subject type="local">sexually-transmitted infections (sti)</subject>
            <subject type="local">diagnosis</subject>
            <subject type="local">clinical epidemiology</subject>
            <description type="Chief Investigator">Dr Yasmin Hughes</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Syphilis is an important global health problem. Rates of
                syphilis have climbed dramatically in Australia, with heterosexual populations
                increasingly affected and rises in congenital syphilis. This research project has
                three objectives: i) to optimize diagnosis of syphilis in general practice using new
                testing methods; ii) to design and evaluate clinic systems to improve screening for
                syphilis; and iii) to improve partner notification using internet based contact
                tracing.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014100</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014100</identifier>
            <identifier type="nhmrc">2014100</identifier>
            <name type="primary">
                <namePart>Understanding Cirrhotic Cardiomyopathy</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05gvja138</identifier>
                <title>Centenary Institute of Cancer Medicine and Cell Biology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cirrhosis </subject>
            <subject type="local">portal hypertension</subject>
            <subject type="local">liver transplantation</subject>
            <subject type="local">cardiomyopathy</subject>
            <subject type="local">metabolomics</subject>
            <description type="Chief Investigator">Dr Madeleine Gill</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Liver transplant is the only life-saving option for people with
                end-stage liver disease. People with liver disease can also have a type of heart
                failure that can be problematic with liver transplant because of the major stress on
                the body. This project aims to enrich our understanding of how often, and why this
                disease happens. We will use a new technique called "metabolomics" to look for
                specific bloods markers and also follow patients and the changes in their hearts
                before and after transplant</description>
            <description type="fundingAmount">$123,793.50</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014110</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014110</identifier>
            <identifier type="nhmrc">2014110</identifier>
            <name type="primary">
                <namePart>Radial artery conduits in coronary artery bypass surgery: the impact of
                    prior instrumentation with a focus on the vascular biology and clinical
                    outcomes.</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">coronary artery bypass surgery </subject>
            <subject type="local">coronary artery disease</subject>
            <subject type="local">vascular biology</subject>
            <subject type="local">arterial flow dynamics</subject>
            <subject type="local">angiography</subject>
            <description type="Chief Investigator">Dr Garry Hamilton</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Certain patients with severely narrowed coronary arteries may
                require bypass (open heart) surgery, with the radial artery in the forearm
                frequently used as a bypass graft. Prior to surgery, this artery is also used to
                insert wires and plastic tubes which are fed up the arm to the heart to perform a
                coronary angiogram. This research aims to assess what damage a coronary angiogram
                does to the radial artery, and whether this impacts on its ability to be used as a
                coronary artery bypass graft.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014111</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014111</identifier>
            <identifier type="nhmrc">2014111</identifier>
            <name type="primary">
                <namePart>An integration of multi-omics and machine learning to stratify patients
                    with lupus nephritis for precision medicine</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">lupus nephritis </subject>
            <subject type="local">gene transcription</subject>
            <subject type="local">expression profiling</subject>
            <subject type="local">metabolomics</subject>
            <subject type="local">artificial neural networks</subject>
            <description type="Chief Investigator">Dr Prianka Puri</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project will investigate genetic and metabolic changes
                associated with Lupus Nephritis (LN). I will undertake transitional, genomic and
                metabolic profiling of patients to assess alterations associated with disease
                activity in LN. I will then analyse this data using machine learning to stratify
                patient disease class and generate non- invasive disease markers to predict LN
                activity and uncover new drug targets. This approach will provide personalised
                medicine for patients with LN.</description>
            <description type="fundingAmount">$131,265.83</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014112</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014112</identifier>
            <identifier type="nhmrc">2014112</identifier>
            <name type="primary">
                <namePart>Cardiovascular Screening in Cancer Patients Treated with Immune Checkpoint
                    Inhibitors</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cancer immunotherapy </subject>
            <subject type="local">cardiovascular disease</subject>
            <subject type="local">cardiovascular disease prevention</subject>
            <subject type="local">cardiovascular risk factors</subject>
            <subject type="local">preventive screening</subject>
            <description type="Chief Investigator">Dr Sean Tan</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Patients with cancer treated with immunotherapy are at higher
                risk of cardiovascular disease. As cancer survival with immunotherapy is improving,
                it is important to address cardiovascular risk and screening in cancer patients to
                reduce the burden of cardiovascular disease and improve overall survivorship. We aim
                to evaluate cardiovascular risk and guide screening policies that could help prevent
                cardiovascular disease in cancer patients receiving immunotherapy.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014114</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014114</identifier>
            <identifier type="nhmrc">2014114</identifier>
            <name type="primary">
                <namePart>The role of cytochrome polymorphisms in primaquine metabolism and effects
                    on its activity in radical cure of Plasmodium vivax infection</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">malaria </subject>
            <subject type="local">antimalarial</subject>
            <subject type="local">pharmacogenetics</subject>
            <subject type="local">clinical pharmacology</subject>
            <subject type="local">tropical medicine</subject>
            <description type="Chief Investigator">Dr Alexandra Stewart</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Malaria is a mosquito-borne infection that can be life
                threatening. Globally there were 228 million cases and 405,000 deaths in 2018. One
                species, vivax malaria, can cause recurrent infection due to a dormant stage in the
                liver. The drug primaquine kills this dormant stage. However, recent studies have
                shown that genetic variations may limit primaquine effectiveness. This research will
                investigate how genetic variations affect primaquine metabolism and the prevention
                of recurrent vivax malaria.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014122</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014122</identifier>
            <identifier type="nhmrc">2014122</identifier>
            <name type="primary">
                <namePart>Informing future recommendations for prevention and treatment of ovarian
                    cancer using population data</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">cancer epidemiology </subject>
            <subject type="local">ovarian cancer</subject>
            <subject type="local">survival analysis</subject>
            <subject type="local">quality of life</subject>
            <subject type="local">incidence</subject>
            <description type="Chief Investigator">Dr Tanya Ross</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Ovarian cancer is the eighth most commonly diagnosed cancer in
                females worldwide. Five-year survival remains below 50% and physical and
                psychological symptoms are common amongst survivors. I aim to assess: 1. Factors
                associated with ovarian cancer risk to inform prevention strategies 2. Survival,
                symptom and wellbeing outcomes associated with current care pathways to optimise
                future treatment 3. Lifestyle and genetic factors associated with survival, symptoms
                and wellbeing to improve outcomes</description>
            <description type="fundingAmount">$90,168.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014140</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014140</identifier>
            <identifier type="nhmrc">2014140</identifier>
            <name type="primary">
                <namePart>Cardiometabolic, Genetic and Lifestyle Risk Factors for
                    Arrhythmias</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">atrial fibrillation </subject>
            <subject type="local">arrhythmia</subject>
            <subject type="local">cardiovascular risk factors</subject>
            <subject type="local">lifestyle factors</subject>
            <subject type="local">electrophysiology</subject>
            <description type="Chief Investigator">Mr Samuel Tu</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Abnormal heart rhythms are common conditions that cause
                debilitating symptoms and lead to poorer health outcomes. We have recently begun to
                appreciate the importance of managing lifestyle and other risk factors in these
                disorders; however, we still have an incomplete understanding of the role of alcohol
                consumption, healthy diet, and iron deficiency. This project will inform us of the
                optimal management of these risk factors, to provide the best care for patients with
                heart rhythm disorders.</description>
            <description type="fundingAmount">$77,630.00</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014142</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014142</identifier>
            <identifier type="nhmrc">2014142</identifier>
            <name type="primary">
                <namePart>Perinatal and early childhood risk and protective factors for paediatric
                    infection</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">pregnancy </subject>
            <subject type="local">epidemiology</subject>
            <subject type="local">maternal and child health</subject>
            <subject type="local">birth</subject>
            <subject type="local">risk prediction</subject>
            <description type="Chief Investigator">Ms Isobel Todd</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Infection is the most common reason for children needing
                healthcare. All children are exposed to viruses and bacteria that can cause them to
                become ill. However, some children are more likely to become ill or get a more
                severe illness than other children, and the reasons why are not known. This project
                looks at whether events or conditions during pregnancy, birth and the early years of
                life could change how likely children are to get sick, or how severe their illness
                is.</description>
            <description type="fundingAmount">$93,056.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014147</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014147</identifier>
            <identifier type="nhmrc">2014147</identifier>
            <name type="primary">
                <namePart>Developing a community-based psychosocial intervention for young people
                    with mental illness</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">adolescent </subject>
            <subject type="local">adolescent health</subject>
            <subject type="local">community intervention</subject>
            <subject type="local">psychosocial</subject>
            <subject type="local">participatory action research</subject>
            <description type="Chief Investigator">Ms Melissa Savaglio</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The overall aim is to design, develop, deliver, and evaluate a
                community-based program for youth with serious mental illness. The tangible outcome
                of this research will be the development of a trauma-informed, community-based
                mental health program that has been designed by youth, for youth, to effectively
                meet their unique psychosocial needs. It is intended that the program improves
                psychosocial functioning, reduces symptom severity, and enhances the life trajectory
                of these vulnerable youth.</description>
            <description type="fundingAmount">$67,346.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014148</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014148</identifier>
            <identifier type="nhmrc">2014148</identifier>
            <name type="primary">
                <namePart>Decolonising approaches for Aboriginal and Torres Strait Islander children
                    with complex health needs exposed to the youth justice system in Australia:
                    Reducing incarceration and recidivism rates</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">young offenders </subject>
            <subject type="local">aboriginal child</subject>
            <subject type="local">aboriginal mental health</subject>
            <subject type="local">health inequalities</subject>
            <subject type="local">neurodevelopmental disorders</subject>
            <description type="Chief Investigator">Mrs Lorelle Holland</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Urgent research is required to reduce lifelong harm and the
                over-representation of Aboriginal and Torres Strait Islander youth who are exposed
                to police custody and youth detention. A co-designed culturally appropriate
                diversionary model of care is imperative to identify complex health needs and create
                alternative pathways, away from detention. Scoping literature reviews and yarning
                circles with Aboriginal and Torres Strait Islander youth and their communities will
                inform this process.</description>
            <description type="fundingAmount">$115,801.33</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014162</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014162</identifier>
            <identifier type="nhmrc">2014162</identifier>
            <name type="primary">
                <namePart>Determining health system and public policy elements for successful
                    implementation and sustainability of cervical cancer elimination strategies at a
                    country and regional level</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">cancer prevention </subject>
            <subject type="local">population health</subject>
            <subject type="local">health policy</subject>
            <subject type="local">health systems</subject>
            <subject type="local">cervical cancer</subject>
            <description type="Chief Investigator">Ms Amelia Hyatt</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The global burden of cervical cancer is significant, however
                elimination is possible. This PhD aims to support global cervical cancer elimination
                by determining a best practice approach for member states to achieve optimum
                implementation of WHO strategies and concurrent health system strengthening. Policy
                analysis, stakeholder consultation and expert consensus will be used to develop a
                planning tool for governments to optimise implementation of cervical cancer
                elimination strategies.</description>
            <description type="fundingAmount">$93,056.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014163</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014163</identifier>
            <identifier type="nhmrc">2014163</identifier>
            <name type="primary">
                <namePart>Optimising trial processes and generating translational gains: Studies
                    Within A Trial (SWATs) for the MELSELF randomised controlled trial of
                    patient-led melanoma surveillance.</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">cutaneous melanoma </subject>
            <subject type="local">clinical epidemiology</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">diagnostic test</subject>
            <subject type="local">screening</subject>
            <description type="Chief Investigator">Dr Deonna Ackermann</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">With increasing concerns about research waste in clinical
                trials, there is recognition of the need to improve the design and operation of
                trials. With that in mind the Studies Within a Trial (SWAT) methodology has been
                developed to generate evidence to inform the conduct of future trials. My research
                will evaluate strategies to improve participant recruitment, retention, and
                intervention adherence within a series of SWATs embedded within a melanoma
                surveillance host trial.</description>
            <description type="fundingAmount">$62,204.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014165</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014165</identifier>
            <identifier type="nhmrc">2014165</identifier>
            <name type="primary">
                <namePart>Application of advanced manufacturing technologies to offload
                    diabetes-related foot ulceration</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03pnv4752</identifier>
                <title>Queensland University of Technology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">chronic leg or foot ulcers </subject>
            <subject type="local">diabetic complications</subject>
            <subject type="local">biomedical engineering</subject>
            <subject type="local">allied health</subject>
            <subject type="local">footwear</subject>
            <description type="Chief Investigator">Mr Alexander Terrill</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">People with diabetes can develop wounds on their feet due to
                high pressures. These wounds cause significant health and personal impacts for those
                affected and present a high cost to the health system. Current treatments are not
                always provided and are often not used by patients. This project explores how 3D
                scanning, computer aided design, and 3D printing could be used to make a more
                affordable, accessible and personalised treatment that clinicians are more likely to
                provide and patients use.</description>
            <description type="fundingAmount">$85,244.83</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014166</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014166</identifier>
            <identifier type="nhmrc">2014166</identifier>
            <name type="primary">
                <namePart>Development and evaluation of strategies to improve syphilis screening of
                    pregnant women to prevent congenital syphilis</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">syphilis </subject>
            <subject type="local">antenatal care</subject>
            <subject type="local">antenatal screening</subject>
            <subject type="local">congenital disease</subject>
            <subject type="local">sexual health</subject>
            <description type="Chief Investigator">Stephanie Bond</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This project aims to improve screening for syphilis at a time
                when increasing numbers of babies are being infected with syphilis. It will have
                three main aims: to assess the current situation regarding syphilis screening during
                pregnancy, to implement a new screening policy in pregnancy and to assess the
                efficacy of the new policy and techniques.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014180</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014180</identifier>
            <identifier type="nhmrc">2014180</identifier>
            <name type="primary">
                <namePart>Improving evidence-based practice for comorbid alcohol and other drug and
                    mental health conditions: the role of implementation science and quality
                    improvement toolkits</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">substance use </subject>
            <subject type="local">quality improvement</subject>
            <subject type="local">evidence-based clinical practice</subject>
            <subject type="local">mental health</subject>
            <subject type="local">implementation</subject>
            <description type="Chief Investigator">Ms Erin Madden</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Alcohol and other drug (AOD) and mental disorders frequently
                co-occur, yet there is a lack of evidence-based treatment in AOD services and a lack
                of studies focusing on reducing this evidence-to-practice gap. This thesis seeks to
                improve evidence-based practice in AOD services by developing, implementing and
                evaluating the effectiveness of a quality improvement toolkit that assists services
                to implement evidence-based guidelines for managing comorbid mental health
                conditions in AOD settings.</description>
            <description type="fundingAmount">$93,056.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014206</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014206</identifier>
            <identifier type="nhmrc">2014206</identifier>
            <name type="primary">
                <namePart>Investigating epigenetic regulators of disease and novel epigenetic
                    treatment approaches for imprinting disorders</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">epigenetics </subject>
            <subject type="local">genomic imprinting</subject>
            <subject type="local">gene silencing</subject>
            <subject type="local">alternate pharmacotherapies</subject>
            <subject type="local">abnormal development</subject>
            <description type="Chief Investigator">Anna Le Fevre</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Prader-Willi Syndrome (PWS) and Schaaf-Yang syndrome (SYS) are
                incurable disorders caused by a lack of expression of the paternal copy of
                particular genes. Patients have normal maternal copies but these are switched off. A
                potential treatment is to activate the silenced copies by removing the function of
                proteins that normally repress their expression. Here we will investigate a new
                potential treatment for PWS/SYS targeting the protein called SMCHD1 that normally
                switches off these genes.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014208</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014208</identifier>
            <identifier type="nhmrc">2014208</identifier>
            <name type="primary">
                <namePart>Koolungar Urban Moorditj Healthy Skin: Determining the burden of skin
                    disease in urban Aboriginal children and adolescents.</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">aboriginal health </subject>
            <subject type="local">aboriginal child</subject>
            <subject type="local">dermatology</subject>
            <subject type="local">skin disease</subject>
            <subject type="local">skin infections</subject>
            <description type="Chief Investigator">Dr Bernadette Ricciardo</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Skin infections and their complications are very common in
                remote-living Australian-Aboriginal children, but we do not know if urban Aboriginal
                children have this same risk. This is despite almost 80% of Australia's Aboriginal
                and Torres Strait Islander population living in regional and metropolitan areas.
                Working with Aboriginal Elders, we have designed a project to determine how common
                skin diseases are in urban Aboriginal youth, in order to improve prevention and
                treatment of skin infections.</description>
            <description type="fundingAmount">$123,793.50</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014210</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014210</identifier>
            <identifier type="nhmrc">2014210</identifier>
            <name type="primary">
                <namePart>Defining host immune response and prevention strategies for viral
                    respiratory tract infections in patients with haematological
                    malignancy</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">respiratory viruses </subject>
            <subject type="local">haematological malignancy</subject>
            <subject type="local">host response</subject>
            <subject type="local">vaccination</subject>
            <subject type="local">vaccines</subject>
            <description type="Chief Investigator">Dr Victoria Hall</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Viruses such as COVID-19 and influenza can lead to severe chest
                infections in patients with blood cancers. This research project aims to study the
                immune response to infection by these viruses in patients receiving treatment for
                blood cancers. This information will help us to improve treatment and vaccination
                against these viruses. A major aim is to prevent further infection. Results from
                this project may change current vaccination practice in Australia and lead to
                further research projects.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014215</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014215</identifier>
            <identifier type="nhmrc">2014215</identifier>
            <name type="primary">
                <namePart>Enhancing venetoclax and other pro-apoptotic agents to improve outcomes
                    for patients with haematological malignancies</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">anticancer drug </subject>
            <subject type="local">drug resistance</subject>
            <subject type="local">dna barcoding</subject>
            <subject type="local">acute myeloid leukaemia (aml)</subject>
            <subject type="local">chronic lymphocytic leukaemia (cll)</subject>
            <description type="Chief Investigator">Dr Thomas Lew</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Blood cancers kill &amp;gt;4,500 Australians per year. A new
                drug, venetoclax, has significantly improved outcomes for these patients, but
                relapses frequently occur. This PhD will analyse cancer cells at the single cell
                level to identify and specifically target the resistant populations that cause
                relapse. We will study how to undermine the energy metabolism of cancer cells, which
                may synergise with venetoclax. These projects strive to develop new treatments to
                improve patient care and achieve cures.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014234</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014234</identifier>
            <identifier type="nhmrc">2014234</identifier>
            <name type="primary">
                <namePart>Dissecting the challenge of AML</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">haematology </subject>
            <subject type="local">cancer biology</subject>
            <subject type="local">leukaemia</subject>
            <subject type="local">molecular basis of disease</subject>
            <subject type="local">anticancer drug</subject>
            <description type="Chief Investigator">Dr Yin Yuan</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Acute myeloid leukaemia (AML) is a life-threatening blood
                cancer that is difficult to treat. Recently, several new “targeted therapy” drugs
                have been developed, which work by blocking specific changes in cancer cells that
                help them survive and grow. Unfortunately, resistance to treatment commonly emerges.
                This project aims to understand how resistance can arise and how they affect
                responsiveness to different drugs. This information will help us develop better
                treatments for patients with AML.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014244</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014244</identifier>
            <identifier type="nhmrc">2014244</identifier>
            <name type="primary">
                <namePart>Ventricular arrhythmia mechanisms and therapies</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">arrhythmia </subject>
            <subject type="local">sudden cardiac death</subject>
            <subject type="local">cardiomyopathy</subject>
            <subject type="local">electrophysiology</subject>
            <subject type="local">pharmacotherapy</subject>
            <description type="Chief Investigator">Ashwin Bhaskaran</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Heart disease is the leading cause of death in Australia, with
                heart rhythm disorders being a major cause for debilitating symptoms and sudden
                cardiac death. Our understanding of heart rhythm disorders is incomplete. My aim is
                to study the mechanisms and therapies of heart rhythm disorders, including
                medications and procedural technologies, using advanced techniques and diagnostic
                tools to treat and potentially cure heart rhythm disorders, improve quality of life
                &amp;amp; prevent sudden cardiac death.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014245</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014245</identifier>
            <identifier type="nhmrc">2014245</identifier>
            <name type="primary">
                <namePart>Untangling Neuroinflammation's Role in Alzheimer's Disease Development
                    (UNRAVEL)</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">dementia </subject>
            <subject type="local">geriatrics</subject>
            <subject type="local">neuroinflammation</subject>
            <subject type="local">neurodegeneration</subject>
            <subject type="local">aged care</subject>
            <description type="Chief Investigator">Dr Sarah Holper</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">My PhD will lead to new understandings around the associations
                between tau homeostasis, neuroinflammation, and neurodegeneration, as well as
                identifying clinically useful biomarkers to support the diagnosis, prognosis and
                monitoring of patients with AD. My work will also shed light on the effects of SAMe
                on neuroinflammatory pathways, providing further information on the activity of this
                potential therapeutic, as well as identifying novel potential neuroinflammatory
                therapeutic targets.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014256</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014256</identifier>
            <identifier type="nhmrc">2014256</identifier>
            <name type="primary">
                <namePart>A randomised controlled human challenge trial to evaluate Strep A vaccine
                    efficacy, safety, and immunogenicity</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">group a streptococcal disease </subject>
            <subject type="local">pharyngitis</subject>
            <subject type="local">rheumatic fever</subject>
            <subject type="local">immunity</subject>
            <subject type="local">vaccine development</subject>
            <description type="Chief Investigator">Dr Yara-Natalie Abo</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">In human challenge models, healthy volunteers are given a
                carefully monitored infection to learn how diseases work and how to stop them. In
                this project, a new Australian strep throat human model will be used to test a
                vaccine against Strep A, which affects &amp;gt;750 million and kills &amp;gt;500,000
                annually.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014258</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014258</identifier>
            <identifier type="nhmrc">2014258</identifier>
            <name type="primary">
                <namePart>Improving care and outcomes for vulnerable patients with chronic kidney
                    disease – the young and the elderly</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">public health </subject>
            <subject type="local">kidney disease</subject>
            <subject type="local">patient preference</subject>
            <subject type="local">paediatric</subject>
            <subject type="local">geriatric assessment</subject>
            <description type="Chief Investigator">Ms Chandana Guha</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This study aims to examine patient-centered interventions for
                vulnerable populations with chronic kidney disease that assist with managing their
                condition, accessing care to ultimately improve healthcare outcomes. Specifically
                the study will assess the impact of personalised care plans that integrates patient
                priorities to improve the quality of life and reduce the burden of disease among
                children and older frail people with CKD and their families; and engaging patients
                in translatable research.</description>
            <description type="fundingAmount">$67,346.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014261</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014261</identifier>
            <identifier type="nhmrc">2014261</identifier>
            <name type="primary">
                <namePart>Novel technologies and strategies to identify arrhythmogenic substrate and
                    triggers for sudden cardiac death</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">cardiac arrhythmia </subject>
            <subject type="local">ventricular tachycardia</subject>
            <subject type="local">sudden cardiac death</subject>
            <subject type="local">non-invasive</subject>
            <subject type="local">echocardiography</subject>
            <description type="Chief Investigator">Dr Kasun De Silva</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The most common cause of sudden cardiac death is ventricular
                arrhythmias (VAs) - rapid heart rhythms can cause the heart to stop beating.
                Catheter ablation (CA), where regions of the heart from which these rhythms arise
                (scar) are burned can treat VA however requires accurate identification scar with
                invasive maps. Novel technologies including machine learning, 3D echocardiography
                and ECG imaging allow for non-invasive characterisation. This project aims to
                further validate these technologies.</description>
            <description type="fundingAmount">$90,168.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014262</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014262</identifier>
            <identifier type="nhmrc">2014262</identifier>
            <name type="primary">
                <namePart>Exceptional cognition in old age and interactions with other aspects of
                    successful ageing</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">healthy ageing </subject>
            <subject type="local">dementia</subject>
            <subject type="local">frailty</subject>
            <subject type="local">psychosocial factors</subject>
            <subject type="local">cognition</subject>
            <description type="Chief Investigator">Alice Powell</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Research on adults who function successfully at older ages
                could provide insights into what determines wellbeing in old age, how dementia could
                be prevented and what services might be required for older adults. This research
                will examine not just memory and other cognitive processes but also physical
                function and social connectedness to see how these aspects of functioning interact
                in successful ageing.</description>
            <description type="fundingAmount">$123,793.50</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014266</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014266</identifier>
            <identifier type="nhmrc">2014266</identifier>
            <name type="primary">
                <namePart>Evaluating the use of an open access self-collection cervical screening
                    pathway: The solution to declining participation and to long standing
                    inequities?</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">cervical screening </subject>
            <subject type="local">women's health</subject>
            <subject type="local">health systems</subject>
            <subject type="local">evaluation</subject>
            <subject type="local">implementation</subject>
            <description type="Chief Investigator">Miss Nicola Creagh</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Australia’s renewed National Cervical Screening Program enabled
                an alternative self-collection pathway for women who were under-screened. Data
                collected from early adopters indicates it is highly acceptable, however,
                significant implementation issues with the strict eligibility criteria and limited
                promotion have led to a low uptake of the pathway. This research will evaluate the
                use of open access to self-collection as a solution to addressing longstanding
                inequities in Australia’s program.</description>
            <description type="fundingAmount">$93,056.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014285</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014285</identifier>
            <identifier type="nhmrc">2014285</identifier>
            <name type="primary">
                <namePart>A Cognitive Ageing Risk Evaluation (CARE) Tool to Support Clinical
                    Diagnosis of Dementia for Aboriginal and Torres Strait Islander
                    Peoples</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">aboriginal health </subject>
            <subject type="local">cognitive impairment</subject>
            <subject type="local">dementia</subject>
            <subject type="local">risk factors</subject>
            <subject type="local">primary care</subject>
            <description type="Chief Investigator">Dr Huong Nguyen</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Dementia among Aboriginal and Torres Strait Islander peoples is
                much greater than the general Australian population. There is need to better
                understand the risk factors that account for this and the role of brain imaging and
                blood tests in assessment of Aboriginal and Torres Strait Islander peoples
                vulnerable to cognitive decline. This research will look at the risk factors and
                blood markers to improve diagnosis, management and support for patients and families
                affected.</description>
            <description type="fundingAmount">$105,112.67</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014292</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014292</identifier>
            <identifier type="nhmrc">2014292</identifier>
            <name type="primary">
                <namePart>The Science of Cold Snare Polypectomy</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">colorectal cancer prevention </subject>
            <subject type="local">non-familial adenomatous polyposis</subject>
            <subject type="local">colonoscopy</subject>
            <subject type="local">colorectal cancer risk</subject>
            <subject type="local">colorectal cancer</subject>
            <description type="Chief Investigator">Dr Oliver Cronin</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Colorectal cancer (CRC) was the third most commonly diagnosed
                cancer in Australia in 2017 with an estimated incidence rate of 67 per 100,000.
                Screening by colonoscopy can lead to a reduced cancer incidence as well as mortality
                through early detection of cancer and pre-cancerous lesions. Endoscopy training is
                heuristic and imperfect. Identifying risk factors for incomplete polypectomy and
                quantifying adequate resection margin will help frame world polypectomy
                guidelines.</description>
            <description type="fundingAmount">$101,376.50</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014294</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014294</identifier>
            <identifier type="nhmrc">2014294</identifier>
            <name type="primary">
                <namePart>How does methamphetamine use, mental health and treatment interventions
                    affect one another?</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">drug dependence </subject>
            <subject type="local">mental health</subject>
            <subject type="local">amphetamine</subject>
            <subject type="local">drug abuse</subject>
            <subject type="local">epidemiology</subject>
            <description type="Chief Investigator">Ms Thi Tran</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Within Australia, an increasing proportion of people are using
                crystalline methamphetamine, or ice. Using amphetamines has been linked to various
                harms and an increased risk of comorbid mental health disorders. However, exploring
                the link between comorbid mental health and treatment outcomes has been limited. The
                proposed PhD aims to explore this link further through linking multiple cohorts of
                people dependent on methamphetamine as well as methamphetamine-related hospital
                presentations.</description>
            <description type="fundingAmount">$117,839.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014320</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014320</identifier>
            <identifier type="nhmrc">2014320</identifier>
            <name type="primary">
                <namePart>Modulation of the gut microbiome and mucosal immune response in
                    IBD</namePart>
            </name>
            <name type="alternative">
                <namePart>Postgraduate Scholarships</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">inflammatory bowel disease (ibd) </subject>
            <subject type="local">clinical microbiology</subject>
            <subject type="local">gut immunity</subject>
            <subject type="local">chronic inflammation</subject>
            <subject type="local">drug effects</subject>
            <description type="Chief Investigator">Dr Robert Little</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Inflammatory bowel disease (IBD) is an incurable condition with
                significant morbidity and mortality. Australia has one of the highest prevalence
                rates in the world, costing $3.1 billion dollars annually. The gut microbiome
                appears to be a key player in the onset and trajectory of IBD. Over the course of a
                4 year PhD, we aim to evaluate how the gut microbiome affects the gut immune system
                and how this can be utilised to develop and target drug therapy to better control
                and potentially cure IBD.</description>
            <description type="fundingAmount">$135,002.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2008433</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2008433</identifier>
            <identifier type="nhmrc">2008433</identifier>
            <name type="primary">
                <namePart>Innovative point-of-care diagnostics and environmental surveillance tools
                    for the elimination of Asian schistosomiasis</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/004y8wk30</identifier>
                <title>QIMR Berghofer Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">schistosomiasis </subject>
            <subject type="local">molecular diagnostics </subject>
            <subject type="local">immunodiagnosis </subject>
            <subject type="local">environmental epidemiology </subject>
            <subject type="local">quantitative polymerase chain reaction (pcr) </subject>
            <description type="Chief Investigator">Dr Pengfei Cai</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Accurate and rapid diagnostics are one of the key cornerstones
                for control and elimination of schistosomiasis in Asia. This cooperative research
                project aims to develop and trial rapid, cost-effective, field-friendly
                point-of-care (POC) diagnostics and environmental DNA (eDNA) detection tests for
                Asian schistosomiasis. Integrating the POCs and eDNA detection to the current
                schistosomiasis control programs within Asia and beyond can lead control policy and
                assess elimination goals.&lt;/field&gt;&lt;field id="e-Asia Project
                Title"&gt;Innovative point-of-care diagnostics and environmental surveillance tools
                for the elimination of Asian schistosomiasis</description>
            <description type="fundingAmount">$749,987.00</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009545</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009545</identifier>
            <identifier type="nhmrc">2009545</identifier>
            <name type="primary">
                <namePart>Ending HIV transmission by Optimizing Pre-exposure prophylaxis in East
                    Asia (HOPE)</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">human immunodeficiency virus (hiv) </subject>
            <subject type="local">infectious diseases </subject>
            <subject type="local">public health </subject>
            <subject type="local">health economics </subject>
            <subject type="local">randomised controlled trial (rct) </subject>
            <description type="Chief Investigator">Assoc Prof Jason Ong</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">This cooperative research project aims to bring together
                regional experts to co-design strategies with affected communities in Australia,
                Thailand and Philippines to optimize adherence to pre-exposure prophylaxis (PrEP)
                for HIV. Activities include networking and capacity building through cross-country,
                multidisciplinary workshops and conferences; and implementing interventions informed
                by innovative methods (crowdsourcing, discrete choice experiments) to optimize
                adherence among PrEP users.&lt;/field&gt;&lt;field id="e-Asia Project
                Title"&gt;Ending HIV transmission by Optimizing Pre-exposure prophylaxis in East
                Asia (HOPE)</description>
            <description type="fundingAmount">$667,191.20</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009656</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009656</identifier>
            <identifier type="nhmrc">2009656</identifier>
            <name type="primary">
                <namePart>Vector sero-surveillance tools to accelerate malaria
                    elimination</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05ktbsm52</identifier>
                <title>Burnet Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">malaria transmission </subject>
            <subject type="local">mosquito transmission </subject>
            <subject type="local">infectious diseases </subject>
            <subject type="local">immune surveillance </subject>
            <subject type="local">malaria control </subject>
            <description type="Chief Investigator">Prof Freya Fowkes</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Measuring antibody responses to mosquito salivary proteins in
                human sera may be a practical, highly sensitive alternative approach to estimate
                human biting rates and exposure to vector-borne diseases such as malaria. We will
                measure these salivary antibodies in a human biting challenge trial where volunteers
                are repeatedly bitten by mosquitoes to define antibody thresholds which predict
                biting rates. Furthermore, we will validate this sero-surveillance tool in field
                trials of vector control.</description>
            <description type="fundingAmount">$745,125.35</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2009816</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2009816</identifier>
            <identifier type="nhmrc">2009816</identifier>
            <name type="primary">
                <namePart>Targeting MYCN/NCYM for cancer therapy</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">p53 </subject>
            <subject type="local">neuroblastoma </subject>
            <subject type="local">liver cancer </subject>
            <subject type="local">gene transcription </subject>
            <subject type="local">cancer treatment </subject>
            <description type="Chief Investigator">Assoc Prof Tao Liu</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Primary liver cancer is a common cause of death from cancer in
                adults. Hepatocellular carcinoma represents approximately 90% of all cases of
                primary liver cancer. Cancer is the most common cause of death from diseases in
                children. Neuroblastoma is the most common solid tumour in early childhood. In this
                project, we will identify a novel therapeutic strategy targeting hepatocellular
                carcinoma and neuroblastoma for clinical translation.</description>
            <description type="fundingAmount">$699,317.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014513</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014513</identifier>
            <identifier type="nhmrc">2014513</identifier>
            <name type="primary">
                <namePart>COgNiTive propagation in pRodrOmaL Parkinson’s disease:
                    CONTROL-PD</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">rapid eye movement (rem) sleep </subject>
            <subject type="local">parkinson disease </subject>
            <subject type="local">dementia with lewy bodies </subject>
            <subject type="local">parkinsonism </subject>
            <subject type="local">phenotype </subject>
            <description type="Chief Investigator">Prof Simon Lewis</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">It has long been felt that not all patients with Parkinson’s
                disease are affected by the same pattern of cell death, which results in differences
                in their presentation, progression and response to treatment. This program will link
                international research teams who have can perform detailed assessments not only
                patients with the condition but also in the prodromal phases of disease to help
                better understand these differences and improve outcomes.</description>
            <description type="fundingAmount">$462,501.00</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014629</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014629</identifier>
            <identifier type="nhmrc">2014629</identifier>
            <name type="primary">
                <namePart>Effects of early-Stress On Lipid mediators and Inflammation for early
                    Detection of neurodegeneration (SOLID)</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04ttjf776</identifier>
                <title>RMIT University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Basic Science</subject>
            <subject type="local">alzheimer disease </subject>
            <subject type="local">microglia </subject>
            <subject type="local">omega-3 fatty acids </subject>
            <subject type="local">neuroinflammation </subject>
            <subject type="local">cognition </subject>
            <description type="Chief Investigator">Prof Sarah Spencer</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">The next frontier in Alzheimer’s Disease (AD) research is to
                find easily measurable biomarkers for neurodegeneration and cognitive dysfunction.
                Our translational project will leverage data and samples from 4 established human
                cohorts and 10+ rodent models. We will identify i) early biomarkers predictive of
                neurodegeneration and cognitive dysfunction ii) the causal role of early-life
                adversity on predisposition to AD and iii) an intervention strategy for alleviating
                these effects.</description>
            <description type="fundingAmount">$499,604.90</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014651</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014651</identifier>
            <identifier type="nhmrc">2014651</identifier>
            <name type="primary">
                <namePart>Leveraging medical records to identify patients at risk of
                    neurodegenerative disease</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Health Services Research</subject>
            <subject type="local">neurodegenerative disorders </subject>
            <subject type="local">electronic health information </subject>
            <subject type="local">complex genetic disease </subject>
            <subject type="local">brain imaging </subject>
            <subject type="local">health economics </subject>
            <description type="Chief Investigator">Dr Allan McRae</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Neurodegenerative diseases represent one of the main public
                health issues in our western societies and one of the greatest challenges in drug
                development. Therapeutic intervention for these disease works best with early
                intervention, ideally at pre-symptomatic stages. LeMeReND proposes to use electronic
                health records (EHR) to identify biomedical risk factors through studying previous
                diagnoses (pre-clinical comorbidities), drug prescription, clinical care usage, and
                biological test results.</description>
            <description type="fundingAmount">$482,706.14</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014745</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014745</identifier>
            <identifier type="nhmrc">2014745</identifier>
            <name type="primary">
                <namePart>A randomised CONtrolled trial of Tailored Acceptance and Commitment
                    Therapy for older people with treatment resistant Generalised Anxiety Disorder
                    (CONTACT-GAD)</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Public Health</subject>
            <subject type="local">general anxiety disorder (GAD)</subject>
            <subject type="local">geriatrics</subject>
            <subject type="local">clinical trial</subject>
            <subject type="local">psychological treatment</subject>
            <subject type="local">mental health services</subject>
            <description type="Chief Investigator">Prof Viviana Wuthrich</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Generalised anxiety disorder (GAD) is one of the most common
                mental disorders in later life. It is characterised by excessive and uncontrollable
                worry that is often chronic and associated with poorer quality of life, increased
                disability and greater use of medication and health services. Current treatments for
                GAD are not always well tolerated in this population. Acceptance and Commitment
                therapy (ACT) is a promising psychological therapy. This clinical trial will compare
                ACT to usual care.</description>
            <description type="fundingAmount">$358,767.46</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2014792</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2014792</identifier>
            <identifier type="nhmrc">2014792</identifier>
            <name type="primary">
                <namePart>The neoGASTRIC trial: Avoiding routine gastric residual volume measurement
                    in neonatal critical care, a multi-centre, randomised controlled
                    trial</namePart>
            </name>
            <name type="alternative">
                <namePart>International Collaborations</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <subject type="local">Clinical Medicine and Science</subject>
            <subject type="local">very preterm birth</subject>
            <subject type="local">feeding and nutrition</subject>
            <subject type="local">extremely low birth weight</subject>
            <subject type="local">abdominal surgery</subject>
            <subject type="local">neonatal intensive care (NICU)</subject>
            <description type="Chief Investigator">Dr Calum Roberts</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Before feeding preterm babies, nurses aspirate the contents of
                the stomach from the feeding tube to assess the ‘residual volume’ of feed, to
                determine the feeding plan. It is not clear if this is helpful (by detecting gut
                issues early), or harmful (by unnecessarily delaying feeding). In this trial, half
                of included infants will have gastric residual volumes routinely measured, and half
                will not. This will show which approach is best, for establishing feeding and
                avoiding any harm.</description>
            <description type="fundingAmount">$739,020.10</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015634</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015634</identifier>
            <identifier type="nhmrc">2015634</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05kf27764</identifier>
                <title>ANZAC Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Mrs Julie Taranto</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$6,414.35</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015635</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015635</identifier>
            <identifier type="nhmrc">2015635</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/019wvm592</identifier>
                <title>Australian National University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Marie-Helene Rousseau</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$87,443.83</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015636</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015636</identifier>
            <identifier type="nhmrc">2015636</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03rke0285</identifier>
                <title>Baker Heart and Diabetes Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Ms Cherry Yu</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$52,172.69</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015637</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015637</identifier>
            <identifier type="nhmrc">2015637</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/006jxzx88</identifier>
                <title>Bond University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Haley Jacobi</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$26,683.43</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015638</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015638</identifier>
            <identifier type="nhmrc">2015638</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05ktbsm52</identifier>
                <title>Burnet Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Ms Nadine Barnes</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$56,285.25</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015639</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015639</identifier>
            <identifier type="nhmrc">2015639</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05gsbkp40</identifier>
                <title>Cancer Council NSW</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr John Williams</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Charities and Philanthropic</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$5,705.78</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015640</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015640</identifier>
            <identifier type="nhmrc">2015640</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/023m51b03</identifier>
                <title>Cancer Council VIC</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Miss Amy Shelly</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Charities and Philanthropic</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$6,171.32</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015641</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015641</identifier>
            <identifier type="nhmrc">2015641</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05gvja138</identifier>
                <title>Centenary Institute of Cancer Medicine and Cell Biology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Mr Nicholas Keilar</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$5,753.55</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015642</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015642</identifier>
            <identifier type="nhmrc">2015642</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sqdef20</identifier>
                <title>Centre for Eye Research Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Raja Choudhury</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$16,116.04</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015643</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015643</identifier>
            <identifier type="nhmrc">2015643</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02n415q13</identifier>
                <title>Curtin University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Mr Dhruv Shah</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$41,939.59</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015644</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015644</identifier>
            <identifier type="nhmrc">2015644</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02czsnj07</identifier>
                <title>Deakin University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Kelly Windmill</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$76,782.94</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015645</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015645</identifier>
            <identifier type="nhmrc">2015645</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05jhnwe22</identifier>
                <title>Edith Cowan University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Ms Sharon York</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$12,365.71</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015646</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015646</identifier>
            <identifier type="nhmrc">2015646</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01kpzv902</identifier>
                <title>Flinders University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Mr Gareth Rees</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$96,569.96</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015647</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015647</identifier>
            <identifier type="nhmrc">2015647</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03a2tac74</identifier>
                <title>Florey Institute of Neuroscience and Mental Health</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Andrea Richardson-Wynd</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$75,486.89</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015648</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015648</identifier>
            <identifier type="nhmrc">2015648</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02sc3r913</identifier>
                <title>Griffith University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Lynette Farquhar</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$59,216.91</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015649</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015649</identifier>
            <identifier type="nhmrc">2015649</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04gsp2c11</identifier>
                <title>James Cook University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Mr Javier Balanzategui</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$30,327.30</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015650</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015650</identifier>
            <identifier type="nhmrc">2015650</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01rxfrp27</identifier>
                <title>La Trobe University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr Georgina Caruana</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$64,440.12</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015651</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015651</identifier>
            <identifier type="nhmrc">2015651</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sf06y89</identifier>
                <title>Macquarie University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Erin Semon</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$81,317.36</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015652</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015652</identifier>
            <identifier type="nhmrc">2015652</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/006mbby82</identifier>
                <title>Menzies School of Health Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Ms Christina Spargo</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$90,444.34</description>
            <coverage>
                <spatial type="text">NT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015653</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015653</identifier>
            <identifier type="nhmrc">2015653</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02bfwt286</identifier>
                <title>Monash University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Mrs Helen Partridge</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$799,596.83</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015654</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015654</identifier>
            <identifier type="nhmrc">2015654</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Ms Marianne Ciavarella</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$184,050.91</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015655</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015655</identifier>
            <identifier type="nhmrc">2015655</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00r4sry34</identifier>
                <title>Murdoch University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Lucy Johnston</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$10,214.79</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015656</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015656</identifier>
            <identifier type="nhmrc">2015656</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03pnv4752</identifier>
                <title>Queensland University of Technology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Ms Katie York</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$42,658.52</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015657</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015657</identifier>
            <identifier type="nhmrc">2015657</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04ttjf776</identifier>
                <title>RMIT University</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr Jane Holt</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$29,335.98</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015658</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015658</identifier>
            <identifier type="nhmrc">2015658</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03e3kts03</identifier>
                <title>South Australian Health and Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Leanne Sutherland</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$10,963.07</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015659</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015659</identifier>
            <identifier type="nhmrc">2015659</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02k3cxs74</identifier>
                <title>St Vincents Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr Colleen Elso</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$47,437.62</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015660</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015660</identifier>
            <identifier type="nhmrc">2015660</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/031rekg67</identifier>
                <title>Swinburne University of Technology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Sheila Hamilton-Brown</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$15,611.78</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015661</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015661</identifier>
            <identifier type="nhmrc">2015661</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05e4f1b55</identifier>
                <title>Bionics Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Janine Clarey</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$8,257.32</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015662</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015662</identifier>
            <identifier type="nhmrc">2015662</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/004y8wk30</identifier>
                <title>QIMR Berghofer Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr Marc Campitelli</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$136,321.82</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015663</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015663</identifier>
            <identifier type="nhmrc">2015663</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03s4x4e93</identifier>
                <title>George Institute for Global Health</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Kerry Jenson</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$8,929.21</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015664</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015664</identifier>
            <identifier type="nhmrc">2015664</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/008cfxd05</identifier>
                <title>Sax Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Michael Frommer</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$19,445.35</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015665</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015665</identifier>
            <identifier type="nhmrc">2015665</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00892tw58</identifier>
                <title>University of Adelaide</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr Cameron van den Heuvel</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$145,277.34</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015666</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015666</identifier>
            <identifier type="nhmrc">2015666</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00eae9z71</identifier>
                <title>University of Newcastle</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Ms Judy Alexander</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$146,290.51</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015667</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015667</identifier>
            <identifier type="nhmrc">2015667</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00rqy9422</identifier>
                <title>University of Queensland</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Lucy Buzacott</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$442,841.34</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015668</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015668</identifier>
            <identifier type="nhmrc">2015668</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr Catherine Hayden</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$260,377.21</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015669</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015669</identifier>
            <identifier type="nhmrc">2015669</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/04s1nv328</identifier>
                <title>University of Canberra</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Arvind Reddy</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$5,198.36</description>
            <coverage>
                <spatial type="text">ACT</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015670</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015670</identifier>
            <identifier type="nhmrc">2015670</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ej9dk98</identifier>
                <title>University of Melbourne</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr Wade Moore</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$865,017.58</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015671</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015671</identifier>
            <identifier type="nhmrc">2015671</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03r8z3t63</identifier>
                <title>University of New South Wales</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Ms Debbie Docherty</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$613,830.21</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015672</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015672</identifier>
            <identifier type="nhmrc">2015672</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01p93h210</identifier>
                <title>University of South Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr Mark Geier</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$87,388.69</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015673</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015673</identifier>
            <identifier type="nhmrc">2015673</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/0384j8v12</identifier>
                <title>University of Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Nicole Makoviney</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$585,231.86</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015674</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015674</identifier>
            <identifier type="nhmrc">2015674</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01nfmeh72</identifier>
                <title>University of Tasmania</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Jodie Lamont</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$56,462.17</description>
            <coverage>
                <spatial type="text">TAS</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015675</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015675</identifier>
            <identifier type="nhmrc">2015675</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03f0f6041</identifier>
                <title>University of Technology Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Ms Kerrie Alexander</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$43,342.90</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015676</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015676</identifier>
            <identifier type="nhmrc">2015676</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/047272k79</identifier>
                <title>University of Western Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Ieuan Linck</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$205,719.62</description>
            <coverage>
                <spatial type="text">WA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015677</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015677</identifier>
            <identifier type="nhmrc">2015677</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00jtmb277</identifier>
                <title>University of Wollongong</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr Monica Birrento</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$26,337.26</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/2015678</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/2015678</identifier>
            <identifier type="nhmrc">2015678</identifier>
            <name type="primary">
                <namePart>2021 Equipment Grant</namePart>
            </name>
            <name type="alternative">
                <namePart>Equipment Grant</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03t52dk35</identifier>
                <title>University of Western Sydney</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr Liesel Senn</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">University</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$12,224.39</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000699</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000699</identifier>
            <identifier type="nhmrc">9000699</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05kf27764</identifier>
                <title>ANZAC Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Mrs Julie Taranto</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$181,896.26</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000700</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000700</identifier>
            <identifier type="nhmrc">9000700</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03rke0285</identifier>
                <title>Baker Heart and Diabetes Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Ms Rebecca Erlich</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$1,479,498.74</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000714</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000714</identifier>
            <identifier type="nhmrc">9000714</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05e4f1b55</identifier>
                <title>Bionics Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Janine Clarey</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$234,158.74</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000701</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000701</identifier>
            <identifier type="nhmrc">9000701</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05ktbsm52</identifier>
                <title>Burnet Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Nadine Barnes</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$1,596,121.62</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000702</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000702</identifier>
            <identifier type="nhmrc">9000702</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05gsbkp40</identifier>
                <title>Cancer Council NSW</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr John Williams</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Charities and Philanthropic</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$161,803.05</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000703</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000703</identifier>
            <identifier type="nhmrc">9000703</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/023m51b03</identifier>
                <title>Cancer Council VIC</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Amy Shelly</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Charities and Philanthropic</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$175,004.73</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000704</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000704</identifier>
            <identifier type="nhmrc">9000704</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/05gvja138</identifier>
                <title>Centenary Institute of Cancer Medicine and Cell Biology</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Mr Nicholas Keilar</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$163,157.50</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000705</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000705</identifier>
            <identifier type="nhmrc">9000705</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01sqdef20</identifier>
                <title>Centre for Eye Research Australia</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr Aniruddha Choudhury</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$457,014.16</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000706</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000706</identifier>
            <identifier type="nhmrc">9000706</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01bsaey45</identifier>
                <title>Children's Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Ms Ramona Grimm</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$25,149.17</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000707</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000707</identifier>
            <identifier type="nhmrc">9000707</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03a2tac74</identifier>
                <title>Florey Institute of Neuroscience and Mental Health</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Andrea Richardson-Wynd</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$2,140,636.57</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000716</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000716</identifier>
            <identifier type="nhmrc">9000716</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b3dvp57</identifier>
                <title>Garvan Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Miss Sonja Bates</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$33,816.14</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000717</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000717</identifier>
            <identifier type="nhmrc">9000717</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03s4x4e93</identifier>
                <title>George Institute for Global Health</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Prof Peter Dolnik</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$253,212.18</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000708</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000708</identifier>
            <identifier type="nhmrc">9000708</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00ymae584</identifier>
                <title>Institute for Breathing and Sleep</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Rosalba Drummond</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$93,673.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000709</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000709</identifier>
            <identifier type="nhmrc">9000709</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/048fyec77</identifier>
                <title>Murdoch Childrens Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Ms Marianne Ciavarella</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$5,219,265.21</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000710</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000710</identifier>
            <identifier type="nhmrc">9000710</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/00200ya62</identifier>
                <title>National Ageing Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Marcia Fearn</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$61,562.69</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000715</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000715</identifier>
            <identifier type="nhmrc">9000715</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/004y8wk30</identifier>
                <title>QIMR Berghofer Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr Marc Campitelli</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$3,865,776.91</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000711</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000711</identifier>
            <identifier type="nhmrc">9000711</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01ftvnv05</identifier>
                <title>Royal Brisbane and Women's Hospital Foundation</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Julie Wright</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Health</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$48,453.76</description>
            <coverage>
                <spatial type="text">QLD</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000718</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000718</identifier>
            <identifier type="nhmrc">9000718</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/008cfxd05</identifier>
                <title>Sax Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Michael Frommer</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$551,425.94</description>
            <coverage>
                <spatial type="text">NSW</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000712</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000712</identifier>
            <identifier type="nhmrc">9000712</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/03e3kts03</identifier>
                <title>South Australian Health and Medical Research Institute</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Leanne Sutherland</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$310,887.83</description>
            <coverage>
                <spatial type="text">SA</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000713</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000713</identifier>
            <identifier type="nhmrc">9000713</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/02k3cxs74</identifier>
                <title>St Vincents Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Dr Colleen Elso</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$1,345,223.00</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
    <registryObject group="National Health and Medical Research Council">
        <key>http://purl.org/au-research/grants/nhmrc/9000719</key>
        <originatingSource>www.nhmrc.gov.au/grants/research-funding-statistics-and-data</originatingSource>
        <activity type="grant">
            <identifier type="purl">http://purl.org/au-research/grants/nhmrc/9000719</identifier>
            <identifier type="nhmrc">9000719</identifier>
            <name type="primary">
                <namePart>IRIISS - 2021</namePart>
            </name>
            <name type="alternative">
                <namePart>Independent Research Institutes Infrastructure Support Scheme
                    (IRIISS)</namePart>
            </name>
            <relatedInfo type="party">
                <identifier type="doi">10.13039/501100000925</identifier>
                <title>National Health and Medical Research Council</title>
                <relation type="isFundedBy"/>
            </relatedInfo>
            <relatedInfo type="party">
                <identifier type="uri">https://ror.org/01b6kha49</identifier>
                <title>Walter and Eliza Hall Institute of Medical Research</title>
                <relation type="isManagedBy"/>
            </relatedInfo>
            <description type="Chief Investigator">Sejal Kendal</description>
            <description type="Date Announced">2022-01-11T00:00:00</description>
            <description type="Sector">Research Institutes</description>
            <description type="full">Not Applicable</description>
            <description type="fundingAmount">$7,383,705.50</description>
            <coverage>
                <spatial type="text">VIC</spatial>
            </coverage>
        </activity>
    </registryObject>
</registryObjects>